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ABSTRACT 
Background: TB is the commonest cause of death among people living with HIV (PLHIV) 
in Nigeria. It is difficult to diagnose TB among PLHIV and diagnosed patients often 
experience poor treatment outcome. Although, PLHIV are living longer because of increased 
access to antiretroviral therapy (ART), hypertension is emerging as a major co-morbidity in 
this population. This study explored better means of diagnosing TB among individuals with 
and without HIV, described TB treatment outcomes and their determinants, and assessed the 
burden of hypertension among PLHIV. 
Methods: This thesis comprises four studies conducted in University of Abuja Teaching 
Hospital (UATH): one cross-sectional study of PLHIV to assess the performance of the 
WHO TB symptom screening algorithm; a prospective study to evaluate whether C-reactive 
protein (CRP) and Interferon gamma-inducible protein 10 (IP-10) could be used to screen 
individuals for TB; a retrospective study to describe the TB treatment outcome of PLHIV and 
HIV-negative patients and the risk factors for poor treatment outcome and a retrospective 
study to describe the prevalence and incidence of hypertension and its determinants among 
PLHIV registered over a period of 3 years. 
Results: 202 PLHIV were screened for TB and 72.3% had symptoms of TB. However, only 
3% and 6.5% had culture or culture plus smear confirmed TB, respectively. The WHO 
algorithm had 83.3% sensitivity, 29.1% specificity and 98.2% negative predictive value. CRP 
and IP-10 were measured in 408 patients with TB symptoms, of which, 21% had culture-
confirmed TB. CRP had 91.4% and 33.2% sensitivity/specificity among all participants, 
95.3% and 42.6% among HIV-negative patients, and 84.8% and 22.1% sensitivity/specificity 
among PLHIV, respectively. IP-10 had 87.3% and 40.9% sensitivity/specificity among all 
participants and 87.5% and 50.3% among HIV-negative and 79.4% and 47.2% among 
PLHIV, respectively.  998 patients were treated for TB by the hospital in the last 5 years. Of 
these, 62% had treatment success, 8.4% died and 18% were lost-to-follow up (LTFU). 
TB/HIV-coinfection rate was 44.3%. Treatment success was 52.3% among PLHIV and 70% 
among HIV-negative patients (p = 0.001) with higher deaths (15.5% versus 2.9%, p = 0.001) 
and LTFU (22.5% versus 14.3%, p = 0.001) among PLHIV. Poor treatment outcome and 
LTFU were more frequent among older individuals, PLHIV, those without sputum smear 
results and low body weight. Low weight and not receiving Co-trimoxazole were associated 
with poor outcome and LTFU among PLHIV.  12.8% of 883 PLHIV had hypertension at 
enrolment and 11.2% developed hypertension 12 months after enrolment. Hypertension was 
associated with older age, higher BMI, hepatitis B and higher CD4 counts. Patients with 
incident hypertension had higher systolic and diastolic blood pressure on enrolment. 
Conclusion: The WHO TB screening algorithm performed as reported by WHO. However, 
most patients had symptoms of TB and required further tests, which limits its efficiency in 
high burden settings. CRP performed better than IP-10 and both markers performed better in 
HIV-negative than among PLHIV. TB treatment outcome was poor and was worse among 
PLHIV. Hypertension is a common problem among PLHIV. There is a need for better 
screening tools for TB among HIV-positive patients and to develop interventions to improve 
the outcome of patients with TB, especially among the elderly, PLHIV and those presenting 
with underweight. The high burden of hypertension among HIV patients signals the need to 
integrate care of hypertension and other noncommunicable diseases into HIV care programs. 
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Chapter 1 
General Introduction 
1.1 Introduction 
Acquired Immune Deficiency Syndrome (AIDS) and Tuberculosis (TB) are the top two 
leading causes of death due to an infectious agent in the world 1. Nigeria has about 3.2 
million individuals infected with the Human Immunodeficiency Virus (HIV) 2 and the World 
Health Organization (WHO) classifies the country as fourth in the list of high TB burden 
countries 3, with an estimated 407,000 new cases in 2016 4. These two pathogens interact, and 
TB is the most important opportunistic infection and major cause of death among the HIV 
positive patients.  
 In spite of its high TB burden, the case detection rate in Nigeria is very low (16%) 5. 
Diagnosis of TB in HIV patients is difficult because a high proportion of co-infected patients 
are sputum smear negative or have extrapulmonary forms of the disease 6-9. A large 
proportion of TB cases are diagnosed late or remain undiagnosed, and autopsy studies from 
Sub-Saharan Africa, have reported that undiagnosed TB is a major cause of death among 
people living with HIV (PLHIV) 10-12 and cases diagnosed late have poor treatment outcome.  
HIV prevalence varies across the states of Nigeria, as shown in Figure 1. The prevalence 
ranged from <1% in 5 states in the southern (Ogun, Ekiti, Edo, Delta and Ebonyi states) and 
4 states in the northern (Kebbi, Zamfara, Katsina and Bauchi states) regions, to > 9% in a 
state in the southern (Rivers) and two states in the northern (Kaduna and Taraba) regions of 
the country. This study took place in the Nigeria’s Federal Capital Territory (FCT), located at 
the centre of the country, and HIV prevalence there is in the range of 7 to 9%. 
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Figure 1.1. Map of Nigeria describing HIV prevalence by state. Source: Nigeria’s National 
Reproductive and Health Survey (NARHS), 2012. 
 
Sputum smear microscopy is still the most commonly used diagnostic test for TB diagnosis in 
Nigeria and globally. Though, it is cheap, fast and can be used at all levels of health care, its 
sensitivity is low, especially among HIV patients 13,14. Sputum culture has high sensitivity but 
it takes up to 17 days for liquid and up to two months for solid culture to produce test results.  
 Given the difficulty and consequences of making a TB diagnosis among HIV-infected 
individuals, the WHO developed an algorithm for screening for (and excluding) TB among 
HIV patients.  Patients without symptoms suggestive of TB (absence of cough > 2 weeks, 
fever, chronic weight loss or excessive night sweating) are considered to be unlikely to have 
TB and are provided with Isoniazid Preventive Therapy (IPT). Patients with any of the 
symptoms should undergo further testing for TB diagnosis and, if confirmed, commence anti-
TB medication  15,16. Several studies evaluating the 2007 WHO algorithm reported sensitivity 
and specificity ranging from 20% to 72% and 22% to 72.9%, respectively 15,17,18.  Surveys in 
high TB burden countries also reported that more than half of the patients with 
bacteriologically confirmed TB did not meet the WHO criteria and that many of patients 
presented without symptoms 13,19,20. Consequently, the algorithm was modified in 2011 to 
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include any of the symptoms of fever, cough, weight loss and night sweats of any duration. 
The performance of the revised algorithm has not been evaluated in Nigeria or West Africa.  
In 2010, the WHO approved the use of Xpert MTB/RIF for TB diagnosis 21,22. Xpert 
MTB/RIF has high sensitivity (92% and 75% for sputum smear-positive and negative, 
respectively) and specificity of 99% 23, and in 2014, the WHO recommended that, when 
available, Xpert- MTB/RIF should be used as the first diagnostic test in HIV-infected 
individuals with signs and symptoms suggestive of TB13,24. To improve TB case detection 
among HIV-infected patients, WHO therefore recommends utilizing the standardized 
algorithms and to use Xpert MTB/RIF as the first diagnostic test.   Although Xpert MTB/RIF 
availability is increasing in high burden settings, the test requires stable power supply and 
laboratory facilities, which make it difficult to be used at the lowest level of healthcare. 
Consequently, its implementation in some countries has not reduced the time to TB treatment 
initiation 25 or improved treatment outcome 26, and may not be cost-effective 27. These 
challenges highlight the need for better diagnostics for TB.   
 
The WHO conveyed a meeting in April 2014 to develop a consensus of four high-priority 
target product profiles (TPPs) for new TB diagnostics 28. These include; a non-sputum-based 
point-of-care (POC) that can detect all forms of TB through identification of biomarkers or 
bio-signatures, a POC triage test that is simple, not costly, and can be used to rule out TB at 
the lowest level of healthcare, a sputum-based POC test that could replace smear microscopy, 
and a rapid Drug Susceptibility Testing (DST) at the microscopy level 28,29. Of these, the 
most urgently needed diagnostic is the non-sputum-based POC that can accurately detect all 
forms of TB with a sensitivity higher than smear microscopy. As there are no products that 
are close to market, in this thesis, we evaluated the performance of C-reactive Protein (CRP) 
and Interferon Gamma Inducible Protein 10 (IP-10) as biomarkers to rule out active TB. 
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TB still carries a high risk of death in Nigeria.  In addition to deaths due to undiagnosed TB, 
thousands of people die, are lost-to-follow up (LTFU) or fail to improve clinically during TB 
treatment, every year. In 2016, one million (17% of the global notified TB cases) either died, 
were LTFU, failed treatment or were not evaluated 30. A review of 44516 TB patients 
registered between 2011and 2015 in Lagos, Nigeria, reported that 1424 (3.2%), 4717 (10.6%) 
and 937 (2.1%) of the patients died, LTFU or failed treatment, respectively 31. A better 
understanding of TB treatment outcome and its determinants is needed to reduce poor 
outcomes. However, there are few studies from Abuja, Nigeria, comparing TB treatment 
outcome and its associated factors, between HIV-positive and HIV-negative patients. 
In addition to TB, cardiovascular diseases are emerging as the leading cause of death among 
patients with HIV 32. Although, increasing access to ART has improved their life expectancy 
and quality of life, these populations are now at risk of age-related non-communicable 
diseases, such as hypertension and diabetes 33,34 35. HIV-infected patients in Nigeria may have 
metabolic complications of ART 36,37, which are coupled with a high prevalence of other 
traditional risk factors 38,39. As hypertension is the most important risk factor for CVD, we 
conducted a survey to explore whether this is also a major health problem among patients 
with HIV in Nigeria.   
1.2 Aim and scope of the study 
This study assessed the performance and effectiveness of the current WHO symptom screen 
algorithm for TB diagnosis among HIV patients, evaluated the performance of two non-
sputum-based biomarkers for TB screening, and determined TB treatment outcome and 
burden of hypertension among PLHIV, with a view to improving diagnosis and management 
of TB and hypertension among HIV patients, thereby preventing avoidable deaths in this 
population. 
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1.3 Main Objectives  
(1) To assess the predictive value of the WHO symptom screening algorithm to exclude 
TB among people living with HIV (PLHIV) 
(2) To determine the performance of CRP and IP-10 as screening tools for active TB  
(3) To retrospectively determine the treatment outcome of patients with TB with and 
without HIV.  
(4) To retrospectively determine the prevalence of hypertension among new patients with 
HIV at the time of enrolment. 
(5) To retrospectively determine the incidence of hypertension among the same patients 
one year after initiation of ART. 
1.4 Thesis structure 
Each chapter focuses on one main objective and each chapter has a brief introduction, a 
literature review, methodology, results and discussion sections.  
Chapter one gives an overall introduction to the thesis and presents the aim and objectives.  
Chapter two evaluates the WHO algorithm for TB symptom screening among HIV patients.  
Chapter three, evaluates the performance of CRP and IP-10 as screening tools for active TB.  
Chapter four presents a retrospective study on TB treatment outcome and its determinants for 
treatment success, and lost to follow up among HIV-negative and HIV-positive patients.  
Chapter five presents a retrospective study on the prevalence and incidence of hypertension 
among HIV patients.  
Chapter six presents the general discussion/conclusion, which integrates all the components 
of this thesis 
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Chapter 2 
Performance of the WHO symptom screening algorithm for TB diagnosis among HIV 
patients 
2.1 Introduction 
TB is preventable and curable; however, it is still the commonest cause of death among HIV 
patients. To reduce the catastrophic impact of TB/HIV-coinfection in high burden countries, 
the WHO TB symptom screening algorithm was developed to ensure early case detection and 
prompt treatment and prevention of TB among HIV patients. No published study has 
however evaluated the algorithm in Nigeria or West Africa.  
TB case detection is low in Nigeria, according to the 2015 global TB report, Nigeria 
contributed 15% of the 3 million cases of TB that were not reported to WHO in 2013 40 and 
close to half  of the unreported TB cases in 2015, were in either Indonesia or Nigeria 41. Since 
the symptom screening aims to improve TB case detection and prevent active TB, there is a 
need to evaluate the screening algorithm in the Nigeria. 
This cross-sectional study consecutively recruited newly diagnosed HIV-positive patients, 
screened them for TB symptoms, and performed sputum smear microscopy and culture on all 
the patients, irrespective of the symptom screening outcome, with a view to assessing the 
performance of the algorithm. 
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2.2 Literature review 
HIV is the strongest risk factor for the development of TB 41,42. The risk of developing active 
TB among PLHIV is 17 – 22 times more than that of individuals not infected with HIV 43.   
About one-third of the world population is infected with latent TB infection, but with 
competent host immunity, only very few of these will develop to active TB in their life time 
44-46. The risk of developing TB disease after exposure to MTB is about 10% for life-time for 
people without HIV and half of the risk will occur within the first two years after being 
infected 44,47. Conversely, in PLHIV, this risk is increased to 10% per annum in the early and 
to 30% in the late stages of HIV infection 47.  HIV co-infection increases the risk of 
reactivation of latent TB, susceptibility to primary infection and re-infection after exposure to 
MTB 48-51. Unlike other opportunistic infections, TB can occur at any stage of HIV, though 
its risk increases with the level of immunosuppression 47. HIV also accelerates the rate of 
progression of TB disease 47. Therefore, HIV patients are at higher risk of developing and 
dying from the disease compared to individuals who are not infected with HIV. 
Furthermore, TB and HIV co-infection is a great threat against the survival of PLHIV, being 
the most important opportunistic infection and cause of death among them 12,43,52-54. It is 
estimated that 1.2 million PLHIV developed TB in 2015 worldwide 41,55,56. In the same year, 
about one-third (390,000) of 1.2 million deaths occurring among HIV patients across the 
globe, were associated with TB and 75% of these occurred in sub-Saharan Africa 41,43.  
Ironically, Africa, which has between 12% and 15% of the world population 57, bears the 
majority of the global TB/HIV burden 40. According to the 2016 global TB report, the region 
has 22 of   the 30 high TB/HIV burden countries of the world and the highest average 
TB/HIV co-infection rates 41. Studies across sub-Saharan Africa showed that the prevalence 
of TB among HIV patients ranges from 8% in Botswana to 35% in South Africa 58.  
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Nigeria, the most populous country in Africa, has the second largest number of PLHIV in the 
world and ranks 4th among the 30 high burden TB countries 3,40,59 and an average of 22% of 
TB patients are co-infected with HIV 60. There are no national data on the prevalence of TB 
among HIV patients. However, four studies using smear microscopy reported that HIV/TB-
coinfection ranged from 10.5% to 56.9% 61-64. The huge variation in the prevalence may be 
due to disparity in the studies’ methods of data collection and their target populations. For 
instance, a study of 1320 patients in an HIV clinic in Kano, in the North-west zone of the 
country, reported a TB prevalence of 10.5% 62, while a further study of 940 HIV patients with 
TB symptoms conducted at two ART clinics: one in Jos and the other in Lagos (in the North-
central and South-west zones of the country, respectively) had a TB prevalence of 56.9% 61. 
A third study of 200 HIV-infected patients with TB symptoms in Ile-Ife (South-west zone) 
found TB in 34.5% 64, while a fourth study of 86 HIV patients with TB symptoms in Lafia, in 
the North-central zone of the country, found a TB prevalence of 13.8% 63.   
 
The main obstacles against adequate control of TB among HIV patients globally, particularly 
in sub-Saharan Africa, are the lack of well-equipped laboratory facilities 65-69  and the unusual 
clinical presentation of TB 70 . The clinical presentation of TB is altered in HIV patients. For 
instance, HIV infected patients may present with non-specific symptoms, which overlap with 
other opportunistic infections or patients may not have symptom at all and their sputum is 
more likely to be smear-negative 6,15,68. Also, Chest X-ray findings are non-specific or normal 
in most cases.  Because of this, conventional TB diagnostics such as smear microscopy and 
radiography perform poorly among HIV patients and the sensitivity of sputum smear 
microscopy may be as low as 9%-23% 66,68,71,72. Therefore, the difficulty of TB diagnosis in 
sub-Saharan Africa is associated with a high mortality and morbidity among HIV patients. 
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To reduce the burden of TB among PLHIV, WHO recommends four strategies, which 
include antiretroviral therapy (ART) and the 3’I’s (Intensified case-finding (ICF), Isoniazid 
preventive therapy (IPT) and Infection control for TB) 73-75. ICF involves the systematic 
screening of all HIV patients for symptoms of TB and is the entry point to IPT. Patients 
without symptoms are eligible for IPT and symptomatic individuals can be investigated 
further, diagnosed and treated early 76. Initially, chronic cough (> 2weeks) was the only 
symptom for screening 14,16. However, this led to poor sensitivity as more than half of 
bacteriologically-confirmed cases were missed 14,20,77,78. A meta-analysis of 12 observational 
studies from resource-constrained countries 79 reported  that presence of any one of four 
symptoms (current cough, weight loss, fever and night sweats) performed better in 
determining whether PLHIV were  likely to have TB, while the absence of symptoms had a 
high negative predictive value.  WHO included this algorithm in its 2011 guidelines for ICF 
and IPT, and recommended its use  at the time of initial presentation for HIV care 76 (figure 
2.1). 
 
Some changes have been made to the 2011 WHO algorithm. In 2013, it was recommended 
that Xpert MTB/RIF should be the primary TB diagnostic test, instead of sputum smear 
microscopy 80. Patients with negative Xpert MTB/RIF should be given IPT and should 
continue to be screened for TB symptoms at every clinic visit. All patients with positive 
Xpert MTB/RIF but no Rifampicin resistance, should be treated for TB and those with RIF 
positive results should undergo further drug susceptibility testing (DST). In 2016, WHO also 
indicated a repeat Xpert MTB/RIF, chest X-rays and a workup for diagnosing extra-
pulmonary TB, should be conducted among Xpert/MTB negative patients81.  
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Figure 2.1. WHO TB symptom screening algorithm for HIV-positive adults and 
adolescents, 2011 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Adults and adolescents living with HIV 
Screen for TB with any one of the following symptoms:  
Current cough  
Fever  
Weight loss  
Night sweats 
Assess for contraindications to IPT 
No  
Give IPT 
Yes 
Defer 
IPT 
 
Other diagnosis Not TB TB 
Give 
appropriate 
treatment and 
consider IPT 
Follow up 
and consider 
IPT 
         Screen for TB regularly at each encounter with a health worker or visit to a health facility 
No TB symptom TB symptom present 
Source: WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventive 
therapy for people living with HIV in resource- constrained settings  
 
Investigate for TB and other diseases 
 
Treat for TB 
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The sensitivity and specificity of the 2011 WHO TB symptoms screening is said to be 79% 
and 50% respectively, and when combined with chest X-ray, the sensitivity increases to 91% 
but specificity reduces to 39%. Most importantly, the absence of symptoms has a high 
negative predictive value of 97.7%79 in a population with a TB prevalence of 5%. High 
negative predictive values are needed as a screening test to rule out a disease. A test’s 
negative predictive value is affected by disease prevalence. The higher the disease 
prevalence, the lower the negative predictive value of a test. For instance, if the symptom 
screening were used among HIV patients with 10%, 20% and 30% TB prevalence, the 
negative predictive values would be 95.5%, 90.5% and 84.7% respectively. Which means 
that 4.5%, 9.5% and 15.3% of patients without any of the TB symptoms, will have TB and 
could be missed. Because the prevalence of TB among HIV patients in most of the high TB 
burden countries is above 5% 41,58, the performance of the symptom screening may be 
different from what was estimated in the initial meta-analysis. 
To assess the performance of the WHO algorithm, a study needs to meet the criteria used in 
the original meta-analysis 79. The criteria are: availability of data on the four symptoms, 
collection of sputum samples irrespective of signs and symptoms, and culturing at least one 
sputum sample for TB diagnosis for each participant. 
Nine studies that meet these criteria have been published after the meta-analysis, but only 
seven were purposely designed to assess the symptom screening’s performance 82-90. Of these 
, 6 were conducted in South Africa 83-87,89, one in Ethiopia 82, one in Kenya 90 and one was a 
multi-national study from South Africa, Botswana, Malawi and Zimbabwe 88. Seven studies 
were conducted among patients in ART clinics (of which, 4 were on ART-naïve  patients 
only 72,87,88,90 and 3 on both ART-naïve and on ART patients) 85,89,90, one took place among 
pregnant women in antenatal clinics 84, and one on newly admitted HIV-positive patients on 
medical wards 86. The symptom screening positivity rate, TB prevalence and performance of 
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the studies varied, as shown in summary table 2.1. The proportion of participants with 
positive symptom ranged from 6.6% to 91.1%, with  the largest proportion of patients with 
symptoms (91.1%) found among patients on the medical wards 86. Three of the four studies 
that recruited ART-naïve patients reported that between 70.1% to 80.2% of the patients had 
TB symptoms 82,87,88 and one study found symptoms in 53.2% of participants 90. TB 
symptoms were present in 25.6%, 58.1% and 61.8% of pregnant, non-pregnant women and 
men, respectively 90. Two of the 3 studies that included patients with or without ART, found 
a higher proportion of symptoms among ART-naïve patients 83,85 but the third study found 
little differences (88% and 82.7%, respectively) 89. A higher proportion of positive TB 
symptoms screening was found among those not on ART.  
In summary, almost all acutely ill patients admitted to medical wards and more than two-
thirds of ART-naïve patients attending HIV clinics had at least one symptom. However, the 
prevalence of symptoms was low among those on ART and pregnant women attending ANC 
and lowest among participants on ART and those previously screened or treated for TB. 
The prevalence of PTB in the nine studies ranged from 2.5 % to 32.6%. The prevalence was 
2.5%, 4.1%-5.9%, 8.4%-17.3% and 32.6% among pregnant women, patients on ART, 
patients not on ART and patients in the medical wards, respectively. In a study conducted 
among patients on ART, TB was found in 11.2% participants. However, when participants 
were stratified into pregnant, non-pregnant women, and men, the prevalence was 5.9%, 
11.5% and 13.6%, respectively 90. 
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Table 2.1. Summary of findings from studies that assessed the 2011 WHO’s TB symptom screening algorithm 
Author/Date Country Sample  Positive 
symptom 
screening 
TB 
prevalence 
Sensitivity Specificity PPV NPV 
Ahmad Khan /2014 85 South Africa 737 215 (Pre ART) 71.2% 15.8% 91.2% 32.6% 20.3% 95.2% 
522 (On ART) 44.6% 5.9% 51.6% 55.8% 6.8% 94.8% 
Balcha 2014 82 Ethiopia 784 80% 16.9% 92.6% 23% 20% 94% 
Hoffmann 2013 84 South Africa 1368 16% 2.5% 28% 84% 4.4% 98% 
Kufa 2012 89 South Africa 422 85.6% 6.4% 100% 15.4% 7.5% 100% 
Lawn, 2011 87 South Africa  468 70.1% 17.3% 84% 22.5% 18.5% 87% 
Lawn 2015 86 South Africa 427 91.1% 32.6% 96.4% 11.4% 33.7% 86.8% 
Rangaka 2012 83 South Africa 1429 657(PreART) 23.7% 13% 47.6% 79.8% 25.8% 91.1% 
772 (OnART) 6.6% 5.4% 23.8% 94.4% 19.6% 95.6% 
Swindells 2013 88 Botswana, Malawi, South 
Africa, Zimbabwe 
445 80.2% 12% 91% 21% 14% 94% 
Surbhi Modi 2016 90 Kenya 738 738 (All) 53.2% 11.2% 74.1% 49.5% 15.6% 93.8% 
134 (pregnant) 25.6% 5.9% 28.2% 74.6% 5.9% 94.8% 
 353 (other women) 58.1% 11.5% 78.3% 44.5% 15.8% 93.9% 
251 (men) 61.8% 13.6% 77.2% 40.6% 16.8% 92.0% 
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The performance of the WHO symptom screening in ruling out PTB, varies across studies. Of 
four studies that included ART-naïve patients, two reported the screening performed well 
82,88, one reported inadequate  performance 87 and one that it performed well among non-
pregnant women 90 (sensitivity (78.3%) and negative predictive value (NPV) 93.9%) and men 
(sensitivity (77.2%) and NPV (92.0%)), but had a poor performance among pregnant women 
(sensitivity (28.2%) and NPV (94.8%)) 90. 
One of the 3 studies that enrolled patients without or with ART reported good performance 
without stratification 89, one study reported it performed well among ART-naïve, but poorly 
among patients on ART 85 and one that the screening’s performance was poor irrespective of 
ART status and poorer among patients on ART 83 (See table 2.1). This latter study also 
reported 52.4% and 76.2% of culture-confirmed TB cases were missed by the screening 83.  
Among HIV-positive pregnant women, the sensitivity of symptom screening was very poor 
(28%)84 (See table 2.1),  as symptoms were absent in 76% of culture confirmed TB cases 84. 
Also,  symptom screening was not useful among acutely ill patients admitted to medical 
wards 86.  
Some of the studies have reported that the addition of CD4 count, Body mass index (BMI) 
and Haemoglobin (Hb) improved the performance of the screening and reduced the number 
of patients that needed further diagnostic work ups 82,83. However, these findings are not 
consistent across studies88.  
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2.3 Methodology 
2.3.1 Study design   
This was a cross-sectional study from July 2016 to June 2017, among newly diagnosed HIV-
positive patients attending the ART clinic of University of Abuja Teaching Hospital (UATH) in 
Abuja, Nigeria.  
2.3.2 Description of study location 
UATH is a 500-bed tertiary health facility of the Federal Government of Nigeria. It is located in 
Gwagwalada Area Council of the Federal Capital Territory (FCT) and provides specialized 
services in all disciplines of medicine. The hospital has the largest ART site in the FCT, with 
more than 15,000 HIV patients enrolled.  
This health facility offers HIV Counselling and Testing (HCT) services.  Patients attend 
voluntarily or are referred by other services for testing. New patients diagnosed at the HCT unit 
or referred from other centres are referred to the ART site for HIV care. The ART site receives 
referred patients from government, faith-based and private hospitals within FCT and its 
environs. The services provided include chronic HIV Care; ART adherence preparation, 
initiation and monitoring; prophylaxis and treatment of opportunistic infections (OIs); 
TB/HIV co-management; Prevention of Mother-to-Child Transmission (PMTCT); patients’ 
education on positive living; Home-based care, various forms of patients’ support, and 
cervical cancer screening. The ART site has the following units: Monitoring and Evaluation 
(M&E), Home-based Care and patients’ Support, Medical teams, ART Adherence 
Counselling, Pharmacy, Laboratory, Paediatrics, and Cervical Cancer Screening. Newly 
diagnosed HIV patients report to the M&E unit, which enrols new patients into the program. 
Patients are then sent to the Home-based care and support unit, for first-visit counselling, 
history taking and documentation. Afterwards, patients attend the laboratory for baseline 
investigations, which include CD4 count, full blood count (FBC), renal (RFT) and liver 
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function tests (LFT) and Hepatitis B Virus (HBV) screening. Each newly enrolled patient is 
allocated to one of the medical teams, which comprises a doctor, a nurse and an ART 
Adherence counsellor. New patients are initially seen by the doctor, who takes a medical 
history, physical examination, clinical HIV staging and treatment of OI. Patients with 
symptoms of TB undergo chest X-rays and are referred to the Directly Observed Therapy 
Short-course (DOTS) unit, for sputum smear microscopy. Seriously ill patients are admitted 
to the medical wards. Patients with OI are sent to the Adherence Counsellors for counselling 
on the drug(s), HIV/AIDS and positive living, and to the pharmacy to collect drugs. Drugs for 
OI are provided for one week and patients are asked to return to collect the baseline 
investigations’ results and for assessment of ART eligibility. Patients co-infected with TB 
commence TB treatment and two weeks later, if there are no problems, start ART that does 
not interact with TB medications. Patients without TB symptoms eligible for ART, receive 
ART adherence preparation and commence Co-trimoxazole Prophylaxis Therapy (CPT). 
Patients are given a two-week appointment on CPT alone. At the end of the two weeks, 
patients are assessed regarding CPT adherence and their understanding of ART adherence.  
Misunderstandings and problems with adherence are addressed during this visit. If the 
patient’s adherence preparation is satisfactory, ART is initiated, and CPT is continued. 
Patients not eligible for ART are followed using CD4 counts and clinical staging every three 
months. 
 
2.3.3 Sample size calculations 
This study is like a prevalence study, the formula for the minimum acceptable sample size 
(N) = Z2 pq/(d2) 
Where, p = prevalence of disease among study population 
             q = (1-p) 
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             d = precision (0.05) 
             Z = Z score at 95% confidence interval (1.96) 
There is no study from Nigeria or West Africa that has evaluated the WHO TB symptom 
screening algorithm for TB diagnosis among HIV patients. The prevalence of TB obtained 
from studies elsewhere among newly diagnosed/pre-ART HIV patients, ranged from 8.4% to 
17.3%. Since 17.3% will give the largest sample size, we decided to use it for sample size 
calculations. Using the above formula, the minimum acceptable sample size (N) = 1.962 X 
0.173 X 0.827/ (0.05)2 = 220.  To make room for attrition during data collection, 10% of the 
sample size (22) was added, making the sample size 242, which was rounded up to 250.  
This ideal sample size however was not achieved because of prolonged healthcare workers 
strikes during data collection, coupled with the decentralization of HIV care which reduced 
the number of patients at the study’s site.  We could only recruit 202 newly diagnosed HIV 
patients over a period of 12 months. All patients that met the study’s selection criteria, gave 
consent to participate and could produce sputum (either on the spot or after given a cup to try 
to produce early morning sputum at home and bring it to the clinic) were recruited. 
 
2.3.4 Inclusion criteria 
(1) Confirmed HIV positive status 
(2) Age of 18 years and above 
(3) Newly diagnosed 
(4) Consent to participate in the study 
(5) Enrolled at the ART site 
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2.3.5 Exclusion criteria 
(1) Patients on temporary enrolment (because, these patients were usually passer-
by/visitors who fell sick during their visit to Abuja and were diagnosed to be HIV-
positive). 
(2) Patients already diagnosed to have TB. 
(3)  Patients unable to provide informed consent and did not have legally assigned 
representatives. 
(4) Patients with a high risk of imminent death (these are patients with severe respiratory 
distress, loss of consciousness, un-recordable blood pressure or any other sign of life 
threatening conditions). 
  
2.3.6 Participant selection  
Participants were identified through the ART site’s M&E unit. All newly diagnosed HIV 
patients > 18 years enrolled at the ART site between 21st July 2016 and 15th June 2017, were 
invited to participate in the study.  After obtaining consent, patients were interviewed and 
screened for TB symptoms (presence and duration of cough, fever, weight loss and night 
sweats) using a questionnaire (see appendix 6, section 8.6.1). Thereafter, patients were 
classified as having/not having symptoms of TB.  Newly enrolled patients were consecutively 
recruited. A daily register of all newly diagnosed HIV patients was kept, whether they were 
recruited or not into the study (to make adjustment during data analysis). 
Participants were interviewed using a structured questionnaire to assess their medical history 
and reasons for attending, ask for the presence of TB symptoms and undertake physical 
examination. All routine HIV care baseline investigations (CD4 Count, Full Blood Count, and 
Renal function test) were competed by the site staff.  
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2.3.7 Sample collection  
Patients were asked to attempt producing a sputum sample on the spot. Specimens were 
examined to ascertain their quality and quantity, and specimens with deficient quality (mainly 
salivary or containing food particles) or quantity (< 0.5ml) were retaken. As patients without 
TB symptoms are more likely to produce sputum in the morning, patients unable to produce 
sputum on the spot, were taught how to produce good quality sputum, given a sputum 
collection cup, and asked to attempt to produce further sample during consecutive morning and 
bring the specimens to the clinic.   
2.3.8 Laboratory tests 
Sputum samples were transported (using a cold chain) to Zankli Medical Centre (ZMC) 
Laboratory, which is an accredited research laboratory, where it underwent smear microscopy, 
using a Light-emitting diode fluorescence microscopy (LED-FM) and culture. To ensure 
specimens were cultured within twenty-four hours of collection, a dedicated driver transported 
specimens to the laboratory, as soon as he was informed. In some instances, sputum samples 
were kept up to 48 hours in a refrigerator to maintain a cold chain.  
Smear microscopy was done by LED-FM with auramine staining at a minimum of 30 low-
power fields. After sputum decontamination and digestion with Mycoprep reagent, containing 
Sodium hydroxide, N-Acetyl-L-Cysteine, and sodium citrate (NaOH-NALC-Citrate), culture 
was performed using two solid Lowenstein-Jensen (LJ) culture media slopes per patient and 
monitored for 2 months for evidence of growth. Thereafter, MTB identification was done on 
specimens with growth, using SD Bioline TB Ag MPT64 Rapid test (SD, Korea). The 
laboratory staff were blinded to the outcomes of TB symptom screening and other clinical 
parameters of the participants. 
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Classification of patients 
Patients were classified as culture-confirmed TB, bacteriologically-confirmed TB and TB-
negative, based on the results of smear microscopy and culture.   
Culture-confirmed:  patients with positive M. tuberculosis culture.   
Bacteriologically-confirmed: patients with positive culture and/or positive smear 
microscopy.  
TB-negative: patients with negative smear microscopy and negative culture. 
Patients deemed TB-negative were provided IPT and ART. Patients with TB were provided TB 
treatment and initiated ART two weeks later, as per the Nigerian ART guidelines. 
Patients were also classified according to the WHO HIV clinical staging (see table 2.2) 
Table 2.2.  WHO HIV clinical staging of HIV disease in adults and adolescents 
Clinical stage 1 
Asymptomatic  
Persistent generalized lymphadenopathy 
Clinical stage 2 
Moderate unexplained weight loss (<10% of presumed or measured body weight)  
Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis)  
Herpes zoster  
Angular cheilitis 
Recurrent oral ulceration  
Papular pruritic eruption  
Fungal nail infections  
Seborrhoeic dermatitis 
Clinical stage 3 
Unexplained severe weight loss (>10% of presumed or measured body weight)  
Unexplained chronic diarrhoea for longer than 1 month  
Unexplained persistent fever (intermittent or constant for longer than 1 month)  
Persistent oral candidiasis  
Oral hairy leukoplakia  
Pulmonary tuberculosis  
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint 
infection, meningitis, bacteraemia)  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis  
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Unexplained anaemia (<8 g/dl), neutropaenia (<0.5 × 109/L) and/or chronic 
thrombocytopaenia (<50 × 109/L) 
Clinical stage 4 
HIV wasting syndrome  
Pneumocystis (jirovecii) pneumonia  
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month in 
duration or visceral at any site)  
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)  
Extrapulmonary tuberculosis 
Kaposi sarcoma  
Cytomegalovirus infection (retinitis or infection of other organs) 
Central nervous system toxoplasmosis  
HIV encephalopathy 
Extrapulmonary cryptococcosis, including meningitis 
Disseminated nontuberculous mycobacterial infection  
Progressive multifocal leukoencephalopathy  
Chronic cryptosporidiosis  
Chronic isosporiasis  
Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis)  
Lymphoma (cerebral or B-cell non-Hodgkin)  
Symptomatic HIV-associated nephropathy or cardiomyopathy  
Recurrent septicaemia (including nontyphoidal Salmonella)  
Invasive cervical carcinoma  
Atypical disseminated leishmaniasis 
Source: WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection 91. 
 
2.3.9 Ethical consideration 
Ethical approval was obtained from the Research Ethics Committees of the Liverpool School 
of Tropical Medicine (LSTM), University of Abuja Teaching Hospital (UATH) and the 
Nigeria’s Federal Capital Territory (FCT). Written and verbal informed consent were 
obtained from every participant. For participants that could not read or write, the study 
patient’s information sheet was read in their local language in the presence of an approved 
representative, who served as a witness and signed the consent form on behalf of the patient. 
A stamp pad was made available for such patients, for thumb printing. Patients were made 
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aware their participation was voluntary and that refusing to participate would not affect the 
quality of treatment. All information collected was kept confidential. 
2.3.10 Data analysis 
Epi-Info 7 (US Centers for Disease Control and Prevention (CDC)) and the Statistical 
Package for the Social Science (SPSS) (IBM, version 24) were used for data analysis. Data 
entry, parts of descriptive statistics and bivariable analysis were conducted in Epi-Info. Data 
in Epi-Info were exported into SPSS for descriptive statistics, bi- and multivariable analyses. 
Descriptive statistics included counts, percentages, means and standard deviations (SD), 
medians and interquartile ranges.  The characteristics of patients with and without TB 
symptoms were compared in bivariate analysis, using Chi-Square and Fisher’s Exact tests 
and “Student t” tests. Mann-Whitney’s U-tests were used for non-normally distributed 
continuous variables. Crude Odds ratios (COR) and 95% Confidence Interval (95% CI)) and 
mean differences with 95% CI, medians differences (95% CI) and P values were obtained. 
Variable with p < 0.2 were adjusted for age and gender in multivariable analysis, using binary 
logistic regression. As only 6 participants had positive culture, the performance of the WHO 
TB screening algorithm was determined in two scenarios: (1) using culture alone and (2) 
among bacteriologically confirmed TB cases (culture or smear-positive).  The sensitivity, 
specificity, positive predictive value (PPV) and NPV were estimated. 
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Figure 2.2. Flow chart for the study on evaluation of the WHO algorithm for TB diagnosis among HIV patients 
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2.4 RESULTS 
 
2.4.1 Demographic, clinical and laboratory characteristics of participants 
Two hundred and two patients with a new diagnosis of HIV-infection were screened at the 
time they attended the clinics for the first time. Eighty (39.6%) participants were male and 
122 (60.4%) female (ratio 2: 3). The age ranged from 17 to 75 years, with a mean (SD) of 
35.5 (9.7) years and 182 (90.1%) were between 20 and 49 years. The mean (SD) age for 
males and females were 41 (7.9) and 31.9 (9.0) years, respectively (p = 0.001). Most patients 
were married/with partner (104, 51.5%) or single (61, 30.2%), as shown in table 2.3. Twenty 
three (12.1%) patients had no formal education, 78 (41.1%) and 55 (28.9%) had secondary 
and higher education, respectively. There was a wide range of occupations, with civil 
servants (33, 16.3%) and traders/business (80, 39.6%) being the most frequent occupations. 
There was also a large number of ethnic groups with Igbo (39, 19.3%) and Hausa (20, 9.9%) 
having the highest frequencies. One hundred forty-two (70.3%) participants were Christian 
and 60 (29.7%) Muslims. 
Seventy-four (36.6%) patients had cough, 79 (39.1%) fever, 122 (60.7%) weight loss and 27 
(13.4%) night sweats, resulting in 146 (72.3%) having at least one of the four symptoms. The 
median (IQR) duration of cough, fever, weight loss and night sweats were 3 (1 – 10), 2 (1 – 
4), 8 (3.5 – 16) and 3 (1.5 – 6) weeks, respectively. Nine patients (4.5%) had a history of TB 
treatment and 11 (5.5%) did not know whether they had been treated for TB. The clinical 
staging of HIV infection classified 123 (61.5%), 33 (16.5%), 42 (21.0%) and 2 (1.0%) 
patients as stage 1, 2, 3, and 4, respectively.  
The mean (SD) BMI, waist and hip circumference and Waist-to-hip ratios were 22.1 (3.8) 
kg/m2, 82 (9.0) cms, 91.7 (8.9) cms and 0.90 (0.06), respectively. Hypertension (defined as 
systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg) was present in 
23 (12.3%) patients. The median (IQR) CD4 cell count was 197 (101 – 350) cells/mm3 with a 
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mean (SD) haemoglobin concentration of 9.7 (1.9) g/dl. Hepatitis B virus co-infection was 
present in 21 (13.4%) of 157 patients screened. 
TB investigations were conducted for 201 participants.  These, comprised 145 (99.3%) of the 
146 symptomatic patients and all 56 patients without TB symptoms.  
Sputum smear microscopy was positive in 10 (5.0%) and negative in 191 (94.6%) patients 
(one missing). Sputum culture was positive in 6 (3.0%), negative in 180 (89.1%), Non-TB 
Mycobacterium (NTM) in 9 (4.5%) and contaminated in 6 (3.0%). One culture was missing. 
If contaminated or missing, results are removed. The proportion of patients with culture-
confirmed TB was 6/195 (3.1%).  Smear microscopy was positive in seven patients with 
negative culture. Therefore, if smear or culture positive, results are considered 
bacteriologically confirmed, and 13/201 (6.5%) had bacteriologically confirmed TB, table 
2.5. 
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Table 2.3. Characteristics of study participants 
Characteristics Category  N = 202* Missing  
Mean (SD) [Range] age (Years)  All       35.5 (9.7) [17.0 – 75.0]  
 Male  41.0 (7.9) [17.0 – 60.0]  
 Female 31.9 (9.0) [18.0 – 75.0]  
Age group  10 – 19  3 (1.5)  
 20 – 29  58 (28.7)  
 30 – 39  74 (36.6)  
 40 – 49  50 (24.8)  
 50 – 59  14 (6.9)  
 ≥ 60  3 (1.5)  
Gender Male 80 (39.6)  
 Female 122 (60.4)  
Marital status Single 61 (30.2)  
 Married/with partner 104 (51.5)  
 Separated 11 (5.5)  
 Divorced 8 (4.0)  
 Widowed 18 (8.9)  
Educational Level No formal education 23 (12.1)    12 
 Primary 34 (17.9)  
 Secondary 78 (41.1)  
 Higher education 55 (28.9)  
Occupation Students 11 (5.4) 1 
 Unemployed 11 (5.4)  
 Civil Servants 33 (16.3)  
 Artisans 15 (7.4)  
 Business/Trading 80 (39.6)  
 Farming 14 (6.9)  
 House-wife 15 (7.4)  
 Others 22 (10.9)  
Ethnicity Igbo 39 (19.3)  
 Hausa 20 (9.9)  
 Yoruba 14 (6.9)  
 Gbagyi 13 (6.4)  
 Tiv 12 (5.9)  
 Ebira 7 (3.5)  
 Igala 7 (3.5)  
 Fulani 6 (3.0)  
 Others  81 (40.1)  
* Number and percentage unless specified 
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Table 2.4. Clinical characteristics and medical history of participants 
Characteristics Category  N = 202* Missing  Duration, Median (IQR) Missing 
TB-related Symptoms Cough 74 (36.6)  3 (1 – 10) 3 
 Fever 79 (39.1)  2 (1 – 4) 7 
 Weight loss 122 (60.7)  1 8 (3.5 – 16) 5 
 Night sweats 27 (13.4)  3 (1.5 – 6)  
 Any of the above 4  146 (72.3)    
Duration of illness (weeks) 
 
  6 (2 – 16) 33 
Functional Status  Working 168 (84.0) 2   
 Ambulatory 32 (16.0)    
 Bedridden  0 (0.0)    
WHO HIV clinical staging I 123 (61.5) 2   
 II 33 (16.5)    
 III 42 (21.0)    
 IV 2 (1.0)    
Previous history of TB 
 
9 (4.5)    
BMI (kg/m2) Mean (SD)  22.1 (3.8) 25   
Waist circumference (cm) Mean (SD) [Range] 82.0 (9.0) [65.0 – 109.0] 50   
Hip circumference (cm) Mean (SD) [Range] 91.7 (8.9) [70.0 – 118.0] 51   
Waist-to-Hip ratio  Mean (SD) [Range] 0.90 (0.06) [0.78 – 1.00] 51   
Systolic Blood Pressure (mmHg) Mean (SD) 110.8 (15.6) [80 – 170] 15   
Diastolic Blood Pressure (mmHg) Mean (SD) 71.5 (10.5) [40 – 110] 15   
Hypertension  
 
23 (12.3) 15   
CD4 Cells count (Cells/mm3) Median (IQR) 197 (101 – 350) 1   
CD4 count ranges (Cells/mm3) < 100  50 (24.9) 1   
 100 – 199  52 (25.9)    
 200 – 350  49 (24.4)    
  > 350  50 (24.9)    
Haemoglobin (g/dl) Mean (SD) 9.7 (1.9) 54   
White Blood Cells X 109/L  Median (IQR) 4.6 (4.1 – 6.1)  54   
Platelets count X 109/L  Median (IQR) 237.5 (180 – 277) 54   
Hepatitis B Virus screening  Positive 21 (13.4) 45   
* Number and percentage unless specified.  
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Table 2.5. Participants’ smear microscopy and culture results 
Characteristics Category  N = 202* Missing  
Smear microscopy  Negative 191 (94.6)  
 Scanty 9 (4.5)  
 + 0 (0.0)  
 ++ 0 (0.0)  
 +++ 1 (0.5)  
 Not done 1 (0.5)  
Culture  Negative 180 (89.1)  
 NTM 9 (4.5)  
 MTB 6 (3.0)  
 Contaminated 6 (3.0)  
 Missing 1 (0.5)  
Smear or Culture positive 
 
13 (6.5) 1 
* Number and percentage unless specified 
 
2.4.2 Participants’ characteristics by WHO symptom screening  
Patients with symptoms (positive WHO screening) had similar age to patients without 
symptoms (36.2 (10.2) versus 33.7 (7.8), p = 0.063) and there were no differences in terms of 
gender, marital status, education, ethnicity, and religion (see table 2.6). Similarly, there were 
no differences in the median (IQR) CD4 cells counts and the proportion of participants with 
hepatitis B.   
Patients with symptoms were more likely to have illnesses that hindered their daily activities 
(p = 0.001), to be at AIDS stage 2 (p = 0.025), 3 and 4 (p = 0.001), and to have lower blood 
pressure than patients without symptoms, table 2.7. The mean (SD) BMI for patients with 
symptom was lower than for patients without symptoms (21.8 (3.6) versus 23.3 (4.1), p = 
0.021).  Patients with symptoms had lower mean (SD) haemoglobin (9.4 (1.8) versus 10.3 
(1.9), p = 0.005) and higher median (IQR) white blood cells (5.0 (4.1 – 6.7) versus 4.1 (3.8 – 
4.9), p = 0.001) than patients without symptoms.  
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2.4.3 Multivariable analysis of the characteristics of participants with positive WHO TB 
symptom screening 
Variables with p values < 0.2 in bivariable analysis were adjusted for age and gender. After 
the adjustment, the variables that remained statistically significant were the functional status, 
the WHO clinical staging, the systolic and diastolic blood pressures, BMI, haemoglobin 
concentration and white blood cell count (see table 2.8). 
Patients with TB symptoms were less likely to carry out daily activities (p = 0.001), more 
likely to be in WHO clinical stages 2 (AOR (95 CI) = 2.8 (1.1 – 7.2)) or 3 and 4 (14.1 (3.2 – 
62.4)) and to have lower systolic (0.97 (0.94 – 0.99)) and diastolic (0.93 (0.90 – 0.97)) blood 
pressure; BMI (0.88 (0.81 – 0.96)), and haemoglobin (0.7 (0.6 – 0.9)). Conversely, patients 
with TB symptoms had higher white blood cells count (1.5 (1.2 – 2.0), p = 0.003). 
 
Table 2.6. Participants’ characteristics stratified by WHO symptom screening outcome 
Characteristics Category  WHO symptom screening OR (95% CI)  P 
value Positive 
N = 146 (%)  
Negative 
N = 56 (%)  
Mean (SD) Age (years)  All 36.2 (10.2) 33.7 (7.8) 2.5 (1.3 – -0.1)* 0.063 
 Male 41.7 (7.9) 38.8 (7.8) 2.9 (-1.1 – 7.0)* 0.152 
 Female 32.3 (9.9) 30.8 (6.4) 1.5 (-2.0 – 5.0)* 0.402 
Age Group 10 – 19  3 (2.1) 0 (0.0)  0.509 
 20 – 29 38 (26.0) 20 (35.7)   
 30 – 39 52 (35.6) 22 (39.3)   
 40 – 49 38 (26.0) 12 (21.4)   
 50 – 59 12 (8.2) 2 (3.6)   
 ≥ 60  3 (2.1) 0 (0.0)   
Gender Male 60 (41.1) 20 (35.7) 1.3 (0.7 – 2.4) 0.484 
 Female 86 (58.9) 36 (64.3)   
Marital status Single 44 (30.1) 17 (34.0) 1  
 Married 71 (48.6) 33 (58.9) 0.8 (0.4 – 1.7) 0.603 
 Separated 8 (5.5) 3 (5.4) 1.0 (0.2 – 4.3) 0.968 
  Divorced 7 (4.8) 1 (1.8) 2.7 (0.3 – 23.7) 0.369 
 Widowed 16 (11.0) 2 (3.6) 3.1 (0.6 – 14.9) 0.160 
Educational Level  None 17 (12.4) 6 (11.3) 1  
 Primary 29 (21.2) 5 (9.4) 2.1 (0.5 – 7.7) 0.291 
 Secondary 53 (38.7) 25 (47.2) 0.7 (0.3 – 2.1) 0.587 
 Higher Ed. 38 (27.7) 17 (32.1) 0.8 (0.3 – 2.4) 0.671 
Ethnicity Hausa 16 (11.0) 4 (7.1) 1.9 (0.6 – 5.9) 0.291 
 Igbo 32 (21.9) 7 (12.5) 2.1 (0.9 – 5.2) 0.099 
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 Yoruba 10 (6.8) 4 (7.1) 1.2 (0.3 – 3.9) 0.806 
 Others 88 (60.3) 41 (73.2)             1  
Religion Christianity 100 (68.5) 42 (75.0) 0.7 (0.4 – 1.5) 0.365 
 Islam 46 (31.5) 14 (25.0)   
 *Mean difference (95% CI).   
31 
 
Table 2.7. Clinical characteristics and medical history of participants, stratified by WHO symptom screening outcome 
Characteristics Category  WHO symptom screening OR (95% CI)  P 
value Positive 
N = 146 (%)  
Negative 
N = 56 (%)  
Functional Status  Working 112 (77.8) 56 (100.0) Undefined 0.001 
 Ambulatory 32 (22.2) 0 (0.0)   
WHO clinical staging  I 75 (52.1) 48 (85.7)  0.001 
 II 27 (18.8) 6 (10.7)   
 III 40 (27.8) 2 (3.6)   
 IV 2 (1.4) 0 (0.0)   
WHO clinical staging  I 75 (52.1) 48 (85.7) 1  
 II 27 (18.8) 6 (10.7) 2.9 (1.1 – 7.5) 0.025 
 III/iv 42 (29.2) 2 (3.6) 13.4 (3.1 – 58.1) 0.001 
Previous TB Yes 9 (6.2) 0 (0.0)  0.171 
 No 129 (88.4) 53 (94.6)   
 Don’t know 8 (5.5) 3 (5.4)   
Systolic BP (mmHg) Mean (SD) 109.0 (15.3) 115.0 (15.7) -5.9 (-10.9 – -1.0)* 0.019 
Diastolic BP (mmHg) Diastolic  70.2 (10.4) 75.0 (10.0) -4.8 (-8.2 – -1.5)* 0.005 
BMI (kg/m2)  Mean (SD)  21.8 (3.6)  23.3 (4.1) -1.5 (-2.8 – -0.2)* 0.021 
BMI Range (kg/m2)  < 18.0  14 (10.7) 1 (2.2) 4.9 (0.6 – 38.7) 0.131 
 18.0 – 24.9  97 (74.0) 34 (73.9) 1  
 25.0 – 29.9 13 (9.9) 7 (15.2) 0.7 (0.2 – 1.8) 0.399 
 ≥ 30.0  7 (5.3) 4 (8.7) 0.6 (0.2 – 2.2) 0.457 
Waist-to-Hip ratio  Mean (SD) 0.90 (0.054) 0.89 (0.047) 0.01 (-0.01 – 0.03)* 0.315 
CD4 count (cells/mm3) Median (IQR)  193 (89 – 363) 207 (142 – 277) -11.0 (-59.0 – 45.0)* 0.677 
CD4 cell count range  < 100  41 (28.3) 9 (16.1) 1  
 100–199  34 (23.4) 18 (32.1) 0.4 (0.2 – 1.0) 0.061 
 200 - 350  30 (20.7) 19 (33.9) 0.3 (0.1 – 0.9) 0.024 
 > 350  40 (27.6) 10 (17.9) 0.9 (0.3 – 2.4) 0.799 
Haemoglobin (g/dl) Mean (SD) 9.4 (1.8) 10.3 (1.9) -0.9 (-1.6 – -0.3)* 0.005 
White Blood Cell X 109/L  Median (IQR) 5.0 (4.1 – 6.7) 4.1 (3.8 – 4.9) 0.9 (0.3 – 1.5)† 0.001 
Platelets X 109/L Median (IQR)  235 (182 – 296) 210 (167 – 259) 25.0 (-3.0 – 51.0)† 0.080 
Hepatitis B Virus  Negative 97 (64.6) 39 (69.6) 1  
 Positive 16 (11.0) 5 (8.9) 1.3 (0.4 – 3.8) 0.645 
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 Unknown 33 (22.6) 12 (21.4) 1.1 (0.5 – 2.4) 0.795 
Smear microscopy††  Negative 137 (94.5) 54 (96.4) 0.6 (0.1 – 3.1) 0.569 
 Positive 8 (5.5) 2 (3.6) 1  
Sputum Culture (n = 195)** Negative 127 (87.6) 53 (94.6) 1  
 NTM 7 (4.8) 2 (3.6) 1.5 (0.3 – 7.3) 0.642 
 MTB 5 (3.4) 1 (1.8) 2.1 (0.2 – 18.3) 0.498 
Smear or Culture positive Yes 10 (6.9) 3 (5.4) 1.3 (0.3 – 4.9) 0.691 
 No 135 (93.1) 53 (94.6)   
 *Mean difference (95% CI).     †Median difference (IQR). **Five cases with contaminated culture and one case with culture not done, were excluded.                              
WBC = White blood cell. ††A patient without sputum smear microscopy result was excluded. 
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Table 2.8. Multivariable analysis of the clinical characteristics and medical history of participants, stratified by WHO symptom 
screening outcome 
Characteristics Category  WHO symptom screening OR (95% CI)  P 
value 
AOR (95% CI) P value 
Positive 
N = 146 (%)  
Negative 
N = 56 (%)  
Functional Status  Working 112 (77.8) 56 (100.0) Undefined 0.001 Undefined 0.001 
 Ambulatory 32 (22.2) 0 (0.0) 1  1  
WHO clinical staging  I 75 (52.1) 48 (85.7) 1  1  
 II 27 (18.8) 6 (10.7) 2.9 (1.1 – 7.5) 0.025 2.8 (1.1 – 7.2) 0.033 
 III/IV 42 (29.2) 2 (3.6) 13.4 (3.1 – 58.1) 0.001 14.1 (3.2 – 62.4) 0.001 
Systolic BP (mmHg) Mean (SD) 109.0 (15.3) 115.0 (15.7) -5.9 (-10.9 – -1.0)* 0.019 0.97 (0.94 – 0.99) 0.002 
Diastolic BP (mmHg) Diastolic  70.2 (10.4) 75.0 (10.0) -4.8 (-8.2 – -1.5)* 0.005 0.93 (0.90 – 0.97) 0.001 
BMI (kg/m2)  Mean (SD)  21.8 (3.6)  23.3 (4.1) -1.5 (-2.8 – -0.2)* 0.021 0.88 (0.81 – 0.96) 0.003 
BMI Range (kg/m2)  < 18.0  14 (10.7) 1 (2.2) 4.9 (0.6 – 38.7) 0.131 4.7 (0.6 – 35.8) 0.136 
 18.0 – 24.9  97 (74.0) 34 (73.9) 1  1  
 25.0 – 29.9 13 (9.9) 7 (15.2) 0.7 (0.2 – 1.8) 0.399 0.6 (0.2 – 1.6) 0.275 
 ≥ 30.0  7 (5.3) 4 (8.7) 0.6 (0.2 – 2.2) 0.457 0.5 (0.1 – 1.6) 0.242 
CD4 cell count range  < 100  41 (28.3) 9 (16.1) 1  1  
 100–199  34 (23.4) 18 (32.1) 0.4 (0.2 – 1.0) 0.061 0.5 (0.2 – 1.2) 0.108 
 200 - 350  30 (20.7) 19 (33.9) 0.3 (0.1 – 0.9) 0.024 0.4 (0.1 – 1.0) 0.051 
 > 350  40 (27.6) 10 (17.9) 0.9 (0.3 – 2.4) 0.799 1.1 (0.4 – 3.2) 0.855 
Haemoglobin (g/dl) Mean (SD) 9.4 (1.8) 10.3 (1.9) -0.9 (-1.6 – -0.3)* 0.005 0.7 (0.6 – 0.9) 0.005 
White Blood Cell X 109/L  Median (IQR) 5.0 (4.1 – 6.7) 4.1 (3.8 – 4.9) 0.9 (0.3 – 1.5)† 0.001 1.5 (1.2 – 2.0) 0.003 
Platelets X 109/L Median (IQR)  235 (182 – 296) 210 (167 – 259) 25.0 (-3.0 – 51.0)† 0.080 1.0 (0.99 – 1.0) 0.125 
 *Mean difference (95% CI).     †Median difference (IQR). **Five cases with contaminated culture and one case with culture not done, were excluded.                              
WBC = White blood cell. ††A patient without sputum smear microscopy result was excluded. 
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2.4.4 Performance of the WHO TB symptom screening algorithm 
Table 2.9 shows the performance of the WHO screening algorithm, using culture as the 
reference standard. One hundred and thirty-nine (71.3%) of 195 patients with culture results 
had positive symptoms and 56 had no symptoms. Six patients had positive culture and 13 
positive culture or smear microscopy. Among the 139 symptomatic participants, 5 (3.6%) had 
positive MTB culture, 8 (5.8%) had positive smear-microscopy and 10 (7.2%) positive 
culture or smear-microscopy. Among the 56 asymptomatic participants, 1 (1.8%) had positive 
culture, 2 (3.6%) had positive smear-microscopy and 3 (5.4%) positive culture or smear-
microscopy (p = 0.675), as shown in table 2.9 
Table 2.9. Performance of the WHO TB symptom screening algorithm 
WHO symptom 
screening 
Sputum culture Total 
Positive Negative 
Positive 5 (3.6%) 134 (96.4%) 139  
Negative 1 (1.8%) 55 (98.2%) 56  
   P = 0.675 
 Culture/smear microscopy  
 Positive Negative  
Positive 10 (6.9%) 135 (93.1%) 145  
Negative 3 (5.4%) 53 (94.6%) 56  
   P = 0.691 
 
 Taking culture as the reference standard, the sensitivity and specificity of the symptom 
screening score to identify patients with and without TB were 83.3% (95% CI = 35.9 - 99.6) 
and 29.1% (95% CI = 22.7 - 36.1), respectively.  These resulted in a PPV and NPV of 3.6% 
(95% CI = 1.2 - 8.2) and 98.2% (95% CI = 90.5 – 100), respectively. The sensitivity and 
specificity were 100% (95% CI = 100- 100) and 26.3% (95% CI= 16.9 – 37.7) for males and 
75% (95% CI = 19.4 – 99.4) and 31.0% (95% CI = 22.6 – 40.4) for females (p = 0.608) with 
PPV and NPV of 3.4% (95% CI = 0.4- 11.9) and 100% (95% CI = 100 – 100) for males and 
2.8% (95% CI = 0.1- 14.5) and 96.3% (95% CI = 89.6 – 99.2) for females (p vales = 0.7), 
(see table 2.10) 
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Using bacteriologically confirmed TB as positive culture or smear-microscopy, the sensitivity 
and specificity of the symptom screening score was 76.9% (95% CI = 46.2 – 95.0) and 28.2% 
(95% CI = 21.9 – 35.2), resulting in a PPV and NPV of 6.9% (95%CI = 3.4 – 12.3) and 
94.6% (95% CI = 85.1 – 98.9), respectively. The sensitivity and  specificity were 71.4% 
(95% CI = 29.0 – 96.3) and  24.7% (95% CI = 15.3 – 36.1) for males and 83.3% (95% CI = 
35.9 – 99.6) and 30.4% (95% CI = 22.2 – 39.7) for females (p = 0.626 and 0.716), with a 
PPV and NPV of 8.3% (95% CI = 2.8 – 18.4) and 90.0% (95% CI = 68.3 – 98.8) for males 
and 5.9% (95% CI = 1.9 – 13.2) and 97.2% (95% CI = 85.5 – 99.9) for females (see table 
2.11). 
36 
 
Table 2.10. Performance of WHO symptom screening algorithm using sputum culture as the reference standard 
Category 
 
N WHO symptom 
screening, n (%) 
Culture + 
(%) 
Sensitivity 
(95%CI) 
Specificity  
(95%CI) 
PPV  
(95%CI) 
NPV  
(95%CI) 
  Positive Negative      
All  195* 139 (71.3) 56 (28.7) 6 (3.1) 83.3 (35.9– 99.6) 29.1 (22.7 – 36.1) 3.6 (1.2 – 8.2) 98.2 (90.5 – 100.0) 
Male  78 58 (74.4) 20 (25.6) 2 (2.6) 100 (100 – 100) 26.3 (16.9 – 37.7) 3.4 (0.4 – 11.9) 100 (100 – 100) 
Female  117 81 (69.2) 36 (30.8) 4 (3.4) 75.0 (19.4 – 99.4) 31.0 (22.6 – 40.4) 2.8 (0.1 – 14.5) 96.3 (89.6 – 99.2) 
*Six cases with contaminated culture and one case with missing culture were excluded 
 
Table 2.11. Performance of WHO symptom screening algorithm using bacteriologically confirmed TB diagnosis (smear or culture-
positive) as the reference standard 
Category 
 
N WHO symptom 
screening, n (%) 
Bact + 
(%) 
Sensitivity 
(95%CI) 
Specificity  
(95%CI) 
PPV  
(95%CI) 
NPV  
(95%CI) 
  Positive Negative      
All  201* 145 (72.1) 56 (27.9) 13 (6.5) 76.9 (46.2 – 95.0) 28.2 (21.9 – 35.2) 6.9 (3.4 – 12.3) 94.6 (85.1 – 98.9) 
Male  80 60 (75.0) 20 (25.0) 7 (8.8) 71.4 (29.0 -96.3) 24.7 (15.3 – 36.1) 8.3 (2.8 – 18.3) 90.0 (68.3 – 98.8) 
Female  121 85 (70.2) 36 (29.8) 6 (5.0) 83.3 (35.9 – 99.6) 30.4 (22.2 – 39.7) 5.9 (1.9 – 13.2) 97.2 (85.5 – 99.9) 
*A patient without sputum smear microscopy result was excluded. Bact+ = culture or smear positive.
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2.5 DISCUSSION 
2.5.1 Summary of study findings 
This is the first study from Nigeria evaluating the performance of the WHO TB symptom 
screening algorithm among PLHIV. The study evaluated the algorithm by collecting sputum 
samples from all newly diagnosed PLHIV, irrespective of TB symptoms, and screened them 
for TB using sputum smear microscopy and culture to determine the sensitivity, specificity, 
PPV and NPVs using culture then culture plus smear microscopy as the reference standards. 
Seventy two percent of participants had at least one TB symptom. Factors independently 
associated with the presence of symptoms were a higher HIV/AIDS clinical staging, higher 
white blood cell counts and lower systolic and diastolic blood pressure, BMI and 
haemoglobin concentration.  Only 3% of participants had culture-confirmed TB, and 6.5% 
were culture or smear-positive. Using culture, the algorithm had a sensitivity of 83.3%, 
specificity of 29.1%, with PPV and NPV of 3.6% and 98.2%. The sensitivity, specificity, 
PPV and NPV for males were 100%, 26.3%, 3.4% and 100% and 75%, 31%, 2.8% and 
96.3% for females, respectively. Using culture plus smear microscopy, the algorithm had 
sensitivity of 76.9%, specificity of 28.2% and PPV and NPV of 6.9% and 94.6%. For males 
the sensitivity was 71.4%, specificity 24.7%, PPV and NPV of 8.3% and 90%, while females 
had 83.3% sensitivity, 30.4% specificity and PPV and NPV of 5.9% and 97.2%. 
2.5.2 TB symptom screening 
The finding that most participants had TB symptoms is consistent with studies from South 
Africa (70.1% to 88%) 85,87,89, Ethiopia (80%) 82, Nepal (77.3%) 92, Botswana, Malawi and 
Zimbabwe (80.2%) 88 . A further South African study screening newly diagnosed HIV 
patients admitted to medical wards reported 91% of patients had symptoms 86. Some studies 
have reported lower prevalence of symptoms among HIV patients not on ART from South 
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Africa (23.7%) 83 and Kenya (53.2%) 90. In Thailand and Vietnam, studies reported  that 
48.3% of patients had TB symptoms 93. In South Africa, 6.6% of participants pre-ART 83 and 
44.6% 85 on ART had TB symptoms. Two studies  using the algorithm in pregnant HIV-
positive patients in South Africa 84 and Kenya 90 and reported that 16% and 26% of the 
participants had symptoms. 
The variation in the proportion of patients with symptoms is likely due to timing when 
patients present to the services. If patients mostly come when are acutely ill or had been 
admitted, it is likely hospital-based studies would enrol patients in advanced stages of HIV, 
when OIs can present with the same symptoms. In contrast, studies with a lower proportion 
of symptoms may be due to the effect of ART reducing the risk TB and OIs 94-96 89.  
2.5.3 Prevalence of TB among the study population 
Only 3% of patients had culture-confirmed TB, which is lower than reported in previous 
studies, except in one study conducted among HIV-positive pregnant women in South Africa 
84. Four cross-sectional studies screening newly diagnosed/pre-ART HIV-positive patients in 
South Africa reported that 6.4% to 17.3% had TB 83,85,87,89. In Ethiopia 82 and Kenya 90, 
16.9% and 11.2% of participants were culture positive and in Botswana, Malawi, and 
Zimbabwe 12% had TB 88.  A systematic review and meta-analysis of studies up to 2011 
found the pooled prevalence of TB to be 8.5% 79.  
The possible reasons for the lower proportion of culture-confirmed cases in this study are that 
solid culture has a lower sensitivity 88. Another possibility is the higher TB prevalence in 
Southern Africa. Thirdly, our sample size is smaller than previous studies, and this resulted in 
a low power and wide confidence intervals.  
Some patients were smear-positive, but culture negative and the diagnostic yield increased to 
6.5%. It is thus highly likely that some cultures may have been false negative.  This could be 
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due to the need to transport sputum, the ZRL moving to new premises at the same time the 
study took place, and the need to keep sputum in the hospital over weekends.  These issues 
may have compromised the integrity of the sputum, resulting in false negative samples.  
2.5.4 Performance of the algorithm 
Using culture, the sensitivity and NPV of the screening algorithm were 83.3% and 98.2%, 
respectively. This is similar to the 78.9% sensitivity and 97.7% NPV reported in the initial 
WHO systematic review and meta-analysis 79. The good performance of the symptom 
screening among our patients may be because our population is similar to the populations 
included in the meta-analysis 79. Findings from studies evaluating the performance of the 
algorithm have been inconsistent within and across different populations. Of the five South 
African studies among ART-naïve patients 83,85,87-89, three found that symptom screening 
performed well 85,88,89, but two showed it performed sub-optimally 83,87. In one of the latter 
studies, 52.4% of culture-confirmed TB cases among ART-naïve patients did not have TB 
symptoms 83.  
The study’s findings have several implications. The algorithm’s main target is patients who 
are yet to start ART.  As 72.3% had symptoms and would need further TB diagnostic 
workups, this may lead to a large laboratory workload in most high TB and HIV burden 
settings.  There is therefore a need for more specific screening methods to reduce the false 
positive rate among the population. 
Second, the heterogeneity of the algorithm’s performance, means that its applicability may 
not be extended across all populations of HIV patients. Its performance is better among 
patients who have not started ART and have not been screened for TB symptoms.  However, 
its low specificity, makes a large proportion of patients undergo further TB diagnosis, 
delaying the initiation of IPT. However, as Xpert MTB/RIF is now the recommended primary 
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screening test, the delay may be reduced and its performance in this population should be 
evaluated. Alternatively, screening methods that are more sensitive, simple and cheap, will be 
needed to overcome the challenge posed by the large number of patients for further 
diagnostic workup. 
When bacteriologically confirmed TB was used as the reference standard, the specificity of 
the screening algorithm dropped from 83.3% to 76.9%. Its NPV also decreased from 98.2% 
to 94.6%. This means that using this classification could potentially increase the proportion 
of false negatives and false positives, as LED smear microscopy has a lower specificity than 
culture and patients may have other Non-MTB mycobacteria. 
2.5.5 Limitations and strength of the study 
There are many limitations in this study. Firstly, the use of solid culture, which has lower 
sensitivity than liquid culture, may have missed cases. Though, liquid culture could have 
higher contamination rate 97-99. Secondly, because of small number of cultured-confirmed TB 
cases, we could not determine factors associated with misclassifications. Thirdly, because the 
research laboratory was far from the hospital, some samples were not processed within 48 
hours of collection, which might have affected the integrity of the specimens. This could be a 
reason for the high proportion of smear-positive but culture-negative TB cases found in this 
study. Lastly, we only diagnosed PTB, since non-sputum samples were not collected. Hence, 
we might have underestimated the TB burden among the studied population, since HIV-
positive patients are more likely to have EPTB than the general population. 
Nevertheless, this study has some strengths. This is the first study from West Africa, which 
evaluates the algorithm. In addition, the laboratory staff were blinded to the participants’ 
symptom screening outcome and clinical parameters. Culture positive samples were 
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differentiated from MTBC and NTM (using SD Bioline TB Ag MPT64 rapid test), and 9 
cases of NTM were isolated. 
2.5.6 Conclusion 
More than 70% of participants in this study had at least one TB symptom, using the screening 
algorithm, and therefore, most patients had to be tested for TB. However, only 3% and 6.5% 
of the participants had culture or bacteriologically-confirmed TB. The algorithm had 
sensitivity of 83.3% and NPV of 98.2%.  The low specificity of the algorithm requires the 
majority of patients to undergo further TB diagnostic workup, reducing its benefits to the 
patient and the health system. 
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Chapter 3 
C-reactive protein (CRP) and Interferon-gamma inducible protein 10 (IP-10) as 
screening tools for TB 
3.1 Introduction 
This chapter presents a prospective study that assessed the performance of two non-sputum-
based biomarkers (CRP and IP-10) as potential screening tools for TB. Most of the current 
TB diagnostics are sputum-based.  However, due to the unusual clinical presentation of TB 
among HIV patients, these diagnostics may miss many TB cases and new approaches are 
needed to improve TB case detection among HIV-infected and uninfected patients.   
We recruited consecutive patients with TB symptoms, collected blood to measure the acute 
marker and tested sputum samples with Xpert MTB/RIF and culture to determine the serum 
levels of the biomarkers and the ideal cut-offs for ruling in/out TB.   
3.2 Literature review 
3.2.1 Background 
The need for simple and inexpensive TB screening tools in high burden settings has 
stimulated research efforts towards immunodiagnosis, by looking for biomarkers that may be 
potential candidates to identify or rule out TB. Biological markers measured in blood or body 
fluids that accurately detect someone with or without TB, would greatly overcome the 
difficulty associated with TB diagnosis among HIV patients and be good for diagnosing 
EPTB or culture-negative TB 67.  
Several biomarkers have been assessed as possible TB diagnostics or screening tools 100,101 
and two,  C-reactive protein (CRP) 102 and Interferon-gamma inducible protein 10 (IP-10) 
have potential as screening tests. 
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Most studies of these markers have focused on their performance for TB diagnosis and 
treatment monitoring 67. We therefore reviewed the literature to describe their sensitivity and 
specificity within the context of TB diagnosis, with a view to prospectively evaluating their 
potential when used alone or in combination for screening purposes.  This is a critical issue, 
because researchers reporting their performance for diagnosis would have selected a cut of 
point that is close to the upper left corner of a receiver operating curve (ROC).  If we 
repositioned these markers for screening purposes, and positive tests were followed by 
confirmatory tests, it would be possible to select a marker with a higher sensitivity and lower 
specificity. 
3.2.2 Performance of serum C-reactive protein for TB diagnosis  
CRP is a non-specific acute phase protein that is a marker of inflammatory stages.  Its level is 
higher in individuals with active TB than in latent TB infections (LTBI) or healthy controls. 
CRP could be used as a Point of Care (POC) screening tool with results available within 5 
minutes 102,103. Seven studies (3 from South Africa 104-106,  two from South Korea 107,108, one 
from China 109, and one multi-country study in Brazil, Haiti, India, Malawi, Peru, South 
Africa, Thailand, United States and Zimbabwe 110 compared serum CRP levels between 
patients with TB, other respiratory diseases or healthy controls (table 3.1). Two studies in 
Africa, were conducted among HIV infected patients with symptoms of TB.  104,105 and one in 
HIV-negative and -positive participants 106.  
A CRP cut-off of 8mg/L was a good marker to exclude patients without TB (NPV of 96%) 104 
and a rapid CRP quantification method (NycoCard CRP test, Axis-Shield; Oslo, Norway) had 
similar sensitivity, specificity, PPV/NPV of 95%, 51%, 63% and 93% correspondingly 104. A 
second study on PLHIV screened participants before ART initiation 105 and found that 
patients with TB had median CRP concentrations 9 times higher (57.8mg/L) than patients 
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without TB (6.4mg/L). A cut off < 1.5mg/L would rule out TB in all individuals without TB 
(NPV = 100%), while a cut off > 400mg/l would identify all participants with TB (PPV = 
100%). However, only 14.3% and 2.0% of the patients screened were included by these two 
cut-off points and only 12.3% of TB cases would have been included 105. The best performing 
cut-off in the study was a CRP < 5mg/L, which had sensitivity, specificity, PPV and NPV of 
90%, 44%, 24% and 96% respectively 105.  
The study from South Africa recruiting both HIV-negative and -positive patients, reported 
that a CRP ≤ 5mg/L had good value to rule out TB with sensitivity, specificity, PPV and 
NPV of 98%, 59%, 74% and 96%, respectively 106.   
Two studies in South Korea  among HIV-negative military personnel 107 and among 
participants with unknown HIV status 108 aimed to differentiate TB from non-TB respiratory 
disease (pneumonia) 107,108.  One study used several cut-off points (< 2.5, < 5.0, < 11.2 and < 
15.0 mg/dl) and found that CRP concentrations < 11.2mg/dl had the best performing cut-off 
with sensitivity, specificity, PPV and NPV of 97%, 41%, 44% and 96%, respectively 107. The 
second study aimed to exclude TB and a cut off < 12.5mg/dl had sensitivity, specificity, PPV 
and NPV of 90%, 59%, 54% and 92%, respectively 108.  
In China however, serum CRP was higher in subjects with community-acquired pneumonia 
than in patients with TB, although the difference was not statistically significant 109. A cut-off 
< 15mg/L distinguished patients with TB and those without TB, with a sensitivity and 
specificity of 82% and 60%, respectively 109. Lastly, the multi-country study of PLHIV at the 
start of ART 110 reported that patients with TB were 2 – 3 times more likely to have serum 
CRP in the highest quartile. However, using a cut-off ≤ 12 mg/dl performed poorly 
(sensitivity, specificity, PPV and NPV of 44%, 81%, 41% and 83% respectively) to rule out 
TB 110. Therefore, most (5/7) studies assessing the performance of serum CRP found that the 
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marker may be a promising tool to rule out TB. However, its performance was poor/sub-
optimal in two studies 109,110. 
3.2.3 Performance of IP-10 as screening tool for TB 
IP-10 is also a non-specific biomarker and is secreted by monocytes, neutrophils, endothelial 
cells, and fibroblasts in response to inflammation 111. Its biological functions include 
chemotaxis induction, cell growth inhibition, apoptosis, and mobilization of inflammatory 
cells such as activated T cells, macrophages, and Natural Killer cells to the sites of 
inflammation 112. Alterations in IP-10 serum concentrations are high in viral, bacterial, 
autoimmune, vascular, and neurological diseases. 
Although, IP-10 is non-specific, studies have shown that it could be a promising biomarker 
for diagnosing or excluding TB 113-115, as IP-10-positive cells are present in bronchoalveolar 
lavage 116 or lymph node aspirates 117. IP-10 responses have been described in two forms: (a) 
naturally released in response to TB or LTBI and measured unstimulated in blood or (b) 
stimulated using TB-specific antigens. High levels of the two forms have been found in urine 
and blood of patients with TB 118,119. Stimulated IP-10 requires cell incubation 120 and the 
process is not feasible for POC assays to rapidly rule out TB in high burden countries. 
Although stimulated responses are more likely to have higher specificity, this review focuses 
on the value of unstimulated IP-10. 
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Table 3.1. Characteristics of the CRP and IP-10 studies reviewed 
Author, 
year 
Country HIV  Study 
subjects 
Method used for  
TB diagnosis 
Controls Method for 
analysis  
CRP       
Choi,  
2007 107 
South 
Korea 
Neg 46 TB  
67 non-
TB. 
Culture or SM  Non-TB patients: sick adults who were initially suspected 
of PTB, but who ended up had other disease. 
Turbidimetry 
Kang,  
2009 108 
South 
Korea 
NK 30 TB 
57 non-
TB. 
Culture or SM 
Symptoms, X-ray 
Non-TB patients: sick adults who were initially suspected 
of PTB, but who ended up had other disease. 
Immuno-
turbidimetry 
Wilson,  
2011 106 
South 
Africa 
Neg/Pos 135 TB  
115 non-
TB 
Culture or SM 
Symptoms, X-ray 
tissue biopsy 
Non-TB patients: adults who were initially suspected of 
active TB, but who ended up had other disease. 
Turbidimetry/ 
spectrophotometry 
Lawn,  
2013 103 
South 
Africa 
Pos 81 TB  
415 non-
TB. 
Culture or SM Non-TB patients: HIV Positive patients without TB. ELISA 
Niu,  
2013 109 
China Neg 78 TB  
113 non-
TB 
Culture or SM 
Symptoms, X-ray 
Non-TB patients: sick adults who were initially suspected 
of PTB, but who ended up had other disease. 
immune scatter 
turbidimetry 
Drain,  
2014 104 
South 
Africa 
Pos 45 TB  
47 non-
TB 
SM  
Culture 
Non-TB patients: sick adults who were initially suspected 
of PTB, but who ended up not having TB. 
Immunometric 
semi-quantitative 
assay/ 
spectrophotometry 
Tenforde,  
2015 110 
9 
countries* 
Pos 77 TB 
255 non-
TB 
Expert panel  
culture Broncho 
alveolar lavage  
or lung tissue. 
Non-TB patients: HIV Pos patients without TB. ELISA 
IP-10       
Hong,  
2012 121 
South 
Korea 
Neg 46 TB 
22 LTBI 
32 healthy 
Culture or SM LTBI patients: household contacts with a TST Pos who 
had lived with a confirmed TB. 
ELISA 
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Health controls: heathy adults with a Neg TST who had 
not lived with a confirmed TB. 
Shiratori,  
2014 122  
Philippines Neg 37 TB  
30 
healthy. 
Culture or SM 
Symptoms, X-ray 
Health controls: healthy volunteers with unknown history 
for other diseases 
Luminex xMap 
Yang,  
2014 120 
China NK 123 TB 
91 non-
TB 
33 LTBI  
36 healthy 
Culture or SM 
Symptoms, X-ray 
histology 
Non-TB patients: sick adults who were initially suspected 
of active TB, but who ended up had but other disease.  
LTBI patients: household contacts with a TST Pos who 
had lived with a confirmed TB. 
Health controls: healthy adults 
ELISA 
Tenforde,  
2015 110 
9 
countries* 
Pos 77 TB  
255 non-
TB 
Expert panel  
culture Broncho 
alveolar lavage or 
lung tissue. 
Non-TB patients: HIV Pos patients without TB ELISA 
Petrone,  
2015 123 
Uganda Neg/Pos 32 TB  
79 non-
TB  
Culture or SM 
Symptoms, X-ray 
tissue  
Non-TB patients: sick individuals who were initially 
suspected of PTB, but who ended up had other disease. 
ELISA 
 
* Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, United States and Zimbabwe. 
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Table 3.2. Performance of C-reactive protein and IP-10 as screening tools for TB. All 
studies were case control studies. 
 
Author, Year Cut-off point Sensitivity  Specificity           PPV NPPV 
CRP      
Choi, 2007 107 11.2mg/dl 97% 41% 44% 96% 
Kang, 2009 108 15mg/dl 100% 50% 52% 100% 
Wilson, 2011 106 5mg/L 98% 59% 74% 96% 
Lawn, 2013 103 5mg/L 90% 44% 24% 96% 
Niu, 2013 109 15mg/l 82% 60% 59% 83% 
Drain, 2014 104 8mg/L 97% 54% 74%  96% 
8mg/L 95% 51% 63% 92% 
Tenforde, 2015* 110 12mg/dl 44% 81% 41% 83% 
IP-10      
Hong, 2012 121 119.5pg/ml 88% 91% 89% 89% 
Shiratori, 2014 122 348pg/ml 95% 93% 95% 93% 
Yang, 2014 120 1008pg/ml 88% 92% 97% 67% 
Petrone, 2015 123 209.1pg/Ml 79% 94% 93% 82% 
209.1pg/Ml 79% 53% 34% 89% 
209.1pg/Ml 100% 17% 46% 100% 
Tenforde, 2015* 110 2922.43pg/ml 51% 71% 34% 83% 
      
* Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, United States and Zimbabwe 
 
Five studies (China 120, Philippines 122, South Korea 121, Uganda 123, and the same multi-
country study described for CRP 110) assessed the performance of unstimulated IP-10 as a 
screening tool for TB.  All compared IP-10 serum levels between individuals with and 
without TB (table 3.1). In China, an IP-10 cut-off < 1008pg/ml had sensitivity and specificity 
of 88% and 92% to differentiate TB and LTBI 120. In South Korea, patients with TB (HIV 
status not stated) had higher IP-10 concentration (174.9pg/ml) than patients with LTBI 
(102.7pg/ml) and those without infection (71.1pg/ml) 121. A cut-off of 119.5pg/ml had 
sensitivity of 88% and specificity of 91% for differentiating between TB and LTBI 121.  
In the Philippines 122, HIV-negative individuals with TB had a higher mean 1P-10 level 
(1290pg/ml) than healthy controls (242.6pg/ml). A cut-off of 342pg/ml had sensitivity and 
specificity of 95% and 93%, respectively 122.  
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In Uganda, IP-10 did not distinguish children with TB and non-TB respiratory disease 124. 
HIV-negative and HIV-positive children with TB were compared to healthy adult donors. A 
cut-off of 209.1pg/ml had sensitivity, specificity, PPV and NPV of 79%, 93%, 94% and 
81.6% respectively. Comparing HIV-negative children with TB and those with non-TB 
respiratory disease, had; sensitivity, specificity, PPV and NPV of 79%, 53%, 34% and 89% 
respectively. Comparing HIV-positive children with TB and children with non-TB 
respiratory diseases, had; sensitivity, specificity, PPV and NPV of 100%, 17%, 46% and 
100% respectively.   
The multi-country study recruited HIV-positive patients free of TB at the time they started 
ART and were followed to see if serum IP-10 predicted incident TB. A cut-off < 
2922.43pg/dl had a sensitivity, specificity, PPV and NPV of 51%, 71%, 34% and 83% 
respectively 110. However, there was no information on wether patients were receiving IPT or 
not. Higher baseline levels of IP-10 were associated with increased risk of incident TB, but 
the biomarker performed poorly in ruling out incident TB.  
Although, different cut-off points were used throughout the studies, IP-10 levels had sub-
optimal performance irrespective of HIV status.  
In summary, CRP performed better than unstimulated IP-10 in ruling out TB or 
discriminating between TB and LTBI or other respiratory disease, though, different cut-off 
points were used across studies. 
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3.3 Methodology 
3.3.1 Study design 
This prospective study was conducted on patients with TB symptoms presenting at Asokoro 
General Hospital (AGH) and Nyanyan General Hospital (NGH), both in Abuja, Nigeria, 
between 17th August 2017 and 8th January 2018. 
3.3.2 Description of study area/site 
Abuja, the Federal Capital Territory (FCT) of Nigeria, is located in the North-central 
geopolitical zone of the country and is a rapidly growing city, with a population of about 3.6 
million (3,564,100). The FCT has three tertiary, 14 secondary and 179 public health facilities, 
and 673 registered private health facilities across six area councils. HIV prevalence and 
TB/HIV-coinfection rate in the FCT are 7.5% and 32.3%, respectively.  
This study was conducted at the DOTS clinics of the hospitals. AGH is a 160-bedded hospital 
and serves about 250,000 – 500,000 residents of Abuja. The hospital provides services in all 
major specialities, and comprehensive TB and HIV care.  NGH is a 68-bedded hospital and 
serves people of lower socioeconomic status than AGH.  
All patients attending the hospitals, report to the General Outpatients Department (GOP), 
where each of them will be seen by a Medical Officer, who will take the clinical history.  
Patients with symptom suggestive of TB are then referred to the DOTS clinic, for TB 
screening. At the DOTS clinic, patients receive investigation forms for smear microscopy or 
Xpert MTB/RIF and chest X-rays. Thereafter, patients go to the laboratory for investigations 
and collect the investigations’ results at the DOTS clinic. Patients with positive TB test are 
registered for treatment and counselled. The staff of DOTS clinic ask about contacts and 
arrange for contact tracing. 
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Patients with drug susceptible TB receive a six-month-regimen, comprising a two-month 
intensive phase and a continuation phase of four months. The intensive phase consists of 
fixed dose combination (FDC) of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol. The 
continuation phase contains FDC of Rifampicin and Isoniazid. Patients with drug-resistant 
TB are referred for DST and to the drug-resistant TB treatment centres.  
3.3.3 Patients’ recruitment and data collection  
Every consecutive patient with TB symptoms referred to the DOTS clinics was approached to 
participate in the study. After full informed consent, patients that agreed to participate were 
recruited by a trained community extension worker (CHEW), using a structured questionnaire 
(Appendix 6, section 8.6.2). Two sputum samples were collected from each participant to 
conduct culture and Xpert MTB/RIF. A rapid CRP test was conducted at the DOTS clinic, 
using the Actim CRP (Medix Biomedica). This is a semiquantitative 
immunochromatographic dipstick test, that is visually interpreted, and its result can be read 
within five minutes. The test was carried out by trained CHEWS, on whole blood collected 
from fingertips, and interpreted according to its manufacturer’s instructions. 
A 5ml blood sample was collected for serum IP-10 and CRP immunoassays. Specimens’ 
were transported in a cold chain on a daily basis to Zankli Research Laboratory by a 
dedicated driver. 
3.3.4 Inclusion criteria  
(1) Age ≥ 18 years 
(2) Cough of ≥ 2 weeks 
(3) Consented to participate 
(4) Agreed to provide the needed specimens’ samples (blood and sputum) 
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3.3.5 Exclusion criteria 
(1) Currently on TB treatment 
(2) Already diagnosed of TB but has not commenced TB 
(3) Patients with language barriers and no appropriate interpreter 
(4) Patients willing to participate but could not read/write and no legally assigned 
representative to sign consent form and act as a witness. 
3.3.6 Laboratory analysis of samples 
The first sputum sample was tested with Xpert MTB/RIF. The second sputum sample was 
decontaminated and digested, using sodium hydroxide- N-acetyl-L-cysteine-Citrate solution 
(Mycoprep reagent), for culture using solid culture in LJ medium.  Culture or Xpert-positive 
samples were classified as TB-positive, while those with both negative culture and Xpert 
results were classified as TB-negative.  
The blood sample collected was analysed for serum IP-10 using an ELISA (R&D systems, 
Inc., Minneapolis, MN, USA) that uses a quantitative sandwich enzyme immunoassay.  
 3.3.7 Ethical Considerations 
Ethical approvals were obtained from the Research Ethics Committees of LSTM and the 
Nigeria’s FCT. Written informed consent was obtained from all participants. 
3.3.8 Data analysis 
Data entry was conducted using Epi-Info 7 (CDC) and analysis of the data was performed in 
SPSS (IBM). Descriptive statistics were run to obtain counts, percentages, medians and 
interquartile ranges, as appropriate. Thereafter, crosstabulations and ROC curves were 
prepared to determine sensitivity and specificity of the CRP and IP-10 at various cut-off 
points and to ascertain the best cut-off point for the biomarkers.  
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Figure 3.1 The study flow chart 
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3.4 RESULTS 
3.4.1 Participants characteristics and laboratory investigations  
A total of 408 patients were recruited and had blood samples collected for CRP and IP-10. 
One hundred and ninety-four (47.5%) were male and 214 (52.5%) female. Their median 
(IQR) age was 36 (28.5 – 43.0) years.  
All the patients had cough > 2 weeks, with a median (IQR) cough duration of 4 (2 - 6.5) 
weeks. Other frequent clinical symptoms were fever (271, 66.4%); weight loss (280, 68.6%); 
night sweats (210, 51.5%); chest pain (256, 62.7%); body weakness (233, 57.1%); loss of 
appetite (140, 34.3%) and haemoptysis (56, 13.7%). Almost all the patients (388, 95.1%) had 
HIV testing results and 182 (46.9%) were positive. Sixty (14.7%) participants had been 
previously treated for TB and were being re-investigated (table 3.3). 
Nearly all (396, 97%) participants had sputum culture and 326 (82.3%) were culture-
negative, with 62 (15.7%) being culture-positive and 8 (2%) contaminated. In addition, 407 
(99.8%) patients had valid GeneXpert results. Of these, MTB was not detected in 329 
(80.8%%), 77 (19%) had MTB and 1 (0.2%) an invalid result. Xpert MTB grades were very 
low in 10 (13%); low in 16 (20.8%); medium in 23 (29.9%) and high in 28 (36.3%). 
Rifampicin resistance was detected in 7 (9.1%) patients. TB was confirmed by either culture-
or Xpert in 86 (21.1%) of the participants. 
Rapid CRP test was available for 382 (93.6%) participants. Of these, 107 (28%), 126 (33%), 
38 (9.9%) and 111 (29.1%) had serum CRP levels < 10000 ug/l, 10000 – 39999 ug/l, 40000 – 
80000 ug/l, and > 80000 ug/l respectively. The median (IQR) IP-10 concentration was 148 
(73 – 449) pg/ml (table 3.4). 
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Table 3.3 Characteristics of participants 
Characteristics Category N = 408 
n (%) 
Missing  
Age (Years)  Median (IQR) 36.0 (28.5 – 43.0)  
Gender Male 194 (47.5)  
 Female 214 (52.5)  
Cough No 0 (0)  
 Yes 408 (100)  
Cough duration (weeks) Median (IQR) 4.0 (2.0 – 6.5)  
Nose bleeding No 352 (86.3)  
 Yes 56 (13.7)  
Fever No 137 (33.6)  
 Yes 271 (66.4)  
Weight loss No 128 (31.4)  
 Yes 280 (68.6)  
Night sweats No 198 (48.5)  
 Yes 210 (51.5)  
Chest pain No 152 (37.3)  
 Yes 256 (62.7)  
Body weakness No 175 (42.9)  
 Yes 233 (57.1)  
Loss of appetite No 268 (65.7)  
 Yes 140 (34.3)  
Other illness No 353 (86.5)  
 Yes 55 (13.5)  
HIV status Negative 206 (53.1) 20 
 Positive 182 (46.9)  
Previous TB treatment None 348 (85.3)  
 Previous 58 (14.2)  
 Current 2 (0.5)  
If previously treated, treatment 
class 
Relapse 32 (53.3)  
 Retreatment 2 (3.3)  
 Not known 26 (43.3)  
Months since last treatment Median (IQR) 24.0 (7.0 – 58.0)  
* Number and percentage unless specified, IQR = Interquartile Range,  
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Table 3.4. Laboratory results of participants 
Characteristics Category  N = 408 
n (%) 
Missing  
Culture done Yes 396 (97)  
Culture results Negative 326 (82.3)  
 Positive 62 (15.7)  
 Contaminated 8 (2.0)  
Xpert  Xpert MTB/RIF 400 (98.0)  
 Ultra Xpert 7 (1.7)  
 Not done 1 (0.2)  
Xpert result MTB not detected 329 (80.8)  
 MTB detected 77 (19.0)  
 Invalid 1 (0.2)  
Xpert grading Very low 10 (13.0)  
 Low 16 (20.8)  
 Medium 23 (29.9)  
 High 28 (36.3)  
Xpert RIF resistance Not detected 70 (90.9)  
 Detected 7 (9.1)  
Confirmed TB No 322 (78.9)  
 Yes 86 (21.1)  
CRP rapid test done  382 (93.6)  
CRP rapid test result < 10000 ug/l  107 (28.0) 26 
 10000-40000 ug/l 126 (33.0)  
 40000-80000 ug/l 38 (9.9)  
 > 80000 ug/l  111 (29.1)  
IP 10 result (pg/ml) Median (IQR)  148 (73 – 449) 16 
* Number and percentage unless specified. IQR = Interquartile Range 
 
3.4.2 Performance of CRP and IP-10 as a screening marker for TB 
Three cut-off points of CRP (≥ 10 mg/l, ≥ 40 mg/l and > 80 mg/l) were assessed, using 
sputum culture as the reference standard. CRP ≥ 10 mg/l performed fairly well among the 
study population but had a poorer performance among HIV-positive patients.   
For all participants, a CRP   ≥ 10 mg/l had 94.1% (95% CI = 83.0 – 95.6%) sensitivity with 
33.2% (95% CI = 27.9 – 38.9%) specificity, PPV of 26.9% (95% CI = 21.8 – 32.6%) and 
NPV of 93.5% (95% CI = 87.0 – 97.3%).  
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Among HIV-negative patients, the sensitivity, specificity, PPV and NPV were; 95.3% (95% 
CI = 84.2 – 99.4%), 42.6% (95% CI = 34.7 – 50.8%), 31.5% (95% CI = 23.7 – 40.3%) and 
97.1% (95% CI = 89.8 – 99.6%), respectively.  
Among HIV-positive patients, the sensitivity, specificity, PPV and NPV were; 84.8% (95% 
CI = 68.1 – 94.9%), 22.1% (95% CI = 15.4 – 30.0%), 20.9% (95% CI = 14.4 – 28.8%), and 
85.7% (95% CI = 69.7 – 95.2%), respectively.  
A CRP cut-off ≥ 40 mg/l reduced the sensitivity but increased the specificity among all 
patients. The sensitivity and specificity were > 70% and NPV > 90% for the entire study 
population (sensitivity 72.8% (95% CI = 61.8 – 82.1%), specificity 70.1% (95% CI = 64.6 – 
75.2%), PPV 39.6% (95% CI = 31.7 – 47.9%) and NPV 90.6% (95% CI = 86.1 – 94.0%)). 
Among HIV-negative patients, cut-off ≥ 40 mg/l had a sensitivity of 76.7% (95% CI = 61.4 – 
88.2%), specificity 75.5% (95% CI = 67.9 – 82.0%), PPV 46.5% (95% CI = 34.5 – 58.7%) 
and NPV 92.1% (95% CI = 86.0 – 96.2%). Among HIV-positive patients, the sensitivity was 
66.7% (95% CI = 48.2 – 82.0%), specificity of 64.7% (95% CI = 56.1 – 72.7%), PPV of 
31.4% (95% CI = 20.9 – 43.6%) and NPV of 88.9% (95% CI = 81.0 – 94.3%).  
A cut-off point of CRP > 80mg/l, had lower sensitivity but higher specificity, as expected, as 
shown in table 3.5.  
The performance of IP-10 at six different cut-off points (> 50 pg/ml, > 100 pg/ml, > 150 
pg/ml, > 200 pg/ml, > 250 pg/ml and > 300 pg/ml) is shown in table 3.5.  
For the whole study population, an IP-10 cut-off > 100 pg/ml had sensitivity of 87.3% (95% 
CI = 78.0 – 93.8%), specificity 40.9% (95% CI = 35.4 – 46.6%), PPV 27.2% (95% CI = 21.8 
– 33.1%) and NPV 92.8% (95% CI = 87.1 – 96.5%).  
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The same cut-off point had sensitivity of 87.5% (95% CI = 73.2 – 95.8%), specificity of 
50.3% (95% CI = 42.3 – 58.3%), PPV 30.7% (95% CI = 22.4 – 40.0%) and NPV 94.1% 
(95% CI = 86.8 – 98.1%) among HIV-negative patients.  
HIV-positive patients had sensitivity of 85.3% (95% CI = 68.9 – 95.0%), specificity 32.4% 
(95% CI = 24.8 – 40.8%), PPV 23.2% (95% CI = 16.1 – 31.6%) and NPV of 90.2% (95% CI 
= 78.6 – 96.7%).  
Increasing the IP-10 cut-off to > 150 pg/ml reduced the sensitivity but increased specificity. 
At this cut-off point, the sensitivity, specificity, PPV and NVP for all participants were 79.7% 
(95% CI = 69.2 – 88.0%), 58.1% (95% CI = 52.5 – 63.7%), 32.5% (95% CI = 25.9 – 39.6%) 
and 91.9% (95% CI = 87.2 – 95.3%), respectively.  
For HIV-negative patients, IP-10 > 150 pg/ml had sensitivity of 80% (95% CI = 64.4 – 
90.9%), specificity 69.2% (95% CI = 61.4 – 76.3%), PPV 39.5% (95% CI = 28.8 – 51.0%), 
and NPV 93.2% (95% CI = 87.1 – 97.0%).  
Among HIV-positive patients, the cut-off had sensitivity of 79.4% (95% CI = 62.1 – 91.3%), 
specificity 47.2% (95% CI = 38.8 – 55.7%), PPV of 26.5% (95% CI = 18.2 – 36.1%) and 
NPV of 90.5% (95% CI = 81.5 – 96.1%). As shown in table 3.5, increasing the cut-off point, 
did not improve the performance of the biomarker.  
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       Table 3.5 Performance of each of CRP and IP-10 as a screening tool for active TB 
Population Test Cut-off Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI) 
All CRP rapid > 10 mg/L 91.4 (83.0 – 96.5) 33.2 (27.9 – 38.9) 26.9 (21.8 – 32.6) 93.5 (87.0 – 97.3) 
  > 40 mg/L 72.8 (61.8 – 82.1) 70.1 (64.6 – 75.2) 39.6 (31.7 – 47.9) 90.6 (86.1 – 94.0) 
  > 80 mg/L 61.7 (50.3 – 72.3) 79.7 (74.7 – 84.1) 45.0 (35.6 – 54.8) 88.6 (84.2 – 92.1) 
       
 IP 10 > 50 pg/ml 94.9 (87.5 -  98.6) 17.6 (13.5 – 22.2) 22.5 (18.1 – 27.4) 93.2 (83.5 – 98.1) 
  > 100 pg/ml 87.3 (78.0 – 93.8) 40.9 (35.4 – 46.6) 27.2 (21.8 – 33.1) 92.8 (87.1 – 96.5) 
  > 150 pg/ml 79.7 (69.2 – 88.0) 58.1 (52.5 – 63.7) 32.5 (25.9 – 39.6) 91.9 (87.2 – 95.3) 
  > 200 pg/ml 75.9 (65.0 – 84.9) 65.5 (59.9 – 70.8) 35.7 (28.5 – 43.5) 91.5 (87.1 – 94.8) 
  > 250 pg/ml 69.6 (58.2 – 79.5) 70.6 (65.2 – 75.6) 37.4 (29.6 – 45.8) 90.2 (85.8 – 93.6) 
  > 300 pg/ml 62.0 (50.4 – 72.7) 75.7 (70.6 – 80.4) 39.2 (30.6 – 48.3) 88.8 (84.3 – 92.3) 
       
HIV -ve CRP rapid > 10 mg/L 95.3 (84.2 – 99.4) 42.6 (34.7 – 50.8) 31.5 (23.7 – 40.3) 97.1 (89.8 – 99.6) 
  > 40 mg/L 76.7 (61.4 – 88.2) 75.5 (67.9 – 82.0) 46.5 (34.5 – 58.7) 92.1 (86.0 – 96.2) 
  > 80 mg/L 62.8 (46.7 – 77.0) 81.9 (75.0 – 87.6) 49.1 (35.4 – 62.9) 88.8 (82.5 – 93.5) 
       
 IP 10 > 50 pg/ml 95.0 (83.1 – 99.4) 23.9 (17.5 – 31.3) 23.9 (17.5 – 31.3) 95.0 (83.1 – 99.4) 
  > 100 pg/ml 87.5 (73.2 – 95.8) 50.3 (42.3 – 58.3) 30.7 (22.4 – 40.0) 94.1 (86.8 – 98.1) 
  > 150 pg/ml 80.0 (64.4 – 90.9) 69.2 (61.4 – 76.3) 39.5 (28.8 – 51.0) 93.2 (87.1 – 97.0) 
  > 200 pg/ml 75.0 (58.8 – 87.3) 77.4 (70.1 – 83.6) 45.5 (33.1 – 58.2) 92.5 (86.6 – 96.3) 
  > 250 pg/ml 67.5 (50.9 – 81.4) 81.1 (74.2 – 86.9) 47.4 (34.0 – 61.0) 90.8 (84.9 – 95.0) 
  > 300 pg/ml 57.5 (40.9 – 73.0) 85.5 (79.1 – 90.6) 50.0 (34.9 – 65.1) 88.9 (82.8 – 93.4) 
       
HIV +ve CRP rapid > 10 mg/L 84.8 (68.1 – 94.9) 22.1 (15.4 – 30.0) 20.9 (14.4 – 28.8) 85.7 (69.7 – 95.2) 
  > 40 mg/L 66.7 (48.2 – 82.0) 64.7 (56.1 – 72.7) 31.4 (20.9 – 43.6) 88.9 (81.0 – 94.3) 
  > 80 mg/L 57.6 (39.2 – 74.5) 78.7 (70.8 – 85.2) 39.6 (25.8 – 54.7) 88.4 (81.3 – 93.5) 
       
 IP 10 > 50 pg/ml 94.1 (80.3 – 99.3) 11.3 (6.6 – 17.7) 20.3 (14.3 – 27.4) 88.9 (65.3 – 98.6) 
  > 100 pg/ml 85.3 (68.9 – 95.0) 32.4 (24.8 – 40.8) 23.2 (16.1 – 31.6) 90.2 (78.6 – 96.7) 
  > 150 pg/ml 79.4 (62.1 – 91.3) 47.2 (38.8 – 55.7) 26.5 (18.2 – 36.1) 90.5 (81.5 – 96.1) 
  > 200 pg/ml 76.5 (58.8 – 89.3) 51.4 (42.9 – 59.9) 27.4 (18.7 – 37.5) 90.1 (81.5 – 95.6) 
  > 250 pg/ml 70.6 (52.5 – 84.9) 58.5 (49.9 – 66.7) 28.9 (19.5 – 39.9) 89.2 (81.1 – 94.7) 
  > 300 pg/ml 64.7 (46.5 – 80.3) 64.1 (55.6 – 72.0) 30.1 (19.9 – 42.0) 88.3 (80.5 – 93.8) 
CRP = C-reactive protein, IP-10 = Interferon Gamma-inducible protein 10, PPV = Positive predictive value, NPV = Negative predictive value, 95% CI = 95% 
Confidence Interval, HIV -ve = HIV-negative, HIV +ve = HIV-positive 
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3.4.3 Performance of CRP and IP-10 combined  
Table 3.6 shows the performance of the best combinations of CRP and IP-10.  At a cut-off point 
of CRP ≥ 10 mg/l and an IP-10 > 500 pg/ml the sensitivity and specificity were 92.0% (95% CI 
= 83.4 – 97.0%) and 32.9% (95% CI = 27.5 – 38.6%), respectively. 
 Among HIV-negative participants, these combinations had a sensitivity of 97.5% (95%CI 86.8 – 
99.9) and specificity of 43.0 (35.1 – 51.3), while among HIV-positive participants, sensitivity 
and specificity were 83.9 (66.3- 94.5%) and 21.1 (14.5 – 29.0), respectively. 
A CRP cut-off point ≥ 40 mg/l combined with various IP-10 cut-off points are also shown in 
table 3.6.  None of these combinations resulted in a higher yield of a better accuracy of the tests.  
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Table 3.6 Performance of CRP and IP-10 as a combined screening tool for active TB 
Rapid CRP 
cut-off 
IP-10 cut-off Sensitivity (95% CI) Specificity (95% CI) 
  All HIV -ve HIV +ve All HIV -ve HIV +ve 
> 10 mg/L > 50 pg/ml 98.7 (92.8 - 100) 100 (91.2 - 100) 96.8 (83.3 – 99.9) 10.6 (7.3 – 14.7) 15.2 (9.9 – 22.0) 5.3 (2.1 – 10.5) 
 > 100 pg/ml 97.3 (90.7 – 99.7) 100 (91.2 - 100) 93.5 (786 – 99.2) 20.2 (15.8 – 25.3) 26.5 (19.6 – 34.3) 13.5 (8.2 – 20.5) 
 > 150 pg/ml 96.0 (88.8 – 99.2) 100 (91.2 - 100) 90.3 (74.2 – 98.0) 27.4 (22.4 – 32.9) 37.1 (29.4 – 45.3) 16.5 (10.7 – 24.0) 
 > 200 pg/ml 93.3 (85.1 – 97.8) 97.5 (86.8 – 99.9) 87.1 (70.2 – 96.4) 27.7 (22.7 – 33.3) 37.7 (30.0 – 46.0) 16.5 (10.7 – 24.0) 
 > 250 pg/ml 92.0 (83.4 – 97.0) 97.5 (86.8 – 99.9) 83.9 (66.3 – 94.5) 28.8 (23.6 – 34.3) 39.1 (31.2 – 47.3) 17.3 (11.3 – 24.8) 
 > 300 pg/ml 92.0 (83.4 – 97.0) 97.5 (86.8 – 99.9) 83.9 (66.3 – 94.5) 29.8 (24.6 – 35.4) 40.4 (32.5 – 48.7) 18.0 (11.9 – 25.6) 
 > 350 pg/ml 92.0 (83.4 – 97.0) 97.5 (86.8 – 99.9) 83.9 (66.3 – 94.5) 30.8 (25.6 – 36.5) 42.4 (34.4 – 50.7) 18.0 (11.9 – 25.6) 
 > 400 pg/ml 92.0 (83.4 – 97.0) 97.5 (86.8 – 99.9) 83.9 (66.3 – 94.5) 31.2 (25.9 – 36.8) 42.4 (34.4 – 50.7) 18.0 (11.9 – 25.6) 
 > 450 pg/ml 92.0 (83.4 – 97.0) 97.5 (86.8 – 99.9) 83.9 (66.3 – 94.5) 31.2 (25.9 – 36.8) 42.4 (34.4 – 50.7) 18.0 (11.9 – 25.6) 
 > 500 pg/ml 92.0 (83.4 – 97.0) 97.5 (86.8 – 99.9) 83.9 (66.3 – 94.5) 32.9 (27.5 – 38.6) 43.0 (35.0 – 51.3) 21.1 (14.5 – 29.0) 
> 40 mg/L > 50 pg/ml 94.7 (86.9 – 98.5) 95.0 (83.1 – 99.4) 93.5 (78.6 – 99.2) 14.7 (10.9 – 19.3) 20.5 (14.4 – 99.4) 8.3 (4.2 – 99.2) 
 > 100 pg/ml 90.7 (81.7 – 96.2) 92.5 (79.6 – 98.4) 87.1 (70.2 – 96.4) 32.2 (26.9 – 37.9) 40.4 (32.5 – 48.7) 24.1 (17.1 – 32.2) 
 > 150 pg/ml 88.0 (78.4 – 94.4) 92.5 (79.6 – 98.4) 80.6 (62.5 – 92.5) 46.9 (41.1 – 52.8) 56.3 (48.0 – 64.3) 37.6 (29.3 – 46.4) 
 > 200 pg/ml 85.3 (75.3 – 92.4) 90.0 (76.3 – 97.2) 77.4 (58.9 – 90.4) 51.0 (45.1 – 56.9) 62.3 (54.0 – 70.0) 39.1 (30.8 – 47.9) 
 > 250 pg/ml 82.7 (72.2 – 90.4) 87.5 (73.2 – 95.8) 74.2 (55.4 – 88.1) 53.8 (47.9 – 59.6) 64.9 (56.7 – 72.5) 42.1 (33.6 – 51.0) 
 > 300 pg/ml 81.3 (70.7 – 89.4) 85.0 (70.2 – 94.3) 74.2 (55.4 – 88.1) 56.2 (50.3 – 61.9) 66.9 (58.8 – 74.3) 44.4 (35.8 – 53.2) 
 > 350 pg/ml 81.3 (70.7 – 89.4) 85.0 (70.2 – 94.3) 74.2 (55.4 – 88.1) 58.6 (52.7 – 64.3) 70.2 (62.2 – 77.4) 45.9 (37.2 – 54.7) 
 > 400 pg/ml 81.3 (70.7 – 89.4) 85.0 (70.2 – 94.3) 74.2 (55.4 – 88.1) 59.6 (53.7 – 65.3) 71.5 (63.6 – 78.6) 45.9 (37.2 – 54.7) 
 > 450 pg/ml 81.3 (70.7 – 89.4) 85.0 (70.2 – 94.3) 74.2 (55.4 – 88.1) 59.6 (53.7 – 65.3) 71.5 (63.6 – 78.6) 45.9 (37.2 – 54.7) 
 > 500 pg/ml 76.0 (64.7- 85.1) 80.0 (64.4 – 90.9) 67.7 (48.6 – 83.3) 68.8 (63.2 – 74.1) 74.2 (66.4 – 80.9) 63.2 (54.4 – 71.4) 
> 80 mg/L > 50 pg/ml 94.7 (86.9 – 98.5) 95.0 (83.1 – 99.4) 93.5 (78.6 – 99.2) 16.4 (12.4 – 98.5) 21.9 (15.5 – 29.3) 10.5 (5.9 – 17.0) 
 > 100 pg/ml 89.3 (80.1 – 95.3) 90.0 (76.3 – 97.2) 87.1 (70.2 – 96.4) 36.0 (30.5 – 41.8) 45.0 (36.9 – 53.3) 27.1 (19.7 – 35.5) 
 > 150 pg/ml 85.3 (75.3 – 92.4) 87.5 (73.2 – 95.8) 80.6 (62.5 – 92.5) 51.4 (45.5 – 57.2) 60.9 (52.7 – 68.8) 42.1 (33.6 – 51.0) 
 > 200 pg/ml 81.3 (70.7 – 89.4) 82.5 (67.2 – 92.7) 77.4 (58.9 – 90.4) 56.5 (50.6 – 62.3) 67.5 (59.5 – 74.9) 45.1 (36.5 – 54.0) 
 > 250 pg/ml 77.3 (66.2 – 86.2) 77.5 (61.5 – 89.2) 74.2 (55.4 – 88.1) 60.6 (54.8 – 66.3) 70.9 (62.9 – 78.0) 50.4 (41.6 – 59.2) 
 > 300 pg/ml 76.0 (64.7 – 85.1) 75.0 (58.8 – 87.3) 74.2 (55.4 – 88.1) 63.7 (57.9 – 69.2) 72.8 (65.0 – 79.8) 54.1 (45.3 – 62.8) 
 > 350 pg/ml 76.0 (64.7 – 85.1) 75.0 (58.8 – 87.3) 74.2 (55.4 – 88.1) 66.1 (60.4 – 71.5) 76.2 (68.6 – 82.7) 55.6 (46.8 – 64.2) 
 > 400 pg/ml 76.0 (64.7 – 85.1) 75.0 (58.8 – 87.3) 74.2 (55.4 – 88.1) 67.5 (61.8 – 72.8) 78.1 (70.7 – 84.5) 55.6 (46.8 – 64.2) 
 > 450 pg/ml 76.0 (64.7 – 85.1) 75.0 (58.8 – 87.3) 74.2 (55.4 – 88.1) 67.5 (61.8 – 72.8) 78.1 (70.7 – 84.5) 55.6 (46.8 – 64.2) 
 > 500 pg/ml 65.3 (53.5 – 76.0) 67.5 (50.9 – 81.4) 58.1 (39.1 – 75.5) 78.8 (73.6 – 83.3) 80.8 (73.6 – 86.7) 77.4 (69.4 – 84.2) 
CRP = C-reactive protein, IP-10 = Interferon Gamma-inducible protein 10, PPV = Positive predictive value, NPV = Negative predictive value, 95% CI = 95% 
Confidence Interval, HIV -ve = HIV-negative, HIV +ve = HIV-positive 
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Table 3.7 is a hypothetical scenario of the number of cases that would be correctly diagnosed 
/excluded by the biomarkers at CRP and IP-10 cut offs, when applied to a population of 1000 
participants and with a TB prevalence of 21%.  
Among HIV-negative patients, a CRP ≥ 10 mg/l (sensitivity 95.3%, specificity 42.6%) would 
detect 200 out of 210 TB cases. In addition, 453 patients without TB would be CRP-positive and 
would undergo further TB diagnostic tests. Furthermore, CRP ≥ 10 mg/l and IP-10 > 500 pg/ml 
would improve the performance, increasing sensitivity from 95.3% to 97.5%, with a stable 
specificity (42.6% and 43.0%), thereby reducing the number of TB cases missed (from 10 to 5).   
Other cut-off points of the biomarkers (either individually or in combination) would result in 
higher number of TB patients being missed. Also, the table shows that the biomarkers performed 
fairly well among HIV-negative patients, but poorly among HIV-positive patients.  
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Table 3.7. Number of patients that would be selected for further TB tests using CRP and IP-10 as TB screening tools with a TB prevalence 
of 21%. 
    Bact. Positive, n = 210  Bact. Negative, n = 790 
  Sensitivity Specificity Correctly 
selected 
Missed Correctly 
excluded 
Included for 
further tests 
All CRP > 10mg/l 91.4% 33.2% 192 18 262 528 
 > 40mg/l 72.8% 70.1% 153 57 554 336 
 > 80mg/l 61.7% 79.7% 130 80 630 160 
 IP-10 > 100pg/ml 87.3% 40.9% 183 27 323 467 
 > 150pg/l 79.7% 58.1% 167 143 459 331 
 CRP > 10mg/l & IP-10 > 500pg/ml 92.0% 32.9% 193 17 260 530 
 CRP > 40mg/l & IP-10 > 150pg/ml 88.0% 46.9% 185 25 371 419 
 CRP > 40mg/l & IP-10 > 450pg/ml 81.3% 59.6% 171 39 471 319 
 CRP > 80mg/l & IP-10 > 100pg/ml 89.3% 36.0% 188 22 284 506 
 CRP > 80mg/l & IP-10 > 150pg/ml 85.3% 51.4% 179 31 406 384 
HIV-ve CRP > 10mg/l 95.3% 42.6% 200 10 337 453 
 > 40mg/l 76.7% 75.5% 161 49 596 194 
 > 80mg/l 62.8% 81.9% 132 78 647 143 
 IP-10 > 100pg/ml 87.5% 50.3% 184 26 397 393 
 > 150pg/ml 80.0% 69.2% 168 42 547 243 
 CRP > 10mg/l & IP-10 > 500pg/ml 97.5% 43.0% 205 5 340 450 
 CRP > 40mg/l &     IP-10 > 150pg/ml 92.5% 56.3% 194 16 445 345 
 CRP > 40mg/l &     IP-10 > 200pg/ml 90.0% 62.3% 189 21 492 298 
 CRP > 40mg/l &     IP-10 > 450pg/ml 85.0% 71.5%% 179 31 565 225 
 CRP > 40mg/l &     IP-10 > 500pg/ml 80.0% 74.2% 168 42 586 204 
 CRP > 80mg/l &     IP-10 > 100pg/ml 90.0% 45.0% 189 21 356 434 
 CRP > 80mg/l &     IP-10 > 150pg/ml 87.5% 60.9% 184 26 481 309 
HIV +ve CRP > 10mg/l 84.8% 22.1% 178 32 175 615 
 > 40mg/l 66.7% 64.7% 140 70 511 279 
 > 80mg/l 57.6% 78.7% 121 89 622 168 
 IP-10 > 100pg/ml 85.3% 32.4% 179 31 256 534 
 > 150pg/ml 79.4% 47.2% 167 43 373 417 
 CRP > 10mg/l &     IP-10 > 500pg/ml 83.9% 21,1% 176 34 167 623 
 CRP > 40mg/l &     IP-10 > 150pg/ml 80.6% 37.6% 169 41 297 493 
 CRP > 80mg/l &     IP-10 > 150pg/ml 80.6% 42.1% 169 41 333 457 
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3.4.4 ROC for CRP as a TB screening tool  
Figure 3.2 shows a Receiver Operating Characteristic (ROC) curve for the performance CRP 
at ≥ 10 mg/l, ≥ 40 mg/l and > 80 mg/l for the whole study’s population. 
The highest point on the curves occurred at ≥ 10 mg/l, had a sensitivity of 91.4%, and 
specificity of 33.2%. CRP ≥ 40 mg/l had a lower sensitivity (72.8%), but a higher specificity 
(70.1%). The third point (CRP > 80 mg/l) had a sensitivity of 61.7% and specificity of 
79.7%.  
Figure 3.2 ROC for performance of CRP as a TB screening tool for all symptomatic patients 
 
 
3.4.5 ROC curve for performance of CRP as a TB screening tool among HIV-negative 
patients 
Figure 3.3 shows that CRP performed better among HIV-negative patients compared to the 
whole study population. The CRP’s highest sensitivity among HIV-negative patients was 
95.3% and its corresponding specificity was 42.6%. This occurred at CRP ≥ 10 mg/dl. The 
next point to the highest occurred at CRP ≥ 40 mg/l. Its sensitivity was 76.7% and its 
corresponding specificity was 75.5%.  
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Figure 3.3 ROC curve for CRP among HIV-negative patients 
 
 
3.4.6 ROC curve for CRP among HIV-positive patients 
Figure 3.4 displays the ROC of CRP among HIV-positive patients. The highest point on the 
curve was at CRP ≥ 10 mg/l, and sensitivity at this point was 84.8%, with specificity of 
22.1%. The point below this (CRP ≥ 40 mg/l) had a sensitivity of 66.7% and a specificity of 
64.7%.  
Figure 3.4 ROC curve for CRP among HIV-positive patients 
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3.4.7 ROC curve for IP-10 among all patients with TB symptoms 
Figure 3.5 shows a ROC curve for IP-10 at different cut-off points (> 50 pg/ml, > 100 pg/ml, 
> 150 pg/ml, > 200 pg/ml, > 250 pg/ml and > 300 pg/ml). For the whole study population, the 
best-performing cut-off was > 100 pg/ml, with a sensitivity of 87.3% and a specificity of 
40.9%.  
 
3.5 ROC curve for performance of IP-10 as a screening tool among patients with TB symptoms 
 
 
3.4.8 ROC curve for IP-10 among HIV-negative patients 
Among HIV-negative participants, the ROC curve (figure 3.6) best-performing IP-10 cut-off 
point had sensitivity of 87.5% and specificity of 50.3%.  The sensitivity (87.5% versus 
87.3%) and specificity (50.3% versus 40.9%) were slightly higher among HIV-negative 
patients. 
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Figure 3.6 ROC curve of IP-10 among HIV-negative patients 
 
3.4.9 ROC curve of IP-10 among HIV-positive patients. 
As shown in figure 3.7, the highest point on the curve (IP-10 > 50 pg/ml) had a sensitivity of 
94.1% but a specificity of 11.3%. The next point below this, was at a cut-off > 100 pg/ml 
with sensitivity of 85.3% and specificity 32.4%. The third cut off (> 150 pg/ml) had 
sensitivity and specificity of 79.4% and 47.2%, respectively. Hence, performance of IP-10 as 
a TB screening tool was poorer among HIV-positive patients compared to HIV-negative 
patients.  
Figure 3.7 ROC curve of IP-10 among HIV-positive patients 
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3.5 Discussion 
3.5.1 Summary of the study and its findings 
In this study, 408 patients with cough of ≥ 2 weeks were recruited. Of these, 86 (21%) had 
TB and 46.9% were HIV-positive. CRP at a cut-off point of ≥ 10 mg/L had the best 
performance and sensitivity of 91.4% but specificity of 33.2%. The performance was better 
among HIV-negative patients (sensitivity 95.3%, specificity 42.6%) and worse among HIV-
positive patients (sensitivity 84.8%, specificity 22.1%).  When CRP cut-offs were increased 
the sensitivity decreased and specificity increased slightly, as expected.  
IP-10 at a cut-off > 100 pg/ml had the best performance.  In the whole group the sensitivity 
was 87.3% and specificity 40.9%. Again, performance was better among HIV-negative 
patients (sensitivity and specificity 87.5% and 50.3%) than among HIV-positive participants 
(sensitivity 85.3%, specificity 32.4%).  Increasing the cut-off point to IP-10 decreased the 
sensitivity but increased specificity.  
The combination of CRP and IP-10 in the whole study population with a CRP ≥ 40 mg/L & 
IP-10 > 150 pg/ml had sensitivity of 88% and specificity of 46.9%. However, among HIV-
negative patients, the optimal cut-off point was CRP ≥ 10 mg/L & IP-10 > 500 pg/ml, which 
resulted in sensitivity and specificity of 97.5% and 43.0%, respectively. For HIV-positive 
patients, the optimal cut-off point was CRP > 80 mg/L & IP-10 > 150 pg/ml, with sensitivity 
of 80.6% and specificity of 42.1%. 
3.5.2 Performance of CRP among patients with TB symptoms 
We did not find any study that evaluated performance of rapid CRP on a study population 
comprising HIV-positive and HIV-negative patients. However, a study has shown that the 
performance of rapid CRP is comparable to that of ELISA (or other Lab-based CRP), when 
used in parallel with each other, with sensitivity (95% versus 97%) and specificity (51% 
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versus 54%) 104. Hence, we may compare this finding with findings from previous studies 
that assessed performance of lab-based CRP among populations comprising HIV-positive and 
HIV-negative patients. The performance of rapid CRP among this study’s whole population, 
is worse than findings from a prospective study in South Africa, conducted on 250 patients 
with TB symptoms (in which 135 patients with confirmed TB were compared with 115 
patients without TB), and showed that the test had sensitivity of 98% and specificity of 59% 
106. Though, a lower cut-off point (CRP ≥ 5mg/L) than ours (CRP ≥ 10mg/L) was used in the 
study. The TB cases in the South Africa study were smear-negative cases, which might have 
lower bacillary load and different level of CRP production. In this study, we used solid 
culture and Xpert MTB/RIF, while in the South Africa study used liquid culture and 
histology, a major difference is the study design.  While our study used a cross sectional 
design, the South Africa study used a case control design.  The latter is an inadequate design 
to assess diagnostics, because it often generates over optimistic results, and this is likely one 
of the main differences. Similarly, the high proportion of participants with TB (> 50%) is 
likely to result in significant differences when a major issue with the test is a low specificity. 
Our findings also differ from a systematic review and meta-analysis of 9 studies (of which 8 
were from high burden settings) with 1299 participants, which assessed the accuracy of CRP 
for TB diagnosis 125. The meta-analysis showed that CRP performed well, with a pooled 
sensitivity and specificity of 92% (95% CI = 83 – 97%) and 68% (95% CI = 49 – 82%), for 
patients recruited from outpatients settings. These differences could be due to the sample 
sizes, methods of TB confirmation and CRP analysis, the cut-off point used, and the studies 
combined in the meta-analysis. 
Among HIV-positive patients, CRP performed poorly , which is contrary to findings from a 
prospective study from South Africa on 93 HIV-positive patients with TB symptoms 104, 
which reported that a cut-off ≥ 8 mg/L had 97% sensitivity and 51% specificity 104. Two 
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prospective studies from Uganda used rapid CRP among HIV-positive patients and found that 
the biomarker had 89% sensitivity, which was similar to the WHO TB symptom screening 
algorithm and better specificity, leading to more patients starting IPT and ART 126,127. One of 
the two studies was conducted on 1177 pre-ART patients 126 and found that CRP ≥ 10 mg/L 
had sensitivity of 89% and specificity of 72%.  
Furthermore, a systematic review and meta-analysis of studies that assessed the diagnostic 
accuracy of CRP for active TB among HIV-positive patients in outpatient settings, also found 
that the biomarker performed well, with a pooled sensitivity and specificity of 92% and 70%, 
respectively 125. 
Possible reasons for the difference between our study’s finding and findings from the 
previous studies, may be due to difference in the studies’ participants’ characteristics, 
methods of TB confirmation and sample size. Firstly, for instance, two of the studies 
mentioned above, recruited HIV patients irrespective of TB symptom 126,127, but we recruited 
patients with cough of ≥ 2 weeks. Hence, it could be that patients in our study had longer 
symptom duration and possibly, other opportunistic infections that could have affected the 
performance of the diagnostics. As a meta-analysis 125 and some studies have shown that 
CRP had poor specificity among patients with TB symptoms who needed admission 125 or 
self-reported the symptom (due to high prevalence of pyogenic infections ) 126.  
However, our study findings are similar to a multi-centre case-control study nested into a 
clinical trial, which recruited participants from nine countries and determined the ability of 
CRP to discriminate between patients who had incident TB at 96 weeks after initiating ART 
and those who did not have TB, and showed that at a cut-off  of  ≥ 12 mg/L, the sensitivity 
and specificity of CRP were 44% and 81% respectively 110. Though, this study was done on 
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patients who had been on ART for close to two years, and this might have decreased their 
risk of TB and immune response to CRP production. 
For HIV-negative participants, CRP had better performance. Its sensitivity was good 
(95.3%), but its specificity was still lower (42.6%) than the WHO recommended TB 
screening tool28. This finding is corroborated by findings from a prospective study from 
South Korea, which evaluated the performance of CRP among HIV-negative patients 
(sensitivity 97% and specificity 41%) 107. However, findings from another prospective study, 
among HIV-negative patients in China showed lower sensitivity (82%) but higher specificity 
(60%), at a cut-off of CRP ≥ 15 mg/L 109.  
3.5.3 Performance of IP-10 as a screening tool 
The performance of unstimulated IP-10 was sub-optimal among all categories of patients. 
Overall, IP-10 had sensitivity of 87.3% and specificity of 40.9%. This is consistent with 
findings from previous studies. For example, in Uganda, 111 children (comprising 80 HIV-
negative and 31 HIV-positive) with presumptive TB and 33 healthy adults (as controls), 
found that the IP-10 performed poorly in differentiating patients with TB and other 
respiratory diseases (sensitivity 79%, specificity 94%) 123. In addition, a systematic review 
and meta-analysis of 14 studies with 2075 participants, assessed the diagnostic sensitivity of 
IP-10 was 72% and specificity 82% 128. However, a prospective study in Norway, of 164 
subjects, found that unstimulated IP-10 differentiate active and LTBI, irrespective of HIV 
status 113.  
Similar to CRP, IP-10 performance was better in HIV-negative than HIV-positive patients.  
The poor performance of IP-10 among HIV-positive patients is supported by a prospective 
study from Uganda which showed that IP-10 performance was poor in differentiating TB and 
not TB in HIV-negative and HIV-positive groups 123. On the other hand, two prospective 
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studies conducted among HIV-negative patients: one from South Korea 121 and the other from 
Philippines 122, found that unstimulated IP-10 performed well in differentiating between 
patients with active TB and LTBI, with sensitivity and specificity of 88% and 91% 121 and 
95% and 93%122, respectively.  
To see if using both CRP and IP-10 (one after the other) for TB screening, will lead to better 
performance of the biomarkers as a screening tool for active TB, we assessed the 
performance of the combination of each cut-off point of CRP with each of the cut-off points 
of IP-10. Our finding showed that the combination only led to slight improvement in the 
performance of the biomarkers, among HIV-negative patients. It increased the sensitivity by 
2.2% (from 95.3% to 97.5%) and the specificity by 0.4% (from 42.6% to 43%). We did not 
find any study that assessed the performance of combination of the two biomarkers as a 
screening tool for active TB. 
3.5.4 Limitations and strength of the study 
This study has some limitations. Firstly, the use of solid culture as the reference standard, 
might have missed some TB cases that could be detected by liquid culture, and this might 
affect this study’s findings. However, contamination rate could be higher in liquid culture 
compared to solid culture 97-99. Secondly, we could not compare the performance of the 
biomarkers to that of the WHO TB symptoms screening, because we did not recruit patients 
irrespective of TB symptoms (we recruited only patients with cough of ≥ 2weeks)). Lastly, 
because we diagnosed only PTB, some EPTB cases might have been missed and this could 
make us to underrate the burden of TB in our study population.  
However, this study has some strength. This study might be the first study from Nigeria, that 
assessed the performance of CRP and IP-10 as screening tools for active TB. Also, this could 
be one of the few studies that compared the performance of the biomarkers between HIV-
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positive and HIV-negative patients. We also did not find any published previous study that 
assessed the performance of the combination of CRP and IP-10 as a screening tool for active 
TB. Hence, this might be the first study on the topic. 
3.5.5 Conclusion 
This study showed that close to half of the study population are HIV-infected and 21% of 
them had TB. In addition, the performance of rapid CRP was poor among HIV-positive 
patients, fair in the whole study’s population and better among HIV-negative patients. IP-10’s 
performance was poor among all categories of patients.  Diagnostic algorithms that consider 
testing for CRP as a triage step for TB diagnosis, need to include screening for HIV.  It is 
likely that HIV-infected individuals will need to be tested directly by a molecular test such as 
Xpert, while HIV-negative patients could undergo CRP screening and patients with CRP > 
10 mg/L could undergo further tests.    
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Chapter 4  
TB Treatment Outcome among HIV-infected and -uninfected patients  
  
4.1 Introduction 
Tuberculosis treatment success is a key indicator for monitoring the implementation of the 
End TB Strategy, which aims to drastically reduce the public health impacts of TB by 2035 
129. The treatment success targeted is ≥ 90%, for both drug-susceptible and drug-resistant TB 
cases in all countries by 2025 41,129, however, only one country in Sub-Saharan Africa 
(Tanzania) has reached this target among drug-susceptible patients. In 2015, 5,893,106 new 
and relapsed TB cases were registered globally, with a treatment success of 83%. In the same 
year, treatment success across Africa, ranged from 71% in Congo to 90% in Tanzania, with 
treatment outcome being worse among HIV-positive patients, ranging from 20% in Congo to 
83% in Tanzania130. 
Few studies have compared the TB treatment outcomes between HIV-positive and HIV-
negative patients in Nigeria or systematically described all unfavourable TB treatment 
outcomes. There is therefore a need for quality studies to create the evidence of the impact of 
HIV infection on TB treatment outcome in Nigeria. This study therefore systematically 
reviewed the records of TB patients treated at a large DOTS clinic at the University of Abuja 
Teaching Hospital (UATH), between January 2012 and December 2016. 
The specific objectives of the study were to: 
• Determine treatment outcome among TB patients treated in UATH between January 
2012 and December 2016 
• Compare TB treatment outcome between HIV-positive and HIV negative patients  
• Determine risk factors to poor treatment outcome (death/treatment failure) 
• Identify factors associated with loss-to-follow up among the patients 
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4.2 Literature review 
It is well established that TB treatment is less successful among HIV-positive than HIV-
negative patients. According to the 2016 Global TB report 41, only 75% of HIV-positive 
patients had a successful TB treatment outcome in 2014, compared to 83% for HIV-negative 
patients and these differences were similar across all regions, as shown in the table 4.1 41. 
Table 4.1. TB treatment success of HIV-positive and HIV-negative patients by WHO region.  
WHO Region            TB treatment success  
HIV-negative              HIV-positive      Difference 
Africa 83% 77% 6% 
Americas 77% 56% 21% 
Eastern Mediterranean 92% 53% 39% 
Europe 80% 41% 39% 
South-East Asia 79% 74% 5% 
Western Pacific 93% 72% 21% 
Source: Global Tuberculosis Report, 2016 
 For example, a review of TB treatment records of 61,138 patients across Europe, reported a 
successful treatment outcome of 56.9% and 78.7% among HIV-infected and HIV-uninfected 
patients 131. A further study from India of 57,045 patients, showed that 74.3% and 79.9% of 
patients with and without HIV achieved treatment success, respectively 132 and many other 
studies outside Africa have reported that HIV is associated with worse TB treatment outcome 
133-135.  
In Africa, treatment success was reported to be lower for HIV-infected patients in seven 
studies 131,132,136-140, similar in one study 141 and higher in nine studies  142-150.  
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Although TB treatment outcome is less successful among HIV-infected patients, only the 
death rates are consistently higher, which are between two times higher in Africa and 7.5 
times higher in the Western Pacific Region  41. In sub-Saharan Africa the death rate is 
between 2 and 8 times higher among HIV-positive compared to HIV-negative patients. 
TB treatment default rates of HIV infected individuals are more heterogeneous, with lower 
default rates in eight studies   132,136,138,140,141,145-147 and higher rates in eleven studies 
131,137,139,142-144,148-152 (see table 4.2).  
Finally, 9 studies showed that a higher proportion of TB/HIV-co-infected patients were 
transferred out 132,136-138,144,145,147,151,152, but one study had similar rates 139 and three studies 
indicated HIV patients, were less likely to be transferred out 142,146,152, which is likely to 
reflect the heterogeneity of the participants and the study settings .  
In sub-Saharan Africa, HIV/TB co-infection also worsens TB treatment outcome. Most 
studies in Ethiopia 138,145,147,148,150,152-156, Benin 144,151,157, Cameroon 137, Gabon 146, Malawi 139, 
South Africa 140 and Uganda 149 have consistently reported  TB treatment is less successful 
among HIV patients, as summarised in table 4.2. TB treatment success ranged from 34.0% to 
97.0% among HIV-positive and from 53.0% to 96.4% for HIV-negative patients, but was 
consistently less successful among HIV-infected patients, with a difference ranging from 
0.5% to 29.7%, which is close to the gaps reported from other regions. 
The treatment success rate among HIV-positive and negative patients with drug susceptible 
TB in Nigeria was 79% and 88.6%, respectively 41. TB treatment outcome of HIV-infected 
and uninfected patients in the country, was described in five studies and all reported a lower 
treatment success among HIV-infected patients, ranging from 48.8% to 73.4% for HIV-
positive and 73.6% to 90.2% for HIV negative patients, with a difference from 6.3% to 
29.7% 136,142,143,158,159.  
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Various factors have been attributed to the poor TB treatment outcome among HIV-positive 
patients. The first one is the interaction between TB and HIV, whereby one pathogen 
accelerates the natural progression of the other 131,160. Secondly, it is often stated that the late 
diagnosis and delayed treatment of TB or ART initiation among TB/HIV-co-infected 
patients, lead to poor treatment outcome 41.  
Factors that modify TB treatment outcome among patients with HIV co-infection 
Factors known to affect TB treatment outcome include ART. Patients on ART have better TB 
treatment outcome than those not on ART 132,139,144,158,161-163. However, some studies have 
reported that the treatment outcome for patients with and without ART can be similar 
151,162,164 or better than patients without HIV 163,165. Patients who start ART early have 
generally better TB treatment outcome than those who initiate ART late 166-169. 
Another factor affecting treatment outcome is the level of immunosuppression or CD4 count 
at the time of TB diagnosis, with the outcome being poorer among patients with CD4 counts 
< 200 cells/m3 163,170. 
Poor outcome is associated with age among HIV-positive patients, with worse outcome in 
patients at the extremes of life (particularly in infants and the elderly) 136,159,163,165,171.  
Treatment outcome is also better among HIV-infected new TB cases compared to retreatment 
cases 172,173 and HIV-positive patients with smear-positive TB have better treatment outcome 
than smear-negative cases with HIV 144,170, which is likely due to their remaining ability to 
create cavitations, which reflect an immunological response to TB. 
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Table 4.2. Studies on TB treatment outcomes by HIV status  
Author/Year Country Sample  
size 
HIV  
status 
                  Treatment outcome 
Successful Unsuccessful 
Default  Failure  Transferred out            Died 
Ade/2016 157 Benin 220 HIV- 93.4% 6.6%    
   HIV+ 97.0% 3.0%    
Ade/2014 151 Benin 378 HIV- 88.2% 3.6%  1.3% 6.9% 
   HIV+ 77.8% 5.5%  1.4% 15.3% 
Ade/2013 144  Benin 3070 HIV- 91.4% 1.8% 2.1% 0.4% 4.2% 
   HIV+ 78.4% 4.4% 2.4% 1.4% 13.4% 
Pefura Yone/2012 137 Cameroon 1647 HIV- 74.3% 18.0% 0.4% 5.4% 1.8% 
   HIV+ 65.0% 19.3% 0.0% 5.8% 9.8% 
Amante/2015 155 Ethiopia 639 HIV- 71.3% 28.7%    
   HIV+ 58.6% 41.4%    
Asres/2016 154 Ethiopia 790 HIV- 90.1% 9.9%    
   HIV+ 83.1% 16.9%    
Belayneh/2016 147 Ethiopia 403 HIV- 77.2% 2.4% 0.4% 13.3% 3.6% 
   HIV+ 76.7% 0.6% 0.6% 14.8% 7.1% 
Ejeta/2015 148 Ethiopia 1143 HIV- 74.0% 6.2% 0.1% 13.8% 5.8% 
   HIV+ 55.7% 9.1% 8.7% 10.5% 16.0% 
Endris/2014 152 Ethiopia 206 HIV- 92.3% 0.5% 0.0% 3.3% 3.8% 
   HIV+ 83.4% 4.2% 0.0% 8.3% 4.2% 
Gebreegziabher/2016 156 Ethiopia 697 HIV- 96.4% 3.6%    
   HIV+ 81.7% 18.3%    
Gebremariam/2016 138 Ethiopia 1562 HIV- 89.6% 1.6% 0.4% 6.2% 2.2% 
   HIV+ 73.0% 0.6% 0.0% 9.1% 16.7% 
Mekonnen/2016 150 Ethiopia 931 HIV- 92.3% 2.4% 2.0%  3.3% 
   HIV+ 82.8% 3.5% 3.1%  10.6% 
Tesfahuneygn/2015 145 Ethiopia 4275 HIV- 90.5% 2.2% 0.3% 5.0% 2.0% 
   HIV+ 84.5% 1.7% 0.5% 6.7% 6.6% 
Zenebe/2016 153 Ethiopia 380 HIV- 85.3% 14.7%    
   HIV+ 64.0% 36.0%    
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Belard/2016 146 Gabon 175 HIV- 59.3% 19.4% 2.8% 18.5% 0% 
   HIV+ 44.8% 17.9% 3.0% 9.0% 25.4% 
Tweya/2013 139 Malawi 2264 HIV- 88.0% 6.0% 1.0% 2.0% 3.0% 
   HIV+ 85.0% 7.0% 0.5% 2.0% 6.0% 
Adejumo/2016 136 Nigeria 535 HIV- 79.7% 14.6% 0.6% 1.1% 4.0% 
   HIV+ 73.4% 14.0% 0.0% 1.4% 11.2% 
Babatunde/2016 142 Nigeria 600 HIV- 73.6% 17.6% 5.5% 1.8% 1.5% 
   HIV+ 64.1% 18.5% 6.8% 0.9% 9.7% 
Ofoegbu/2015 143 Nigeria 389 HIV- 78.5% 17.0% 4.0%   
   HIV+ 48.8% 36.8% 10.8%   
Ogbudebe/2016 158 Nigeria 647 HIV- 90.2% 9.8%    
   HIV+ 71.3% 29.7%    
Oshi/2014 159 Nigeria 1668 HIV- 78.6% 21.4%    
   HIV+ 65.8% 34.2%    
Budgell/2016 140 South 
Africa 
448 HIV- 83.0% 10.6% 3.2% 0.0% 3.2% 
   HIV+ 80.2% 9.6% 0.6% 0.0% 9.6% 
Kirenga/2014 149 Uganda 96 HIV- 53.0% 13.0% 3.0%  31.0% 
   HIV+ 34.0% 16.0% 11.0%  39.0% 
McGreevy/2012 141 Haiti 153 HIV- 81.0% 10.0% 4.0%  4.0% 
   HIV+ 73.0% 5.0% 4.0%  18.0% 
Karo /2016 131 Europe 61,138 HIV- 78.7% 10.2% 2.4%  6.2% 
   HIV+ 56.9% 20.2% 1.5%  13.5% 
Lucenko/2014 134 Latvia 2476 HIV- 89.0% 11.0%    
   HIV+ 73.0% 23.0%    
Shastri/2013 132 India 57,045 HIV- 79.9% 8.8% 2.8% 1.4% 7.1% 
   HIV+ 74.3% 4.4% 0.5% 5.1% 15.7% 
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4.3 METHODOLOGY 
4.3.1 Study design and site description 
This was a retrospective descriptive study of TB patients treated at the DOTS clinic of the 
University of Abuja Teaching Hospital (UATH), between January 2012 and December 2016.  
The clinic receives patients referred from the wards and clinics within UATH and private, 
faith-based and government hospitals in Abuja and its environs. Most patients are referred 
from Gwagwalada town. The treatment provided to patients is supplied by the National 
Tuberculosis and Leprosy Control Programme (NTBLCP) and the drugs are free-of-charge to 
the patients. TB screening and follow up tests for TB and HIV testing are provided free of 
charge to the patients. For treatment purposes, TB patients are categorized into two, based on 
whether patients had never had TB before (new cases) or patients return for treatment after 
default or relapse from previous TB (retreatment cases). New TB cases are treated with 
category 1 anti-TB regimen, which comprises an intensive phase of two months (during 
which patient receives a daily fixed dose combination of Rifampicin, Isoniazid, Ethambutol 
and Pyrazinamide) and a continuation phase of four months (during which patient receives a 
daily fixed dose combination of Rifampicin and Isoniazid). While retreatment cases received 
category 2 regimen.174. The treatment consists of a three-month intensive phase (which 
comprises daily injectable Streptomycin and a fixed-dose combination of Rifampicin, 
Isoniazid, Ethambutol and Pyrazinamide for the first two months, thereafter, injectable 
Streptomycin is removed while patient continues the fixed-dose combination for the 
remaining one month) and a five-month continuation phase, during which patient will be on a 
daily fixed-dose combination of Rifampicin, Isoniazid and Ethambutol. However, this 
regimen is now an obsolete treatment, because WHO has recommended that it should no 
longer be prescribed for this category of TB patients 174. TB treatment outcomes are 
described in table 4.3. 
81 
 
 
Table 4.3. TB treatment outcome definitions 
Outcome Definition 
Cured A pulmonary TB patient with bacteriologically confirmed TB at the 
beginning of treatment who was smear- or culture-negative in the last 
month of treatment and on at least one previous occasion. 
 
Treatment completed A TB patient who completed treatment without evidence of failure BUT 
with no record to show that sputum smear or culture results in the last 
month of treatment and on at least one previous occasion were negative, 
either because tests were not done or because results are unavailable. 
 
Treatment failed A TB patient whose sputum smear or culture is positive at month 5 or 
later during treatment 
 
Died A TB patient who dies for any reason before starting or during the course 
of treatment 
 
Lost to follow-up A TB patient who did not start treatment or whose treatment was 
interrupted for 2 consecutive months or more 
 
Not evaluated A TB patient for whom no treatment outcome is assigned. This includes 
cases “transferred out” to another treatment unit as well as cases for 
whom the treatment outcome is unknown to the reporting unit 
 
Treatment success The sum of cured and treatment completed 
 
Source: WHO. Definitions and reporting framework for TB 175. 
 
4.3.2 Method of data collection 
 
With the permission of the UATH’s TB programme coordinator, all TB treatment registers 
and cards of patients diagnosed to have TB and initiated treatment at the centre, from January 
2012 to December 2016, were retrieved from the clinic record room.  With the help of two 
research assistants, the records were reviewed and a proforma/data extraction form was used 
to collect information regarding the patients’ HIV status (positive, negative or undetermined), 
whether the diagnosis had microbiological confirmation by smear microscopy, Xpert 
MTB/RIF or culture; clinical presentation (as pulmonary or extra-pulmonary), treatment 
regimen started and date treatment initiated,  treatment outcome (cured, treatment completed, 
treatment success (cured + treatment completed), loss-to-follow up, treatment failure, 
transferred out or not evaluated), basic demographic characteristics (age, gender, educational 
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status, occupation) and factors that could be associated with treatment outcomes (weight, new 
or re-treatment, ART use or CPT for HIV-positive patients). 
4.3.3 Data analysis 
Data analysis was conducted using Epi-Info 7 (Centers for Disease Control and Prevention) 
and SPSS (version 24). After adequate data cleaning, descriptive statistics were done to 
obtain counts and percentages, means, standard deviations and charts for variables, as needed. 
Thereafter, bivariable analyses compared the characteristic of categorical variables between 
groups (e.g. HIV-positive and negative, treatment success versus treatment failure etc) using 
Chi-Square and Fisher’s Exact tests, and OR with 95%CI.  Comparisons of continuous 
variables were done using Student’s t tests and the mean differences (95% CI) were 
determined and tested using paired T tests. Variables with p values < 0.2 were included in 
multivariable analyses using logistic regression adjusted for age, gender and HIV status to 
obtain Adjusted ORs (AOR)s to determine factors independently associated with treatment 
outcome.  P values < 0.05 were considered statistically significant. Kaplan Meir survival 
analysis curves were drawn to compare death and LTFU trends by HIV status.  
4.3.4 Ethical considerations 
Ethical approvals were obtained from the Research Ethics committees of LSTM, UATH and 
FCT. Permission to have access to TB treatment records was sought from the UATH’s TB 
coordinator and clinic staff. Informed consent from the patients was not obtained, as data had 
been collected from the patients and this requirement was waived by the ethics committees. 
All patient information was handled to maintain confidentiality. 
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Figure 4.1. TB treatment outcome study’s flow chart 
       
                                          
   
 
 
 
 
 
 
Patients treated for TB in UATH 
January 2012 - December 2016 
N = 998 
 
HIV status unknown n = 5 
 
NK 
n = 30 
(5.4%) 
Transferred  
n = 36 
(6.9%) 
Died 
n = 16 
(2.9%) 
Failed 
n = 5 
(0.9%) 
LTFU 
n = 79 
(14.3%) 
Successful 
n = 387 
(70.0%) 
NK 
n = 14 
(3.2%) 
Transferred  
n = 27 
(6.1%) 
 
n =  
Died 
n = 68 
(15.5%)  
Failed 
n = 2 
(0.5%) 
Successful 
n = 230 
(52.3%) 
LTFU 
n = 99 
(22.5%) 
HIV-negative 
n = 553 (55.7%) 
HIV-positive 
n = 440 (44.3%) 
Abbreviations 
LTFU –  Loss-to-follow-up 
NK – Not known (for TB 
cases with no documented 
treatment outcome) 
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4.4 RESULTS 
4.4.1 Baseline characteristics and treatment outcome  
Nine hundred and ninety-eight patients were treated at the DOTS clinic of UATH from 
January 2012 to December 2016.  Of these, 571 (57.2%) were male and 427 (42.8%) female 
(table 4.4). Their age ranged from 0 to 92 years with a mean (SD) of 34.5 (16.4) years for 
males and 29.7 (14.7) for females (p = 0.001).   One hundred and twenty-four (12.4%) were 
children ≤ 14 years old.  Of 895 patients with known marital status, 395 (44.1%) were single, 
482 (53.9%) married, and 18 (2%) separated, divorced or widowed. Two hundred and ten 
(23.4%) were traders or business men/women and 159 (17.8%) students, with less frequent 
occupations including civil servants, artisans, farmers and others.  Only 34 (3.8%) indicated 
they were unemployed. The majority (540, 62.5%) of patients belonged to minority ethnic 
groups such as Igala (50, 5.8%); Idoma (45, 5.2%); Tiv (35, 4.1%) and others. The three 
major Nigerian ethics groups (Igbo, Yoruba and Hausa) represented 19.6%, 9.4% and 8.6% 
of the participants, respectively. 
Most (970, 97.2%) patients were classified as new and 28 (2.8%) as re-treatment TB cases. 
Nine hundred and forty-three (94.5%) cases were treated with category 1 and 55 (5.5%) with 
category 2 drugs. The majority (848, 85.0%) of cases had PTB and 150 (15%) EPTB. EPTB 
included 32 (21.3%) cases with enlarged lymph nodes, 22 (14.7%) abdominal TB and 21 
(14%) TB of the spine.  Forty (26.6%) patients had other forms of EPTB, with 35 not being 
documented. Of 848 PTB cases, 347 (40.9%) were smear-positive and 234 (27.6%) smear-
negative. A further 196 (23.1%) were diagnosed with Xpert MTB/RIF and 71 (8.4%) with 
chest X-rays only, as shown in table 4.4. Two (1%) of the 196 cases tested with Xpert 
MTB/RIF were Rifampicin resistant and two (1%) had indeterminate results.  
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HIV status was documented for 993 (99.5%) participants and 440 (44.3%) were HIV-
positive.  
The mean (SD) weight at baseline, 2 and 5 months of treatment for males was 52.1 (15.9), 
54.5 (16.3) and 58.6 (15.8) Kgs, with mean (SD) weight differences of 2.3 (4.4) and 5.2 (5.2) 
Kgs at 2 and 5 months, respectively. Similarly, the mean (SD) weight at baseline, 2 and 5 
months for females, were 46.2 (16.6), 49.4 (14.7) and 52.4 (15.4) Kgs, with mean (SD) 
weight differences of 1.6 (4.6) and 3.7 (4.9) Kgs, respectively. 
Treatment outcome was recorded as cured in 222 (22.2%) and completed in 397 (39.8%) 
patients, with successful treatment (cured + completed) in 619 (62%) patients.  One hundred 
and eighty (18%) patients were LTFU, 7 (0.7%) had treatment failure, 63 (6.3%) were 
transferred out, 84 (8.4%) died and 45 (4.5%) were not evaluated. If patients not evaluated or 
transferred out are excluded, treatment success was 69.6%, with 9.4% of patients dying 
during the follow up.  
Table 4.4. Baseline characteristics of patients treated for TB in UATH, 2012 – 2016. 
Characteristics Category N = 998 (%) Missing  
Gender  Male 571 (57.2)  
 Female 427 (42.8)  
Mean (SD) [Range] age 
(years) 
All 32.5 (15.8) [0 – 92]  
 Male 34.5 (16.4) [0 – 92]  
 Female 29.7 (14.7) [0 – 85]  
Age group (years) < 5  58 (5.8)  
 5 – 14 66 (6.6)  
 15 – 24  152 (15.2)  
 25 – 34  282 (28.3)  
 35 – 44  243 (24.4)  
 45 – 54  114 (11.4)  
 55 – 64  46 (4.6)  
 ≥ 65 37 (3.7)  
Marital status Single 395 (44.1) 103 
 Married 482 (53.9)  
 Separated 3 (0.3)  
 Divorced 2 (0.2)  
 Widowed 13 (1.5)  
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Occupation Student 159 (17.8) 102 
 Unemployed 34 (3.8)  
 Civil servant 88 (9.8)  
 Artisan 70 (7.8)  
 Trading/Business 210 (23.4)  
 Farming 50 (5.6)  
 House-wife 86 (9.6)  
 Others 199 (22.2)  
Ethnicity Igbo 169 (19.6) 134 
 Yoruba 81 (9.4)  
 Hausa 74 (8.6)  
 Igala 50 (5.8)  
 Idoma 45 (5.2)  
 Tiv 35 (4.1)  
 Gbagyi 31 (3.6)  
 Ebira 30 (3.5)  
 Gwari 21 (2.4)  
 Fulani 17 (2.0)  
 Bassa 15 (1.7)  
 Ibiobio 13 (1.5)  
 Koro  12 (1.4)  
 Nupe 11 (1.3)  
 Jabba 10 (1.2)  
 Other  250 (28.9)  
Religion Christian 643 (74.7) 137 
 Islam 216 (25.1)  
 Others 2 (0.2)  
TB treatment category  New  970 (97.2)  
 Retreatment  28 (2.8)  
Anti-TB regimen category   Category 1 943 (94.5)  
 Category 2 55 (5.5)  
Anatomical site of TB  Pulmonary 848 (85.0)  
 Extra-pulmonary  150 (15.0)  
Type of PTB SM-positive 347 (40.9)  
 SM-negative 234 (27.6)  
 SM-not done 267 (31.5)  
Forms of EPTB Lymphadenitis 32 (21.3)  
 Abdominal  22 (14.7)  
 Spine 21 (14.0)  
 Breast 6 (4.0)  
 Prostatic  3 (2.0)  
 Meningitis 3 (2.0)  
 Pericarditis  3 (2.0)  
 Pleuritis 3 (2.0)  
 Endometrial  2 (1.3)  
 Other forms  20 (13.3)  
 Not documented 35 (23.3)  
†Mode of diagnosis  SM 349 (35.0)  
 X-rays 474 (47.5)  
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 Xpert MTB/RIF 196 (19.6)  
 Clinical  88 (8.8)  
 Histology 56 (5.6)  
 Spine X-rays  21 (2.1)  
 Mantoux 2 (0.2)  
 MRI 1 (0.1)  
SM grade (n = 349)a Scanty 35 (10.0)  
 + 91 (26.1)  
 ++ 125 (35.8)  
 +++ 98 (28.1)  
Xpert MTB grade  Very low 34 (17.7) 4 
(n = 192)b  Low 64 (33.3)  
 Medium 60 (31.3)  
 High 34 (17.7)  
Xpert RIF (n = 196) Positive 2 (1.0)  
 Negative 192 (98.0)  
 Indeterminate 2 (1.0)  
HIV-infected   440 (44.3) 5 
Baseline weight (kg) Mean (SD) [Range] 49.6 (16.5) [3.5 – 105.5] 106 
Weight gain at 2 m Mean (SD) [Range] 2.0 (4.4) [-22.0 – 33.0] 454 
Weight gain at 2 m Mean (SD) [Range] 4.6 (5.2) [-12.0 – 32.0] 591 
TB treatment outcome     Cured 222 (22.2)  
 Completed 397 (39.8)  
 Cured + completed 619 (62.0)  
 Loss-to-follow up 180 (18.0)  
 Failed 7 (0.7)  
 Transferred out 63 (6.3)  
 Died 84 (8.4)  
 Not evaluated 45 (4.5)  
† Some TB cases were diagnosed by more than one method                                                                                     
a In addition to the 347 smear-positive PTB cases, two EPT cases were smear-positive                                   
bFour patients with positive Xpert MTB but had no grading for MTB detection, were excluded   
 
4.4.2 Baseline characteristics of patients by HIV status 
HIV-positive patients were less likely to be male (OR 95% CI = 0.6, 0.5 – 0.8, p = 0.001) and 
to be older (mean (SD) 33.7 (14.8) years) than HIV-negative patients (31.5 (16.7), p = 0.025), 
as shown in table 4.5. HIV-positive patients were older than HIV-negative patients of the 
same sex. HIV-positive patients were more likely to be married (p = 0.001), 
separated/divorced (p = 0.051) or widowed (p = 0.001) and less likely to be single. 
HIV-positive patients were more likely to have PTB than HIV-negative patients (p = 0.001) 
and were more likely to have negative or missing smear microscopy (p = 0.001).  The latter is 
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explained because patients with HIV are more likely to be screened with Xpert MTB/RIF as 
the first test for diagnosis (p = 0.001). Xpert MTB/RIF bacterial loads of HIV-positive 
patients were more likely to be very low than for HIV-negative patients (p < 0.05). However, 
there was no significant difference in Rifampicin resistance (p = 0.480).  
HIV-positive patients had lower mean (SD) baseline body weight than HIV-negative patients 
(47.5 (16.6) Kgs versus 51.3 (16.2) Kgs, p = 0.001) and at 2 (50.1 (16.9) versus 53.7 (15.1), p 
= 0.001) and 5 months follow up (54.3 (17.0) versus 57.0 (15.2), p = 0.098).  However, the 
mean (SD) weight difference at 2 and 5 months were not statistically significantly. 
Table 4.5. Baseline characteristics of patients treated for TB in UATH by HIV status 
Characteristics Category HIV-
positive  
N = 440 (%) 
HIV-
negative  
N = 553 (%) 
Odds ratio    
(95% CI)  
P  
Gender Male 223 (50.7) 346 (62.6) 0.6 (0.5 – 0.8) 0.001 
 Female 217 (49.3) 207 (37.4)   
Mean [SD] age (years) All 33.7 (14.8)  31.5 (16.7)  2.2 (0.3 – 4.2) a 0.025 
 Male 37.0 (15.4)  33.0 (16.8)  3.7 (1.2 – 6.7) a 0.005 
 Female 30.4 (12.9)  29.0 (16.2)  1.4 (-1.4 – 4.2) a 0.318 
Age group (years) 0 – 9  42 (9.5) 56 (10.1)  0.001 
 10 – 19  26 (5.9) 51 (9.2)   
 20 – 29   64 (14.5) 163 (29.5)   
 30 – 39  149 (33.9) 133 (24.1)   
 40 – 49   112 (25.5) 71 (12.8)   
 50 – 59   30 (6.8) 36 (6.5)   
 60 – 69   12 (2.7) 23 (4.2)   
 ≥ 70 5 (1.1) 20 (3.6)   
Marital Status Single 134 (34.5) 261 (51.8) 1  
 Married 240 (61.9) 239 (47.4) 2.0 (1.5 – 2.6) 0.001 
 Separated 4 (1.0) 1 (0.2) 7.8 (0.9 – 70.4) 0.051 
 Widowed 10 (2.6) 3 (0.6) 6.5 (1.8 – 24.0) 0.001 
Occupation  Student 35 (9.1) 124 (24.5)  0.001 
  Unemployed 13 (3.4) 21 (4.1)   
  Civil servant 51 (13.2) 36 (7.1)   
  Artisan 32 (8.3) 38 (7.5)   
  Trading/Business 111 (28.8) 99 (19.5)   
  Farming 19 (4.9) 31 (6.1)   
 House-wife 37 (9.6) 48 (9.5)   
 Others 88 (22.8) 110 (21.7)   
Ethnicity Hausa 23 (6.2) 51 (10.4)  0.112 
 Igbo 74 (19.9) 94 (19.2)   
 Yoruba 31 (8.3) 49 (10.0)   
 Other  244 (65.6) 296 (60.4)   
Religion Christianity 302 (80.7) 340 (70.2)  0.001 
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 Islam 71 (19.0) 143 (29.5)   
 Others 1 (0.3) 1 (0.2)   
TB treatment category New  427 (97.0) 538 (97.3) 0.9 (0.4 – 1.9) 0.819 
 Retreatment  13 (3.0) 15 (2.7)   
Treatment used Category 1 420 (95.5) 518 (93.7) 1.4 (0.8 – 2.5) 0.222 
  Category 2 20 (4.5) 35 (6.3)   
Anatomical site of TB Pulmonary (PTB) 400 (90.9) 445 (80.5) 2.4 (1.6 – 3.6) 0.001 
 Extra-pulmonary 
(EPTB) 
40 (9.1) 108 (19.5)   
Type of PTB Smear-positive 95 (23.8) 252 (56.6) 1  
 Smear-negative 144 (36.0) 88 (19.8) 4.3 (3.0 – 6.2) 0.001 
 SM not done 161 (40.3) 105 (23.6) 4.1 (2.9 – 5.2) 0.001 
Smear grade (n = 349)b Scanty 13 (13.5) 22 (8.7) 1  
  + 25 (26.0) 66 (26.1) 0.6 (0.3 – 1.5) 0.291 
 ++ 30 (31.3) 95 (37.5) 0.5 (0.2 – 1.2) 0.124 
 +++ 28 (29.2) 70 (27.7) 0.7 (0.3 – 1.5) 0.347 
Xpert MTB (n = 192)c Very low 24 (24.2) 10 (10.8) 1  
 Low 32 (32.3) 32 (34.4) 0.4 (0.2 – 1.0) 0.053 
 Medium 29 (29.3) 31 (33.3) 0.4 (0.2 – 0.9)         0.039 
 High 14 (14.1) 20 (21.5) 0.3 (0.1 – 0.8) 0.016 
Xpert RIF (n = 196) Positive 0 (0.0) 2 (2.1)  0.480 
 Negative 100 (99.01) 92 (96.8)   
 Indeterminate 1 (0.9) 1 (1.1)   
Mean [SD] weight (kg) At baseline 47.5 (16.6)  51.3 (16.2)  -3.8 (-5.9 – -1.6)a 0.001 
 At 2 months  50.1 (16.9)  53.7 (15.1)  -3.6 (-6.4 – -0.9) a 0.009 
 At 5 months  54.3 (17.0)  57.0 (15.2)  -2.7 (-5.9 – 0.5) a 0.098 
Mean (SD) weight  At 2 months 1.7 (5.6)  2.2 (3.4)  -0.5 (-1.3 – 0.4) a 0.279 
difference (kg) At 5 months 4.7 (5.7)  4.5 (4.8)  0.2 (-0.9 – 1.3) a 0.704 
 aMean difference  (95% CI)                                                                                                                                         
bIn addition to the 347 smear-positive PTB, two EPTB were also smear-positive and were included                                                                                                                                                                                                     
cFour patients with positive Xpert MTB but no grading for MTB detection, were excluded 
 
4.4.3 TB treatment outcome by HIV status  
HIV-positive patients were less likely to be cured (68, 15.5%) or to complete treatment (162, 
36.8%) than HIV-negative patients (154, (27.9%) and 233 (42.1%)) respectively), as shown 
in table 4.6 and Figure 4.2.  Treatment success (cured + completed) was lower for HIV-
positive patients (53.2% versus 70.0%, p = 0.001). HIV-positive patients had higher mortality 
(15.5% versus 2.9%, p = 0.001) and were more likely to be LTFU than patients without HIV 
(22.5% versus 14.3%, p = 0.001).    
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Table 4.6. Treatment outcome of TB patients between 2012 and 2016 by HIV status 
Treatment Outcome HIV-positive 
n = 440 (%) 
HIV-negative 
n = 553 (%) 
P value 
Cured 68 (15.5) 154 (27.9) 0.001 
Completed 162 (36.8) 233 (42.1) 0.089 
Successful (cured + completed) 230 (52.3) 387 (70.0) 0.001 
Loss-to-follow up 99 (22.5) 79 (14.3) 0.001 
Failed 2 (0.5) 5 (0.9) 0.476 
Transferred out 27 (6.1) 36 (6.5) 0.810 
Died 68 (15.5) 16 (2.9) 0.001 
Not evaluated 14 (3.2) 30 (5.4) 0.088 
 * HIV status of 5 patients was unknown. 
 
Figure 4.2. TB treatment outcome by HIV status at UATH, 2012 – 2016. 
4.4.4 Kaplan-Meier Survival analysis for death by HIV status 
Figure 4.3 describes the survival analysis for death by HIV status.  There was a significant 
difference in the survival of HIV-negative and HIV-positive cases, throughout the course of 
treatment (Log Rank (p = 0.001)), with a higher death rate among HIV-positive patients.  The 
majority of deaths occurred within the first 10 weeks of TB treatment. 
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Figure 4.3. Kaplan-Meier Survival analysis for death among TB patients by HIV status 
 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 49.747 1 .000 
Breslow (Generalized 
Wilcoxon) 
51.295 1 .000 
Tarone-Ware 50.742 1 .000 
Test of equality of survival distributions for the different levels of 
HIV_Status. 
 
4.4.5 Factors associated with treatment failure or death  
Table 4.7 compares the characteristics of patients who died/failed treatment with those who 
had successful treatment. Patients who died/failed treatment were older (mean (SD) 37.8 
(15.7) years) than patients with successful treatment (31.4 (15.3), p = 0.001). Patients who 
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died/failed treatment were more likely to be HIV-positive than patients with treatment 
success (OR, 95% CI: 5.6, 3.4 – 9.4, p = 0.001). 
Patients who died/ failed treatment were more likely to be smear-negative (OR, 95% CI: 2.0, 
1.1 – 3.8, p < 0.026), to be diagnosed by X-ray or Xpert MTB/RIF (p = 0.001) and to have 
lower weight gain at 2 and 5 months (-1.4 and 0.6 versus 2.1 and 4.6 Kgs, respectively, p = 
0.008 and 0.057, respectively).  
Table 4.7. Bivariable analysis of factors associated with death/failed TB treatment  
Variable Category            Treatment outcome Odds ratio 
(95% CI)  
P 
 
 Death/ 
failure        
N = 91 
Success 
 
N = 619 
  
Mean (SD) age  All    37.8 (15.7)  31.4 (15.3)  6.4 (3.1 – 9.8)a 0.001 
(years) Male  40.8 (15.9)  33.0 (16.2)  7.8 (3.1 – 12.5) a 0.001 
 Female  33.7 (14.5) 29.2 (13.6) 4.5 (0.1 – 9.2) a 0.058 
Age group* 0 – 9  6 (6.6) 60 (9.7)  0.001 
 10 – 19  3 (3.3) 56 (9.1)   
 20 – 29  15 (16.5) 150 (24.2)   
 30 – 39  22 (24.2) 188 (30.4)   
 40 – 49  24 (26.4) 100 (16.2)   
 50 – 59  13 (14.3) 31 (5.0)   
 60 – 69  5 (5.5) 21 (3.4)   
 ≥ 70 3 (3.3) 13 (2.1)   
Gender Male  53 (58.2) 361 (58.3) 1.0 (0.6 – 1.6) 0.989 
 Female 38 (41.8) 258 (41.7)   
Treatment category      New  91 (100.0) 600 (96.9) Undefined 0.155 
 Retreatment  0 (0.0) 19 (3.1)   
Anatomical site Pulmonary 80 (87.9) 529 (85.5) 1.2 (0.6 – 2.4) 0.532 
 EPTB 11 (12.1) 90 (14.5)   
Smear microscopy Positive 21 (26.3) 262 (49.5) 1  
 Negative 24 (30.0) 148 (28.0) 2.0 (1.1 – 3.8) 0.026 
 Not done 35 (43.8) 119 (22.5) 3.7 (2.0 – 6.6) 0.001 
Treatment used Category 1 87 (95.6) 589 (95.2) 1.1 (0.4 – 3.2) 0.851 
  Category 2 4 (4.4) 30 (4.8)   
HIV status Positive 70 (76.9) 230 (37.3) 5.6 (3.4 – 9.4) 0.001 
  Negative 21 (23.1) 387 (62.7)   
Smear grade (n = 283) Scanty 4 (19.0) 21 (8.0) 1  
  + 6 (28.6) 68 (26.0) 0.5 (0.1 – 1.7) 0.248 
  ++ 4 (19.0) 96 (36.6) 0.2 (0.05 – 0.9) 0.042 
 +++ 7 (33.3) 77 (29.4) 0.5 (0.1 – 1.8) 0.272 
Xpert grade (n = 142)  Very low 3 (13.6) 24 (20.0) 1  
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  Low 10 (45.5) 33 (27.5) 2.5 (0.6 – 10.1) 0.192 
 Medium 8 (36.4) 38 (31.7) 2.0 (0.5 – 8.0) 0.341 
 High 1 (4.5) 25 (20.8) 0.3 (0.0 – 3.4) 0.355 
Mean (SD) weight Baseline  49.8 (16.4) 50.3 (16.3)  -0.5 (-4.1 – 3.2) a 0.795 
 2 months  55.8 (8.1)  52.6 (15.9) 3.2 (-6.2 – 12.6) a 0.505 
 5 months  61.0 (6.0)  55.9 (16.1) 5.1 (-7.9 – 18.0) a 0.441 
Weight difference At 2 months -1.4 (3.4) 2.1 (4.3) -3.5 (-6.1 – -0.9) a 0.008 
 At 5 months 0.6 (2.5) 4.6 (5.2) -4.0 (-8.2 – 0.1) a 0.057 
*n (%) unless otherwise stated.  aMean (95%CI). bFour patients without HIV status excluded; cOnly sputum 
smear-positive included; dThree positive Xpert MTB patients had no MTB grading and were excluded  
 
4.4.6 Kaplan-Meier Survival analysis for LTFU by HIV status 
There was higher rate of LTFU among HIV-positive than HIV-negative patients throughout 
the course of TB treatment (p < 0.001) as shown in figure 4.4. In contrast to deaths, LTFU for 
HIV-positive patients continued to occur throughout the course of TB treatment. 
 
Figure 4.4. Kaplan-Meier Survival curve analysis for LTFU among TB patients by HIV 
status 
 
 
 
94 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 15.899 1 .000 
Breslow (Generalized 
Wilcoxon) 
14.817 1 .000 
Tarone-Ware 15.156 1 .000 
Test of equality of survival distributions for the different levels of HIV 
Status. 
 
4.4.7 Risk factors for LTFU 
Patients LTFU were also more likely to be HIV-positive (p = 0.001) and to be older (mean 
(SD) age 34.8 (17.4)) than patients with successful treatment (31.4 (15.3), p = 0.017). Males 
LTFU were significantly older than males with successful treatment (38.3 (17.5) versus 33.0 
(16.2), p = 0.005). However, women LTFU and with successful treatment had similar age 
(30.6 (16.5) versus 29.2 (13.6) years, respectively, p = 0.448). Patients LTFU were more 
likely to be smear-negative (p = 0.07), not to have smear microscopy and to be diagnosed by 
X-rays or GeneXpert (p = 0.001). The TB treatment category (new or retreatment), 
anatomical site and treatment used, were not associated with LTFU.  
The mean (SD) weight at 2 months of treatment for LTFU patients was significantly lower 
(45.5 (16.6) Kgs) than for patients with successful treatment (52.6 (15.9), p = 0.03), although 
there was not significant weight change at 2 or 5 months, between the groups.  
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Table 4.8. Bivariable analysis of risk factors for LTFU  
Variable Category    Treatment outcome Odds ratios      
(95% CI) 
P  
Loss-to-
follow up 
N= 180 
Successful 
 
N= 619 
Mean (SD) age All    34.8 (17.4)  31.4 (15.3)  3.4 (0.6 – 6.3)a 0.017 
(years) Male  38.3 (17.5)  33.0 (16.2)  5.3 (1.6 – 8.9) a 0.005 
 Female  30.6 (16.5)  29.2 (13.6)  1.4 (-2.2 – 5.0) a 0.448 
Age group* 0 – 9  19 (10.6) 60 (9.7)  0.022 
 10 – 19  9 (5.0) 56 (9.1)   
 20 – 29  35 (19.4) 150 (24.2)   
 30 – 39  44 (24.4) 188 (30.4)   
 40 – 49  43 (23.9) 100 (16.2)   
 50 – 59  15 (8.3) 31 (5.0)   
 60 – 69  7 (3.9) 21 (3.4)   
 ≥ 70 8 (4,4) 13 (2.1)   
Gender Male  100 (55.6) 361 (58.3) 0.9 (0.6 – 1.2) 0.509 
 Female 80 (44.4) 258 (41.7)   
Treatment category New  174 (96.7) 600 (96.9) 0.9 (0.41 – 2.3) 0.858 
 Retreatment  6 (3.3) 19 (3.1)   
Anatomical site  Pulmonary 155 (86.1) 529 (85.5) 1.1 (0.7 – 1.7) 0.827 
 EPTB 25 (13.9) 90 (14.5)   
Type of PTB SM-positive 43 (27.7) 262 (49.5) 1  
 SM-negative 38 (24.5) 148 (28.0) 1.6 (1.0 – 2.5) 0.068 
 Not done 74 (47.7) 119 (22.5) 3.8 (2.5 – 5.8) 0.001 
Treatment used Category 1 169 (93.9) 589 (95.2) 0.8 (0.4 – 1.6) 0.499 
 Category 2 11 (6.1) 30 (4.8)   
HIV status  Positive 99 (55.6) 230 (37.3) 2.1 (1.5 – 3.0) 0.001 
(n = 795)b Negative 79 (44.4) 387 (62.7)   
Smear grade  Scanty 7 (16.3) 21 (8.0) 2.6 (0.9 – 7.6) 0.087 
(n=305)c + 8 (18.6) 68 (26.0) 0.9 (0.3 – 2.4) 0.799 
 ++ 18 (41.9) 96 (36.6) 1.4 (0.6 – 3.3) 0.385 
 +++ 10 (23.3) 77 (29.4) 1  
Xpert MTB/RIF  Very low 4 (13.8) 24 (20.0) 1.0 (0.2 – 4.6) 0.957 
(n = 149)d Low 11 (37.9) 33 (27.5) 2.1 (0.6 – 7.3) 0.252 
 Medium 10 (34.5) 38 (31.7) 1.6 (0.5 – 5.8) 0.441 
 High 4 (13.8) 25 (20.8) 1  
Mean (SD) weight  Baseline  48.1 (17.0)  50.3 (16.3)  -2.2 (-5.0 – 0.6) a 0.125 
(Kgs) After 2 months  45.5 (16.6)  52.6 (15.9)    -7.1 (-13.4 – -0.8) a 0.027 
 After 5 months  54.0 (0.0)  55.9 (16.1)  -1.9 (-33.6 – 29.7) a 0.905 
Weight difference At 2 months 1.4 (5.5)  2.1 (4.3)  -0.7 (-2.5 – 1.1) a 0.429 
 At 5 months 3.0 (0.0)  4.6 (5.2)  -1.6 (-11.8 – 8.6) a 0.753 
*n (%) unless otherwise stated.  aMean (95%CI). bFour patients without HIV status excluded; cOnly sputum 
smear-positive included; dThree positive Xpert MTB patients had no MTB grading and were excluded,           
SM = Smear Microscopy  
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 4.4.8 Factors associated with death or treatment failure among HIV-positive patients 
with TB 
HIV was a key factor associated with death and treatment failure. Therefore, we conducted a 
further analysis of risk factors for death/treatment failure among this subgroup. HIV-positive 
patients who died/failed treatment were older (p = 0.016) and less likely to receive Co-
trimoxazole preventive therapy (CPT) than HIV-positive patients with TB treatment success 
(p = 0.002). There was no significant association between death/treatment failure and gender, 
treatment category, anatomical site affected by TB, smear-positivity, smear grade, treatment 
used, Xpert MTB grade or ART (“Not on ART” versus “On ART”, p = 0.794). The average 
body weight on enrolment, 2 or 5 months follow up, was not different between HIV-positive 
patients with death/treatment failure and successful treatment.  
Table 4.9. Bivariable analysis of factors associated with death or treatment failure among HIV-
positive TB patients 
Variable Category          Treatment outcome Odds ratio (95% 
CI)  
        
  P  
Death/Failure 
N = 70 (%) 
Success 
N= 230 
(%) 
Mean (SD) age  All    37.8 (15.6) 33.1 (13.8)  4.7 (0.9 – 8.5) a 0.016 
(years) Male  40.6 (16.3) 36.3 (15.5) 4.3 (-1.4 – 10.0) a 0.136 
 Female  33.9 (13.9) 30.0 (11.0) 3.9 (-0.9 – 8.9) a 0.107 
Age group (years) 0 – 9  5 (7.1) 21 (9.1)  0.118 
 10 – 19  3 (4.3) 14 (6.1)   
 20 – 29  7 (10.0) 34 (14.8)   
 30 – 39  20 (28.6) 87 (37.8)   
 40 – 49  20 (28.6) 55 (23.9)   
 50 – 59  9 (12.9) 12 (5.2)   
 60 – 69  4 (5.7) 5 (2.2)   
 ≥ 70 2 (2.9) 2 (0.9)   
Gender  Male  41 (58.6) 114 (49.6) 1.4 (0.8 – 2.5) 0.187 
 Female 29 (41.4) 116 (50.4)   
Treatment category  New  70 (100.0) 222 (96.5) Undefined 0.205 
 Retreatment  0 (0.0) 8 (3.5)   
Anatomical site of TB Pulmonary 64 (91.4) 208 (90.4) 1.1 (0.3 – 2.9) 0.802 
 Extrapulmonary 6 (8.6) 22 (9.6)   
Type of PTB Smear-positive 15 (23.4) 57 (27.4) 1  
 Smear-negative 19 (29.7) 83 (39.9) 0.9 (0.4 – 1.9) 0.718 
 Smear not done 30 (46.9) 68 (32.7) 1.7 (0.8 – 3.4) 0.155 
Treatment used Category 1 66 (94.3) 216 (93.9) 1.1 (0.3 – 3.4) 0.908 
 Category 2 4 (5.7) 14 (6.1)   
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Smear grade (n = 73)b  Scanty 3 (20.0) 5 (8.6) 1  
 + 5 (33.3) 15 (25.9) 0.6 (0.1 – 3.2) 0.511 
 ++ 2 (13.3) 20 (34.5) 0.2 (0.02 – 1.3) 0.085 
 +++ 5 (33.3) 18 (31.0) 0.5 (0.1 – 2.6) 0.386 
Xpert MTB/RIF (n = 
71)c 
Very low/Low 
11 (57.9) 29 (55.8) 1.1 (0.4 – 3.2) 0.873 
 Medium/High 8 (42.1) 23 (44.2) 1  
ART status  On ART 48 (68.6) 153 (66.5) 1  
 Not on ART 20 (28.6) 69 (30.0) 0-9 (0.5 – 1.7) 0-794 
 Unknown 2 (2.9) 8 (3.5) 0.8 (0.2 – 3.9) 0.779 
CPT status On CPT 34 (48.6) 158 (68.7) 1  
 Not on CPT 30 (42.9) 56 (24.3) 2.5 (1.4 – 4.4) 0.002 
 Unknown 6 (8.6)      16 (7.0) 1.7 (0.6 – 4.8) 0.281 
Mean [SD] weight (kg) At baseline 48.1 (16.2) 48.9 (16.5) -0.711 (-5.2 – 3.8) a 0.757 
 At 2 months 58.3 (10.4) 50.1 (16.7) 7.3 (-11.9 – 26.4) a 0.455 
 At 5 months  64.0 (0.0) 54.2 (17.1) 17.1 (-24.1 – 43.7) a 0.569 
Mean [SD] weight  At 2 months 0.0 (6.1) 1.8 (5.5) -1.8 (-8.1 – 4.5) a 0.570 
difference (kg) At 5 months -3.0 (0.0) 4.7 (5.7) -7.7 (-19.1 – 3.6) a 0.180 
aMean difference and its 95% Confidence Interval.        bOnly sputum smear-positive patients were included.        
cTwo patients with positive Xpert MTB but no grading for MTB detection, were excluded.                              
CPT = Co-trimoxazole preventive therapy.  Xpert = Xpert MTB/RIF 
      
4.4.9 Factors associated with death/treatment failure among HIV-negative TB patients. 
For completion, table 4.10 also shows the risk factors associated with death/treatment failure 
among HIV-negative patients. Males who died/failed treatment were older than males with 
treatment success (41.5 (15.2) versus 31.5 (16.4), p = 0.039) but this age difference was not 
observed in females. Patients who died/failed treatment were similar to patients with 
successful treatment with respect to gender, treatment category, anatomical site of TB, 
treatment used and proportion with Rifampicin resistance. The mean (SD) weight change at 2 
months after commencement of TB treatment was lower for patients who died/failed 
treatment compared to patients with successful treatment (-1.9 (2.2) versus 2.2 (3.4), p = 
0.001).  
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Table 4.10. Bivariable analysis of risk factors for death/treatment failure among HIV-negative 
TB patients  
Variable Category         Treatment outcome Odds ratio (95% 
CI) 
 
P  
Death/Failure 
N = 21 (%) 
Success 
N= 387 (%) 
Mean (SD) age  All    38.0 (16.3) 30.3 (16.0)  7.7 (0.6 – 14.7) a 0.033 
(years) Male  41.5 (15.2) 31.5 (16.4) 10.0 (0.5 – 19.6) a 0.039 
 Female  33.2 (17.3) 28.3 (15.1) 5.0 (-5.4 – 15.3) a 0.346 
Age group (years) 0 – 9  1 (4.8) 39 (10.1)  0.039 
 10 – 19  0 (0.0) 42 (10.9)   
 20 – 29  8 (38.1) 116 (30.0)   
 30 – 39  2 (9.5) 100 (25.8)   
 40 – 49  4 (19.0) 45 (11.6)   
 50 – 59  4 (19.0) 19 (4.9)   
 60 – 69  1 (4.8) 15 (3.9)   
 ≥ 70 1 (4.8) 11 (2.8)   
Gender  Male  12 (57.1) 246 (63.6) 0.8 (0.3 – 1.9) 0.552 
 Female 9 (42.9) 141 (36.4)   
Treatment category New  21 (100.0) 376 (97.2) Undefined 1.000 
 Retreatment  0 (0.0) 11 (2.8)   
Anatomical site of TB Pulmonary 16 (76.2) 320 (82.7) 0.7 (0.2 – 1.9) 0.447 
 Extrapulmonary 5 (23.8) 67 (17.3)   
Type of PTB Smear-positive 6 (37.5) 205 (64.1) 1  
 Smear-negative 5 (31.3) 64 (20.0) 2.7 (0.8 – 9.0) 0.115 
 Smear not done 5 (31.3) 51 (15.9) 3.4 (0.98 – 11.4) 0.053 
Treatment used Category 1 21 (100.0) 371 (95.9) Undefined 1.000 
 Category 2 0 (0.0) 16 (4.1)   
Smear grade  Scanty 1 (16.7) 16 (7.8) 1  
(n =212)b + 1 (16.7) 55 (26.7) 0.3 (0.02 – 4.9) 0.392 
 ++ 2 (33.3) 76 (36.9) 0.4 (0.04 – 4.9) 0.491 
 +++ 2 (33.3) 59 (28.6) 0.5 (0.05 – 6.4) 0.626 
Xpert MTB/RIF  Very low/Low 2 (66.7) 28 (41.2) 2.9 (0.3 – 33.0) 0.570 
(n = 71)c Medium/High 1 (33.3) 40 (58.8)   
Mean (SD) weight (kg) At baseline 55.0 (16.5) 51.1 (16.1) 3.9 (-3.2 – 11.0) a 0.280 
 At 2 months 54.9 (7.6) 53.5 (15.3) 1.4 (-9.3 – 12.0) a 0.804 
 At 5 months 60.4 (6.5) 56.9 (15.4) 3.5 (-10.1 – 17.1) a 0.615 
Mean (SD) weight  At 2 months -1.9 (2.2) 2.2 (3.4) -4.2 (-6.5 – -1.8) a 0.001 
difference (kg) At 5 months 1.3 (2.0) 4.6 (4.8) -3.3 (-7.5 – 1.0) a 0.134 
aMean difference and its 95% Confidence Interval, bSputum smear-positive PTB cases plus an EPTB case, which 
was also smear-positive were included, cA patient with positive Xpert MTB but no grading for MTB detection, 
was excluded     
 
4.4.10 Risk factors for LTFU among HIV-positive TB patients treated at UATH 
HIV-positive patients LTFU had similar age, gender, treatment category, anatomical site of 
TB, treatment used and Xpert MTB grade compared to patients with successful treatment, as 
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shown in table 4.11. HIV-positive patients LTFU were more likely to have missed CPT (p = 
0.038) than patients with treatment success. The mean (SD) weight of patients LTFU was 
lower than for patients with treatment success on enrolment (44.1 (17.1) versus 48.9 (16.5), p 
= 0.023). Nevertheless, there was not significant weight change at 2 months, between the two 
groups. 
Table 4.11. Bivariable analysis of risk factors for LTFU among HIV-positive TB patients 
Variable   Treatment outcome Odds ratio (95% 
CI)  
        
 
P  
 LTFU 
N = 99 (%) 
Success 
N= 230 (%) 
Mean (SD) age  All    32.9 (15.6) 33.1 (13.8)  -0.2 (-3.6 – 3.2) a 0.900 
(years) Male  36.2 (16.0) 36.3 (15.5) -0.1 (-5.4 – 5.2) a 0.973 
 Female  29.8 (14.6) 30.0 (11.0) -0.2 (-4.3 – 3.9) a 0.921 
Age group (years) 0 – 9  14 (14.1) 21 (9.1)  0.692 
 10 – 19  3 (3.0) 14 (6.1)   
 20 – 29  15 (15.2) 34 (14.8)   
 30 – 39  30 (30.3) 87 (37.8)   
 40 – 49  27 (27.3) 55 (23.9)   
 50 – 59  7 (7.1) 12 (5.2)   
 60 – 69  2 (2.0) 5 (2.2)   
 ≥ 70 1 (1.0) 2 (0.9)   
Gender Male  48 (48.5) 114 (49.6) 1.0 (0.6 – 1.5) 0.857 
 Female 51 (51.5) 116 (50.4)   
Treatment category New  94 (94.9) 222 (96.5) 0.7 (0.2 – 2.1) 0.502 
 Retreatment  5 (5.1) 8 (3.5)   
Anatomical site of TB Pulmonary 90 (90.9) 208 (90.4) 1.1 (0.5 – 2.4) 0.893 
 Extrapulmonary 9 (9.1) 22 (9.6)   
Type of PTB  Smear-positive 15 (16.7) 57 (27.4) 1  
 Smear-negative 31 (34.4) 83 (39.9) 1.4 (0.7 – 2.9) 0.329 
 Smear not done 44 (48.9) 68 (32.7) 2.5 (1.2 – 4.9) 0.010 
Treatment used Category 1 97 (98.0) 216 (93.9) 3.1 (0.7 – 14.1) 0.116 
 Category 2 2 (2.0) 14 (6.1)   
Smear grade (n =73)b          Scanty 4 (26.7) 5 (8.6) 1  
 + 2 (13.3) 15 (25.9) 0.2 (0.0 – 1.2) 0.076 
 ++ 5 (33.3) 20 (34.5) 0.3 (0.1 – 1.6) 0.164 
 +++ 4 (26.7) 18 (31.0) 0.3 (0.1 – 1.5) 0.141 
Xpert MTB/RIF (n = 
73)c 
Very low 
11 (52.3) 29 (55.8) 0.9 (0.3 – 2.4) 0.792 
 Medium/High 10 (47.6) 23 (44.2) 1  
ART status On ART 60 (60.6) 153 (66.5) 1  
 Not on ART 31 (31.3) 69 (30.0) 1.2 (0.7 – 1.9) 0.607 
 Unknown 8 (8.1) 8 (3.5) 2.6 (0.9 – 7.1) 0.073 
CPT status On CPT 55 (55.6) 158 (68.7) 1  
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 Not on CPT 34 (34.3) 56 (24.3) 1.7 (1.0 – 2.9) 0.038 
 Unknown 10 (10.1) 16 (7.0) 1.8 (0.8 – 4.2) 0.176 
Mean (SD) weight (kg) At baseline 44.1 (17.1) 48.9 (16.5) -4.7 (-8.8 – -0.7) a 0.023 
 At 2 months 36.6 (15.6) 50.1 (16.7) -14.5 (-23.4 – -5.7) a 0.001 
 At 5 months  ------------- 54.2 (17.1) --------------------  
Mean (SD) weight  At 2 months 0.8 (7.0) 1.8 (5.5) -1.000 (-4.1 – 2.1) a 0.521 
difference (kg) At 5 months -------------- 4.7 (5.7)   
aMean difference and its 95% Confidence Interval.     LTFU = Loss-to-follow up. bIn addition to the 72 smear-
positive PTB, an EPTB was also smear-positive and included. cTwo patients with positive Xpert MTB but no 
grading for MTB detection, were excluded. ----- data not available. CPT = Co-trimoxazole preventive therapy 
 
4.4.11 Risk factors for LTFU among HIV-negative TB patients treated at UATH  
HIV-negative patients LTFU were older (mean (SD) age (37.8 (19.3) versus 30.3 (16.0), p = 
0.001) and less likely to be on treatment category 1 than patients with successful treatment (p 
= 0.009).  Patients LTFU had similar gender, treatment category, anatomical site of TB, and 
Xpert MTB grade to patients who completed treatment.  
Table 12. Bivariable analysis of risk factors for LTFU among HIV-negative TB patients treated 
UATH  
Variable Category         Treatment outcome Odds ratio (95% 
CI)  
        
 
P  
LTFU Success 
N = 79  
n (%) 
N = 387 
n (%) 
Mean (SD) age (years) All    37.8 (19.3) 30.3 (16.0)  7.4 (3.4 – 11.4) a 0.001 
 Male  40.4 (18.9) 31.5 (16.4) 9.0 (3.9 – 14.1) a 0.001 
 Female  32.7 (19.5) 28.3 (15.1) 4.4 (-2.1 – 10.9) a 0.182 
Age group (years) 0 – 9  5 (6.3) 39 (10.1)  0.009 
 10 – 19  5 (6.3) 42 (10.9)   
 20 – 29  19 (24.1) 116 (30.0)   
 30 – 39  14 (17.7) 100 (25.8)   
 40 – 49  16 (20.3) 45 (11.6)   
 50 – 59  8 (10.1) 19 (4.9)   
 60 – 69  5 (6.3) 15 (3.9)   
 ≥ 70 7 (8.9) 11 (2.8)   
Gender  Male  51(64.6) 246 (63.6) 1.0 (0.6 – 1.7) 0.867 
 Female 28 (35.4) 141 (36.4)   
Treatment category New cases 78 (98.7) 376 (97.2) 2.3 (0.3 – 17.9) 0.700 
 Retreatment  1 (1.3) 11 (2.8)   
Anatomical site of TB Pulmonary 63 (79.7) 320 (82.7) 0.8 (0.5 – 1.5) 0.534 
 Extrapulmonary 16 (20.3) 67 (17.3)   
Type of PTB  Smear-positive 28 (44.4) 205 (64.1) 1  
 Smear-negative 6 (9.5) 64 (20.0) 0.7 (0.3 – 1.7) 0.425 
 Smear not done 29 (46.0) 51 (15.9) 4.2 (2.3 – 7.6) 0.001 
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Treatment used Category 1 70 (88.6) 371 (95.9) 0.3 (0.1 – 0.8) 0.009 
 Category 2 9 (11.4) 16 (4.1)   
Smear grade (n = 234)b Scanty 3 (10.7) 16 (7.8) 1  
 + 6 (21.4) 55 (26.7) 0.6 (0.1 – 2.6) 0.477 
 ++ 13 (46.4) 76 (36.9) 0.9 (0.2 – 3.6) 0.895 
 +++ 6 (21.4) 59 (28.6) 0.5 (0.1 – 2.4) 0.422 
Xpert MTB/RIF (n = 
76)c 
Very low/Low 
4 (50.0) 28 (41.2) 
1.4 (0.3 – 6.2) 0.714 
 Medium/High 4 (50.0) 40 (58.8)   
Mean [SD] weight (kg) Baseline  53.3 (15.4) 51.1 (16.1) 2.2 (-1.8 – 6.2) a 0.283 
 At 2 months 58.0 (8.5) 53.5 (15.3) 4.5 (-5.1 – 14.1) a 0.359 
 At 5 months 54.0 (0.0) 56.9 (15.4) -2-9(-33.3 – 27.4) a 0.850 
Mean (SD) weight 
difference (kg) 
At 2 months 2.1 (2.1) 2.2 (3.4) -0.1 (-2.2 – 2.0) a 0.913 
 At 5 months 3.0 (0.0) 4.6 (4.8) -1.6 (-11.1 – 8.0) a 0.748 
aMean difference and its 95% Confidence Interval.     LTFU = Loss-to-follow up                                                                                                                                                                                                                         
b Sputum smear-positive PTB cases plus an EPTB case, which was also smear-positive were included                                                                                                                                                  
cA patients with positive Xpert MTB but no grading for MTB detection, were excluded     
 
4.4.12 Multivariable analysis of risk factors for death/failed treatment  
Variables with a P values ≤ 0.2 were included in the multivariable analysis and adjusted for 
age, gender and HIV status as shown in table 4.13. After adjustment, patients who died/failed 
treatment were older (AOR (95% CI) = 1.03 (1.01 – 1.04), p = 0.003), were 5 times more 
likely to be HIV-positive (AOR (95% CI) = 5.4 (3.2 – 9.1), p = 0.001) and to have a lower 
weight difference at 2 and 5 months follow up than patients with successful treatment (AOR 
(95% CI) = 0.8 (0.7 – 0.9), p = 0.005 and 0.8 (0.7 – 0.9), p = 0.001). 
4.4.13 Multivariable analysis of risk factors for LTFU  
After adjusting for age, gender and HIV status, patients LTFU were older (AOR (95% CI) = 
1.02 (1.00 – 1.03), p = 0.015), more likely to be diagnosed by Xpert MTB/RIF or Chest X-
rays (AOR (95% CI) = 3.2 (2.0 – 5.1), p = 0.001) and 2 times more likely to be HIV-positive 
(AOR (95% CI) = 2.1 (1.5 – 2.9), p = 0.001) and to have lower weight at baseline (AOR 
(95% CI) = 0.98 (0.97 – 0.99), p = 0.003) and 2 months (AOR (95% CI) = 0.96 (0.94 – 0.99), 
p = 0.003) than patients with treatment success. 
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Table 4.13. Multivariable analysis of factors associated with death/failed treatment among TB patients, UATH 2012 - 2016 
Variable Category      Treatment outcome OR (95% CI)  
 
P 
 
AOR (95% CI) P  
 Death/failure        
N = 91 (%) 
Success 
N = 619 (%) 
Age (years) Mean (SD)   37.8 (15.7)  31.4 (15.3)  6.4 (3.1 – 9.8)a 0.001 1.03 (1.01 – 1.04) 0.003 
Gender Male  53 (58.2) 361 (58.3) 1.0 (0.6 – 1.6) 0.989 1.0 (0.6 – 1.7) 0.869 
 Female 38 (41.8) 258 (41.7) 1    
Smear microscopy Smear-positive 21 (26.3) 262 (49.5) 1  1  
 Smear-negative 24 (30.0) 148 (28.0) 2.0 (1.1 – 3.8) 0.026 1.1 (0.6 – 2.2) 0.707 
 Not done 35 (43.8) 119 (22.5) 3.7 (2.0 – 6.6) 0.001 2.4 (1.3 – 4.6) 0.006 
HIV status Positive 70 (76.9) 230 (37.3) 5.6 (3.4 – 9.4) 0.001 5.4 (3.2 – 9.1) 0.001 
  Negative 21 (23.1) 387 (62.7) 1    
Smear grade (n = 283) Scanty 4 (19.0) 21 (8.0) 1  1  
  + 6 (28.6) 68 (26.0) 0.5 (0.1 – 1.7) 0.248 0.5 (0.1 – 1.9) 0.291 
  ++ 4 (19.0) 96 (36.6) 0.2 (0.05 – 0.9) 0.042 0.3 (0.1 – 1.3) 0.094 
 +++ 7 (33.3) 77 (29.4) 0.5 (0.1 – 1.8) 0.272 0.5 (0.1 – 2.0) 0.300 
Xpert grade (n = 142)  Very low 3 (13.6) 24 (20.0) 1  1  
  Low 10 (45.5) 33 (27.5) 2.5 (0.6 – 10.1) 0.192 3.1 (0.6 – 15.7) 0.165 
 Medium 8 (36.4) 38 (31.7) 2.0 (0.5 – 8.0) 0.341 2.5 (0.5 – 12.2) 0.264 
 High 1 (4.5) 25 (20.8) 0.3 (0.0 – 3.4) 0.355 0.5 (0.0 – 5.7) 0.556 
Weight difference At 2 months -1.4 (3.4) 2.1 (4.3) -3.5 (-6.1 – -0.9) a 0.008 0.8 (0.7 – 0.9) 0.005 
 At 5 months 0.6 (2.5) 4.6 (5.2) -4.0 (-8.2 – 0.1) a 0.057 0.8 (0.7 – 0.9) 0.001 
*AOR = Adjusted odds ratio. n (%) unless otherwise stated.  aMean (95%CI). bFour patients without HIV status excluded; cOnly sputum smear-positive included.           
dThree positive Xpert MTB patients had no MTB grading and were excluded  
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4.4.14 Multivariable analysis of risk factors for death/treatment failure by HIV status 
The type of PTB and use of CPT were predictors of death/treatment failure among HIV-
positive patients, as shown in table 4.15. Patients with death/treatment failure were older 
(AOR (95% CI) = 1.02 (1.00 – 1.05), p = 0.057) and 2 times more likely to have Xpert 
MTB/RIF or a chest X-ray (AOR (95% CI) = 2.1 (1.0 – 4.2), p = 0.047) than patients with 
treatment success. Patients who died/failed treatment were 2.5 times less likely to have 
received CPT (AOR (95% CI) = 2.5 (1.4 – 4.4), p = 0.003) than patients with treatment 
success. 
Age, the type of PTB and weight at 2 and 5 months were predictors of death/treatment failure 
among HIV-negative patients (table 4.16). Patients who died/failed treatment were older 
(AOR (95% CI) = 1.03 (1.01 – 1.05), p = 0.014), 2 times more likely to have smear-negative 
PTB (AOR (95% CI) = 2.4 (0.7 – 7.5), p = 0.146) or 3 times more likely to have PTB 
diagnosed by Xpert MTB/RIF or chest X-rays (AOR (95% CI) = 3.4 (1.0 – 11.6), p = 0.050), 
than patients with treatment success. Patients who died/failed treatment have lower body 
weight at 2 (AOR (95% CI) = 0.7 (0.6 – 0.8), p = 0.001) and 5 months (AOR (95% CI) = 0.9 
(0.8 – 1.0), p = 0.004) than patients with treatment success.  
4.4.15 Multivariable analysis of risk factors for LTFU by HIV status 
After adjusting for age and gender, the variables that remained significant at predicting 
whether HIV-positive patient were LTFU or successfully treated were; the type of TB, use of 
CPT, baseline weight, and weight at 2 months. Patients LTFU were more likely to have 
smear-negative TB (AOR (95% CI) = 1.4 (0.7 – 2.9), p = 0.325) and the diagnosis being 
based on Xpert MTB/RIF or chest X-rays (AOR (95% CI) = 2.5 (1.3 – 5.1), p = 0.009) than 
patients with treatment success, as shown in table 4.17. Patients not on CPT (AOR (95% CI) 
= 1.7 (1.0 – 2.9), p = 0.037) and with a low weight at baseline (AOR (95% CI) = 0.97 (0.95 – 
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0.98), p = 0.001) and 2 months (AOR (95% CI) = 0.94 (0.88 – 0.99), p = 0.032) were more 
likely to be LTFU than patients with treatment success. 
Adjustment was also made for age and gender for HIV-negative patients. After multivariable 
analysis age, type of TB and treatment used were statistically significant (table 4.18). Patients 
LTFU were older (AOR (95% CI) = 1.03 (1.01 – 1.04), p = 0.001) and more likely to have a 
diagnosis based on MTB/RIF or chest X-ray (AOR (95% CI) = 4.3 (2.3 – 7.9), p = 0.001), 
than successfully treated patients. However, patients with LTFU were less likely to be treated 
with category 1 anti-TB regimen (AOR (95% CI) = 0.4 (0.2 – 0.9), p = 0.036).  
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Table 4.14. Multivariable analysis of risk factors for LTFU patients treated at UATH between 2012 and 2016 
Variable     Treatment outcome OR (95% CI)  
 
P  AOR (95% CI) P  
 LTFU 
N= 180 (%) 
Successful 
 N= 619 (%) 
Age (years) Mean (SD) 34.8 (17.4)  31.4 (15.3)  3.4 (0.6 – 6.3)a 0.017 1.02 (1.00 – 1.03) 0.015 
Gender Male  100 (55.6) 361 (58.3) 0.9 (0.6 – 1.2) 0.509 0.9 (0.6 – 1.3) 0.637 
 Female 80 (44.4) 258 (41.7) 1  1  
Type of PTB Smear-positive 43 (27.7) 262 (49.5) 1  1  
 Smear-negative 38 (24.5) 148 (28.0) 1.6 (1.0 – 2.5) 0.068 1.2 (0.7 – 2.0) 0.507 
 Not done 74 (47.7) 119 (22.5) 3.8 (2.5 – 5.8) 0.001 3.2 (2.0 – 5.1) 0.001 
HIV status (n = 795)b Positive 99 (55.6) 230 (37.3) 2.1 (1.5 – 3.0) 0.001 2.1 (1.5 – 2.9) 0.001 
 Negative 79 (44.4) 387 (62.7) 1    
Smear grade (n = 305)c Scanty 7 (16.3) 21 (8.0) 2.6 (0.9 – 7.6) 0.087 2.3 (0.8 – 6.8) 0.125 
 + 8 (18.6) 68 (26.0) 0.9 (0.3 – 2.4) 0.799 0.8 (0.3 – 2.2) 0.692 
 ++ 18 (41.9) 96 (36.6) 1.4 (0.6 – 3.3) 0.385 1.5 (0.7 – 3.6) 0.329 
 +++ 10 (23.3) 77 (29.4) 1  1  
Mean (SD) weight  Baseline  48.1 (17.0)  50.3 (16.3)  -2.2 (-5.0 – 0.6) a 0.125 0.98 (0.97 – 0.99) 0.003 
(Kgs) After 2 months  45.5 (16.6)  52.6 (15.9)    -7.1 (-13.4 – -0.8) a 0.027 0.96 (0.94 – 0.99) 0.003 
*n (%) unless otherwise stated.  aMean (95%CI). bFour patients without HIV status excluded; cOnly sputum smear-positive included; dThree positive Xpert MTB patients had 
no MTB grading and were excluded 
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Table 4.15. Multivariable analysis of factors associated with death or treatment failure among HIV-positive TB patients 
Variable Category       Treatment outcome OR (95% CI)   
        
  P  AOR (95% CI) P  
Death/Failure 
N = 70 (%) 
Success 
N= 230 (%) 
Age (years) Mean (SD) 37.8 (15.6) 33.1 (13.8)  4.7 (0.9 – 8.5) a 0.016 1.02 (1.00 – 1.05) 0.057 
Gender  Male  41 (58.6) 114 (49.6) 1.4 (0.8 – 2.5) 0.187 1.2 (0.7 – 2.2) 0.479 
 Female 29 (41.4) 116 (50.4) 1  1  
Type of PTB Smear-positive 15 (23.4) 57 (27.4) 1  1  
 Smear-negative 19 (29.7) 83 (39.9) 0.9 (0.4 – 1.9) 0.718 0.9 (0.4 – 1.9) 0.727 
 Smear not done 30 (46.9) 68 (32.7) 1.7 (0.8 – 3.4) 0.155 2.1 (1.0 – 4.2) 0.047 
Smear grade (n = 73)b  Scanty 3 (20.0) 5 (8.6) 1  1  
 + 5 (33.3) 15 (25.9) 0.6 (0.1 – 3.2) 0.511 0.7 (0.1 – 3.9) 0.661 
 ++ 2 (13.3) 20 (34.5) 0.2 (0.02 – 1.3) 0.085 0.2 (0.0 – 1.6) 0.135 
 +++ 5 (33.3) 18 (31.0) 0.5 (0.1 – 2.6) 0.386 0.4 (0.1 – 2.5) 0.303 
Xpert MTB/RIF (n = 71)c Very low/Low 11 (57.9) 29 (55.8) 1.1 (0.4 – 3.2) 0.873 1.1 (0.4 – 3.1) 0.919 
 Medium/High 8 (42.1) 23 (44.2) 1  1  
CPT status On CPT 34 (48.6) 158 (68.7) 1  1  
 Not on CPT 30 (42.9) 56 (24.3) 2.5 (1.4 – 4.4) 0.002 2.5 (1.4 – 4.4) 0.003 
 Unknown 6 (8.6)      16 (7.0) 1.7 (0.6 – 4.8) 0.281 1.8 (0.7 – 5.1) 0.253 
aMean difference and its 95% Confidence Interval.        bOnly sputum smear-positive patients were included.        cTwo patients with positive Xpert MTB but no grading for 
MTB detection, were excluded.    CPT = Co-trimoxazole preventive therapy.  Xpert = Xpert MTB/RIF 
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Table 4.16. Multivariable analysis of factors associated with death or treatment failure among HIV-negative TB patients treated UATH between 
2012 and 2016 
Variable Category         Treatment outcome OR (95% CI)  
 
P  AOR (95% CI) P  
Death/Failure 
N = 21 (%) 
Success 
N= 387 (%)  
Age (years) Mean (SD)   38.0 (16.3) 30.3 (16.0)  7.7 (0.6 – 14.7) a 0.033 1.03(1.01 – 1.05) 0.014 
Gender  Male  12 (57.1) 246 (63.6) 0.8 (0.3 – 1.9) 0.552 0.7 (0.3 – 1.7) 0.404 
 Female 9 (42.9) 141 (36.4) 1  1  
Type of PTB Smear-positive 6 (37.5) 205 (64.1) 1  1  
 Smear-negative 5 (31.3) 64 (20.0) 2.7 (0.8 – 9.0) 0.115 2.4 (0.7 – 7.5) 0.146 
 Smear not done 5 (31.3) 51 (15.9) 3.4 (0.98 – 11.4) 0.053 3.4 (1.0 – 11.6) 0.050 
Mean (SD) weight 
difference (kg) 
At 2 months -1.9 (2.2) 2.2 (3.4) -4.2 (-6.5 – -1.8) a 0.001 0.7 (0.6 – 0.8) 0.001 
 At 5 months 1.3 (2.0) 4.6 (4.8) -3.3 (-7.5 – 1.0) a 0.134 0.9 (0.8 – 1.0) 0.004 
aMean difference and its 95% Confidence Interval         bSputum smear-positive PTB cases plus an EPTB case, which was also smear-positive were included                                                                                                                    
cA patient with positive Xpert MTB but no grading for MTB detection, was excluded    
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Table 4.17. Multivariable analysis of risk factors for LTFU among HIV-positive TB patients treated at UATH  
 
Variable Category   Treatment outcome OR (95% CI)  
        
 
P  AOR (95% CI) P  
LTFU 
N = 99 (%) 
Success 
N = 230 (%) 
Age (years) Mean (SD) 32.9 (15.6) 33.1 (13.8)  -0.2 (-3.6 – 3.2) a 0.900 0.999 (0.982 – 1.017) 0.933 
Gender Male  48 (48.5) 114 (49.6) 1.0 (0.6 – 1.5) 0.857 1.0 (0.6 – 1.6) 0.877 
 Female 51 (51.5) 116 (50.4) 1  1  
Type of PTB  Smear-positive 15 (16.7) 57 (27.4) 1  1  
 Smear-negative 31 (34.4) 83 (39.9) 1.4 (0.7 – 2.9) 0.329 1.4 (0.7 – 2.9) 0.325 
 Smear not done 44 (48.9) 68 (32.7) 2.5 (1.2 – 4.9) 0.010 2.5 (1.3 – 5.1) 0.009 
Treatment used Category 1 97 (98.0) 216 (93.9) 3.1 (0.7 – 14.1) 0.116 3.1 (0.7 – 14.1) 0.135 
 Category 2 2 (2.0) 14 (6.1) 1  1  
Smear grade (n =73)b          Scanty 4 (26.7) 5 (8.6) 1  1  
 + 2 (13.3) 15 (25.9) 0.2 (0.0 – 1.2) 0.076 0.2 (0.0 – 1.2) 0.080 
 ++ 5 (33.3) 20 (34.5) 0.3 (0.1 – 1.6) 0.164 0.3 (0.1 – 1.7) 0.179 
 +++ 4 (26.7) 18 (31.0) 0.3 (0.1 – 1.5) 0.141 0.3 (0.0 -1.9) 0.197 
Xpert MTB/RIF (n = 
73 )c 
Very low 
11 (52.3) 29 (55.8) 0.9 (0.3 – 2.4) 0.792 0.9 (0.3 – 2.4) 0.775 
 Medium/High 10 (47.6) 23 (44.2) 1  1  
ART status On ART 60 (60.6) 153 (66.5) 1  1  
 Not on ART 31 (31.3) 69 (30.0) 1.2 (0.7 – 1.9) 0.607 1.1 (0.7 – 1.9) 0.614 
 Unknown 8 (8.1) 8 (3.5) 2.6 (0.9 – 7.1) 0.073 2.6 (0.9 – 7.2) 0.071 
CPT status On CPT 55 (55.6) 158 (68.7) 1  1  
 Not on CPT 34 (34.3) 56 (24.3) 1.7 (1.0 – 2.9) 0.038 1.7 (1.0 – 2.9) 0.037 
 Unknown 10 (10.1) 16 (7.0) 1.8 (0.8 – 4.2) 0.176 1.8 (0.8 – 4.2) 0.178 
Mean (SD) weight (kg) At baseline 44.1 (17.1) 48.9 (16.5) -4.7 (-8.8 – -0.7) a 0.023 0.97 (0.95 – 0.98) 0.001 
 At 2 months 36.6 (15.6) 50.1 (16.7) -14.5 (-23.4 – -5.7) a 0.001 0.94 (0.88 – 0.99) 0.032 
aMean difference and its 95% Confidence Interval.     LTFU = Loss-to-follow up    bIn addition to the 72 smear-positive PTB, an EPTB was also smear-positive and included       
cTwo patients with positive Xpert MTB but no grading for MTB detection, were excluded          ----- data not available.  CPT = Co-trimoxazole preventive therapy                                                                                                                                                    
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Table 18. Multivariable analysis of risk factors for LTFU among HIV-negative TB patients treated UATH  
Variable Category         Treatment outcome OR (95% CI)   
        
 
P  AOR (95% CI) P  
LTFU Success 
N = 79 (%) N = 387 (%) 
Age (years) Mean (SD)   37.8 (19.3) 30.3 (16.0)  7.4 (3.4 – 11.4) a 0.001 1.03 (1.01 – 1.04) 0.001 
Gender  Male  51(64.6) 246 (63.6) 1.0 (0.6 – 1.7) 0.867 0.9 (0.6 – 1.6) 0.808 
 Female 28 (35.4) 141 (36.4) 1  1  
Type of PTB  Smear-positive 28 (44.4) 205 (64.1) 1  1  
 Smear-negative 6 (9.5) 64 (20.0) 0.7 (0.3 – 1.7) 0.425 0.6 (0.2 – 1.6) 0.303 
 Smear not done 29 (46.0) 51 (15.9) 4.2 (2.3 – 7.6) 0.001 4.3 (2.3 – 7.9) 0.001 
Treatment used Category 1 70 (88.6) 371 (95.9) 0.3 (0.1 – 0.8) 0.009 0.4 (0.2 – 0.9) 0.036 
 Category 2 9 (11.4) 16 (4.1)   1  
aMean difference and its 95% Confidence Interval.     LTFU = Loss-to-follow up                                                                                                                                                                                                                         
b Sputum smear-positive PTB cases plus an EPTB case, which was also smear-positive were included                                                                                                                                                  
cA patients with positive Xpert MTB but no grading for MTB detection, were excluded   
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4.5 Discussion  
4.5.1 Summary of study’s findings 
This study describes the outcome of patients initiating TB treatment and identifies risk factors 
for death/treatment failure and LTFU. TB and HIV-co-infection was observed in 44.3% of 
patients. Overall, TB treatment success was low, with a high proportion of patients 
experiencing death or treatment failure and many being LTFU. HIV-positive patients were 
more likely to die and to be LTFU. Independent risk factors for death/treatment failure and 
for LTFU were older age, a diagnosis based on Xpert MTB/RIF or Chest X-rays, a positive 
HIV status and lower body weight on baseline.  
The factors associated with poor outcomes varied among HIV-infected and uninfected 
patients. Among HIV-positive patients, risk factors for death/treatment failure included; an 
older age, a diagnosis not being based on smear microscopy, the lack of use of Co-
trimoxazole and a low baseline body weight. Risk factors for LTFU were; not being 
diagnosed by smear microscopy, a lack of CPT use and a low body weight at baseline and at 
the 2-month follow up. For HIV-negative patients, older age and a diagnosis not based on 
smear microscopy were independent risk factors for both poor treatment outcome and LTFU. 
A low body weight differences at 2 and 5 months were risk factors for poor treatment 
outcome only and the use of category 2-treatment, was a risk factor for LTFU.  
4.5.2 Prevalence of TB/HIV-coinfection among the study population 
 The proportion of patients co-infected with HIV (44.3%) is similar to reports from two other 
studies in Northern Nigeria: in Abuja, 42.7% of 1424 patients 143 and in Kano 45.5% of 389 
patients were co-infected 176. These two studies were also retrospective and conducted at the 
DOTs clinics of similar teaching/referral hospitals. The proportion of TB/HIV-coinfection in 
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our study was more than two times higher than in other retrospective studies from Southern 
Nigeria (16.9% 158, 19.7% 177, 20.6% 142 and 21.6% 178). 
HIV infection rates in Nigeria vary by State, from as high as 15.2% in Rivers state to as low 
as 0.2% % in Ekiti state 179, with a national of TB/HIV-co-infection rate of 16% 130 . Abuja 
has an HIV prevalence of 7.5% and this is reflected in the high TB and HIV co-infection rates 
among patients attending the hospitals. 
Abuja has the fifth highest HIV prevalence in the country 179. with a high proportion of 
migrant workers from all over Nigeria, who travel alone in search of employment. The 
UATH is also a teaching and a referral centre for patients not responding to treatment or 
difficult to diagnose. A further reason for the high TB/HIV co-infection rate, is the recent 
integration of the TB/HIV care and the implementation of the WHO algorithm for active TB 
case finding among HIV-positive patients, which may have increased TB case detection 
among HIV-infected patients.  
The high TB/HIV-coinfection rate is also indicative of high transmission of TB in the 
community and underlines the importance of implementing Isoniazid Preventive Therapy 42, 
to prevent TB among newly diagnosed HIV infected patients.  
4.5.3 Treatment outcome of patients with TB 
The TB treatment success rate (62%) is lower than the WHO target of ≥ 90% 130.  This low 
rate is not unusual in Nigeria’s referral hospitals.  Ukwaja et al reported that at a Federal 
Medical Centre in Ebonyi State, Southern Nigeria, only 57.7% achieved treatment success 
180, and two former studies in Abuja 143 and Kano 176, reported that only 65.8% and 52.3% of 
patients achieved treatment success. These three studies were five-year retrospective studies, 
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conducted at referral/teaching hospitals, which usually receive very sick or complicated 
patients.  
Higher treatment success rates have been reported in other Nigerian studies, with treatment 
success ranging from 71.5% to 86.3% 136,142,158,177,178,181. Although, these studies were also 
retrospective, four were conducted in primary health facilities and one in a secondary health 
facility, which are likely to treat mild and uncomplicated cases.  
The low treatment success in UATH might also be due to the high proportion of patients co-
infected with HIV and this hypothesis is supported by the low treatment success rate of all 
studies with high TB/HIV-co-infection rates in Nigeria 143,176,180.   
The 8.4% case fatality is similar to two studies from southern Nigeria (8.2% 180 and 9.5% 181). 
One was a five-year retrospective study, conducted at a DOTS clinic of a tertiary health 
facility 180, and the other, a four-year review of TB treatment records in primary health 
facilities 181. This case fatality however is higher than reported by other four Nigerian studies, 
with mortality between 1% and 6% 136,142,143,158. These latter studies comprised retrospective 
studies from southern 142,158,178 and northern Nigeria 143. Two studies reviewed TB treatment 
records in teaching hospital clinics 142,143, one was a review of TB treatment records in rural 
areas 158 and one reviewed TB treatment records of a secondary health facility in Lagos 178.  
Overall, deaths during TB treatment in high income countries with a low incidence of drug 
resistance range from 5% in Australia 182 to 9.9% in Israel 183. In middle income countries, 
mortality ranges from 3.3% in India 184 to 15.9% in Taiwan 185; and in low income countries. 
from 3.4% in Ethiopia 186 to 15.1% in Mozambique 162.  National rates however are not 
homogeneous at a lower scale, and the mortality is usually higher in settings treating 
advanced, referral cases or patients with social complications 170 and lower among immune-
competent patients with early or mild infections.   
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Eighteen percent of UATH TB patients were LTFU. This is consistent with the 18.2% 
reported by a study from another Nigerian teaching hospital 142, but higher than in five studies 
conducted in primary or secondary health facilities (1% 181, 5.6% 158,  8.2% 177, 9.6% 178 and 
15% 136). These studies might have been located closer to where patients live. There are also 
studies reporting higher LTFU frequencies, ranging from 25.7% - 28.6% 142,176,180,187. These 
studies were retrospective and conducted in teaching/referral hospitals, like our study, and 
may indicate that hospital receive referred patients from more remote locations or, given their 
retrospective design, that there was no effort to promote patients’ adherence, as it could be 
expected in prospective studies.   
Internationally, similar results were reported from Gabon (17.6%) 146 and Brazil (18.9%) 188, 
but most frequently, studies from other African (0.2% - 13.2%) 155,162,163,186,189-195, Asian 
(2.6% to 14.2%) 184,196-200 and European (5.0% to 10.7%) countries 131,201,202 reported lower 
LTFU, with very few studies reporting higher LTFU (Peru, 22.5%; 203 South Africa, 25.9% 
204 and India, 30%) 205. 
The high LTFU proportion in our study might be due to the study location in a referral centre. 
The centre may be far from where most of the patients live and result in financial and time 
commitments, which some patients might not be able to afford. Some patients referred to the 
hospital might have died during treatment, but their deaths were not recorded in the TB 
treatment registers. As many of the possible causes for the LTFU were not recorded, there is 
a need to put in place adequate tracking mechanisms (such as regular contact through phone 
call, visit by CHEWs, TB patients’ support group, and community-based treatment) to 
elucidate the causes of the high LTFU with a view to addressing this problem. 
Less than one percent of patients failed their TB treatment. This finding is similar to other 
studies from Nigeria (0.03% - 0.4%) 136,180,181,206, Ethiopia (0.3%  186 and 0.7% 190)  , South 
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Africa (0.4%) 195, India (0.3%) 205 and Pakistan (0.2%) 200. However, higher treatment failure 
has been reported from Nigeria (2.3% 176, 2.5% 207 and 6.9% 143) and other African countries 
(2.1 to 8.6%) 146,163,189,208, Pakistan (2.6% 198 and 5.0% 199) and Uzbekistan (3.0%) 209. Most 
studies with treatment failure ≥ 1% in Nigeria were conducted in teaching/referral hospitals, 
hence, a possible reason for the higher treatment failure rate, could be patient selection. 
The low proportion of patients with treatment failure in our study, could be the result of a 
cohort effect due to the high mortality and LTFU resulting in the attrition of the cohort.   
4.5.4 TB treatment outcome of HIV-positive and HIV-negative patients 
Patients with TB with and without HIV had very different treatment outcomes. HIV-positive 
patients had lower treatment success rate. This finding is corroborated by many studies in 
Nigeria 136,142,143,158,159,178 and other African countries 138,148,149,155,156,191,204,210,211. A few 
studies however have reported similar treatment success between HIV-positive and HIV-
negative patients (e.g. Malawi 139 and South Africa 140) and rarely a higher treatment success 
rate among HIV-positive patients in Benin 157.  
The poor treatment success of HIV-positive patients is associated with the more aggressive 
and disseminated clinical presentations of TB, the difficulty of reaching a diagnosis, which 
results in many patients being diagnosed clinically (with a high likelihood of having other 
infections) and the well-established TB/HIV interaction, leading to accelerated progression of 
both HIV infection and TB 212.  Patients with advanced immunosuppression also have other 
opportunistic infections and malabsorption of TB drugs 213-215, drug-drug interactions 
(particularly Rifampicin and ARVs) and the pill burden from ART and TB medications 
216,217. 
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HIV-positive patients were more likely to die during TB treatment. There is an established 
association between HIV-infection and increased risk of death during TB treatment 
189,193,194,218-220, which may be due to a late TB diagnosis and the risk factors for low treatment 
success listed above. Most deaths among HIV-infected patients occurred within the first 12 
weeks of TB treatment. This early mortality has been reported in other studies 176,221,222 and 
may be due to late TB diagnosis and the occurrence of IRIS, which usually occurs within the 
first few weeks after initiating ART 223. Our data suggests that strategies to reduce deaths 
(such as, standard risk assessment (SRA) and enhance case management (ECM), targeted at 
patients who are HIV-positive, older or underweight) should work as early as possible, during 
TB treatment. 
HIV-positive patients were more likely to be LTFU. There is a large number of studies 
reporting this finding in the medical literature (see for example 224-226). HIV-TB co-infected 
patients are often frail and unemployed, and are often abandoned and stigmatised by their 
communities. These might result in their poor socioeconomic status and lack of support 
needed for them to keep TB treatment clinic appointment. Despite the enormous barriers that 
patients with TB-HIV co-infections face, not all studies report a high LTFU, with similar 
rates between HIV-positive and HIV-negative reported in several studies (see for example 
201,203,227).  
The higher LTFU for TB/HIV-coinfected patients may reflect that many HIV-infected 
patients die at home but are not traced and their death is not captured in the registers. The 
negative socioeconomic impact of TB/HIV-coinfection also increases the risk of LTFU 224,228 
and socioeconomic support has been shown to improve TB treatment outcome 229-231.  
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4.5.5 Risk factors for death/treatment failure 
We defined poor treatment outcome as death/treatment failure, since the treatment outcome 
of patients transferred out or LTFU was unknown. Only 7 patients had treatment failure and 
we decided to combine deaths and treatment failure in the analysis. Older age and HIV status 
were independently associated with poor treatment outcome. Besides HIV, as previously 
discussed, poor outcome was associated with older age, as described by others 191,202 193,194,218. 
Older patients’ comorbidities, such as DM 232, reduced immunity and increased TB treatment 
adverse effects 233,234 could increase their risk of poor treatment outcome.  
Our study also showed a spurious association between death/treatment failure and the lack of 
a smear-based diagnosis. This is due to patients with HIV being more likely to be smear-
negative and the implementation of the national policy to test HIV-positive individuals with 
presumptive TB with Xpert MTB/RIF as the first diagnostic test.  Patients with presumptive 
TB and no smear-results, therefore are those with a difficult diagnosis, those too ill to 
produce sputum and those known to have HIV infections, who did not have the smear 
examinations. 
A further marker associated with poor treatment outcome was the body weight difference at 2 
and 5 months of follow up. Studies have shown an association between low body 
weight/underweight on admission and death 185,220,235-237.  Poor weight gain could be a marker 
of the same risk or reflect additional issues on follow up, such as poor medication adherence, 
poor treatment response or a wrong diagnosis in difficult to diagnose patients.  
Some studies have reported associations between male gender and treatment outcome 
162,183,189,218,227,238. However, we did not find this association. Similarly, we did not find an 
association with retreatment, which could be due to > 97% of cases in the case series being 
newly diagnosed TB cases.  Re-treatment cases often have drug-resistant TB and in Nigeria, 
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patients with Rifampicin resistance are considered to have MDR-TB.  As MDR-TB cases are 
referred to specialist treatment centres, it is likely these are missing from the study cohort. 
Older age, a lack of baseline smear microscopy and low body weight were also associated 
with poor treatment outcome for both HIV-positive and negative patients, and not receiving 
CPT was an additional risk factor for HIV-positive patients. The latter has been identified as 
a risk factor in some  220,239-243 but not all studies 191,194,237, and likely reflects the local context 
and the reasons why CPT was withheld during patient management. 
Although, it is well established that not receiving ART during TB treatment is a risk factor 
for death 244, we did not find any association between ART and death/treatment failure. In a 
likely manner, some other studies have found similar associations to ours 162,191,220,221,237,245. 
Some possible explanations for this finding could be that, because of the implementation of 
the WHO’s recommendation in December 2009, that all patients with TB and HIV should be 
placed on ART, irrespective of their CD4 counts, all patients in the study were placed on 
ART during their TB treatment. However, many new patients would not have been on ART 
at the start of their TB treatment, as their TB diagnosis prompted the services to initiate HIV 
investigations.  It is also likely the ART status was not updated in the TB treatment 
register/cards, which is a common problem in our setting. In addition, some HIV-positive 
patients might have died of IRIS during the early stages of TB treatment, and this could have 
masked the beneficial effect of ART on TB treatment outcome. 
4.5.6 Risk factors for LTFU  
Five patient’s characteristics were associated with LTFU. Older age is a factor consistently 
reported in previous studies 159,187,198,226,246. Older age is also associated with the risk of death 
and it could be that some of the patients classified as LTFU had died, but their deaths were 
not reported. Additionally, older patients might have retired from work and in the study 
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location context, retirement may lead to poverty, which is a risk factor for LTFU 196,198,224. 
Comorbidities associated with ageing could also result in polypharmacy and an increased risk 
of drug adverse effects 198,247,248. 
Similar to poor treatment outcome, patients with no smear microscopy were more likely to be 
LTFU. As explained above, this is likely a selection bias due to the way patients were 
diagnosed in the study setting.  
Low body weights at baseline and 2 months later were associated with LFTU. It is likely the 
low body weight was a sign of advanced disease stages, poor treatment response and 
unreported/unnotified deaths misclassified as LTFU. Underweight could also make it 
impossible for patients to work and earn money, thereby resulting in poverty. 
Among HIV-positive patients, were found four independent risk factors for LTFU. We could 
not find other studies identifying a lack of baseline smear results as a risk factor. This could 
be due to the same reasons discussed above. Other factors such as  “not receiving CPT” or 
ART were discussed previously and one report reported a similar finding 242. Low body 
weight at baseline and 2 months later, were risk factors for LTFU in this group of patients, as 
discussed above 249-251. Our inability to find the association with ART could be due to 
improper documentation/updating of patients’ status, and the implementation of the WHO’s 
recommendations. 
4.5.7 Limitations and strength of the study 
This study has many limitations associated with the use of secondary data. The first one is 
that data on some important variables, such as socioeconomic status, height, CD4 count (for 
HIV-positive patients) and duration of symptoms, were not always captured in the registers 
and missing or incomplete data could not be recollected. There could also be 
misclassification of cases and whether patients received ART or CPT. Another limitation is 
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the location of the study.  Teaching hospitals often receive complex and referred patients and 
its findings might not be generalisable to patients attending primary health care facilities.  
However, this study has some strengths, which include a fairly large sample size, a 
comprehensive data analysis, the systematic screening and recording of HIV status and the 
addition of data on TB treatment outcome to the few existing studies in Nigeria. This is one 
of the very few studies that present data on risk factors for death and treatment failure and 
predictors of poor treatment outcome and LTFU. 
4.5.8 Conclusion 
This study describes a high TB/HIV-coinfection rate, poor treatment outcome and high 
LTFU. TB/HIV-infected patients had lower treatment success, higher risk of death and 
LTFU. Older age, a positive HIV status, a diagnosis not based on smear microscopy, and low 
body weight differences at 2 and 5 months, were independent predictors of death/treatment 
failure and LTFU. HIV-positive patients who died or had treatment failure, were more likely 
to be older, to have a diagnosis not based on smear microscopy and not receiving CPT.  Risk 
factors for LTFU among this group were also a lack of smear results, not receiving CPT, and 
low weight at baseline and two months.  Among HIV-negative patients, independent risk 
factors for death/treatment failure and LFTU were older age, a lack of smear results, a low 
body weight at baseline and the use of category 2 TB treatment. 
To improve TB treatment outcomes among the study population, there is a need to scale up 
prevention of TB among HIV patients and HIV prevention in the communities, with a view to 
reducing TB/HIV-coinfection. Strategies and diagnostics for early detection of active TB 
among HIV patients in the community at large, should be put in place. There is also a need 
for better tracking of TB patients on treatment, to prevent LTFU.  Standard risk assessment 
and enhanced case management should be considered for TB and TB/HIV-coinfected 
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patients, those with; older age, underweight, no baseline smear results and those on category 
2 TB treatment. CPT should be given to all HIV-positive TB patients to reduce the risk of 
death among them. 
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Chapter 5  
Prevalence and incidence of hypertension among HIV patients  
5.1 Introduction 
This chapter focuses on hypertension, a frequent comorbidity among HIV-positive patients, 
which may be due to increased risk of age-related diseases (as they are now living longer 
because of increased access to ART) and the metabolic complications of ART. Failure to 
detect and promptly treat hypertension among these patients, could worsen their HIV 
treatment outcome.  
Currently, there are few studies on prevalence of hypertension among HIV-positive patients 
in Nigeria, and only one study from the country, has reported the incidence of hypertension 
among HIV-positive patients, in the last 5 years. Hence, there is a need for more studies, on 
the burden and risk factors for hypertension, and the steps needed for its proper control 
among HIV-positive patients. This chapter describes a retrospective review of medical 
records of HIV-positive patients enrolled in UATH, between January 2014 and December 
2016 to describe the prevalence of hypertension at the time of enrolment and one year after 
enrolment to assess the disease’s incidence in this cohort of patients. 
Specific objectives 
The objectives of this study were to determine: 
i) The prevalence of hypertension among HIV-infected individuals at the time of 
enrolment at an HIV centre.   
ii) The risk factors associated with hypertension among HIV-positive patients. 
iii) The incidence of hypertension and risk factors for incident hypertension among 
HIV-positive patients 
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5.2 Literature review 
5.2.1 Background 
Hypertension or high blood pressure is a disease of public health importance globally, 
though, its burden is highest in low and middle-income countries. A systematic review and 
meta-analysis on the global prevalence of hypertension, pooling data from 1479 population-
based studies with 19.1 million participating adults in 200 countries, reported that 1.13 billion 
persons have hypertension worldwide.  The age-adjusted prevalence was 22.2% (24.1% for 
men and 20.1% women) 252.  The highest prevalence of hypertension occurred in low income 
countries, with 33% of women in African countries having hypertension. The WHO also 
reported a global prevalence of hypertension of 22% in 2014, which was highest (30%) in 
Africa 253.  
The burden of hypertension among HIV-infected individuals varies from one part of the 
world to another, and a systematic review of studies in sub-Saharan Africa reported an 
association between hypertension and HIV prevalence 254.  According to a recent systematic 
review, the prevalence of hypertension among HIV-infected individuals ranges from 4.7% to 
54.4% in high income countries and from 8.7% to 45.9% in low income countries 255.  In 
addition, a clinical trial (Strategic Timing of AntiRetroviral Treatment or START) conducted 
among HIV-patients recruited from all continents, found an overall prevalence of 
hypertension of 19.3% 256, but variations from 8.4% in Asia, 14.8% in South America, 19.3% 
in Europe/Australia/Israel, 21.2% in Africa, and 29.4% in North America 256.  
Studies of hypertension among HIV patients in Sub-Saharan Africa have reported that the 
prevalence ranged from 4.8% in Kenya to 49.5% in Malawi 257-274 (table 5.1). In Nigeria, six 
studies reported a wide range of prevalence ranging from 9.5% to 46.0% of participants 275-
280(See tables 5.1 and 5.2). 
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5.2.2 Incidence of hypertension among HIV-infected individuals 
HIV-infected patients who are normotensive at the time of enrolment into care, may develop 
hypertension.  Incident hypertension among these patients may be due to the established risk 
factors for hypertension among the general population (e.g. age, obesity) or result from HIV-
related factors (HIV infection itself or the side effects of ART).  In contrast to studies on the 
prevalence of hypertension however, there are very few studies documenting the incidence of 
hypertension among PLHIV. In Uganda, 13.1% of initially normotensive HIV patients 
developed hypertension (incidence 111.5/1000 persons/year) after a median follow up period 
of 394 days 281. In the US studies, one study comparing the incidence of hypertension 
between HIV-infected and HIV-uninfected subjects, found that there was no different in the 
incidence among the groups (20.4% and 20.7%, respectively) 282. A further two US studies 
conducted among HIV-infected subjects; one reported an incidence of 64.1/1000 person-
years283 and in the other study, 24.1% of participants had incident hypertension 284. Although, 
these studies used different methods and reported findings differently, the incidence of 
hypertension seemed high among HIV patients, although it is unclear whether this incidence 
is higher than among HIV-uninfected counterparts. 
5.2.3 Pathogenesis of hypertension among HIV patients  
Three factors might increase the prevalence and incidence of hypertension among PLHIV. 
The increasing access to ART has improved the life expectancy of PLHIV 285-287.  As 
hypertension is associated with increasing age, ART is likely to be a confounder of an 
increasing lifespan.  However, there is also evidence that HIV-infected persons experience 
premature ageing, by comparing their telomere length with HIV-uninfected counterparts 288.   
It is also postulated that the chronic viremia and sustained immune activation of HIV 
infection, disrupts the endothelial nitric oxide synthase-nitric oxide (eNOS-NO) system, 
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which maintains vascular endothelial integrity.  This disruption causes vascular endothelial 
damage, arterial stiffness and premature atherosclerosis, increasing the risk of hypertension. 
However, studies that measured arterial stiffness by pulse wave velocity and subclinical 
atherosclerosis (Carotid intima-media thickness) are inconsistent, with some studies reporting 
arterial stiffness and subclinical atherosclerosis 289-292, but others reporting similar findings to 
uninfected individuals 293-296. A further potential factor increasing the risk of incident 
hypertension is the side effects of ART.  Some ART regimens (Protease Inhibitors (PIs)) and 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)) cause dyslipidaemia, 
hyperglycaemia, lipodystrophy and insulin resistance297,298. Some studies have reported 
increased aortic stiffness 299 or Carotid intima-media thickness 300 among patients on ART 
compared to patients not on ART, but others studies have not found this association 264,301. 
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Table 5.1. Prevalence of hypertension among HIV patients 
 
Author/Date Country Study population Study design Sample 
size 
Prevalence of 
Hypertension 
Menanga/2015 257 Cameroon Adults Cross-sectional 44 43.2% 
Ekali/2013 258 Cameroon Adults Cross-sectional 143 14.7% 
Abebe/2016 259 Ethiopia Adults Cross-sectional 262 17.1% 
Mohammed/2015 260 Ethiopia Adults Cross-sectional 393 34.4% 
Guehi/2016 302 Ivory Coast Adults Clinical Trial 733 4.9% 
Bloomfield/2011 262 Kenya Adults Retrospective 12194 8.7% 
Bloomfield/2014 263 Kenya Adults Retrospective 49475 4.8% 
Muronya/2011 264 Malawi Adults on ART Cross-sectional 174 49.5% 
Iwuala/2015 275 Nigeria Adults Cross-sectional 145 40.7% 
Muhammad/2016 277 Nigeria Adults Cross-sectional 200 9.5% 
Osegbe/2016 280 Nigeria Adults Cross-sectional 200 17.5% 
Diouf/2012 265 Senegal Adults on ART Retrospective 242 28.1% 
Nguyen/2016 266 South Africa Adults Retrospective 748 14.7% 
Julius/2011 267 South Africa Adults on ART Cross-sectional 304 19.1% 
Rabkin/2015 268 South Africa Adults on ART Cross-sectional 175 37.8% 
Schoffelen/2015 269 South Africa Adults Cross-sectional 904 23.0% 
Wensink/2015 270 South Africa Adults Cross-sectional 903 23.0% 
Njelekela/2016 303 Tanzania ART-naïve adults Cross-sectional 34111 12.5% 
Kagaruki/2014 271 Tanzania Adults Cross-sectional 671 26.2% 
Mateen/2013 272 Uganda Adults Cross-sectional 5563 27.9% 
Okello/2015 281 Uganda Adults Retrospective 4122 7.9% 
Sander/2015 301 Uganda Adults Clinical trial 1006 11.9% 
Muyanja/2016 273 Uganda Adults on ART Cross-sectional 250 5.2% 
Magodoro/2016 274 Zimbabwe Adults Cross-sectional 1033 10.2% 
126 
 
 
5.2.4 HIV infection and hypertension 
Studies comparing the prevalence of hypertension among HIV-infected and HIV-uninfected 
individuals in Africa  and South America indicated that hypertension was lower among 
PLHIV (nine studies, 278,289,293,294,304-308), similar between the two groups  in one 279 and 
higher among PLHIV in one study 276. Hypertension ranged from 11% to 46% among PLHIV 
and 10% to 44% among HIV-negative subjects (table 5.2). A recent systematic review 
reported a lower prevalence of hypertension among PLHIV 309, but a further systematic 
review among pregnant women, found no association between infected and uninfected 
mothers 310. Therefore, findings from this review are heterogeneous, although, the majority of 
the studies indicated that HIV infection is associated with a lower prevalence of hypertension. 
Most of these studies also reported that older age, male gender and a higher body mass index 
(BMI) were associated with hypertension among PLHIV 278,279,304,305,308. Hence, the high 
burden of hypertension in regions with high HIV burden 252,253 may be associated with an 
overall increase in the prevalence of traditional risk factors for hypertension. 
5.2.5 ART and hypertension 
A potential determinant of hypertension among PLHIV is the use of ART. This life-saving 
therapy however, is associated with metabolic complications, such as dyslipidaemia, 
hyperglycaemia, lipodystrophy and insulin resistance, which may increase the risk of 
hypertension. Studies comparing the prevalence of hypertension between PLHIV with and 
without ART from Africa (7 studies)  and the United States (two studies) reported a higher 
prevalence of hypertension among individuals on ART than ART-naïve PLHIV (seven 
studies) 277,278,280,311-314, and a lower prevalence in two studies 279,315. The prevalence of 
hypertension ranged from 12.3% to 38.0% among ART-exposed patients and 2.0% to 38% 
among ART-naïve patients, with difference ranging from 3% to 19% (table 5.3). Thus, most 
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studies indicate ART might be associated with a higher prevalence of hypertension. Other 
HIV-related factors such as CD4 count, level of immunosuppression, clinical stage and viral 
load are inconsistently associated with hypertension. 
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Table 5.2. Comparison of prevalence of hypertension between HIV-positive and HIV-negative individuals 
 
 
Author/Date Country Study 
population 
Study design               Sample Size HIV 
status 
Prevalence of 
Hypertension 
Ngatchou/2013 289 Cameroon Adults Cross-sectional 304 96 HIV- 44.0% 
108 HIV+ 41.0% 
Amusa/2016 276 Nigeria Adults Cross-sectional 200 50 HIV- 10.0% 
150 HIV+ 46.0% 
Nduka/2016 278 Nigeria Adults Cross-sectional 512 106 HIV- 42.5% 
406 HIV+ 14.5% 
Ogunmola/2014 279 Nigeria Adults Cross-sectional 403 153 HIV- 13.7% 
250 HIV+ 14.0% 
Malaza/2012 304 South Africa Adults Cross-sectional 10,429 7915 HIV- 27.9% 
2514 HIV+ 19.5% 
Zhou/2012 305 South Africa Adults Cross-sectional 1420 892 HIV- 24.8% 
528 HIV+ 20.3% 
Sliwa/2012 306 Soweto Adults Retrospective 5328 4810 HIV- 44.0% 
518 HIV+ 20.0% 
Peck/2014 308 Tanzania Adults Cross-sectional 454 153 HIV- 16.3% 
301 HIV+ 14.3% 
Kwarisiima/2016 307 Uganda Adults Cross-sectional 65,000 61,455 HIV- 14.0% 
3545 HIV+ 11.0% 
Monteiro/2012 293 Brazil Adults Cross-sectional 343 82 HIV- 32.0% 
261 HIV+ 20.0% 
Pacheco/2016 294 Brazil Adults Cross-sectional 11558 11023 HIV- 36.3% 
535 HIV+ 31.4% 
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        Table 5.3. Comparison of prevalence of hypertension between ART-naïve and ART-exposed HIV patients 
 
 
 
Author/Date Country Study population Study design Sample size ART status Prevalence of 
Hypertension 
Dimala/2016 311 Cameroon Adults Cross-sectional 400 200 ART-naive 19.0% 
200 ART-exposed 38.0% 
Nsagha/2015 312 Cameroon Adults Cohort  215 55 ART-naive 14.5% 
160 ART-exposed 29.4% 
Muhammad/2013 277 Nigeria Adults Cross-sectional 200 100 ART-naive 2.0% 
100 ART-exposed 17.0% 
Nduka/2016 278 Nigeria Adults Cross-sectional 406 100 ART-naive 9.0% 
306 ART-exposed 16.3% 
Ogunmola/2014 279 Nigeria Adults Cross-sectional 250 120 ART-naive 19.0% 
130 ART-exposed 12.3% 
Osegbe/2016 280 Nigeria Adults Cross-sectional 200 100 ART-naive 12.0% 
100 ART-exposed 23.0% 
Botha/2014 315 South Africa Adults Cohort 137 71 ART-naive 38.0% 
66 ART-exposed 28.8% 
Nduka/2016 314 USA Adults Systematic review 44903 9086 ART-naive 10.5% 
28908 ART-exposed 14.5% 
Medina-Torne/2012 313 USA Adults Cross-sectional 707 198 ART-naive 29.0% 
509 ART-exposed 32.0% 
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5.3 METHODOLOGY 
5.3.1 Study design 
This was a retrospective review of the medical records of all patients newly diagnosed to 
have HIV enrolled at the UATH’s ART site from January 2014 to December 2016. 
5.3.2 Description of the study location 
The ART site was described in chapter 2.  Vital signs, including blood pressure, weight and 
height are routinely collected on all patients at the time of their first visit to the ART site and 
at every follow up appointment (except height). These measurements are filed in the registers 
and kept in the hospital central records office by the M&E unit.  The records are then 
digitised into an ART-site database.  
5.3.3 Data collection  
At the time of data collection, it became apparent that the M&E database was not up to date. 
The investigator then requested permission to access the records and the records office staff 
were hired to retrieve the folders. Three research assistants and nursing students reviewed the 
records and extracted data on blood pressure, weight, height, body mass index, age, gender, 
level of education and occupation at the time of enrolment.  
In addition, to compare the effect of HIV on hypertension, we had to include HIV-negative 
controls from the clinical records. However, HIV testing was not being done routinely at the 
hospital, and it was decided to recruit HIV-negative patients from the hospital’s HCT. The 
same data as PLHIV of patients with HIV-negative results were collected prospectively from 
all consecutive patients who tested HIV-negative at the HCT unit, from July to September 
2017 and consented to participate. Since the HCT unit is the major point of entry into the 
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ART clinic, these patients (controls) might be similar to the cases (expect for HIV infection). 
Hypertension was defined as a systolic BP ≥ 140 mmHg or a diastolic BP ≥ 90 mmHg. 
To determine the incidence of hypertension one year after initiation of ART, the blood 
pressure of the PLHIV with a normal blood pressure on enrolment were reviewed to extract 
the blood pressure one year after enrolment.  The blood pressure recorded for the study was 
the BP measurement recorded closer to the 12th month after initiation of ART +/- 2.4 
months. If there were multiple BP measurements, the recording closer to the 12th month was 
taken.  In addition, information extracted includes weight, Body mass index, ART regimen/s 
and date of initiation and co-morbidities at the time of follow up. 
5.3.4 Ethical considerations 
Ethical approvals were described in chapter 2. In addition, written permission was obtained 
from the head of the records unit to access the files.  Records staff were informed of the study 
and their support was sought to retrieve the files. Patients informed consent was not obtained, 
since the study only used secondary data. The information extracted from the records was 
kept confidential and did not include patients’ identifiers. 
5.3.5 Data analysis 
Statistical analysis was done using Epi-Info (US CDC) and SPSS (version 24). Descriptive 
statistics used included percentages, counts, means (SD) or medians and interquartile ranges. 
Comparison of the prevalence of hypertension and categorical variables between HIV-
positive and HIV-negative patients was done, using Chi-Square and Fisher’s exact tests, as 
appropriate. Continuous variables were compared between groups by Student’s T tests and 
Mann-Whitney’s U-test (for non-normally distributed variables). Known confounders for 
hypertension were adjusted in a multivariable analysis, using logistic regression. The 
characteristics of patients with hypertension and those without hypertension were compared 
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by bivariable analyses for HIV-negative and HIV-positive patients separately. The 
characteristics of HIV-positive patients with and without incident hypertension were 
compared by bivariable analyses and variables with p < 0.2 were adjusted for age and gender 
in multivariable analyses. Factors associated with prevalent or incident hypertension were 
determined through multivariable analyses using binary logistic regressions. Crude and 
adjusted odds ratios with 95% CIs, and P values were obtained for each of the included 
variables. 
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Figure 5.1. Flow chart for the prevalence and incidence of hypertension among HIV-positive 
patients 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Blood Pressure 
Newly diagnosed HIV-positive 
patients in UATH, N = 997 
 
    N = 196 N = 883 
Normotensive   
n = 158 (80.6%)  
Hypertensive   
n = 38 (19.4%) 
 
Normotensive   
n = 770 (87.2%) 
Hypertensive     
n = 113 (12.8%) 
n = 427 
Normotensive   
n = 379 (88.8%) 
Incident hypertension   
n = 48 (11.2%) 
n = 343 (44.5%) 
Transferred, LTFU or Dead    
Followed at 12 months       
n = 427 (55.5%) 
n = 46 (40.7%) 
Transferred, 
LTFU or Dead    
HIV-negative patients, UATH’s HCT 
unit     N = 201 
N = 201 
 
114      No 
baseline BP 
5, Age < 17 
years 
Available at 12 months            
n = 67 (59.3%) 
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5.4 RESULTS 
5.4.1 Baseline characteristics of participants 
 
A total of 883 HIV-infected and 196 HIV-uninfected patients were included. Four hundred 
and ninety-four (55.9%) HIV-positive patients were reviewed one year later and of these, 474 
(96.3%) had initiated ART.  The characteristics of the participants are described in table 5.4. 
HIV-positive and -negative patients had similar age, although, HIV-positive males were older 
than HIV-negative males (p = 0.02) and HIV-positive females were younger than HIV-
negative females (p = 0.23). HIV-positive patients were more likely to be female, 
married/widowed and less educated (P < 0.03 for all). Patients with HIV had lower mean 
(SD) BMI than HIV-uninfected patients (22.0 (4.4) and 25.2 (5.9), respectively, p = 0.001).  
The mean (SD) diastolic and systolic blood pressures on enrolment were lower for HIV-
positive than for HIV-negative patients (71.1 (10.7) versus 73.5 (11.7)) and 112.1 (15.5) 
versus 122.0 (18.5) mmm/Hg, respectively, p < 0.01). HIV-positive patients were less likely 
to have hypertension (p = 0.01). 
Table 5.4. Baseline characteristics of participants by HIV status  
Characteristics Category HIV-pos 
N = 883 (%)   
HIV-neg 
N = 196 (%)   
P  Missing  
Age (years) Mean (SD) 35.8 (9.6) 35.9 (11.9) 0.978  
 Male 39.9 (8.7) 36.8 (11.3) 0.020  
 Female   33.6 (9.3) 35.1 (12.3) 0.226  
Age group 10 – 19 8 (0.9) 7 (3.6) 0.013  
 20 – 29 230 (26.0) 56 (28.6)   
 30 – 39 358 (40.5) 68 (34.7)   
 40 – 49 203 (23.0) 38 (19.4)   
 50 - 59 62 (7.0) 18 (9.2)   
 ≥ 60 22 (2.5) 9 (4.6)   
Gender Male 309 (35.0) 85 (43.4) 0.028  
 Female 574 (65.0) 111 (56.6)   
Marital status Single 228 (26.1) 83 (42.3)  10 
 Married 596 (68.3) 108 (55.1) 0.001  
 Separated/Divorced 19 (2.1) 3 (1.5) 0.188  
 Widowed 30 (3.4) 2 (1.0) 0.022  
Education No formal education 57 (8.7) 4 (2.2)  245 
 Primary 138 (21.0) 15 (8.4) 0.454  
 Secondary 226 (34.5) 31 (17.4) 0.224  
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 Higher education 235 (35.8) 128 (71.9) 0.001  
Occupation Student 80 (9.2) 44 (24.4) 0.001 10 
 Unemployed 38 (4.4) 9 (4.6)   
 Civil Servant 93 (10.7) 56 (28.6)   
 Artisan 80 (9.2) 4 (2.6)   
 Trading/business 251 (28.8) 39 (19.9)   
 Farming 42 (4.8) 2 (1.0)   
 Housewife 133 (15.2) 7 (3.6)   
 Others 156 (17.9) 34 (17.3)   
Ethnicity Igbo 156 (18.0) 53 (27.0) 0.003 14 
 Yoruba 72 (8.3) 24 (12.2)   
 Tiv 80 (9.2) 5 (2.6)   
  Igala 59 (6.8) 11 (5.6)   
 Hausa 54 (6.2) 7 (3.6)   
 Gbagyi 47 (5.4) 7 (5.6)   
 Ebira 40 (4.6) 8 (4.1)   
 Idoma 23 (2.6) 12 (6.1)   
  Fulani 16 (1.8) 2 (1.0)   
 Gwari 14 (1.6) 4 (2.0)   
  Ibiobio 15 (1.7) 1 (0.5)   
 Bassa 14 (1.6) 2 (1.0)   
 Nupe 10 (1.2) 5 (2.6)   
 Eggon 12 (1.4) 0 (0.0)   
 Tarok 6 (0.7) 4 (2.0)   
 Bassange 7 (0.8) 2 (1.0)   
 Kataf 5 (0.6) 1 (0.5)   
 Others 239 (27.5) 48 (24.5)   
Religion Christianity 659 (75.8) 160 (81.6) 0.184 14 
 Islam and other (n = 2) 300 (24.1) 36 (18.4)   
BMI Mean (SD)  22.0 (4.4)  25.2 (5.9) 0.001 357 
BMI Group   < 18.0  85 (15.7) 13 (7.2) 0.081  
 18.0 – 24.9 340 (62.7) 91 (50.6) 1  
 25.0 – 29.9 92 (17.0) 43 (23.9) 0.011  
 ≥ 30.0 25 (4.6) 33 (18.3) 0.001  
Systolic BP Mean (SD) 112.1 [15.5]  122.0 [18.5] 0.001  
Diastolic BP Mean (SD) 71.1 [10.7] 73.5 [11.7]  0.009  
Hypertension  113 (12.8) 38 (19.4) 0.011  
BP = Blood pressure (mmHg). BMI = Body mass index ((kg/m2) SD = Standard deviation 
Further characteristics pertaining only to HIV-infected patients are shown in table 5.5. Seven 
hundred and ninety-four (97.3%) HIV-infected patients were working, 19 (2.3%) were 
ambulatory and 3 (0.3%) were bedridden. Five hundred and forty-three (66.8%), 145 
(17.8%), 108 (13.3%) and 17 (2.1%) patients were in AIDS clinical stages 1, 2, 3, and 4, 
respectively.  The median (IQR) CD4 cell count was 214 (91 – 381) cells/mm3, with 206 
(26.5%), 164 (21.1%), 187 (24.0%) and 221 (28.4%) having CD4 cell counts < 100, 100 – 
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199, 200 – 350 and > 350 cells/mm3, respectively. Hepatitis B infection was reported in 45 
(5.1%) of 516 patients with screening results.  
Table 5.5. Baseline characteristics of HIV-positive patients 
Characteristics Category N = 883 
Frequency (%) 
Missing 
values 
Functional status Working 794 (97.3) 67 
 Ambulatory 19 (2.3)  
 Bedridden 3 (0.3)  
WHO stage I 543 (66.8) 
 
 II 145 (17.8)  
 III 108 (13.3)  
 IV 17 (2.1)  
CD4 count 
(cells/mm3) 
Median (IQR)  214.0 (91.0 – 381.3) 105 
CD4 count range < 100  206 (26.5) 105 
 100 – 199  164 (21.1)  
 200 – 350  187 (24.0)  
 > 350  221 (28.4)  
Haemoglobin (g/dl) Mean (SD) 10.6 (1.9)  509 
Platelets X 109/L Median (IQR)  229.5 (185.3 – 298.0) 355 
Creatinine (mMol/L) Median (IQR)  57.0 (48.0 – 75.0) 698 
WBC X 109/L Median (IQR) 4.9 (4.0 – 6.4) 348 
ALT (U/L) Median (IQR) 35.0 (27.0 – 45.0) 710 
Hepatitis B  Yes 45 (5.1) 367 
 No 471 (94.9)  
WBC = White blood cell.   ALT = Alanine Transaminase.   SD = Standard deviation.  IQR = Interquartile 
range.  
 
 
5.4.2 Risk factors for hypertension among HIV-positive patients 
Among HIV-infected individuals, patients with hypertension were older (mean (SD) age 40.0 
(9.3) versus 35.2 (9.5) years for normotensive, p = 0.001) and were more likely to have 
overweight (p = 0.024) and obesity (p = 0.001). Hypertensive patients were more likely to 
have CD4 counts > 100, higher mean (SD) haemoglobin (11.2 (2.2) versus 10.5 (1.9)), p = 
0.014) and to be co-infected with Hepatitis B (OR, 95% CI = 2.0 (0.9 – 4.2), p = 0.076) than 
normotensive patients. 
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Table 5.6. Risk factors for hypertension among HIV-positive patients 
Characteristics Category Hypertensive 
N = 113 (%)   
Normotensive 
N = 770 (%) 
OR (95% CI)* P  
Age (years) Mean (SD)  40.0 (9.3) 35.2 (9.5) 4.7 (2.9 – 6.6)* 0.001 
 Male 43.1 (8.6) 39.3 (8.6) 3.8 (1.2 – 6.3)* 0.004 
 Female   37.3 (9.1) 33.2 (9.2) 4.1 (1.7 – 6.6)* 0.001 
Age group  10 - 19 0 (0.0) 8 (1.0)  0.001 
 20 - 29 17 (15.0) 213 (27.7)   
 30 - 39 36 (31.9) 322 (41.8)   
 40 - 49 41 (36.3) 162 (21.0)   
 50 - 59 16 (14.2) 46 (6.0)   
 ≥ 60 3 (2.7) 19 (2.5)   
Gender Male 52 (46.0) 257 (33.4) 1.7 (1.1 – 2.5) 0.009 
 Female 61 (54.0) 513 (66.6)   
Marital status Single 21 (18.8) 207 (27.2) 1  
 Married 84 (75.0) 512 (67.3) 1.6 (0.97 – 2.7) 0.062 
 Separated 1 (0.9) 18 (2.4) 0.5 (0.1 – 4.3) 0.567 
 Widowed 6 (5.4) 24 (3.2) 2.5 (0.9 – 6.7) 0.077 
Educational level None 7 (7.7) 50 (8.8) 1  
 Primary 20 (22.0) 118 (20.9) 1.2 (0.5 – 3.0) 0.685 
 Secondary 27 (29.7) 199 (35.2) 1.0 (0.4 – 2.4) 0.945 
 Higher Ed. 37 (40.7) 198 (35.0) 1.3 (0.6 – 3.2) 0.513 
Occupation Student 7 (6.2) 73 (9.6)  0.130 
 Unemployed 1 (0.9) 37 (4.9)   
 Civil Servant 18 (15.9) 75 (9.9)   
 Artisan 8 (7.1) 72 (9.5)   
 Trading/ 
business 
38 (33.6) 213 (28.0)   
 Farming 3 (2.7) 39 (5.1)   
 House-wife 17 (15.0) 116 (15.3)   
 Others 21 (18.6) 135 (17.8)   
Ethnicity Hausa 7 (6.4) 47 (6.2)  0.904 
 Igbo 22 (20.0) 134 (17.7)   
 Yoruba 10 (9.1) 62 (8.2)   
 Others  71 (64.5) 516 (68.0)   
Religion  Christianity 87 (77.7) 572 (75.6)  0.790 
 Islam 25 (22.3) 183 (24.2)   
 Others 0 (0.0) 2 (0.2)   
Baseline       
BMI (kg/m2) Mean (SD)  24.3 (5.4) 21.7 (4.1) 2.6 (1.3-3.9)* 0.001 
BMI group < 18.0   4 (5.6) 81 (17.2) 0.4 (0.1 – 1.1) 0.074 
 18.0 – 24.9  39 (54.9) 301 (63.9) 1  
 25.0 – 29.9  19 (26.8) 73 (15.5) 2.0 (1.1 – 3.7) 0.024 
 ≥ 30  9 (12.7) 16 (3.4) 4.3 (1.8 – 10.5) 0.001 
Systolic BP 
(mmHg)  
Mean (SD)  137.9 (15.6) 108.3 (11.3) 29.6 (26.6-32.6)* 0.001 
Diastolic BP Mean (SD)  88.9 (8.3) 68.5 (8.3) 20.4 (18.8-22.1)* 0.001 
Functional status Working 100 (98.0) 694 (97.2)  1.000 
 Ambulatory 2 (2.0) 18 (2.6)   
 Bedridden 0 (0.0) 2 (0.3)   
WHO stage I 78 (77.2) 465 (65.3)  0.024 
 II 17 (16.8) 128 (18.0)   
 III 6 (5.9) 102 (14.3)   
 IV 0 (0.0) 17 (2.4)   
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CD4 count  Median (IQR)  220.0 (128-370)  211.5 (84.5–385.5) 20.0 (-16.0–57)† 0.269 
CD4 count range  < 100  18 (17.3) 188 (27.9) 1  
 100 – 199  28 (26.9) 136 (20.2) 2.2 (1.1 – 4.0) 0.018 
 200 – 350  28 (26.9) 159 (23.6) 1.8 (0.98 – 3.4) 0.057 
 > 350  30 (28.8) 191 (28.3) 1.6 (0.9 – 3.0) 0.116 
Haemoglobin 
(g/dl) 
Mean (SD)  11.2 (2.2) 10.5 [1.9] 0.8 [0.2 – 1.4] 0.014 
Platelets X 109/L Median (IQR)  221.0 (180-290) 230.0 (186.5-300.5) -5.0 (-27– 16)† 0.641 
Creatinine  Median (IQR)  57.0 (48.5 – 74.5) 57.0 (48.0 – 75.0) -1.0 (-9.0 – 6.0)† 0.791 
WBC X 109/L Median (IQR)  4.8 (3.9 – 6.1) 4.9 (4.0 – 6.4) -0.2 (-0.6 – 0.3)† 0.464 
ALT (U/L) Median (IQR) 30.0 (23.5 – 45.5) 36.0 (27.3 – 45.0) -3.0 (-8.0 – 4.0)† 0.400 
Hepatitis B   10 (14.3) 35 (7.8) 2.0 (0.9 – 4.2) 0.076 
* Abbreviations as in table 3.  
 
5.4.3 Factors associated with hypertension on enrolment among HIV-negative patients 
Among HIV-negative patients, participants with hypertension were older (44.6 (13.3) versus 
33.8 (10.5) years for normotensive patients, p = 0.001). for both males and females. 
Hypertensive patients had higher BMI (27.8 (6.3)) than normotensive patients (24.6 (5.6), p = 
0.005), and had higher waist and hip circumference (90.9 (11.7) versus 82.3 (16.3) cms, p = 
0.006 and 101.6 (12.5) versus 95.5 (14.4) cms, respectively, p = 0.035). 
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Table 5.7. Factors associated with hypertension among HIV-negative patients 
Characteristics Category Hypertensive 
N = 38  (%)   
Normotensive 
N = 158 (%)   
OR (95% CI)* P  
Age (years) Mean (SD) 44.6 (13.3) 33.8 (10.5) 10.8 (6.2 – 15.5)* 0.001 
 Male 42.9 (14.0) 35.1 (9.9) 7.8 (0.7 – 14.9)* 0.032 
 Female   46.3 (12.8) 32.8 (10.9) 13.4 (7.8 – 19.1)* 0.001 
Age group  10 - 19 0 (0.0) 7 (4.4)  0.001 
 20 - 29 4 (10.5) 52 (32.9)   
 30 - 39 13 (34.2) 55 (34.8)   
 40 - 49 7 (18.4) 31 (19.6)   
 50 - 59 9 (23.7) 9 (5.7)   
 ≥ 60 5 (13.2) 4 (2.5)   
Gender Male 19 (50.0) 66 (41.8) 1.4 (0.7 – 2.8) 0.358 
 Female 19 (50.0) 92 (58.2)   
Marital status Single 8 (21.1) 75 (47.5)  0.006 
 Married 29 (76.3) 79 (50.0)   
 Separated/Divorced 0 (0.0) 3 (1.9)   
 Widowed 1 (2.6) 1 (0.6)   
Educational level No formal education 2 (6.7) 2 (1.4) 1  
 Primary 5 (16.7) 10 (6.8) 0.5 (0.1 – 4.7) 0.543 
 Secondary 4 (13.3) 27 (18.1) 0.1 (0.0 – 1.4) 0.092 
 Higher education 19 (63.3) 109 (73.6) 0.2 (0.0 – 1.3) 0.090 
Occupation Student 0 (0.0) 44 (27.8)  0.001 
 Unemployed 3 (7.9) 6 (3.8)   
 Civil Servant 11 (28.9) 45 (28.5)   
 Artisan 1 (2.6) 4 (2.5)   
 Trading/business 12 (31.6) 27 (17.1)   
 Farming 1 (2.6) 1 (0.6)   
 House-wife 2 (5.3) 5 (3.2)   
 Others 8 (21.1) 26 (16.5)   
Ethnicity Hausa 2 (5.3) 5 (3.2)  0.930 
 Igbo 10 (26.3) 43 (27.2)   
 Yoruba 5 (13.2) 19 (12.0)   
 Other 21 (55.3) 91 (57.6)   
Religion  Christian 32 (84.2) 128 (81.0) 1.3 (0.5 – 3.3) 0.648 
 Islam 6 (15.8) 30 (19.0)   
BMI Mean (SD) 27.8 [6.3] 24.6 [5.6] 3.1 (1.0 – 5.3)* 0.005 
BMI group < 18.0 1 (3.0) 12 (8.2) 0.5 (0.1 – 4.2) 0.522 
 18.0 – 24.9  13 (39.4) 78 (53.1) 1  
 25.0 – 29.9  8 (24.2) 35 (23.8) 1.4 (0.5 – 3.6) 0.522 
 ≥ 30.0  11 (33.3) 22 (15.0) 3.0 (1.2 – 7.6) 0.021 
      
Waist Circ.   Mean (SD), cm  90.9 (11.7) 82.3 (16.3) 8.7 (2.5 – 14.9)* 0.006 
Hip Circ.  Mean (SD), cm  101.6 (12.5) 95.5 (14.4) 6.1 (0.4 – 11.7)* 0.035 
Waist-to-Hip ratio Mean (SD),  0.90 [0.08] 0.86 [0.02] 0.03 (-0.02 – 0.08)* 0.181 
Systolic BP Mean (SD)  ,mmHg  150.1 (13.3) 115.3 [12.1] 34.8 (30.4 – 39.2)* 0.001 
Diastolic BP Mean (SD),mmHg 87.9 (9.1) 70.0 (9.3) 17.9 (14.5 – 21.2)* 0.001 
* Mean difference for means and its 95% Confidence Interval. BP = Blood pressure (mmHg).  BMI = Body 
mass index ((kg/m2). Waist Circ. = Waist circumference (cm).    Hip Circ. = Hip circumference (cm).              
OR = Odds Ratio.  P = Probability value. 
  
140 
 
5.4.4 Incidence of hypertension and risk factors for incident hypertension among 
PLHIV. 
A total of 389 (44.1%) of the 883 PLHIV included in the cross-sectional survey had been 
transferred out, died or LTFU one year later (table 5.8). Of the remaining 494 patients in the 
cohort, 67 (13.6%) had been hypertensive on enrolment, and 427 patients were available to 
assess the incidence of hypertension. Of these, 48 (11.2%, 95%CI = 8.5%-14.7%) patients 
had developed hypertension.  
As many patients were lost, patients who remained in the cohort were compared to those 
transferred out/LTFU. Patients transferred out/LTFU had similar age, marital or educational 
status, occupation, BMI, baseline hypertension or Hepatitis B infection compared to those 
who remained in care. However, patients LTFU were more likely to be male (p = 0.007), to 
have lower haemoglobin (p = 0.005) and higher serum creatinine (p = 0.009) on admission 
(table 1 in appendix 2). 
The patients’ mean (SD) BMI one year later was 23.6 (4.4), with 89 (24.5%) and 23 (6.3%) 
of 494 patients having overweight or obesity, respectively. The median (IQR) CD4 cell count 
was 340 (212 – 528) cells/mm3 and 474 (96.3%) were on ART. The mean (SD) duration on 
ART was 11.0 (2.4) months as described in table 5.5. Of 116 patients with viral load results, 
74 (63.8%) had undetectable viral load (< 20 copies/ml), 19 (16.4%) had viral loads ranging 
from 20 to 999 copies/ml and 23 (19.8%) > 1000 copies/ml. 
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Table 5.8. Characteristics of HIV-positive patients participating one year later 
Characteristics Category N = 883 (%) Missing  
Patient’s status  Active in care 494 (55.9)  
 Transferred/LTFU/Died 389 (44.1)  
Baseline hypertension  Present 67 (13.6)  
 Absent 427 (86.4)  
BMI  Mean (SD) 23.6 (4.4)  131 
BMI group < 18.0  22 (6.1)  
 18.0 – 24.9  229 (63.1)  
 25.0 – 29.9  89 (24.5)  
 ≥ 30.0  23 (6.3)  
Systolic BP at 1 year Mean (SD) (mmHg) 113.8 (16.8)  
Diastolic BP at 1 year Mean (SD) (mmHg) 72.7 (10.8)  
Incident hypertension (n = 427) Yes 48 (11.2)  
 No 379 (88.8)  
Cell count at 1 year (cells/mm3) Median (IQR)  340.0 (212.0 – 528.0) 167 
CD4 count range (cells/mm3) < 100  14 (4.3)  
 100 – 199  62 (19.0)  
 200 – 350  93 (28.4)  
 > 350  158 (48.3)  
Haemoglobin (g/dl) Mean (SD) 11.5 (1.4) 341 
Platelets count X 109/L Median (IQR) 237.0 (197.0 – 289.0) 319 
White Blood Cells X 109/L Median  4.9 (4.2 – 6.1) 324 
Viral load (copies/ml) Median (IQR) 20.0 (20.0 – 49.0) 378 
Viral load group (copies/ml) < 20) 74 (63.8) 378 
 20 – 999  19 (16.4)  
 ≥ 1000  23 (19.8)  
ART  On ART 474 (96.3) 2 
 Not on ART 18 (3.7)  
Duration on ART (months) Mean (SD)  11.0 (2.4)  
ART regimen TDF/FTC/EFV 403 (85.0)  
 TDF/FTC/NVP 4 (0.8)  
 ZDV/3TC/NVP 26 (5.5)  
 ZDV/3TC/EFV 8 (1.7)  
 Other 33(7.0)  
ART components PI included 9 (2.0) 27 
 PI not included 438 (98.0)  
BP = Blood pressure.   BMI = Body mass index ((kg/m2).   ART = Antiretroviral therapy.   PI = Protease 
Inhibitor.  TDF/FTC/EFV = Tenofovir + Emtricitabine + Efavirenzes.    TDF/FTC/NVP = Tenofovir + 
Emtricitabine + Nevirapine.   ZDV/3TC/NVP = Zidovudine + Lamivudine + Nevirapine.   ZDV/3TC/EFV = 
Zidovudine + Lamivudine + Efavirenzes 
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The 48 patients with incident hypertension were compared to the 379 patients without 
hypertension, to identify risk factors. Patients with incident hypertension were older (mean 
(SD) 39.3 (9.3) versus 34.7 (9.4) years for normotensive participants, p = 0.001) and more 
likely to be male (p = 0.024). Their baseline systolic and diastolic blood pressure was higher 
than for patients without incident hypertension (mean baseline systolic and diastolic BP (SD) 
115.6 (12.7) versus 108.3 (10.5), p = 0.001) and 71.9 (8.2) versus 68.6 (8), p = 0.009), 
respectively). The baseline BMI of patients with incident hypertension was similar to the 
baseline BMI of normotensive patients. Patients with incident hypertension had higher 
median (IQR) baseline serum creatinine and Alanine transaminase (71.5 versus 51.5, p = 
0.021 and 41.5 versus 35.5, p = 0.049), but similar frequencies of Hepatitis B infection. 
The mean (SD) BMI at one year follow up was higher for patients with incident hypertension 
(25.4 (4) versus 23 (4.1), p = 0.001) and patients were more likely to be obese (p = 0.020) 
than for those who remained normotensive. The median white blood cell count was lower for 
patients with incident hypertension (4.4 and 5.0, respectively, p = 0.038), but there were no 
significant differences in the median CD4 count, the type and duration of ART. 
Table 5.9. Factors associated with incident hypertension among HIV-positive patients 
Characteristics Category Hypertensive 
N = 48 (%)   
Normotensive 
N = 379 (%) 
OR (95% CI)* 
 
P  
Age (years) Mean [SD]  39.3 (9.3) 34.7 (9.4) 4.7 (1.8-7.5)* 0.001 
 Male 41.7 (8.0) 38.1 (8.6) 3.6 (-0.4-7.6)* 0.078 
 Female   37.4 (10.0) 33.3 (9.3) 4.2 (0.4-7.9)* 0.029 
Age group  10 - 19 0 (0.0) 5 (1.3)  0.024 
 20 - 29 6 (12.5) 118 (31.1)   
 30 - 39 19 (39.6) 153 (40.4)   
 40 - 49 17 (35.4) 73 (19.3)   
 50 - 59 5 (10.4) 20 (5.3)   
  ≥ 60 1 (2.1) 10 (2.6)   
Gender Male 21 (43.8) 107 (28.2) 2.0 (1.1-3.6) 0.027 
 Female 27 (56.2) 272 (71.8)   
Marital status Single 5 (10.4) 110 (29.3)  0.009 
 Married 40 (83.3) 247 (65.7)   
 Separated 1 (2.1) 7 (1.9)   
 Divorced 2 (4.2) 3 (0.8)   
 Widowed 0 (0.0) 9 (2.4)   
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Education None  2 (6.1) 24 (8.4)  0.652 
 Primary 4 (12.1) 59 (20.6)   
 Secondary 14 (42.4) 100 (35.0)   
 Higher Ed. 13 (39.4) 103 (36.0)   
Occupation Student 1 (2.1) 41 (11.0)  0.249 
 Unemployed 2 (4.3) 17 (4.6)   
 Civil Servant 9 (19.1) 32 (8.6)   
 Artisan 2 (4.3) 30 (8.1)   
 Trading/business 13 (27.7) 101 (27.2)   
 Farming 2 (4.3) 14 (3.8)   
 House-wife 9 (19.1) 68 (18.3)   
 Others 9 (19.1) 69 (18.5)   
Ethnicity Hausa 5 (10.9) 20 (5.3)  0.478 
 Igbo 8 (17.4) 67 (17.9)   
 Yoruba 2 (4.3) 24 (6.4)   
 Others  31 (67.4) 263 (70.3)   
Religion Christianity 32 (66.7) 280 (74.7)  0.313 
 Islam 16 (33.3) 94 (25.1)   
 Others 0 (0.0) 1 (0.3)   
Baseline BMI  Mean (SD) 22.9 (4.5) 21.8 (4.0) 1.1 (-0.2-2.4)* 0.098 
BMI group  < 18.0  4 (9.5) 44 (16.1) 0.6 (0.2-1.8) 0.357 
 18.0 – 24.9  27 (64.3) 177 (64.6) 1  
 25.0 – 29.9  7 (16.7) 43 (15.7) 1.1 (0.4-2.6) 0.887 
 ≥ 30  4 (9.5) 10 (3.6) 2.6 (0.8-9.0) 0.124 
Systolic BP  Mean (SD)  115.6 (12.7) 108.3 (10.5) 7.3 (3.5-11.1)* 0.001 
Diastolic BP Mean (SD)  71.9 (8.2) 68.6 (8.0) 3.2 (0.8-5.6)* 0.009 
Functional status Working 47 (100.0) 366 (98.9) Undefined 1.000 
 Ambulatory 0 (0) 4 (1.1)   
WHO stage I 34 (72.3) 254 (68.8) 1  
 II 8 (17) 72 (19.5) 1.7 (0.7-4.0) 0.213 
 III 3 (6.4) 37 (10.0) 1.2 (0.5- 3.0) 0.670 
 IV 2 (4.3) 6 (1.6) 0.6 (0.2-1.6) 0.286 
CD4 count  Median (IQR) 170 (104- 293) 228 (108 – 401) -40.0 (-97-12)† 0.128 
CD4 count range  < 100  10 (22.2) 84 (23.7) 1  
 100 – 199  15 (33.3) 73 (20.6) 1.7 (0.7- 4.1) 0.213 
 200 – 350  12 (26.7) 83 (23.4) 1.2 (0.5- 3) 0.670 
 > 350  8 (17.8) 114 (32.2) 0.6 (0.2- 1.6) 0.286 
Haemoglobin 
g/dl  
Mean (SD) 10.6 (1.8) 10.7 (1.8) -0.2 (-0.9-0.6)* 0.689 
Platelets X 109/L Median (IQR)  224 (197- 300) 222 (180- 296) 9.0 (-15- 34)† 0.455 
Creatinine  Median (IQR)  71.5 (50- 108.5) 51.5 (46.8-71.3) 13.0 (1- 32)† 0.021 
WBC X 109/L Median (IQR)  5.6 (4.4- 6.6) 5.1 (4.0- 6.5) 0.3 (-0.3- 1)† 0.268 
ALT (U/L) Median (IQR)  41.5 (36.8- 46) 35.5 (27.3-45) 7.0 (0-13.0)† 0.049 
Hepatitis B Yes 3 (10.0) 19 (8.4) 1.2 (0.3- 4.4) 0.770 
 No 27 (90) 207 (91.6)   
1 year later      
BMI (kg/m2) Mean (SD) 25.4 (4) 23.0 (4.1) 2.4 (1.0-3.8)* 0.001 
BMI group  < 18.0  0 (0) 20 (7.3) Undefined 0.229 
 18.0 – 24.9  21 (53.8) 181 (66.1) 1  
 25.0 – 29.9  13 (33.3) 61 (22.3) 1.8 (0.9-3.9) 0.108 
 ≥ 30.0  5 (12.8) 12 (4.4) 3.4 (1.2-11.2) 0.020 
Systolic BP  Mean (SD)   139.9 (17.1) 108.0 (10.1) 31.9 (26.8-36.9)* 0.001 
Diastolic BP  Mean (SD) 90.2 (8.6) 69.1 (7.0) 21.1 (18.9-23.3)* 0.001 
CD4 Cell count  Median (IQR)  261 (180-464) 254 (225-528) -58.0 (-127-7)† 0.077 
CD4 count range  < 100  4 (10.3) 9 (3.6) 1  
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 100 – 199  8 (20.5) 44 (17.7) 0.4 (0.1--1.7) 0.210 
 200 – 350  11 (28.2) 71 (28.6) 0.3 (0.1-1.3) 0.123 
 > 350  16 (41.0) 124 (50.0) 0.3 (0.1- 1.1) 0.060 
CD4 change Median (IQR)  78 (0-211) 101 (7-180) -2.0 (-54-53)† 0.937 
Haemoglobin 
g/dl 
Mean (SD)  11.9 (1.6) 11.4 (1.4) 0.5 (-0.1-1.2)* 0.120 
Platelets X 109/L Median (IQR) 220 (196-252) 245 (199 – 290) -21 (-50-7)† 0.141 
WBC X 109/L Median (IQR)  4.4 (3.9-5.3) 5.0 (4.4 – 5.9) -0.6 (-1.1-0)† 0.038 
Viral load  copies/ml 20 (20-67) 20 (20 – 91) 0.0 [0-0)† 0.795 
Viral Load 
group 
< 20  8 (57.1) 52 (65.0) 1  
(copies/ml) 20 – 999  4 (28.6) 9 (11.3) 2.9 (0.7-11.6) 0.136 
 ≥ 1000  2 (14.3) 19 (23.8) 0.7 (0.1-3.5) 0.649 
Receiving ART  yes 45 (97.8) 346 (95.3) 2.2 (0.3-17) 0.434 
ART (months) Median (IQR) 12.0 (10.5-12.0) 12.0 (10-12.0) -0.1 (-0.8-0.7)† 0.873 
ART regimen TDF/FTC/EFV 45 (100.0) 352 (98.9)  0.732 
 TDF/FTC/NVP 0 (0) 2 (0.6)   
  Others 0 (0) 2 (0.6)   
ART 
components 
PI included 1 (2.2) 6 (1.7) 1.3 (0.2-10.6) 0.837 
 PI not included 45 (97.8) 338 (98.3)   
Functional status Working 44 (95.7) 351 (97.8)  0.394 
 Ambulatory 2 (4.3) 6 (1.7)   
 Bedridden 0 (0.0) 2 (0.6)   
WHO stage  I 41 (89.1) 320 (88.2)  1.000 
 II 4 (8.7) 33 (9.1)   
 III 1 (2.2) 8 (2.2)   
 IV 0 (0) 2 (0.6)   
* Mean difference and its 95% Confidence Interval.   †Median difference and its Interquartile Range.              
BP = Blood pressure (mmHg).    BMI = Body mass index ((kg/m2) 
 
5.4.5 Multivariable analysis of risk factors for prevalent hypertension among HIV-
positive patients  
Variables entered into the multivariable analysis included age, gender, BMI, CD4 count 
range and Hepatitis B. Hypertensive patients were older (AOR (95% CI) = 1.06 (1.03 – 1.08), 
p = 0.001), more likely to be male (AOR (95% CI) = 1.6 (1.0 – 2.8), p = 0.074) and to have 
higher BMI (AOR (95% CI) = 1.1 (1.1 – 1.2), p = 0.001) than patients without hypertension. 
Correspondingly, hypertensive patients were less likely to be underweight (AOR (95% CI) = 
0.4 (0.1 – 1.1), p = 0.068) and more likely to be overweight (AOR (95% CI) = 2.2 (1.2 – 4.2), 
p = 0.011) or obese (AOR (95% CI) = 5.4 (2.0 – 14.6), p = 0.001).  
Hypertensive patients were more likely to have CD4 count ≥ 100 cells/mm3 (100 – 199 
cells/mm3 AOR (95% CI) = 2.1 (1.1 – 4.0), p = 0.022), 200 – 350 cells/mm3 AOR 1.9 (1.0 – 
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3.5), p = 0.059), > 350 cells/mm3 (AOR= 1.9 (1.0 – 3.7), p = 0.042) and to be infected with 
Hepatitis B (AOR (95% CI) = 2.1 (1.0 – 4.5), p = 0.063). 
 
5.4.6 Multivariable analysis of factors associated with baseline hypertension among 
HIV-negative patients 
Patients with hypertension were older than non-hypertensive patients (AOR (95% CI) = 1.07 
(1.03 – 1.11), p = 0.001).  However, all other variables selected became non-statistically 
significant, as shown in table 5.11.  
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Table 5.10. Multivariable analysis of risk factors for hypertension among HIV-positive patients 
Characteristics Category Hypertensive 
N = 113 (%)   
Normotensive 
N = 770 (%) 
OR (95% CI)* P  Adjusted OR (95% 
CI) 
P  
Age (years) Mean (SD)  40.0 (9.3) 35.2 (9.5) 4.7 (2.9 – 6.6)* 0.001 1.06 (1.03 – 1.08) 0.001 
Gender Male 52 (46.0) 257 (33.4) 1.7 (1.1 – 2.5) 0.009 1.6 (1.0 – 2.8) 0.074 
 Female 61 (54.0) 513 (66.6) 1  1  
Marital status Single 21 (18.8) 207 (27.2) 1  1  
 Married 84 (75.0) 512 (67.3) 1.6 (1.0 – 2.7) 0.062 1.1 (0.6 – 1.9) 0.732 
 Separated/Divorced 1 (0.9) 18 (2.4) 0.5 (0.1 – 4.3) 0.567 0.5 (0.1 – 4.5) 0.568 
 Widowed 6 (5.4) 24 (3.2) 2.5 (0.9 – 6.7) 0.077 1.7 (0.6 – 5.4) 0.352 
Educational level None 7 (7.7) 50 (8.8) 1    
 Primary 20 (22.0) 118 (20.9) 1.2 (0.5 – 3.0) 0.685   
 Secondary 27 (29.7) 199 (35.2) 1.0 (0.4 – 2.4) 0.945   
 Higher Ed. 37 (40.7) 198 (35.0) 1.3 (0.6 – 3.2) 0.513   
Occupation Student 7 (6.2) 73 (9.6) 1  1  
 Unemployed 1 (0.9) 37 (4.9) 0.3 (0.0 – 2.4) 0.244 0.2 (0.0 – 1.7) 0.139 
 Civil Servant 18 (15.9) 75 (9.9) 2.5 (1.0 – 6.3) 0.053 1.2 (0.5 – 3.0) 0.759 
 Artisan 8 (7.1) 72 (9.5) 1.2 (0.4 – 3.4) 0.786 0.6 (0.2 – 1.8) 0.332 
 Trading/ business 38 (33.6) 213 (28.0) 1.9 (0.8 – 4.3) 0.152 1.0 (0.4 – 2.5) 0.954 
 Farming 3 (2.7) 39 (5.1) 0.8 (0.2 – 3.3) 0.759 0.3 (0.1 – 1.5) 0.154 
 House-wife 17 (15.0) 116 (15.3) 1.5 (0.6 – 3.9) 0.370 1.1 (0.4 – 2.9) 0.886 
 Others 21 (18.6) 135 (17.8) 1.6 (0.7 – 4.0) 0.293 0.7 (0.3 – 1.9) 0.506 
Baseline         
BMI (kg/m2) Mean (SD)  24.3 (5.4) 21.7 (4.1) 2.6 (1.3-3.9)* 0.001 1.1 (1.1 – 1.2) 0.001 
BMI group < 18.0   4 (5.6) 81 (17.2) 0.4 (0.1 – 1.1) 0.074 0.4 (0.1 – 1.1) 0.068 
 18.0 – 24.9  39 (54.9) 301 (63.9) 1  1  
 25.0 – 29.9  19 (26.8) 73 (15.5) 2.0 (1.1 – 3.7) 0.024 2.2 (1.2 – 4.2) 0.011 
 ≥ 30  9 (12.7) 16 (3.4) 4.3 (1.8 – 10.5) 0.001 5.4 (2.0 – 14.6) 0.001 
Systolic BP 
(mmHg)  
Mean (SD)  137.9 (15.6) 108.3 (11.3) 29.6 (26.6-32.6)* 0.001 1.3 (1.2 – 1.4) 0.001 
Diastolic BP Mean (SD)  88.9 (8.3) 68.5 (8.3) 20.4 (18.8-22.1)* 0.001 1.6 (1.3 – 1.9) 0.001 
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CD4 count range  < 100  18 (17.3) 188 (27.9) 1  1  
 100 – 199  28 (26.9) 136 (20.2) 2.2 (1.1 – 4.0) 0.018 2.1 (1.1 – 4.0) 0.022 
 200 – 350  28 (26.9) 159 (23.6) 1.8 (0.98 – 3.4) 0.057 1.9 (1.0 – 3.5) 0.059 
 > 350  30 (28.8) 191 (28.3) 1.6 (0.9 – 3.0) 0.116 1.9 (1.0 – 3.7) 0.042 
Hepatitis B  Yes 10 (14.3) 35 (7.8) 2.0 (0.9 – 4.2) 0.076 2.1 (1.0 – 4.5) 0.063 
 No 60 (85.7) 411 (92.2) 1  1  
* Mean difference and its 95% Confidence Interval.   †Median difference and its Interquartile Range.   BP = Blood pressure (mmHg). BMI = Body mass index (kg/m2), ALT 
= Alanine Transaminase, WBC = White blood cells 
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Table 5.11. Multivariable analysis of risk factors associated with hypertension among HIV-negative patients 
 
Characteristics Category Hypertensive 
N = 38  (%)   
Normotensive 
N = 158 (%)   
OR (95% CI)* P  AOR (95% CI) P  
Age (years) Mean (SD) 44.6 (13.3) 33.8 (10.5) 10.8 (6.2 – 15.5)* 0.001 1.07 (1.03 – 1.11) 0.001 
Gender Male 19 (50.0) 66 (41.8) 1.4 (0.7 – 2.8) 0.358 1.5 (0.6 – 3.8) 0.408 
 Female 19 (50.0) 92 (58.2) 1  1  
Marital status Never married 8 (21.1) 75 (47.5) 0.3 (0.1 – 0.7) 0.003 0.7 (0.3 – 1.9) 0.510 
 Ever married 30 (78.9) 83 (52.5) 1  1  
Educational level No formal 
education 
2 (6.7) 2 (1.4) 1  1  
 Primary 5 (16.7) 10 (6.8) 0.5 (0.1 – 4.7) 0.543 0.6 (0.1 – 5.3) 0.669 
 Secondary 4 (13.3) 27 (18.1) 0.1 (0.0 – 1.4) 0.092 0.5 (0.5 – 4.8) 0.527 
 Higher education 19 (63.3) 109 (73.6) 0.2 (0.0 – 1.3) 0.090 0.9 (0.1 – 5.7) 0.722 
BMI Mean (SD), kg/m2 27.8 [6.3] 24.6 [5.6] 3.1 (1.0 – 5.3)* 0.005 1.1 (1.0 – 1.1) 0.08 
BMI group < 18.0 1 (3.0) 12 (8.2) 0.5 (0.1 – 4.2) 0.522 0.5 (0.1 – 5.9) 0.617 
 18.0 – 24.9  13 (39.4) 78 (53.1) 1  1  
 25.0 – 29.9  8 (24.2) 35 (23.8) 1.4 (0.5 – 3.6) 0.522 1.2 (0.5 – 3.4) 0.677 
 ≥ 30.0  11 (33.3) 22 (15.0) 3.0 (1.2 – 7.6) 0.021 2.0 (0.7 – 5.7) 0.172 
Waist Circ.   Mean (SD) 90.9 (11.7) 82.3 (16.3) 8.7 (2.5 – 14.9)* 0.006 1.01 (0.97 – 1.06) 0.550 
Hip Circ.  Mean (SD) 101.6 (12.5) 95.5 (14.4) 6.1 (0.4 – 11.7)* 0.035 1.01 (0.96 – 1.06) 0.618 
Waist-to-Hip ratio Mean (SD) 0.90 [0.08] 0.86 [0.02] 0.03 (-0.02 – 0.08)* 0.181 3.0 (0.2 – 51.7) 0.442 
Systolic BP Mean (SD) 150.1 (13.3) 115.3 [12.1] 34.8 (30.4 – 39.2)* 0.001 2.0 (1.2 – 3.1) 0.005 
Diastolic BP Mean (SD) 87.9 (9.1) 70.0 (9.3) 17.9 (14.5 – 21.2)* 0.001 1.3 (1.2 – 1.4) 0.001 
* Mean difference for means and its 95% Confidence Interval. BP = Blood pressure (mmHg).  BMI = Body mass index ((kg/m2). Waist Circ. = Waist circumference (cm).    
Hip Circ. = Hip circumference (cm).     OR = Odds Ratio.  P = Probability value 
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5.4.7 Multivariable analysis of factors associated with incident hypertension among 
HIV-positive patients 
After adjustment, variables that retained statistical significance for incident hypertension 
were age, marital status, baseline BMI, baseline systolic and diastolic blood pressure and 
BMI at 1 year. Newly hypertensive patients were older (AOR (95% CI) = 1.04 (1.02 – 1.07), 
p = 0.001), more likely to be male (AOR (95% CI) = 1.6 (0.9 – 3.1), p = 0.121) and to be 
married (AOR ratio (95% CI) = 2.9 (1.1 – 7.6), p = 0.033) than patients without hypertension. 
Newly hypertensive patients had higher baseline BMI (AOR (95% CI) = 1.1 (1.0 – 1.2), p = 
0.065) and were more likely to be obese (AOR (95% CI) = 4.1 (1.2 – 14.3), p = 0.029). 
Patients with incident hypertension had higher baseline systolic (AOR (95% CI) = 1.06 (1.02 
– 1.09), p = 0.001) and diastolic (AOR (95% CI) = 1.04 (1.00 – 1.08), p = 0.039) blood 
pressures, compared to patients without incident hypertension.  
At one year after enrolment, hypertensive patients had a higher BMI (AOR (95% CI) = 1.1 
(1.1 – 1.2), p = 0.001) and were more likely to be obese (AOR (95% CI) = 4.2 (1.2 – 14.3), p 
= 0.021), than patients without the hypertension.  
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Table 5.12. Multivariable analysis of factors associated with incident hypertension among HIV-positive patients 
Characteristics Category Hypertensive 
N = 48 (%)   
Normotensive 
N = 379 (%) 
OR (95% CI)* P  Adjusted OR (95% 
CI) 
P  
Age (years) Mean [SD]  39.3 (9.3) 34.7 (9.4) 4.7 (1.8 – 7.5)* 0.001 1.04 (1.02 – 1.07) 0.002 
Gender Male 21 (43.8) 107 (28.2) 2.0 (1.1 – 3.6) 0.027 1.6 (0.9 – 3.1) 0.121 
 Female 27 (56.2) 272 (71.8) 1  1  
Marital status Never married 5 (10.4) 110 (29.3) 1  1  
 Ever married 43 (89.6) 266 (70.7) 3.6 (1.4 – 9.2) 0.006 2.9 (1.1 – 7.6) 0.033 
Baseline BMI  Mean (SD) 22.9 (4.5) 21.8 (4.0) 1.1 (-0.2 – 2.4)* 0.098 1.1 (1.0 – 1.2) 0.065 
BMI group  < 18.0  4 (9.5) 44 (16.1) 0.6 (0.2 – 1.8) 0.357 0.6 (0.2 – 2.0) 0.445 
 18.0 – 24.9  27 (64.3) 177 (64.6) 1  1  
 25.0 – 29.9  7 (16.7) 43 (15.7) 1.1 (0.4 – 2.6) 0.887 1.3 (0.5 – 3.4) 0.529 
 ≥ 30  4 (9.5) 10 (3.6) 2.6 (0.8 – 9.0) 0.124 4.1 (1.2 – 14.3) 0.029 
Systolic BP  Mean (SD)  115.6 (12.7) 108.3 (10.5) 7.3 (3.5 – 11.1)* 0.001 1.06 (1.02 – 1.09) 0.001 
Diastolic BP Mean (SD)  71.9 (8.2) 68.6 (8.0) 3.2 (0.8 – 5.6)* 0.009 1.04 (1.00 – 1.08) 0.039 
CD4 count  Median (IQR) 170 (104 – 293) 228 (108 – 401) -40.0 (-97.0 – 12.0)† 0.128 0.999 (0.997 – 1.001) 0.217 
Creatinine  Median (IQR)  71.5 (50.0 – 108.5) 51.5 (46.8 – 71.3) 13.0 (1.0 – 32.0)† 0.021 1.003 (0.997 – 1.009) 0.299 
ALT (U/L) Median (IQR)  41.5 (36.8 – 46.0) 35.5 (27.3 – 45.0) 7.0 (0.0 – 13.0)† 0.049 1.031 (0.987 – 1.077) 0.170 
Measurements at 
1 year 
       
BMI (kg/m2) Mean (SD) 25.4 (4.0) 23.0 (4.1) 2.4 (1.0 – 3.8)* 0.001 1.1 (1.1 – 1.2) 0.001 
BMI group  < 18.0  0 (0.0) 20 (7.3) undefined 0.229 undefined  
 18.0 – 24.9  21 (53.8) 181 (66.1) 1  1  
 25.0 – 29.9  13 (33.3) 61 (22.3) 1.8 (0.9 – 3.9) 0.108 2.2 (1.0 – 5.0) 0.055 
 ≥ 30.0  5 (12.8) 12 (4.4) 3.4 (1.2 – 11.2) 0.020 4.2 (1.2 – 14.3) 0.021 
Systolic BP  Mean (SD)   139.9 (17.1) 108.0 (10.1) 31.9 (26.8 – 36.9)* 0.001 1.3 (1.2 – 1.4) 0.001 
Diastolic BP  Mean (SD) 90.2 (8.6) 69.1 (7.0) 21.1 (18.9 – 23.3)* 0.001 1.5 (1.2 – 1.9) 0.001 
CD4 Cell count  Median (IQR)  261 (180 – 464) 254 (225 – 528) -58.0 (-127.0 – 7.0)† 0.077 0.999 (0.997 – 1.001) 0.192 
CD4 count range  < 100  4 (10.3) 9 (3.6) 1  1  
 100 – 199  8 (20.5) 44 (17.7) 0.4 (0.1 -1.7) 0.210 0.4 (0.1 – 1.9) 0.419 
 200 – 350  11 (28.2) 71 (28.6) 0.3 (0.1 – 1.3) 0.123 0.4 (0.1 – 1.6) 0.189 
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 > 350  16 (41.0) 124 (50.0) 0.3 (0.1 – 1.1) 0.060 0.4 (0.1 – 1.5) 0.162 
Haemoglobin g/dl Mean (SD)  11.9 (1.6) 11.4 (1.4) 0.5 (-0.1 – 1.2)* 0.120 1.3 (0.9 – 1.9) 0.204 
Platelets X 109/L Median (IQR) 220 (196 – 252) 245 (199 – 290) -21.0 (-50.0 – 7.0)† 0.141 0.996 (0.990 – 1.001) 0.138 
WBC X 109/L Median (IQR)  4.4 (3.9 – 5.3) 5.0 (4.4 – 5.9) -0.6 (-1.1 – 0.0)† 0.038 0.7 (0.5 – 1.0) 0.066 
* Mean difference and its 95% Confidence Interval.   †Median difference and its Interquartile Range. BP = Blood pressure (mmHg).   BMI = Body mass index (kg/m2) 
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5.5 DISCUSSION 
 
5.5.1 Summary of the study’s findings 
To determine if there is an association between HIV-infection and the prevalence of 
hypertension, we compared the prevalence of hypertension between HIV-positive patients at 
the time of enrolment into an HIV treatment site and HIV-negative controls. We explored 
risk factors for hypertension among HIV-positive and HIV-negative participants separately. 
Thereafter, we evaluated the incidence of hypertension among HIV-positive patients one year 
after enrolment and determined factors associated with incident hypertension. 
We found that patients with HIV are less likely to have hypertension at the time of first 
attendance (12.8% versus 19.4% among controls). Among HIV-positive patients, 
hypertension was associated with an older age, male gender, higher BMI, higher CD4 count 
(≥ 100 cells/mm3) and Hepatitis B-coinfection. The only risk factor associated with 
hypertension among HIV-uninfected individuals was an older age. Furthermore, 11.2% of 
HIV-positive patients had incident hypertension after 12 months of follow up. Independent 
predictors of incident hypertension included; an older age, if they had been married, 
overweight and obesity a year earlier and higher baseline systolic and diastolic blood 
pressures, a higher BMI with overweight and obesity one year later. ART and other HIV-
related factors were not associated with incident hypertension. 
5.5.2 Effect of HIV infection on hypertension 
Findings from studies comparing the prevalence of hypertension among HIV-infected and 
uninfected patients are inconsistent. Some studies have reported a lower prevalence of 
hypertension among HIV-positive patients, while others have not found this association, with 
a few reporting a higher prevalence of hypertension among HIV-positive patients.  
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Four Nigerian cross-sectional studies have compared the prevalence of hypertension among 
HIV-positive and -negative patients 276,278,279,316. One of these found a lower prevalence  278, 
two studies found no difference 279,316 and one a higher prevalence of hypertension among 
HIV-positive patients 276. Our findings are consistent with a systematic review of Sub-
Saharan Africa studies, which concluded that HIV-infected individuals are more likely to 
have lower systolic and diastolic blood pressure 309. Similar lower prevalence of hypertension 
among HIV-positive patients were reported in cross-sectional 304,307,317,318  and retrospective 
306 studies from other African countries. However, two literature reviews 319,320 and a 
systematic review and meta-analysis 321, reviewing studies across the globe, found that HIV 
infection was associated with an increased risk of hypertension. In like manner, a very large 
study from USA ,which reviewed records of close to 30 million (29,060,418) elderly 
beneficiaries of Medicare and compared cardiovascular risk factors between HIV-positive 
and HIV-negative individuals, found a higher prevalence of hypertension among HIV-
positive groups 322.  
The inconsistency in these studies could be due to difference in the study populations, and 
most importantly, the participants characteristics. For instance, some studies compared ART-
naïve HIV-positive patients with HIV-negative patients, while others compared combinations 
of ART-naïve and ART-exposed HIV-positive patients, with HIV-negative patients 279,316. As 
patients with ART often gain weight, the association reported might be due to these 
confounders, as ART could alter the relationship. A further confounder is the accessibility to 
health services and ART.  In Nigeria and in most of Sub-Saharan countries, patients had very 
limited access to ART in previous decades.  Patients with HIV often had no access to ART 
and therefore were undernourished at the time of accessing the services, and mostly received 
palliative care. In other settings, groups at risk of HIV-infection are often professionals, lorry 
drivers etc, who had more access to health services and were tested at earlier disease stages.  
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These groups of patients often had lifestyles associated with obesity and hypertension, and 
thus, it is not surprising studies provide a wide range of results. Patients in Abuja have 
increasingly been able to access ART.  However, many patients are still diagnosed late and 
patients tend to arrive in a poor overall health condition.  It is thus likely this explains the 
lower prevalence of hypertension among these chronically infected patients. 
 
5.5.3 Prevalence and risk factors for hypertension among HIV-negative patients 
The 19.4% (95% CI = 13.8 – 25.0%) prevalence of hypertension found among HIV-negative 
patients is higher than reported in other cross-sectional studies from Nigeria  276,279,316. One of 
the studies, from northern Nigeria, found a prevalence of 10% 276, and studies in southern 
Nigeria reported prevalence of 10.2% 316 and 13.7% 279. However, one study in northern 
Nigeria, reported a very high prevalence of hypertension (42.5%) 278. These differences could 
be due to the participants characteristics and study design. For instance, one of the studies 
had only 50 participants in its HIV-negative arm, while in another, HIV-negative participants 
were younger than (33.9 years) 276, compared to a mean of 35.9 years in this study.  As we 
observed an increase of 7% in the prevalence of hypertension for every year of age, this 
difference may explain the variation of findings. 
The prevalence of hypertension among HIV-negative patients in this study is similar to cross-
sectional studies in Canada (20.3%) 323 and Italy (19.7%) 324.  
The only risk factor for hypertension among HIV-negative patients, was older age, which is a 
traditional risk factor for hypertension among the general population.  This has also been 
found in many studies conducted on HIV-negative patients 316,325. 
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5.5.4 Prevalence and risk factors for hypertension among PLHIV 
Among HIV-positive patients, 12.8% were hypertensive at the time they were enrolled into 
HIV care. This is similar to a cross-sectional study from Lagos, Nigeria, which reported 12% 
of ART-naïve HIV-positive patients were hypertensive 280. This prevalence is also consistent 
with a systematic review of 44,903 participants from 39 studies across the globe (with a view 
to determining the effect of ART on hypertension), which reported an aggregated prevalence 
of 10.5% among HIV-positive patients not on ART  314. A further systematic review and 
meta-analysis of 63,554 participants from 49 studies worldwide, to determine the global 
prevalence of hypertension among HIV patients, also had similar findings,  with a prevalence 
of 12.7%  326. Additionally, a systematic narrative review (with a focus on the burden, risk 
factors, and drugs used in managing hypertension in this population) showed that the 
prevalence of hypertension among HIV-positive patients, ranged from 8.7 to 45.9% in low 
and middle-income countries and from 4.7 to 54.4% in high-income countries 255. In like 
manner, a large cross-sectional study in Tanzania of 34,111 ART-naïve HIV-positive 
patients, showed that 12.5% had hypertension 303. However, two studies from the north-east 
and South of Nigeria reported a higher prevalence of 19.3% 327 and 19% 279 among ART-
naïve patients. Participants in the north-east study were slightly older with mean age of 37.4 
years.  
The risk factors for hypertension among HIV-positive are mostly the so-called traditional risk 
factors (older age, male gender and higher BMI) which are well established factors 311,327,328. 
Additionally, previous studies have identified a higher CD4 count as an independent risk 
factor for hypertension  303,308,329, which is likely due to the fact that patients with high CD4 
count might be in early stage of HIV infection, which could have made them to have higher 
body weight or BMI compared to patients at the late stage of the infection. In addition, an 
early stage of the infection could be associated with less vascular endothelial damage or 
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atherosclerosis that chronic infection might cause. Hepatitis B as a risk factor for 
hypertension has also been reported by others282, which might reflect the effect of liver 
damage or additional chronic infection with its associated chronic inflammation on blood 
pressure. Some studies have shown an association between hepatitis C and hypertension 
297,330,331, however hepatitis C screening is not routinely done in HIV care in Nigeria. 
5.5.5 Incidence and risk factors for incident hypertension among PLHIV 
The incidence of hypertension 12 months after participants’ enrolment into the ART program 
was 11.2%. This is lower than the incidence of 31% reported by a retrospective study in Jos, 
north-east Nigeria 327.This could be partly due to patients in Jos being older than in Abuja. 
However, our incidence is similar to a longitudinal study of 4122 HIV-positive patients on 
ART in Uganda (13.1%) 281 and a prospective study in North America of 68,405 HIV-
positive patients initiating ART (14%)332. In Tanzania, a prospective study showed that 9.6% 
of 955 HIV-positive patients had incident hypertension 333. This lower incidence may be due 
to the lower mean follow up period of 144 days. Conversely, a higher incidence was found in 
a review of 6816 HIV-positive patients in the USA (20.4%) 334.  Follow up period varied 
across studies and a prospective cohort of 823 HIV-positive women in the USA reported a 
high incidence of 35% after a mean follow up of 9.6 years 335. The inconsistency in reports of 
hypertension incidence could be similar to those discussed from prevalent hypertension, 
reflecting disease severity, adherence to ART, lifestyle changes and differences in the 
studies’ follow up duration and participants’ characteristics, such as age and BMI. 
Independent risk factors for incident hypertension found in this study included; older age, 
ever been married, overweight/obesity at the time of enrolment, a high baseline systolic and 
diastolic blood pressure, BMI or overweight/obesity at 12 months. Previous studies have 
shown that age and higher BMI are independent predictors of incident hypertension 327,333,336. 
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We did not find other studies reporting an association with marriage.  This finding in 
Nigeria’s context may reflect the age of the patient and is likely to be a marker of the lifestyle 
and diet of the participants. Women tend to cook at home and a higher BMI is associated with 
affluence and health. To our knowledge, this is also the first study that reported an 
association between the pre-ART baseline blood pressure (systolic and diastolic) and the 
incidence of hypertension. This could mean that patients with incident hypertension might 
have been in pre-hypertensive stages before ART, and then developed hypertension with the 
increased weight associated with ART and viral suppression. It is likely that the traditional 
risk factors of hypertension might still be the main determinants among this group of patients. 
The implication of this finding could be that blood pressure of every HIV-positive patient 
should be thoroughly monitored, and special attention and preventive measures, should be 
directed at patients in pre-hypertension stages prior to ART initiation. 
Despite similar studies reporting that ART 314 or its components  282 are risk factors for 
incident hypertension, this and other studies 283,327,333 did not find an association. This could 
be due to the fact that almost all (96.3%) participants in this study, were on ART, and that 
98% of the patients on ART did not receive PI.  
5.5.6 Limitations and strength of this study 
Like other retrospective studies, this study has many limitations. The data used were 
collected without having this study or its objectives in mind and many relevant variables were 
not captured. Some data were incomplete, some variables were not standardized and there are 
likely recording and measuring errors that may or may not have occurred by random, 
introducing systematic biases. Patients may have been interviewed under stress with a newly 
diagnosed HIV infection and this may have resulted in recall bias or insincerity in their 
responses and a white coat effect that increased the likelihood of high blood pressure 
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readings.  Though, this may be less likely to happen, due to the fact that patients with incident 
hypertension were found to have higher baseline systolic and diastolic blood pressures.  
A large proportion of the patients available on enrolment were transferred out, LTFU    or 
died in the interim period. These losses would certainly introduce biases, as patients who die 
or LTFU are more likely to have severe HIV infections, and may have very low BMIs and 
thus lower blood pressure. However, the comparison of patients LTFU and those remaining 
in the cohort did not identify significant differences. The prevalence and incidence of 
hypertension in this study could be lower than the true value, because of the short follow up 
period.  Some patients with normal blood pressure on enrolment might have been on anti-
hypertensive treatment, which was not disclosed or recorded by the health workers.  We are 
also limited to make associations of causality, given the cross-sectional nature of the study. 
Lastly, it is not possible to rule out effects of unknown confounders on this study.  
Nevertheless, this study has some strength. Firstly, it is one of the very few studies in Nigeria 
that determined incident hypertension among HIV-positive patients. Secondly, this may be 
the first study that documented that HIV-positive patients with incident hypertension had 
higher systolic and diastolic blood pressures at the time of enrolment. It will also contribute 
data on prevalence of hypertension among HIV-positive patients, to the few studies available 
in Nigeria.  
5.5.7 Conclusion 
This study found a lower prevalence of hypertension among HIV-positive patients compared 
to HIV-negative patients and established that patients who initiate ART have a high incidence 
of hypertension one year after initiation of therapy.  Traditional risk factors of hypertension 
(older age, higher BMI, and male gender) were the main factors associated with both 
prevalence and incidence of hypertension in this population. Hepatitis B infection and a 
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relatively high CD4 count, were independent risk factors for prevalent hypertension, and 
higher blood pressures (systolic and diastolic) on enrolment, were independently associated 
with incident hypertension. 
To control hypertension among HIV-positive patients, health practitioners of HIV/AIDS 
control programs should;  
• Monitor blood pressure after initiation of ART 
• Encourage lifestyle and dietary modifications (healthy eating habits), especially after 
ART initiation.  
• Pay special attention on blood pressure monitoring among older patients 
• Identify patients in pre-hypertensive stage at the time of enrolment and direct strategies 
for the prevention of hypertension towards them. 
• Regularly screen HIV-positive patients for hepatitis B (and C), and institute appropriate 
treatment to reduce the risk of developing hypertension 
• Frequently monitor blood pressures of patients with high CD4 count  
• If possible, patients with hypertension should undergo renal function screening 
Further prospective studies should be used in future research to avoid this study’s limitations. 
Further studies are also needed, because there are very few studies reporting the incidence of 
hypertension among PLHIV, especially in the last decade, when the availability of ART has 
increased. Lastly, the effect of baseline blood pressures on incident hypertension should be 
assessed prospectively among HIV-positive patients. 
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Chapter 6 
General Discussion and Conclusion 
6.1 Introduction 
This chapter integrates the findings of all the sub-studies, suggests future research and 
presents final conclusions.  
Studies presented in this thesis are important because, a holistic approach is needed to sustain 
and improve the life expectancy brought by universal access to ART for PLHIV. Despite TB 
being preventable and treatable, it is the commonest cause of death among HIV-infected 
individuals. Hence, this thesis focuses on improving diagnosis and understanding the risk 
factors for poor treatment outcome of TB among HIV patients. In addition, we determined 
the burden of hypertension, an important risk factor for CVDs, now emerging as the leading 
cause of death among these patients.  
To achieve the aim of this research, we conducted four studies comprising a cross-sectional 
study, a prospective study and two retrospective studies. In the first study, we evaluated the 
performance of the WHO TB symptom screening for early diagnosis and prevention of TB 
among HIV patients. The second study assessed the performance of CRP and IP-10 as 
screening tools for TB. This is a high-priority in TB diagnostic research, particularly for HIV 
patients and other vulnerable populations, such as children, who may not be able to produce 
sputum. The third study reviewed TB treatment records to determine the treatment outcome 
and its determinants and compare these between HIV-positive and HIV-negative patients. In 
the fourth study, medical records of   HIV-positive patients were reviewed to determine the 
prevalence of hypertension on enrolment and the incidence of hypertension 12 months after 
enrolment.  
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6.2 Summary of findings from the studies 
More than 70% of the newly diagnosed HIV patients had at least one of the symptoms of TB, 
but only 3% and 6.5% had culture-confirmed and bacteriologically-confirmed TB. The 
sensitivity and negative predictive value of the screening algorithm was 83.3% and 98.2% 
respectively.  CRP sensitivity and specificity to identify individuals with TB was 91.4% and 
33.2%, and was higher among HIV-negative individuals (95.3% and 42.6%) than in HIV-
positive participants (84.8% and 22.1%). IP-10 sensitivity and specificity were lower than 
CRP and were 87.3% and 40.9% among all participants.  The sensitivity and specificity also 
varied; HIV-negative participants (87.5% and 50.3%) and HIV-positive participants (85.3% 
and 32.4%). The combination of CRP and IP-10 increased the performance slightly among 
HIV-negative participants (sensitivity 97.5% and specificity 43%).  
TB treatment outcome (of patients treated at the DOTS clinic of UATH) was very poor, 
which manifested as low treatment success (62%), and high death (8.4%) and LTFU (18%) 
rates. TB/HIV-coinfection rate was high (44.3%). HIV-positive patients were less likely to 
have treatment success, more likely to die and to be LTFU. However, there was no difference 
in treatment failure rate between the two groups. Risk factors to poor treatment and LTFU 
were older age, HIV infection, lack of baseline smear results, low body weight and 
underweight. Among HIV-positive patients, older age, low body weight, lack of baseline 
smear results, and not receiving CPT were predictors of poor treatment outcome and LTFU. 
ART use was not found to be associated with TB treatment outcome.  For the HIV-negative 
patients’ population, besides older age, low body weight and lack of baseline smear result, 
which were associated with poor treatment outcome and LTFU; being on category 2 anti-TB 
medication was associated with LFTU. 
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The prevalence of hypertension was higher among HIV-negative than HIV-positive patients 
(19.4% versus 12.8%). The incidence of hypertension among HIV-positive patients, one year 
after enrolment was 11.2%. Risk factors for hypertension were the traditional risk factors in 
the general population (older age, higher BMI). Additional risk factors among HIV-positive 
patients were higher CD4 counts and Hepatitis B infection. In addition to the traditional risk 
factors, incident hypertension was associated with higher systolic and diastolic blood pressure 
at enrolment. 
6.3 Implications of the study findings 
Findings from each of the studies presented in this thesis have many theoretical, service and 
policy implications. With respect to the evaluation of the WHO TB symptom screening 
algorithm, the fact that more than 70% of HIV-positive patients had a TB symptom, but only 
very few (3 – 6.5%) of them ended up having TB, means that the current limited laboratory 
services in high burden settings may not be able to cope with the work-overload resulting 
from testing three-quarters of all HIV-positive patients for TB. In addition, this will delay 
initiation of IPT and ART. Therefore, there is a need for better TB screening methods that are 
simple, rapid and not costly, for HIV patients, so that patients who need IPT will be able to 
start it and ART can also be commenced on time. Moreover, as previous studies have shown 
the algorithm does not work well in pregnant women, the screening algorithm may not be 
useful for all categories of HIV-positive patients. Hence, there may be a need to either have 
different TB screening algorithm for different categories of patients or look for one that could 
perform well in all groups of HIV patients. The poor performance of CRP and IP-10 among 
HIV-positive patients, implies that simple, rapid and effectives TB screening tools are still 
needed for early diagnosis and prompt and appropriate initiation of preventive therapy. 
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The high TB/HIV-coinfection rate found in the TB treatment outcome study, could mean that 
there are many undiagnosed HIV patients in the community. Since HIV is the strongest risk 
factor for TB and one-third of the population are infected with LTBI, it could also mean that 
many cases of HIV infection were not diagnosed early. There is a need for community-based 
HIV and TB screening, and institution of IPT for all HIV patients without TB.  
The poor TB treatment outcomes among TB patients treated in UATH suggests a weak TB 
service, limited diagnostic and screening at lower health centres, which might have made 
many of patients to attend the hospital after poor response to treatment or difficulty with 
diagnosis at primary/secondary health facilities. Hence, there may be a need to strengthen TB 
diagnostic and screening capacities of TB treatment centres at the primary health care level, 
with a view to ensuring early diagnosis, prompt treatment and better outcome.  
Regarding the high rate of LTFU, there may be a need to put appropriate and effective 
patients’ tracking mechanisms in place. Also, factors associated with LTFU found in this 
study (such as, HIV-infection, older age, underweight/low body weight, not receiving CPT, 
being on category 2 TB treatment regimen, and lack of baseline smear results), should be put 
into consideration in strategy to address this issue, so that special attention can be directed 
towards patients with any of the risk factors. 
The high burden of hypertension among HIV patients, reinforces the need to integrate 
hypertension (and other non-communicable diseases) management into the existing HIV care 
program, so that any HIV patient with the comorbidity, will receive treatment for it in 
addition to HIV care, at the same clinic and visit. Furthermore, an integrated management of 
these conditions may increase treatment adherence for ART, which is also low in this setting. 
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6.4 Future research 
To address the limitations in the studies presented in this thesis, future researches should aim 
to meet the sample size required. Also, to avoid delay in sputum samples’ processing and 
culture, there is a need to ensure that TB research laboratory and study’s site(s) are not too far 
from each other. 
Moreover, the fact that majority of patients with TB symptom (using the WHO symptom 
screening) ended up not having TB and were consequently delayed in initiating preventive 
therapy and ART, is an indication that more research for a rapid method to rule out TB is 
needed. Additionally, due to the unexpected and unavoidable delay in manufacturers’ release 
of most of the new TB diagnostics (such as Ultra-sensitive GeneXpert, Genedrive, and 
electronic Nose (E-nose)) we had planned to evaluate in this study, the diagnostics were not 
available for this study. Hence, the evaluation of these diagnostics and others promising ones, 
whenever they are available, will be an important research towards overcoming the 
challenges with TB diagnosis among HIV patients. 
Furthermore, future studies that recruit patients irrespective of TB symptoms, will be needed 
to re-evaluate the performance of CRP and IP-10 as a screening tool for active TB, in 
Nigeria/West Africa, to be able to compare the performance of the biomarkers to that of the 
WHO symptom screening algorithm.  Because, we could not do this in our study, since only 
patients with TB symptom were recruited into the study. 
In addition, there may be a need for more studies on factors associated with the combination 
of death and treatment failure, as poor TB treatment outcomes. Because, apart from our 
study, only one published previous study 208 was found to have assessed the factors. Future 
studies, should also determine factors associated with poor TB treatment outcomes among 
HIV-negative patients, since very few studies have done this in Sub-Saharan Africa. 
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Lastly, future studies should assess the effect of baseline blood pressure on incidence 
hypertension among HIV-positive patients, because we did not find any previous study to 
compare our finding on this factor with (association between higher baseline blood pressure 
(systolic and diastolic) and incident hypertension). 
6.5 Conclusion 
Four studies (comprising a cross-sectional, a prospective and two respective studies) were 
presented in this thesis. The main aims of the studies were to; improve TB diagnosis, 
understand determinants of TB treatment outcome and assess the burden of hypertension and 
its associated factors among HIV-patients, with a view to preventing premature deaths among 
the population. Findings from the studies showed that the WHO TB symptom screening 
algorithm performed as expected, however, the fact that the majority (> 70%) of patients with 
TB symptom, who underwent further diagnostic workup, ended up not having the disease, 
will make the implementation of the screening algorithm difficult in resource-limited settings, 
due to the under-equipped and insufficient laboratory services in these settings. In addition, 
the performance of CRP as a TB screening tool, was fair among HIV-negative patients, but 
poor among HIV-positive patients. IP-10 performed poorly in all categories of patients in the 
study. Also, treatment outcomes were poor among TB patients treated at the DOTS clinic of 
UATH. The treatment outcome was poorer among HIV-positive patients compared to HIV-
negative patients. HIV-positive patients were less likely to have treatment success, but more 
likely to die and LTFU, compared to HIV-negative patients. The studies also showed that the 
burden of hypertension is high among HIV patients and its main determinants are the 
traditional risk factors, in addition to Hepatitis B infection. 
To ensure early diagnosis, prompt treatment and prevention of TB among HIV-patients, there 
is therefore, a need to search for and find simple, rapid and inexpensive TB screening tool for 
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the patients. Additionally, TB treatment outcome can be improved by ensuring that special 
attention/care are directed towards HIV-positive, older and underweight patients, and all 
TB/HIV-coinfected patients are placed on CPT. Moreover, the high burden of hypertension 
among HIV patients, may be properly reduced by integrating hypertension screening into the 
current HIV control programs in resource-limited settings. 
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8. Appendices 
8.1 Appendix 1. Additional tables on TB treatment outcome study 
Table 1. Bivariable analysis of factors associated with death during TB treatment  
Variable Category            Treatment outcome Odds ratio 
(95% CI)  
P 
 
 Death 
      
N = 84 
Success 
 
N = 619 
  
Mean (SD) age  All    38.3 (16.1) 31.4 (15.3)  6.9 (3.4 – 10.4) 0.001 
(years) Male  41.1 (16.3) 33.0 (16.2)  8.1 (3.3 – 12.9) 0.001 
 Female  34.2 (15.0) 29.2 (13.6) 5.1 (0.123 – 10.0) 0.045 
Age group* 0 – 9  6 (7.1) 60 (9.7)  0.001 
 10 – 19  3 (3.6) 56 (9.1)   
 20 – 29  11 (13.1) 150 (24.2)   
 30 – 39  22 (26.2) 188 (30.4)   
 40 – 49  21 (25.0) 100 (16.2)   
 50 – 59  13 (15.5) 31 (5.0)   
 60 – 69  5 (6.0) 21 (3.4)   
 ≥ 70 3 (3.6) 13 (2.1)   
Gender Male  50 (59.5) 361 (58.3) 1.1 (0.7 – 1.7) 0.834 
 Female 34 (40.5) 258 (41.7) 1  
Treatment category      New  84 (100%) 600 (96.9) Undefined 0.151 
 Retreatment  0 (0%) 19 (3.1) 1  
Anatomical site Pulmonary 74 (88.1) 529 (85.5) 1.3 (0.6 – 2.5) 0.517 
 EPTB 10 (11.9) 90 (14.5) 1  
Smear microscopy Positive 15 (20.3) 262 (49.5) 1  
 Negative 24 (32.4) 148 (28.0) 2.8 (1.4 – 5.6) 0.003 
 Not done 35 (47.3) 119 (22.5) 5.1 (2.7 – 9.7) 0.001 
Treatment used Category 1 80 (95.2) 589 (95.2) 1.0 (0.3 – 3.0) 0.973 
  Category 2 4 (4.8) 30 (4.8) 1  
HIV status Positive 68 (81.0) 230 (37.3) 7.2 (4.1 -12.6) 0.001 
  Negative 16 (19.0) 387 (62.7) 1  
Smear grade (n = 277) Scanty 3 (20.0) 21 (8.0) 1  
  + 3 (20.0) 68 (26.0) 0.3 (0.1 – 1.6) 0.158 
  ++ 2 (13.3) 96 (36.6) 0.15 (0.02 – 0.9) 0.041 
 +++ 7 (46.7) 77 (29.4) 0.6 (0.2 – 2.7) 0.537 
Xpert grade (n = 139)  Very low 2 (10.5) 24 (20.0) 1  
  Low 9 (47.4) 33 (27.5) 3.3 (0.6 – 16.6) 0.151 
 Medium 7 (36.8) 38 (31.7) 2.2 (0.4 – 11.5) 0.347 
 High 1 (5.3) 25 (20.8) 0.5 (0.04 – 5.6) 0.559 
Mean (SD) weight Baseline  49.0 (16.8) 50.3 (16.3)  -1.3 (-5.1 – 2.5) 0.517 
 2 months  51.0 (2.2) 52.6 (15.9) -1.5 (-4.2 – 1.2) 0.242 
 5 months  ------------ 55.9 (16.1) -------------  
Weight difference At 2 months -2.3 (4.4) 2.1 (4.3) -4.4 (-8.2 – -0.6) 0.024 
 At 5 months ----------- 4.6 (5.2)   
*n (%) unless otherwise stated.  aMean difference (95% CI).  
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Table 2. Multivariable analysis of factors associated with death among TB patients 
Variable Category   Treatment outcome Odds ratio 
(95% CI)  
P 
 
AOR (95% CI) P 
 Death   
N = 84 
Success 
N = 619 
    
Mean (SD) age  All    38.3 (16.1) 31.4 (15.3)  6.9 (3.4 – 10.4)a 0.001 1.03 (1.01 – 1.05) 0.004 
Gender Male  50 (59.5) 361 (58.3) 1.1 (0.7 – 1.7) 0.834 1.1 (0.7 – 1.9) 0.632 
 Female 34 (40.5) 258 (41.7) 1  1  
Type of PTB  Smear-positive 15 (20.3) 262 (49.5) 1  1 1 
 Smear-negative 24 (32.4) 148 (28.0) 2.8 (1.4 – 5.6) 0.003 1.6 (0.7 – 3.3) 0.247 
 Smear not done 35 (47.3) 119 (22.5) 5.1 (2.7 – 9.7) 0.001 3.4 (1.7 – 6.9) 0.001 
HIV status Positive 68 (81.0) 230 (37.3) 7.2 (4.1 -12.6) 0.001 7.0 (3.9 – 12.4) 0.001 
  Negative 16 (19.0) 387 (62.7) 1  1  
Smear grade Scanty 3 (20.0) 21 (8.0) 1  1  
  + 3 (20.0) 68 (26.0) 0.3 (0.1 – 1.6) 0.158 0.4 (0.1 – 1.9) 0.236 
  ++ 2 (13.3) 96 (36.6) 0.15 (0.02 – 0.9) 0.041 0.2 (0.03 – 1.3) 0.091 
 +++ 7 (46.7) 77 (29.4) 0.6 (0.2 – 2.7) 0.537 0.7 (0.1 – 3.6) 0.673 
Xpert grade (n = 139)  Very low 2 (10.5) 24 (20.0) 1  1  
  Low 9 (47.4) 33 (27.5) 3.3 (0.6 – 16.6) 0.151 5.0 (0.8 – 32.1) 0.088 
 Medium 7 (36.8) 38 (31.7) 2.2 (0.4 – 11.5) 0.347 3.7 (0.6 – 22.2) 0.152 
 High 1 (5.3) 25 (20.8) 0.5 (0.04 – 5.6) 0.559 0.9 (0.1 – 12.2) 0.928 
Weight difference At 2 months -2.3 (4.4) 2.1 (4.3) -4.4 (-8.2 – -0.6)a 0.024 0.81 (0.66 – 0.99) 0.036 
*n (%) unless otherwise stated.  aMean difference (95%CI) 
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8.2. Appendix 2. Additional table on prevalence and incidence of hypertension among HIV 
patients 
Table 1. Characteristics of HIV-positive patients transferred/LTFU/dead and patients who 
remained in care 1 year after enrolment. 
Characteristics Category          Patients’ status at 1 year OR (95% CI)* P 
 LTFU/Transferred 
/Died, N = 389(%) 
In care 
N = 494 (%) 
  
Age (years) Mean (SD) 35.7 (9.5) 35.9 (9.6) -0.2 (-1.4-1.1)* 0.794 
 Male 40.1 (8.5) 39.8 (8.9) 0.4 (-1.6-2.3)* 0.719 
 Female   32.8 (.1) 34.2 (9.4) -1.3 (-2.9-0.2)* 0.094 
Age group  10 - 19 3 (0.8) 5 (1.0)  0.741 
 20 - 29 95 (24.4) 135 (27.3)   
 30 - 39 169 (43.4) 189 (38.3)   
 40 - 49 88 (22.6) 115 (23.3)   
 50 - 59 25 (6.4) 37 (7.5)   
 ≥ 60 9 (2.3) 13 (2.6)   
Gender Male 155 (39.8) 154 (31.2) 1.5 (1.1-1.9) 0.007 
 Female 234 (60.2) 340 (68.8)   
Marital status Single 103 (26.9) 125 (25.5)  0.202 
 Married 258 (67.4) 338 (69.0)   
 Separated 5 (1.3) 14 (2.8)   
 Widowed 17 (4.4) 13 (2.7)   
Education None  26 (9.2) 31 (8.3)  0.929 
 Primary 60 (21.1) 78 (21.0)   
 Secondary 100 (35.2) 126 (33.9)   
 Higher Ed.  98 (34.5) 137 (36.8)   
Occupation Student 36 (9.3) 44 (9.1)  0.104 
 Unemployed 18 (4.7) 20 (4.1)   
 Civil Servant 45 (11.6) 48 (9.9)   
 Artisan 43 (11.1) 37 (7.6)   
 Trade/business 107 (27.6) 144 (29.6)   
 Farming 24 (6.2) 18 (3.7)   
 House-wife 46 (11.9) 87 (17.9)   
 Others 68 (17.6) 88 (18.1)   
Ethnicity Hausa 26 (6.8) 28 (5.8)  0.191 
 Igbo 68 (17.7) 88 (18.1)   
 Yoruba 40 (10.4) 32 (6.6)   
 Others  250 (65.1) 337 (69.5)   
Religion  Christianity 298 (78.4) 361 (73.8)  0.207 
 Islam 81 (21.3) 127 (26.0)   
 Others 1 (0.3) 1 (0.2)   
BMI Mean (SD)  21.6 (4.7) 22.2 (4.2) -0.6 (-1.4-0.2)* 0.131 
BMI group  < 18.0  36 (20.3) 49 (13.4) 1.6 (0.99-2.6) 0.052 
 18.0 – 24.9  106 (59.9) 234 (64.1) 1  
 25.0 – 29.9  30 (16.9) 62 (17.0) 1.1 (0.7 – 1.7) 0.793 
 ≥ 30 5 (2.8) 20 (5.5) 0.6 (0.2 – 1.5) 0.247 
Systolic BP Mean (SD)  110.7 (15.3) 113.3 (15.5) -2.6 (4.7– -0.5)* 0.013 
Diastolic BP Mean (SD)  70.4 [10.9] 71.7 [10.6] -1.3 (-2.7-0.1)* 0.073 
Hypertensive  46 (11.8) 67 (13.6) 0.9 (0.6-1.3) 0.443 
Functional status Working 319 (95.2) 475 (98.8)  0.004 
 Ambulatory 14 (4.2) 6 (1.2)   
 Bedridden 2 (0.6) 0 (0.0)   
WHO stage I 205 (61.6) 338 (70.4) 1  
 II 55 (16.5) 90 (18.8) 1.0 (0.7-1.5) 0.969 
 III 64 (19.2) 44 (9.2) 2.4 (1.6-3.7) 0.001 
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 IV 9 (2.7) 8 (1.7) 1.9 (0.7-4.9) 0.211 
CD4 Cell count  Median (IQR) 197.0 (69– 362) 223.0 (109-388) -23.0 (-49–1.0)* 0.063 
CD4 count range  < 100  100 (31.7) 106 (22.9) 1  
 100 – 199  61 (19.4) 103 (22.2) 0.6 (0.4-0.95) 0.029 
 200 – 350  73 (23.2) 114 (24.6) 0.7 (0.5-1.0) 0.058 
 > 350  81 (25.7) 140 (30.2) 0.6 (0.4-0.9) 0.013 
Haemoglobin 
(g/dl) 
Mean (SD) 10.2 (2.0) 10.8 (1.9) -0.6 (-1.0-0.2)* 0.005 
Platelets X 109/L Median (IQR) 239.5 (188– 304) 224.0 (183-296) 10.0 (-5–25)† 0.179 
Creatinine, 
mMol/L 
Median (IQR) 63.0 (49.0 – 83.0) 53.0 (48-72) 7.0 (2–12)† 0.009 
WBC (cells X 
109/L) 
Median (IQR) 4.8 (3.9 – 6.2) 5.1 (4.0- 6.5) -0.2 (-0.5-0.1)† 0.253 
ALT (U/L) Median (IQR)  32.0 (26.0 – 46.0) 36.0 (28- 45) -1.0 (-5.0-3.0)† 0.688 
Hepatitis B  infected 17 (7.8) 28 (9.4) 0.8 (0.4-1.5) 0.525 
* Mean difference and its 95% Confidence Interval.   †Median difference and its Interquartile Range. BP = Blood pressure. 
BMI = Body mass index (kg/m2), ALT = Alanine Transaminase, WBC = White blood cells 
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8.3. Appendix 3. Research Ethics application 
 
FOR OFFICE USE ONLY 
Application Number Date considered Reviewed by 
   
 
Please complete this form in typescript.  It is essential that this form is completed fully and the relevant 
enclosures are received if the study is to receive proper scrutiny by the Research Ethics Committee.  If any 
documentation is missing proposals will not be submitted for review. 
 
 
 
 
Administration Charges: 
An administration charge of £250 for awards of over £10,000 and £50 for those below will be made for ethical 
approval 
Is the proposed work already funded?  Yes  No  n/a  
Total budget of proposal £       45,000.000 
Name of Funding Organisations:    
1. Commonwealth Scholarship Commission (gave a research support fund of £15,000.00) 
2. Epistem, circa (provided £30,000.00 as funds for testing the Genedrive) 
3. National Tuberculosis and Leprosy Control Programme of Nigeria(NTBLCP)- in kind 
contribution of cartridges for Xpert MTB/RIF testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
Applicant contact details 
Name:       Rotimi Samuel, OWOLABI 
Email address: rsowolabi@yahoo.com ,  rowolabi@liv.ac.uk,  
Rotimi.Owolabi@lstmed.ac.uk 
Postal Address (if not LSTM):       
Telephone number:  07459892040 
Administrative Contact Name: 
(if applicable) 
 Kate Robinson 
Administrative Contact Email: Katharyn.Robinson@lstmed.ac.uk 
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Check List: 
The following Check List must be completed. Please confirm that the following are enclosed. 
 Yes Not Applicable 
1 Completed Internal School Transfer Form (ISF) for administration 
charges 
  
8 Copies of the completed Application Form without staples   
1 Copy of the Research Protocol   
8 Copies of the Questionnaire/case record form without staples   
8 Copies of the Consent Form without staples   
8 Copies of the Patient Information Sheet without staples   
8 Copies of the Translator Agreement without staples   
8 Copies of the Draft interview/FGD or observation/Check list enclosed 
(if used) without staples 
  
8 Copies of the Declaration page - last page of application 
(1 signed and initialled by the applicant plus 7 copies) 
  
8 Collated Applications – please ensure you collate all documents into 8 
separate applications and NOT 8 copies of each document 
  
 
The completed forms should be sent to: Lois Thomas, Secretary, Research Ethics Committee, 
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA e-mail: lstmrec@liv.ac.uk   
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APPLICATION FORM FOR ETHICAL APPROVAL 
(Revised December 2013) 
 
Please refer closely to the Guidance Notes when completing this form. 
All questions must be answered. Any form with sections left blank or answered with N/A will be returned. This 
form must contain all information necessary for the Research Ethics Committee to make a decision on Ethical 
Approval. 
 
APPLICANT FULL NAME (w/ 
title)  
Dr.     Rotimi Samuel, OWOLABI 
PROJECT TITLE  Optimizing the Diagnosis and Management of Tuberculosis 
(TB) and Diabetes Mellitus (DM) among HIV Patients in a high 
TB and HIV burden setting. 
 
Ethical Approvals 
Have you submitted this proposal to the LSTM Research Ethics Committee 
before? 
YES     NO  
If ‘YES’, please give date of previous review:       
To which other ethical committees has/will this protocol be submitted? (please list)? 
The ethical committee of University of Abuja Teaching Hospital 
APPROVALS – Please list any ethical review committees which have already approved the protocol. 
 
In-Country Ethical Approval - Please list the country(ies) where the research will be carried out and whether or 
not in-country ethical approval is required. 
Country 1:  Nigeria YES     NO  
Country 2: YES     NO  
Country 3: YES     NO  
Country 4: YES     NO  
Add additional lines if your research is taking place in more than four countries. 
Please note if you have marked ‘NO’ for any country above WRITTEN EVIDENCE must be provided to confirm 
that in-country ethical approval is not required.  This evidence should be attached as an annex to the 
application.  Acceptable evidence includes: 
• a letter from the national Ministry of Health or other relevant regulatory authority 
• a letter from an authorised signatory at a local partner 
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A letter from a co-investigator or other researcher at a local partner institution is NOT sufficient evidence.  
Your ethics application will not be considered until evidence is provided. 
 
Research Team 
List LSTM research team and all collaborators. 
(Please include all overseas collaborators and give their affiliations, qualifications and role in the study). 
 
     NAME ORGANISATION QUALIFICATIONS ROLE IN STUDY GEOGRAPHIC 
LOCATION 
Prof.  Luis 
Cuevas 
LSTM  MD, MTropMed, 
DTCH 
 First Supervisor Liverpool 
Mr. Russell 
Dacombe 
LSTM BSc, MSc  Second 
Supervisor 
Liverpool 
Dr. Emily Adams LSTM  BSc, PhD Advisor Liverpool 
Dr. Derek Sloan LSTM MBBS, PhD Advisor Liverpool 
Prof.  Lovett 
Lawson 
Zankli Medical 
Centre 
MBBS, MSc, 
DTM&H, PhD 
Local Supervisor Abuja, Nigeria 
Emmanuel Agogo National Agency 
for the Control of 
AIDS/HIV(NAC
A) 
MBBS, 
MtropMed 
Advisor and 
facilitator for the 
study in Nigeria. 
Procurement of 
Xpert cartridges. 
Abuja, Nigeria 
Saddiq 
Abdurrahman 
Assistant director 
of the FCT health 
services.  Head of 
Disease control 
programs 
(including the 
FCT-TBLCP) 
 MBBS, 
MtropMed 
Advisor and 
facilitator for the 
study in Nigeria.  
Access to patients 
attending the 
DOTS clinics of 
the TBLCP of the 
FCT 
Abuja, Nigeria 
 
 
 
 If proposal is for work relating to a MPhil/PhD, please state the name and Department of 
Supervisor/Tutor 
Supervisor Prof. Luis Cuevas 
Department  Clinical Sciences 
Signature       
 
Sponsorship and Indemnity Cover   Please see sponsorship and indemnity guidance notes and 
request form on the LSTM intranet 
http://pcwww.liv.ac.uk/lstmintranet/research_management/applyingforRG/intro.htm  
Have you submitted a sponsorship and 
indemnity request form to the Research 
Office? 
YES   NO 
 
If no, do you intend to submit a form and if 
so, when? 
 
If you do not intend to submit the form 
please give reasons. 
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GLOSSARY OF TERMS 
Please provide a list of acronyms used in the application with their full name and any relevant 
explanation that would be helpful to committee members that may not be an expert in your area of 
work. 
AIDS                 :   Acquired Immune Deficiency Syndrome 
ART                   :   Antiretroviral Therapy 
ARV                   :   Antiretroviral 
CD4  Cells            :  Cluster of differentiation 4 cells  
CI                       :   Confidence Interval 
CPT                      :  Co-trimoxazole Prophylaxis Therapy   
DM                     :   Diabetes Mellitus 
DOTS                   :   Directly Observed Therapy Short course  
FACA                   :   FCT’s Agency for the Control of AIDS 
FBC                      :   Full Blood Count 
FCDA                  :    Federal Capital Development Administration 
FCT                    :   The Nigeria’s Federal Capital Territory (FCT), Abuja 
FCT-TBLCP     :    Federal Capital Territory Tuberculosis and Leprosy Control Program 
FMOH               :    Federal Ministry of Health 
GeneXpert         :    Xpert MTB/RIF  
HbA1C                    :   Glycosylated Haemoglobin 
HBV                      :   Hepatitis B Virus  
HCT                     :    HIV Counselling and Testing 
HIV                    :    Human Immunodeficiency Virus 
INH                    :    Isoniazid 
IPT                     :    Isoniazid Preventive Therapy 
LED-FM              :    Light Emitting Diode(LED) Florescent Microscopy  
LFT                      :    Liver Function Tests 
MDR                  :    Multidrug Resistant Tuberculosis   
M&E                    :   Monitoring and Evaluation unit             
MTB/RIF           :    Mycobacterium Tuberculosis/Rifampicin Resistance 
NASCAP              :    National AIDS and STIs Control Program 
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NEPLWHAN      :    Network of People Living with HIV/AIDS in Nigeria 
NTBLCP            :    National Tuberculosis and Leprosy Control Program 
OI                         :   Opportunistic Infection 
OR                      :    Oral Swab  
OSP                    :    Oral Swab PCR 
PCR                    :    Polymerase Chain Reaction 
PEP                      :    Post-Exposure Prophylaxis against HIV infection 
PLWHA               :    People Living with HIV/AIDS 
PMTCT                :   Prevention of Mother-to-Child Transmission of HIV 
POC                   :    Point-of-Care 
RFT                      :   Renal Function Tests 
RIF                     :    Rifampicin 
RR                      :    Rifampicin Resistance 
T2DM                :    Type 2 Diabetes Mellitus 
TB                      :    Tuberculosis 
UATH                  :    University of Abuja Teaching Hospital 
VOCs                   :    Volatile Organic Compounds              
WHO                 :    World Health Organization 
Xpert                 :     Xpert MTB/RIF 
ZMC                    :     Zankli Medical Centre 
95%CI               :    95% Confidence Interval 
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SECTION A 
STUDY OUTLINE 
 
A.1 LAY SUMMARY: Please use simple language which is understandable to a non-scientific/non-
academic audience.  Sufficient detail of the protocol must be given to allow the Committee to 
make an informed decision without reference to other documents.  Please spell out all 
acronyms.  (max 300 words) 
      
Acquired Immune Deficiency Syndrome (AIDS) and Tuberculosis (TB) are the leading 
causes of death due to single infectious agents and Nigeria has a high TB and Human 
Immunodeficiency Virus (HIV) burden, with 590,000 TB (1) and 3.4 million HIV cases 
(2). TB is the most important opportunistic infection causing death among HIV patients.  
Patients with HIV should be screened for TB. The World Health Organization (WHO) 
recommends utilising a standardised algorithm consisting of symptoms of TB. Patients 
without symptoms are then given Isoniazid Preventive Therapy (IPT) and those with 
symptoms are investigated to initiate TB treatment. The algorithms have not been 
evaluated in Nigeria and asymptomatic individuals with TB or symptomatic patients with 
TB may be being missed.  
It is also well established that it is difficult to make a diagnosis of TB among HIV patients 
due to the low bacilli load on presentation and the low sensitivity of the current TB 
diagnostics.   We will evaluate several new diagnostics for TB.  These diagnostics have 
not been evaluated in Nigeria and information on their performance in an HIV population 
is limited. 
Diabetes Mellitus (DM) is a disease that increases the risk of TB and is more prevalence 
in patients with HIV. In 2013, an estimated 15% of the global adult TB cases were 
attributed to DM, and WHO recommends bidirectional screening of TB and DM. There is 
limited data on the prevalence of DM among patients with HIV with/without TB.    
This study will evaluate the WHO-TB diagnostic algorithms among patients with HIV 
with and without symptoms of TB, and explore whether new diagnostics could increase 
the identification of TB cases. The study will explore better ways of diagnosing TB and 
DM among adult patients with HIV, with a view to characterising whether this is a 
problem among the study population. 
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A.2  IMPORTANCE OF THE RESEARCH: Please state the intended value of the research and explain 
how this research fits in with national/international research priorities. (max 300 words) 
The prevalence of HIV is 3% in Nigeria and 7% in Abuja, the Federal Capital Territory 
(FCT). TB/HIV Co-infection rates are 22% and 32.3%, respectively. Despite the high TB 
burden in Nigeria, case detection is estimated to be very low (16%). Nigeria contributes 
500,000(15%) to the 3.3 million cases of TB that are not notified to the WHO each year 
(3).  
Optimizing TB diagnosis in Nigeria will greatly improve TB case detection, and thereby 
significantly reduce the global TB notification gap.  
Most of the current TB diagnostics take a long time to confirm a diagnosis of TB and 
have reduced sensitivity among HIV patients.  My study will explore better ways of 
diagnosing TB among HIV patients by assessing the effectiveness of the two current 
WHO algorithms for exclusion of TB and for improving TB diagnosis among new HIV 
patients; and the performance of selected new TB diagnostics in this population.  
Exclusion of TB among newly diagnosed HIV patients is very important for initiation of 
IPT, as it reduces the risk of developing TB. The study will generate information on how 
to exclude TB among new patients with HIV and to improve the diagnosis of TB among 
HIV patients.  
Type 2 Diabetes mellitus (T2DM) increases the risk of TB and WHO recommends 
screening for DM among TB patients.  HIV increases the overall inflammatory processes 
of the body and patients with HIV have a higher risk of developing insulin resistance.  In 
addition, several ARVs antagonise the effect of insulin and the risk of T2DM increases 
with the administration of ART. 
The DM screening aspect of the study will document the burden of DM in HIV patients, 
highlighting the importance of early detection to reduce the risk of developing TB and the 
metabolic and chronic complications of DM.  
  
A.3 DUPLICATION OF RESEARCH: Indicate what steps have been taken to ensure this work has not 
already been carried out.  If this project or a similar one has been done before what is the value 
of repeating it?  
(max 300 words) 
An extensive literature review of studies conducted in the topics of my dissertation was 
conducted. 
The 2007 WHO guidelines on exclusion of TB among HIV patients recommends that all 
patients with HIV should be asked for symptoms of TB.  Patients who do not have 
symptoms are given a medicine (called Isoniazid) to prevent them from developing TB in 
the future.  This is called Isoniazid Preventive Therapy (IPT). This approach was evaluated 
in Ethiopia.  Guidelines were then updated in 2011.The updated guidelines have not been 
evaluated in Africa.  
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Towards the end of 2010, WHO approved the use of a new test (Xpert MTB/RIF) for TB 
diagnosis.  This automated molecular diagnostic test, can detect TB and drug (Rifampicin) 
resistance within two hours, and can be used in settings outside the reference 
Laboratories. The test has sensitivity of 92% and specificity of 99%, but it is less sensitive 
(75 %) among HIV patients. To improve diagnosis of TB, the manufacturers of Xpert 
MTB/RIF, developed Ultra-sensitive Xpert MTB/RIF (Xpert Ultra), which has higher 
sensitivity than the current Xpert. This new device is currently being evaluated for WHO 
endorsement in 4 countries. There are no studies reported. QuantuMDx Q-POC, xRapid-TB 
and Fluorobot are promising new TB diagnostics which performance need to be evaluated 
before they can be approved for general use.    The e-nose included in the proposal is 
currently being developed.  There is no data published on its performance. There is no 
published data on use of combination of C-reactive protein(CRP) and IP-10 (at higher 
sensitivity but lower specificity) as a screening test in TB diagnosis 
The prevalence of DM among TB patients has been reported from many countries (e.g. 
Uganda and Tanzania), but not from Nigeria. There is no data on the prevalence of DM 
among HIV patients in the FCT. 
 
A.4 OBJECTIVES: List the major objectives of the study.  These must be clearly stated and 
achievable by the proposed design and methods 
 
Objectives 
(1) To assess the predictive value of the WHO algorithm to exclude TB among people 
living with HIV (PLHIV) 
(2) To determine the performance of selected new diagnostics for TB among PLHIV 
(3) To optimize the WHO algorithm to diagnose TB among symptomatic patients 
with HIV using alternative/additional diagnostic pathways and diagnostics. 
(4) To assess the proportion of patients with HIV or TB who have type 2 Diabetes 
Mellitus (T2DM) 
(5) To compare the performance of Fasting Blood Sugar (FBS) and Glycated 
Haemoglobin (HbA1C) for the diagnosis of T2DM among patients with HIV and 
or TB.  
(6) To retrospectively determine the treatment outcome of patients with TB with and 
without HIV.  
(7) To retrospectively determine the prevalence of hypertension and DM among new 
patients with HIV at the time of enrolment. 
(8) To retrospectively determine the incidence of hypertension and DM among the 
same patients one year after initiation of ART. 
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A.5  METHODOLOGY: Please include the methodology for each objective (if different) and justify 
the rationale behind the use of the chosen methodology. Please use simple language which 
is understandable to a non-scientific/non-academic audience and spell out all acronyms.   
Description of study location for patients’ enrolment: 
The following ART sites will be invited to participate in the study:  
(1) University of Abuja Teaching Hospital (UATH), Gwagwalada, Abuja, Nigeria 
(2) Wuse General Hospital, Wuse, Abuja, Nigeria 
The University of Abuja Teaching Hospital (UATH) is a 500-bed tertiary health facility of 
the Federal Government of Nigeria. It is located in Gwagwalada Area Council of the FCT, 
and provides specialised services in all disciplines of medicine. The hospital has the largest 
ART site in the FCT, with more than 15,000 HIV patients enrolled. An average of 8 new 
HIV patients is enrolled per day, with 160 new HIV patients registered per month. 
Wuse General Hospital is a district hospital of the Federal Capital Development 
Administration (FCDA) and is located in Wuse neighbourhood in Abuja Municipal Area 
Council. It provides specialized medical services, and is one of the largest health facilities in 
the FCT with ART services.  The HIV site has more than 5000 HIV patients enrolled and 
30-40 new patients diagnosed per month. 
The two facilities offer HIV Counselling and Testing (HCT) services.  Patients attend 
voluntarily or are referred by other services for testing. New patients diagnosed at the HCT 
unit or referred from other centres are referred to the ART sites for HIV care. ART sites 
receive referred patients from government, faith-based and private hospitals. The services 
provided include chronic HIV Care; ART adherence preparation, initiation and 
monitoring; prophylaxis and treatment of opportunistic infections (OIs); TB/HIV co-
management; Prevention of Mother-to-Child Transmission (PMTCT); patients’ education 
on positive living; Home-based care, various forms of patients’ support, and cervical 
cancer screening. The ART sites have the following units: Monitoring and Evaluation 
(M&E), Home-based Care and patients’ Support, Medical teams, ART Adherence 
Counselling, Pharmacy, Laboratory, Paediatrics, and Cervical Cancer Screening. Newly 
diagnosed HIV patients report to the M&E unit, which enrols new patients into the 
program. Patients are then sent to the Home-based care and support unit, for first-visit 
counselling, history taking and documentation. Afterwards, patients attend the laboratory 
for baseline investigations, which include CD4 count, full blood count (FBC), renal (RFT) 
and liver function tests (LFT) and Hepatitis B Virus (HBV) screening. The patient is 
allocated to one of the medical teams which comprises one doctor, one nurse and one 
ART Adherence counsellor. New patients are initially seen by the doctor, who takes a 
medical history, physical examination, clinical HIV staging and treatment of OI. Patients 
with symptoms of TB undertake chest X-rays and are referred to the Directly Observed 
Therapy Short-course (DOTS) unit for sputum smear microscopy. Seriously ill patients 
are admitted to the medical wards. Patients with OI are sent to the Adherence Counsellors 
for counselling on the drug(s), HIV/AIDS and positive living, and to the pharmacy to 
collect drugs. Drugs for OI are provided for one week and patients are asked to return to 
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collect the baseline investigations and assessment of ART eligibility. Patients co-infected 
with TB commence TB treatment and two weeks later, if there are no problems, start ART 
that does not interact with TB medications. Patients without TB symptoms eligible for 
ART receive ART adherence preparation and commence Co-trimoxazole Prophylaxis 
Therapy (CPT). Patients are given a two-week appointment on CPT alone. At the end of 
the two-weeks, patients are assessed regarding CPT adherence and their understanding of 
ART adherence.  Misunderstandings and problems with adherence are addressed during 
this visit. If the patient’s adherence preparation is satisfactory, ART is initiated and CPT 
is continued. Patients not eligible for ART are followed using CD4 counts and clinical 
staging every three months. 
The study objectives will be achieved as follows; 
(1) To assess the predictive value of the WHO algorithm to exclude TB among 
PLHIV 
This will be a cross-sectional study from January 2016 to December 2016, among newly 
diagnosed HIV-positive patients attending the participating ART sites in Abuja, FCT.  
Study’s participants’ selection  
Participants will be identified through the ART sites’ M&E units of UATH and Wuse 
district hospital. All newly diagnosed HIV patients >18 years enrolled at the ART sites, will 
be invited to participate.  After obtaining consent, patients will be interviewed and screened 
for TB symptoms (presence and duration of cough, fever, weight loss and night sweats) 
using a questionnaire. Patients will be classified as having/not having symptoms of TB. It is 
expected that two-thirds of patients will not have symptoms, will be classified as ‘WHO-
algorithm negative’ and will be eligible to participate in this study component, constituting 
the reference population.  A randomly selected sample of participants will be recruited from 
this reference population. A daily register of all newly diagnosed HIV patients with their 
TB symptoms screening will be kept, whether they are recruited or not into the study (to 
make adjustment during data analysis). 
Participants will be interviewed to describe medical history, reasons for attending, probe the 
lack of TB symptoms and undertake physical examination and all routine HIV 
investigations (CD4 Count, FBC, RFT and LFT and chest X-rays).  
Sample collection  
Patients will be asked to attempt producing three sputum samples, two samples on the spot, 
the second sample, one hour after the first, and one in the morning of the following day. 
  As patients without TB symptoms are more likely to produce sputum in the morning, 
patients unable to produce sputum on the spot will be asked to attempt to produce further 
samples during consecutive mornings and to bring the specimens to the clinic.   
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In addition, we will collect 50 ml of urine and 10ml of blood from each patient at the same 
time of sputum collection. Please see explanation for these samples in objective 2. 
Laboratory tests 
Sputum will be transported to Zankli Medical Centre (ZMC) Laboratory (using a cold 
chain), where it will undergo smear microscopy (using a Light-emitting diode (LED) 
fluorescence microscope (LED-FM)), ULTRA-Xpert MTB/RIF, conventional Xpert and 
culture. To ensure specimens are cultured within twenty four hours of collection, there will 
be daily transportation of specimens to the research laboratory. Please see objective 2 for a 
description of laboratory methods. 
Classification of patients 
Patients will be classified as TB-positive, TB-unlikely and TB possible based on the results 
of WHO endorsed diagnostics.  It is assumed that ULTRA will have been endorsed at the 
time of the study.  However, this can be revised if endorsement is not successful. 
TB-positive: patients who have positive culture, Xpert/ULTRA-Xpert/MTB/RIF results.   
TB-unlikely: patients who have negative culture and negative ULTRA/Xpert MTB/RIF 
results.  
TB-possible: patients with positive smear microscopy (LED-FM) but contaminated 
culture and negative or inconclusive Xpert MTB/RIF results and abnormal X-ray.  
Patients in this group will be asked to provide new specimens for ULTRA. 
Patients deemed not to have TB, will be provided IPT, as per WHO, and ART as per clinic 
guidelines. Patients with TB, will be provided TB treatment and initiate ART two weeks 
later, as per the Nigerian ART guidelines.  Patients with TB-possible, will be re-assessed 
with the repeated investigations and if still unconfirmed, will be re-assessed three months 
later to evaluate their clinical condition (see follow up below).  
Follow up: 
All participants will be followed up according to the clinic routine appointments for 
individuals with and without TB.  At the 3-month follow up, patients will be re-examined to 
confirm they have not developed symptoms of TB. Patients will also be asked for the 
presence of symptoms during each routine appointment. If a ‘TB-negative’ patient is 
discovered to develop symptoms in the course of follow-up, the patient will discontinue IPT 
and will undergo a new round of TB tests.  
The Home-based Care and Support unit has a good patients’ tracking system, and we will 
collaborate with the unit to track the participants who do not come for follow-up.  
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(2)  To determine the performance of new diagnostics for TB among PLHIV 
A cross sectional study design will also be used to evaluate the performance of selected 
new TB diagnostics among symptomatic patients.  These will include the ULTRA Xpert 
MTB/RIF on sputum and urine samples, xRapid-TB, QuantuMDx-Q-POC on sputum and 
C-reactive protein and IP-10 in blood.  
OuantuMDx Q-POC platform (QuantuMDx Group Ltd, Newcastle, UK), is a new 
portable, solar battery-operated and handheld DNA analyser that is being developed to 
detect Mycobacterium TB and drug resistance within 15 minutes, using sputum sample. 
However, the manufacturer has indicated the processed sputum that will undergo the 
molecular test could be screened to identify the bacilli, which could have an application as 
a smear microscopy device.  I will evaluate an early prototype of this device in March 
2016. 
XRapid-TB is a mobile health device that uses the iPhone processor and its imaging to 
recognise the shape and colour of Mycobacterium tuberculosis, when attached to a 
microscope. According to its manufacturer (xRapid, London, UK), the device can 
withstand harsh weather and high temperature. It can be stored, taken and used anywhere 
with minimal training. LSTM will take the device to conduct pilot field evaluation by 
screening ZN stained smears using conventional light microscopy and the new device to 
assess the agreement of the readings and against culture (to assess sensitivity and 
specificity). 
C-reactive protein (CRP) and Interferon gamma-induced protein 10 (IP-10):  are 
acute phase proteins produced in response to inflammation. Although, CRP and IP-10 are 
non-specific biomarkers, a recent systematic review showed that elevated CRP and IP-10 
levels have a median sensitivity of 92% and 90%, respectively and specificity of 62% and 
76% respectively, when used for active TB diagnosis, irrespective of HIV status 
(unpublished). Combination of the two tests for TB screening is likely to give higher 
sensitivity and negative predictive value, thereby making it better to detect patients who 
are not likely to have TB. These markers however have been used as adjunct tests for 
diagnosis and we will explore whether it is possible to use a cut-off with higher sensitivity 
and lower specificity to re-position the test as a screening (not a diagnostic) test for TB. 
Xpert MTB/RIF ULTRA:  The ULTRA-sensitive Xpert MTB/RIF is a new version of 
the current Xpert- MTB/RIF test.  It is expected to have high sensitivity (close to culture) 
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and a limit of detection of 10CFU/ml of MTB (ten times lower than the current Xpert 
MTB/RIF).  It was developed to improve the detection of TB in smear-negative cases, 
which is commonly found among HIV patients. With this diagnostic device, the difficulty 
associated with TB diagnosis among HIV patients may be overcome, and there may also 
be no need for empirical TB treatment, because of the ability of the test to detect very low 
amount of MTB in sputum and other body fluids/tissues. 
Participants’ Selection 
The participants for this objective will be newly diagnosed HIV-positive patients attending 
the same participating centres and who have symptoms of TB at the time of diagnosis of 
HIV and patients without symptoms who are unlikely to have TB.  
As described for objective 1, newly identified HIV patients will be interviewed and 
screened for symptoms suggestive of TB using the WHO screening questionnaire. One 
third of the patients are expected to have TB symptoms. Patients with symptoms will be 
eligible to participate. A register of all the newly diagnosed HIV patients with their TB 
symptoms’ screening outcome will be kept, whether they are recruited into the study or 
not. Patients without symptoms participating in the evaluation of the WHO algorithm will 
be included as controls. The number of participants without symptoms will be determined 
by the sample size calculations (see below). 
Specimen collection 
Each participant will be asked to produce three sputum samples, urine and blood, as 
described in the previous section. Instruction on how to produce good quality sputum 
samples will be given to each patient. Specimens will be examined to ascertain their quality 
and quantity, and specimens with deficient quality or quantity will be retaken. Urine 
samples and exhaled air will be collected at the same time of sputum collection, as 
described for objective 1.  
Specimen Transportation  
After specimen collection, specimens will be transported to ZMC as described for objective 
1.  
Specimen Processing 
The specimens will be processed as follows: 
Every participant will be tested with LED-FM, Xpert MTB/RIF ULTRA, the Xpert 
MTB/RIF, QuantuMDx Q-POC, xRapid-TB, and culture. The first sputum sample will be 
used for ULTRA-Xpert MTB/RIF, LED-FM, Genedrive and BlaC. The second sputum 
sample will be tested with culture, current Xpert MTB/RIF and LED-FM. The third 
sputum sample will be kept under a cold chain in case anything goes wrong with any of 
the first two samples. 
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Sputum: 
In addition to the experimental tests described above, all sputum samples will undergo the 
following tests:  
Smear Microscopy: smears will be prepared as described for objective 1.  LED-FM will 
be used to describe the performance of the new TB diagnostics among smear-positive and 
smear-negative patients. 
Culture: culture will be performed using two solid Lowenstein-Jensen (LJ) culture media 
slopes per patient and monitored for growth for 2 months.  The time to growth and 
number of colonies will be documented. Drug sensitivity testing will be conducted on 
Xpert RIF-positive samples to determine the prevalence of Rifampicin mono-resistance 
and MDR-TB among the study population, and to refer patients for appropriate treatment. 
Urine 
Urine samples will be tested in two ways. Firstly, 2ml of fresh sample will be taken, 
concentrated by centrifugation, suspended in 0.75ml phosphate buffer, and then tested with 
the current Xpert MTB/RIF. Secondly, the remaining volume will be stored at -800C and 
samples will be defrosted, concentrated by centrifugation, and tested using ULTRA-Xpert 
MTB/RIF once the cartridge becomes available.  The delay sampling of ULTRA is due to 
the cartridge only being released in the Spring of 2016. Once cartridges become available 
in the country, fresh urine samples will be tested in duplicate using Xpert and Ultra.  
Blood 
Participants will be directed to the phlebotomy unit (where blood samples for routine 
testing are being collected) where 5 – 10 ml of blood will be collected for CRP and IP-10 
tests. After collection, specimen samples will be transported under appropriate condition 
to our research laboratory, where the samples will be analysed.  
The test performance characteristics (sensitivity, specificity positive and negative 
predictive values of each test will be established using culture as the reference standard. 
(3) To optimize the WHO algorithm for TB among HIV patients, using 
alternative diagnostics. 
This third objective of the study will also be achieved by the combined analysis on 
participants in objectives 1 and 2 above. To achieve this objective, we will use the results 
of the TB diagnostics carried out in objectives 1 and 2 to determine which test or tests 
combination yields the highest proportion of the patients that are correctly diagnosed or 
ruled out of TB.  
The diagnostic yield of the combination of tests listed below, will be determined, using 
culture as the reference standard.  Tests’ combinations were selected depending on the 
intended use, as defined by the manufacturers. 
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The analysis will determine the yield of (a) Xpert MTB/RIF alone (b) Xpert MTB/RIF 
Ultra alone (c) xRapid-TB alone (d) QuantuMDx Q-POC alone (e) (CRP + IP-10) alone 
(f) xRapid-TB followed by Xpert MTB/RIF (g) QuantuMDx Q-POC followed by Xpert 
MTB/RIF (h) (CRP + IP-10) followed by Xpert MTB/RIF (i) Xpert MTB/RIF Ultra and 
QuantuMDx Q-POC (l) xRapid-TB followed by Xpert MTB/RIF Ultra (k) (CRP + IP-10) 
followed by Xpert MTB/RIF Ultra   
Two by n tables will be drawn to determine the sensitivity and specificity of each of the 
combination of tests, using culture as the reference standard. We will plot Receiver 
Operating Characteristic (ROC) curves for the tests, with the sensitivity on the vertical 
(Y) axis and False positive (1-specificity) on the horizontal (X) axis, and determine the 
Area Under the Curve (AUC). The higher the AUC for each test/tests combination, the 
better its diagnostic yield/performance. 
 
 
(4) To assess the proportion of patients with HIV and or TB who have Type 2 
Diabetes Mellitus (T2DM) 
The objective will use a cross sectional study design to screen for type T2DM, all patients 
enrolled for objectives 1 and 2. Blood samples will be collected for Fasting Blood Sugar 
(FBS), for diagnosis to determine the proportion of the patients with T2DM. Patients with 
high FBS will be asked to repeat the test, as recommended by the WHO to confirm an 
abnormal result.   
In addition, a cohort of TB patients who were diagnosed to have diabetes in 
Zankli Medical Centre, and have completed their TB treatment, will be 
contacted and followed up, to determine if they are still diabetic by collecting 
their blood and testing it with Glycosylate Haemoglobin (HbA1C) machine. 
Because, studies have shown that if diabetes is caused by insulin resistance 
associated with TB, once TB is treated, the diabetes may resolve or 
disappear. 
 
(5) To compare the performance of FBS and Glycosylated Haemoglobin (A1C) 
for the diagnosis of type 2 M (T2DM) among patients with T2DM and 
HIV/TB 
FBS has the disadvantage of being measured after several hours of fasting and is a one-
point estimate of glucose homeostasis.  A potentially better and easier marker of glucose 
homeostasis is the use of A1C, which measures the amount of haemoglobin that has been 
glycated and reflects the levels of glucose in blood in the 2-3 months before the 
measurement. The fifth objective will be achieved by a cross sectional survey using FBS 
and A1C to screen the patients in objectives 1 and 2. We will compare the agreement of 
the tests with the result of the reference standard DM diagnostic (2 consecutive FBS), to 
determine the performance of each of the A1C among the study population. 
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(6) To retrospectively determine the treatment outcome of patients with TB with 
and without HIV. 
 
This will be a retrospective descriptive study of patients who have completed their TB 
treatment within the last two years at the Directly Observed Treatment Short-course 
(DOTS) clinic of University of Abuja Teaching Hospital (UATH).  
With the permission of the UATH TB programme coordinator, all TB treatment registers 
of patients diagnosed to have TB in the centre who were recommended to initiate 
treatment in the centre from January 2013 to January 2015 will be retrieved from the 
clinic record room.  The records will be reviewed to extract information regarding the 
patients’ HIV status (positive, negative or undetermined), whether the diagnosis had 
microbiological confirmation or not (i.e. positive smear microscopy, Xpert MTB/RIF or 
culture) , clinical presentation (whether pulmonary or extra-pulmonary), anti-TB drug 
regimen started and date treatment initiated,  treatment outcome according to the TB NTP 
outcomes (abandoned/Loss-to-follow up, cured, completed, treatment failure, relapse or 
transferred out or unknown) basic demographic characteristics (age, gender, educational 
status, occupation) and factors that may be associated with treatment outcomes (smoking 
and known diabetes). A data extraction form will be used and the proportion of missing 
records will be noted. No identifiable variables will be recorded. Patients will only be 
identified by the hospital record number for the purposes of database cleaning. 
  (7) To retrospectively determine the prevalence of hypertension and DM among 
newly diagnosed patients with HIV. 
This will be a retrospective review of records of all patients newly diagnosed to have HIV 
who were enrolled at the UATH’s ART site from July 2014 to July 2015. 
Measurements of vital signs, including blood pressure, weight and height are routinely 
collected at first visit to the HIV site and at every follow up clinic appointment (except 
height). These measurements are filed in the patient register and kept in the hospital’s 
central records by the M&E unit of the ART clinic and medical records of UATH and 
digitised into a unit database.  
The data will be collected from M&E unit database, or if missing, from the patients’ 
physical files records, the PhD candidate will extract the blood pressure, weight, height, 
body mass index, blood glucose, age, gender, level of education and occupation at the 
time of enrolment. After extraction, the data will be entered into a database.  
 (8) To retrospectively determine the incidence of hypertension and DM among the 
same patients one year after initiation of ART. 
The records of all patients identified in objective one HIV patients who had normal blood 
pressure (diastolic BP <90 and systolic BP <120) will be reviewed for this objective to 
extract information on the blood pressure and blood sugar one year after enrolment.  In 
addition, information will be extracted on weight, Body mass index, ART regimen/s used 
and its date of initiation, and co-morbidities/illnesses present at the time of follow up. 
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A.6 PARTICIPANTS: Please state the number of research participants to be recruited.  If you 
are unable to give precise figures, please give estimates. 
A.6.1 
AGE/SEX 
Neonates 
(<28 days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 years) 
Adolescents 
(10-18 years) 
Adults 
(>18years) 
Males                          About 350 
(35%) HIV 
positive 
patients. 
      
      
Females                         About 650 
(65%) HIV 
positive 
patients. 
Males     About 30 
(60%) HIV 
negative 
patients 
Females     About 20 
(40%)HIV 
negative 
patients 
A.6.2
  
ELIGIBILITY CRITERIA 
Inclusion Criteria Exclusion Criteria   
(1) Confirmed HIV positive status 
(2) Age of 18 years and above 
(3) Newly diagnosed 
(4) Consent to participate in the study 
(5) Enrolled at the selected ART sites 
In addition, for the e-nose: 
1. HIV- negative status 
2. Age of 18 years and above 
3. Newly diagnosed patient with smear 
positive TB 
4. Consent to participate in the study 
Patients on temporary enrolment 
Patients already diagnosed to have TB 
(except for the e-nose) 
Patients unable to provide informed consent 
Patients with a high risk of imminent death 
(these are patients with severe respiratory 
distress, loss of consciousness, un-recordable 
blood pressure or any other sign of life 
threatening conditions) 
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5. Enrolled at DOTS clinics of the 
participating health facilities 
 
Justification for eligibility criteria – if you are excluding a particular group you should justify their 
exclusion. 
Newly diagnosed HIV patients on temporary enrolment in the selected health facilities are 
excluded from the study because they are usually on transit through or on a visit to Abuja 
and were screened for HIV because they became ill. These patients usually prefer to go to 
ART sites close to where they live and may not be available for all the required 
investigations and follow up.  We decided to exclude all newly diagnosed HIV patients who 
have been diagnosed of TB (except those for the e-nose Proof of Concept) from this study, 
because this is the focus of the study. 
A.6.3 VULNERABLE GROUPS: Please identify vulnerable groups that will be included in this 
study. Also state how you will minimise any harm to each group identified.   
 
The likely vulnerable groups that may be included in this study are; 
(1) Adults who may be too sick, that they cannot give informed consent for their 
participation in this study (that is, sick patients with no sign of life threatening 
condition) 
(2) Pregnant women (mostly detected during antenatal care and referred to the ART 
clinics for Prevention of Mother-to-Child Transmission of HIV (PMTCT)) 
(3) Patients worried their family would stigmatize them if they know the diagnosis 
(4) Uneducated patients who do not understand English and may not be able to read or 
write 
(5) Patients who are very poor and may not be able to return for routine follow-up 
appointment  
 
Methods to minimize harms to vulnerable groups 
(1) For adults who are too sick or unable to give informed consent due to a disability, 
we will wait until the patients have improved in the hospital, to obtain informed 
consent.  Patients will be approached for written informed consent after they are 
well informed about the study.  In case of patients unable to give informed 
consent, the patient will be excluded from the study and a tally of these patients 
will be kept to inform the data analysis. 
(2) Pregnant women will be included, as this is not an interventional study and all 
specimens for this study will be collected for routine investigations (FBC, LFT, 
RFT and CD4 count, except FBS) for HIV/AIDS care.  The study is not 
considered harmful to pregnant women. The main difference to routine care is the 
use of TB tests which are not routinely done.  These tests will be carried out at a 
well-equipped research laboratory located outside the selected ART sites. 
(3) Patients who are worried of being stigmatized by family members/neighbours if 
they are aware of their HIV or TB status, will be sent to professional counsellors. 
Staff members are well trained, for the needed counselling and patients will be 
assured that no one will be informed of their HIV or TB status, without their 
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permission. They will be encouraged to join patients’ support groups, where they 
can get practical experience of how other patients cope with stigma and 
discrimination. 
(4) Uneducated patients will be approached by an interpreter, who will communicate 
with them in their language. The interpreter will read the patients’ information 
sheet and consent form to them in the presence of two witnesses, and if they agree 
to participate in the study, they will be allowed to thumbprint the consent form. 
(5) We will use the routine clinic appointment system for patients’ follow-up.  
Patients who are very poor and unable to return to clinic appointments are 
routinely referred to the Home-based and patients’ support unit. We will refer 
these patients to the unit for assistance, as needed.  
 
A.6.4
  
RECRUITMENT PROCESS: Please detail the procedures for how you will be approaching 
each group of participants to take part in the project.   Where will recruitment take place?  
Who will be responsible for recruitment of participants? 
 
We will approach the management of each of the selected ART sites for permission to carry 
out the study. We will inform the health care providers in the ART sites about the purpose 
of the study and seek their cooperation/support. Each newly diagnosed HIV patients in the 
health facility will be contacted through the monitoring and evaluation (M&E) unit (which 
is responsible for the enrolment of all newly diagnosed HIV patients) and the Home-based 
Care unit (that takes a comprehensive history of each newly diagnosed HIV patient at 
his/her first visit, before allocating the patient to a doctor) and invited to participate, after 
informing the patient the purpose of the study.  
We will determine the number of sample to be collected per clinic day by dividing the study’s 
total sample size by the number of clinic days within the period of data collection. If the 
number of newly diagnosed HIV patients who meet the selection criteria is not more than the 
sample size per clinic day, all consecutive patients who agree to participate will be recruited 
into the study, otherwise an appropriate random sampling method will be used to recruit 
patients into the study. Every one of the study participants we will be screened for TB 
symptom, using the WHO TB symptoms screening questionnaire, after undergoing the 
routine vital signs’ measurement. After the screening, patients will be classified into those 
with TB symptoms (symptomatic) and those without the symptoms (asymptomatic). Please 
notice the gender ratio stated (35% male and 65% female) reflect the male/female ratio 
observed in the clinics where the study will be conducted.  
Recruitment of HIV negative patients in the DOTS clinics will be as follows; We will 
approach the head of the FCT-TBLCP to ensure collaboration of Gwagwalada and Wuse 
DOTS clinics staff and for the permission to carry out the study. Every consecutive newly 
diagnosed TB patient who is smear-positive will be eligible for this arm of the study, will be 
approached and invited to participate after being fully informed about the study and its 
procedures. Every patient that gives his/her written informed consent to participate, will be 
recruited into the study and will undergo similar tests as described for HIV-positive patients 
(culture, Xpert, BlaC, Genedrive).  
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A.7  OUTCOMES: What is the primary outcome measure for the study?      
What are the secondary outcome measures? (if any) 
Primary Outcomes 
For objective 1 
(1) Proportion of patients correctly identified not to have TB by the WHO algorithm 
(2) Proportion of patients with TB missed by the WHO algorithm 
 
For objective 2 
(1) Proportion of patients with TB correctly identified or ruled out by each diagnostic 
test used 
 
Secondary Outcomes 
(1) Diagnostic or combination of tests yields  
(2) Proportion of HIV and HIV/TB patients with DM  
(3) Agreement between FBS and Hb(A1C) for DM diagnosis among the study population 
(4) E-nose proof of principle and initial performance characteristics.  
 
 
A.8  MAJOR METHODS OF ANALYSIS: What are the major methods you intend to use to analyse 
the data?   
Summary statistics will be presented with their 95% confidence intervals. The case 
detection rate will be calculated using culture as the gold standard.  Rates will be adjusted 
by the expected sensitivity of the reference standard.  The incremental detection yield of 
the tests will be calculated for different combinations of tests.  
We will then use a two-by-two table to compare the results of the symptom screening with 
the result of the reference standard TB diagnostic (which is sputum culture) and determine 
the probability that the study’s participants who do not have any TB symptom are truly free 
of TB .This will give us the predictive value of symptom screening to rule out TB .ROC 
curves  will be plotted for the diagnostics and the Area Under the Curve(AUC) will be used 
to determine the performance of each of the diagnostics. The larger the AUC for a test, the 
better the performance of the test. The same curve and AUC will also be used to determine 
the diagnostic yield of each of the TB test or combination of tests. 
McNemar’s tests for matched data will be used to compare the sensitivity, specificity and 
predictive values of Genedrive, BlaC, current Xpert MTB/RIF and Xpert MTB/RIF Ultra, 
and will be adjusted for the expected sensitivity of culture.  
The accuracy of BlaC, (at high and low sensitivity settings), Genedrive, current Xpert 
MTB/RIF and Xpert MTB/RIF Ultra will be compared against culture. The performance 
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of each test and combination of tests will be compared against culture. The latter is the 
approach we would expect to use if the test performs satisfactorily. 
Each of the new TB diagnostics will be considered to be of sufficient value for 
deployment in the health system if its performance alone or combined with other test (at a 
high sensitivity setting) has  
1. A higher accuracy than the expected 75% accuracy of TB diagnosis which the 
current Xpert MTB/RIF has when used among HIV positive patients or on 
smear-negative TB samples and 
2. The specificity of the approach is not lower than 93% (in other words, the 
difference is not more than a -5% different than the expected Xpert 
MTB/RIF specificity of 98% on smear-negative samples). 
 
Proportion of HIV and HIV/TB patients with DM will be determined by descriptive 
statistics. 
The performance of glycosylated Hb (A1C) and FBS among the study population, will be 
evaluated by determining the agreement between the two tests. 
 
 
A.9 SAMPLE SIZE: Please justify your choice of sample size (as described in A.6.1). Please ensure 
that the sample size calculation is based on the primary outcome measure as detailed in A7. 
Sample size / statistical power 
Comparisons of diagnostic tests 
Sample size has been determined to ensure adequate statistical power to detect clinically 
significant differences (as measured by area under ROC curves) in the performance of pairs 
of diagnostic tests. 
A total of 1000 HIV+ patients will be recruited across two centres.  All of the study 
diagnostic tests will be performed on all recruited patients; patients either unable or 
unwilling to provide sufficient tissue for this will be replaced.   
Assuming a 20% TB prevalence in this population, the study sample will be expected to 
contain 200 TB+ and 800 TB- patients.  This will provide 80% (90%) power to detect a 
4.5% (5.2%) difference (or 87.2% power to detect an exact 5% difference) in a comparison 
of the ROC curve AUCs for any two of the study diagnostic tests.  This assumes an AUC 
of 0.70 for the poorer performing of the two diagnostic tests and up to 75% correlation 
between the results from the two diagnostic tests; should either the lower AUC or the 
between test correlation be higher than these assumed values, the statistical power of the 
study will increase. 
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Estimates of sensitivity and specificity 
Asymptomatic and symptomatic patients combined. 
The proposed sample will provide estimates of: 
1. test sensitivity with a precision of between ±6.4% (for a true sensitivity level of 
70%) and ±3.0% (for a true sensitivity level of 95%); 
2. test specificity with a precision of between ±3.2% (for a true specificity level of 
70%) and ±1.5% (for a true specificity level of 95%). 
Symptomatic patients only 
Based on data from a previous study, it is expected that one-third of patients (1000*0.333 
= 333) will be TB+ symptomatic, of whom 33% (333*0.33 = 111) patients will be truly 
TB+ and 67% (222) will be truly TB-.  This will provide estimates of: 
1. test sensitivity with a precision of between ±8.5% (for a true sensitivity level of 
70%) and ±4.1% (for a true sensitivity level of 95%); 
2. test specificity with a precision of between ±6.0% (for a true specificity level of 
70%) and ±2.9% (for a true specificity level of 95%). 
Asymptomatic patients only 
Based on the same study, it is expected that the remaining two-third of patients (1000*0.667 
= 667) will be TB+ asymptomatic, of whom 11.1% (667*0.111 = 74) patients will be truly 
TB+ 88.9% (593) will be truly TB-.  This will provide estimates of: 
1. test sensitivity with a precision of between ±10.5% (for a true sensitivity level of 70%) 
and ±5.0% (for a true sensitivity level of 95%); 
2. test specificity with a precision of between ±3.7% (for a true specificity level of 70%) 
and ±1.75% (for a true specificity level of 95%). 
E-nose Proof of Concept 
For the e-nose proof of concept, will be restricted to a small sample size, to assess whether 
larger studies are suitable.  Exhaled breath will be collected from 300 symptomatic HIV 
positive cases and additional 50 adults who are confirmed to have smear-positive TB but 
who are HIV-negative. The additional set of patients will be recruited for the e-nose proof 
of concept sub-study because there is no data on HIV-negative patients and to explore 
whether HIV infection interacts with the analysis (because HIV infection may release the 
same VOCs identified and measured by the device). 
 
A.10 QUALITY ASSURANCE: Quality assurance is more than just for data analysis – it should 
include procedures in design and data collection.  What procedures are in place to ensure 
the quality of the data? What consideration has been given to methods of analysis to 
ensure efficiency of data use?   
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To ensure that every segment of this study is of good quality, we will do the following 
at each stage of the study; 
Pre-data collection 
(1) Extensive literature search and expert opinion seeking on the appropriate study 
design for the study. 
(2) Design of appropriate data collection tools that have been piloted in situations 
similar to what is expected during data collection and found suitable. 
(3) Statisticians will be contacted for their expert opinion/advice on the methods of 
data analysis needed for the study 
(4) Necessary training for research assistants and others who will be involved in the 
study. 
(5) We will ensure that all the needed Laboratory equipment/instruments and 
consumables are available and in good condition. 
(6) The laboratory that will be used is well equipped and known for expertise in all 
the planned laboratory work 
(7) Standard Operating Procedures (SOPs) and universal safety precaution measures 
will be made available where needed. 
 
During Data collection  
(1) We will ensure that every aspect of data collection is handled by individuals that 
are well trained. 
(2) Inclusion and exclusion criteria will be properly applied to ensure that right 
participants are recruited, 
(3) Patients will be taught how to produce adequate amount of good quality samples. 
(4) Adequate and uncontaminated amount of appropriate specimen samples will be 
collected for each objective 
(5) There will be regular monitoring/supervision of data collection processes, and 
lapses/deficiencies noted will be promptly attended to. 
(6) Specimens’ samples will be transported under cold chain/appropriate condition to 
the research Laboratory 
(7) Double data entry will be used to enter the participants’ socio-demographic and 
clinical information, and each of the participants will have research codes that will 
be used to link this information with his/her laboratory investigations. 
(8) Each of the transported specimens’ samples will be stored under appropriate 
conditions. 
Laboratory Analysis of the samples  
(9) Everyone participating in the laboratory analysis of the specimens’ samples will 
be reminded of the SOPs and universal safety precaution measures, and 
handbills/posters containing the information, will be posted on the wall or at 
places where it can easily be seen in the Laboratory. 
(10) There will be proper inspection/examination of each of the specimens’ 
samples, diagnostics and consumables, to ensure they are in good condition before 
use. 
(11) Manufacturers’ instructions will be followed in the use of the diagnostics 
and consumables, so that good quality results can be obtained from them. 
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(12) Positive and negative controls will run on the diagnostics to ensure they are 
functioning well. 
(13) There will be regular laboratory inspections by the PI to ensure that the 
SOPs and universal safety precaution measures are strictly adhered to, and to also 
know if there is any challenge/ need that requires urgent attention. 
(14) Results of routine investigations will promptly be communicated to the 
physicians in charge of the patients’ management for prompt treatment decisions 
(15) Results of the laboratory investigations will be recorded in a register 
(which will be properly kept under lock and key) and a highly secured electronic 
database. 
(16) There will also be regular meetings with all the research team members to 
discuss the ongoing research and address any identified challenge/constraint. 
(17) Data will be checked for completeness, and missing data will be sought 
for. 
(18) Assistance/expert input of the statisticians at LSTM will be sought to 
ensure high quality data analysis. 
 
 
 
 
SECTION B 
PROCEDURES AND PATIENT CARE 
B.1 PROCEDURES Please detail any clinical or other research procedures to which 
participants will be subjected. 
Procedure To be carried out by: Who is the person employed 
by? 
1.Enrolment of newly 
diagnosed HIV patients 
into the HIV/AIDS Control 
Program of the selected 
ART sites 
Routinely done by the 
record officers of the 
selected ART sites 
Managements of the selected 
ART sites (UATH and Health 
Management Board of 
FCDA) 
2. Participants invitation 
for participation in the 
study and obtaining 
informed consent 
PI and/or research 
assistants 
PhD Student at 
LSTM/Research Team 
3. Routine patients’ vital 
signs check 
Routinely done by the 
Community Extension 
Health Workers(CHEWS) 
of the selected ART sites 
Managements of the selected 
ART sites (UATH and Health 
Management Board of 
FCDA) 
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4. Routine Patients’ first 
visit’s detailed history 
taking and documentation 
Routinely done by the 
staff of Home-based Care 
and Support unit of the 
selected ART sites 
Managements of the selected 
ART sites (UATH and Health 
Management Board of 
FCDA) 
5. Participants recruitment 
and TB symptoms’ 
screening, physical 
examination, recording of 
the checked patients’ vital 
signs, ordering of routine 
and other investigations, 
interpretation of the 
investigations’ results, 
prescription of the needed 
medication, and 
appropriate referral when 
needed 
PI and other research 
doctor(s) 
(a). PhD Student at LSTM 
(b). Management of UATH 
(though the PI is currently on 
study leave) 
(3) Research Team 
6. Sputum. Exhaled breath 
and urine samples 
collection 
Research assistant      Research team 
7. Blood samples 
collection for routine for 
HIV care, and blood 
sample for FBS  
Routinely done by the 
Phlebotomists of the 
selected ART sites 
Managements of the selected 
ART sites (UATH and Health 
Management Board of 
FCDA) 
8. Samples/specimens 
Transportation to the 
research Laboratory 
Assigned driver by the 
research Laboratory 
Zankli Medical Centre 
9. Specimens’ analysis 
Laboratory Scientists of 
the research Laboratory 
Zankli Medical Centre 
8. Data entry 
PI / and a data entry Clark PhD Student at LSTM 
9. Data Analysis,  
PI with expert advice 
from Statisticians in 
LSTM 
LSTM 
Continue if necessary 
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B.2       STANDARD PATIENT CARE: Please explain if the procedures outlined in B.1 are part of 
the normal clinical work of the staff who will perform the procedure.  If not applicable 
to your study, please write a sentence stating that this is not a clinical study. 
 
The procedures outlined above are part of the normal clinical work of the staff who will be 
performing the procedures and most of these procedures are routinely done for every newly 
diagnosed HIV patient.  
 
All the specimens’ samples (except exhaled breath, which is non-invasive) that will be 
collected for this study, are routinely collected for routine investigations for HIV Care. All 
the specimen samples will be taken to a well-equipped research laboratory, where the routine 
investigations and some specialised ones will be carried out, and the investigations’ results 
will be sent back to the clinics for the needed treatment decision. 
 
 
B.3  END OF TRIAL TREATMENT: For intervention trials, what steps will be taken to make 
successful interventions or treatment available to all trial participants at the end of the trial?  
If not applicable to your study, please write a sentence stating that this is not a clinical 
study. 
 
Though, this study is not an interventional study, the health facilities where the study will be 
carried out have both ART (for HIV care, treatment and support) and DOTS (for TB 
treatment) services, each of the participants will be given the standard treatment for his/her 
case.  
Any case of DR-TB identified in the course of this research will be referred to an appropriate 
treatment centre for DR-TB. Every case of DM found during this study, will also be given 
appropriate referral. 
 
 
B.4 TRAINING Please indicate the basis on which the persons identified in B.1 are 
thought to be competent to carry out these procedures.  List any training 
of staff which will be required prior to commencement of the study. 
Staff Member Experience/competencies Training Required 
Record officers of the 
selected ART sites 
Graduates of reputable 
Nigerian Universities/schools 
of Health Technology, with 
many years of working 
experience at the ART sites 
None, already well trained 
PI A Public Heath Physician 
with more than ten years of 
working experience in 
None, (PI has undergone a 
training on Good Clinical 
Practice(GCP), which was 
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HIV/AIDS Control programs 
at the local, national and 
international levels. 
He has worked for more than 
six years at the UATH’s 
ART site providing 
HIV/AIDS and HIV/TB co-
infection prevention, care, 
treatment and support 
services. 
A current PhD student at 
LSTM 
conducted in LSTM in 
November 2014, and has 
the certificate for the 
training) 
Research Laboratory 
Scientists 
University graduates with 
many years of experience in 
TB/HIV laboratory diagnosis 
Good Clinical Laboratory 
Practice (GCLP) 
Research Assistants 
They will be University 
graduates with good 
knowledge/experience in 
sociology or medical/basic 
medical sciences  
Necessary training may 
include; 
(1). Good Clinical Practice 
(2). How to interpret and 
administer questionnaire 
(3). Good interaction with 
the study participants 
(4). Other necessary 
trainings 
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SECTION C 
RISKS AND CONSEQUENCES 
 
C.1 ADVERSE EFFECTS, DISCOMFORT OR RISKS: Outline the potential adverse effects, 
discomfort or risks that may result from the study for participants, investigators and 
members of the public and how you will minimise them. 
C.1.1 
Participants 
Potential adverse effects, discomfort or risks 
This study is an observational study and most of the specimens’ samples that 
will be used are routinely collected among the study population. As a result 
of this, adverse effects, discomfort or risks caused only by this research, if 
any, will be minimal, and may include; 
(1) Discomfort during sputum induction (in case there is a need), in 
patients unable to produce sputum. 
(2) Pain during blood collection for FBS (though, this will be taken at the 
same time with blood samples for other routine investigations for 
HIV care, and whether a patient participates in this study or not, 
he/she will still experience the pain). 
(3) Fear of stigma and discrimination that may occur if unauthorised 
persons are aware of the participants’ HIV or TB status 
(4) Fear of not knowing/sure of what will really happen to their body 
fluids’ samples that will be taken outside their health care facilities 
 
Steps to be taken to minimise adverse effects, discomfort and risks  
 
(1) For sputum induction, we will use the persons who are well 
trained and can use the method with minimal discomfort within 
the hospital. 
(2) Blood sample collection for FBS will be done during blood 
collection for other routine investigations and by well-trained 
phlebotomists who have several years’ experience in doing it at 
the ART sites. 
(3) Participants will be given full assurance and thorough counselling 
that their TB or HIV status will not be disclosed to any 
unauthorized person. 
(4) We will let them be aware that the laboratory where their 
specimens will be analyzed, is well-equipped and is 
collaborating with the National TB and Leprosy Control 
Program (NTLCP), and that nothing evil (a local common 
belief) will happen or be done to the samples collected. And we 
will also let them know we need to take the samples to the 
laboratory because the new tests are not available in the health 
facilities. 
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C.1.2 
Investigators 
Potential adverse effects, discomfort or risks 
(1) Accidental exposure to TB causing organisms 
(2) Needle prick injury and/or occupational exposure to HIV  
Steps to be taken to minimise adverse effects, discomfort and risks 
(1) To prevent occupationally acquired TB or HIV and other blood born 
infections, we will put in place SOPs and universal safety precaution 
measures, and encourage every investigator to adhere to the SOPs. 
(2) Adequate and appropriate protective devices will also be made 
available. 
(3) There will be regular monitoring of investigators’ adherence to the 
SOPs and universal safety precaution measures. 
(4) Post exposure prophylaxis (PEP) against HIV infection, will be made 
available, in case there is any accidental exposure to any potential HIV-
containing body fluid. 
(5) We will encourage occupational vaccination against hepatitis B 
infection for anyone working in the hospital and the laboratory who 
has not been vaccinated against the infection. 
C.1.3 
Members of 
the public 
Potential adverse effects, discomfort or risks 
(a) Possibility of transmitting TB from one patient to another or from TB 
patients to health care workers or patients’ relatives. 
(b) Transmission of TB during sputum specimen transport to the research 
laboratory 
(c) Stigma and discrimination against participants’ family members if the 
HIV or TB status is known to the community 
Steps to be taken to minimise adverse effects, discomfort and risks 
a. Clinical triage will be done to separate patients who are seriously 
coughing from other patients 
b. Patients will be kept in a well-ventilated area of the clinics 
c. Sputum collection will be done in a well-ventilated area, using the 
necessary protective devices 
d. Sputum samples’ specimens will not be transported with a public 
vehicle 
e. Participants’ information will be kept confidential by the research team 
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C.2 CONSEQUENCES FOR LOCAL HEALTH SERVICES 
 
C.2.1
  
IMPACT ON LOCAL SERVICES: What demands will this research place on local health 
services? 
Most of the processes/procedures in this research follow the routine procedures in 
HIV/AIDS care (for instance, all the specimens’ samples are routinely collected for HIV 
care) and the impact of this research on routine care and staff would be minimal.   
This may include increased patients’ waiting time, due to the time that will be spent on 
patients’ information sheet and consent form. 
However, all participants (who would have been seen by the local doctors) will be clinically 
assessed/seen by the research doctor(s) and their specimens’ samples will be analysed at the 
research laboratory for both routine and specialised TB tests. As a result of this, both the 
hospitals clinical and laboratory workload of the selected facilities will be reduced.   
C.2.2
  
MINIMISING IMPACT ON LOCAL SERVICES: Detail how the design of the research project 
takes into account the demands described above in C.2.1 
 
To minimise the impact that increased patients’ waiting time may have on local health 
services; 
1. All the participants in this study will be seen the PI and/other doctors in the research 
team, who are well trained and have many years of experience in HIV/AIDS and TB 
prevention, care, treatment and support. As a result of this, the workload for the 
health facilities’ doctors will be reduced, and patients will be able to leave the clinic 
on time. 
2. As much as possible, all assessments that are additional to routine care will be 
conducted while the patients are waiting for other clinical assessment or testing. 
3. Adequate and well-trained research assistants will be engaged in the research, so 
that the time spent on patients’ recruitment will be reduced to the minimum. 
4. The specimens’ samples for this study will be transported to a well-equipped 
laboratory, where both routine and specialised investigations will be carried out on 
the specimens, and the investigations will be promptly communicated to the doctors 
in charge of the patients’ management, for prompt treatment decision. By this, the 
workload of the local (health facilities’) laboratories will be reduced, and the 
participants will be screened for TB with the best available diagnostics, thereby get 
the appropriate treatment. 
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SECTION D 
PRIVACY AND INFORMED CONSENT  
D.1 INFORMED CONSENT (please pay particular attention to the guidance notes for this section) 
 
D.1.1   OBTAINING INFORMED CONSENT: Please give details of how you will obtain informed consent.  You 
must include details of (i) information given to participants, (ii) who will deliver the information and 
(iii) consideration of local circumstances.  Please note that reference of transport of samples to 
another country must be included in the consent forms.  Please also give special consideration to 
whether proxy consent is required (for those lacking capacity to consent, minor etc) and give details 
as to how this would be obtained.  
 
The Principal Investigator (PI) and trained research assistants will contact each of the newly diagnosed 
HIV patients in each of the selected health facilities through its monitoring and evaluation (M&E) unit 
(which is responsible for the enrolment of all newly diagnosed HIV patients) and the Home-based Care 
unit (that takes a comprehensive history of each newly diagnosed HIV patient at his/her first visit, 
before allocating the patient to a doctor) and invite them to participate in the proposed research, after 
being fully informed of the purpose of the study and its procedures. They will also be informed that 
their participation is voluntary and their refusal to participate in this study will not deny them of any 
of their rights as patients in the clinic. It will also be made known to them that they still reserve their 
right to withdraw from the study anytime they want to, without affecting their treatment.   
 
Participants will be given 2 hours to consider and make up their mind about participating in the study. 
For patients who are illiterate (who cannot read or write), the research information sheet and consent 
certificate will be read to them in the language they understand, in the presence of two witnesses, to 
ensure that they are well informed about the research. Patients that agree to participate in the study and 
meet its selection criteria will be asked to give his/her written informed consent by signing or thumb-
printing the consent certificate. In case there is any eligible and willing participant who cannot give 
his/her informed consent, as a result of severity of his/her illness or mental incapability, a legally 
assigned/approved relative of the patient will be allowed a proxy to obtain his/her consent. 
D.1.2   CONSTRAINTS: Please outline any potential constraints to consent and indicate how you will reduce 
the impact of these constraints. 
Some of the constraints that may be encountered in the course of obtaining consent from the study’s 
participants are; 
(1) Illiteracy: This challenge will be overcome by communicating to patients in the language he/she 
understands, using an interpreter (for Hausa and Igbo Languages), while the PI will interpret the 
information to Yoruba for any Yoruba speaking patients. Consent forms will be provided in 
Hausa, Igbo and Yoruba languages.  If a patient does not understand these languages, we will 
use the services of a staff member who speaks the language.  This is the current clinic procedure 
to explain all HIV service procedures in the study sites. 
(2) Some women will be unable to provide informed consent (even after patient has made up her 
mind to participate) without first obtaining permission from her husband (this is based on local 
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cultural/religious practices). We will follow local customs and with her agreement, invite the 
patients’ husband or father and they will be given information about the study, and request for 
their approval of the patients’ consent for participation in the study.  This additional procedure 
follows the same procedures used in the HIV services and considers that some women prefer 
not to participate. 
(3) The thought that a patient may not be properly treated or attended to, by his/her doctor if he/she 
refuses to participate in the proposed study: It will be made clear to the prospective participants 
that they have the right to refuse participating in the study without being denied of any of their 
rights/privileges as patients in the clinic.  
 
 
D.2 ASSISTANCE: Please outline any assistance (financial or otherwise) that will be offered to potential 
participants or individuals in return for their participation in this research. 
 
All participants will be tested using Xpert MTB-RIF Ultra and culture (the reference standard TB 
diagnostic), which is not current routine standard at these sites and therefore patients will obtain 
optimal TB diagnosis.   
The timing of sputum collection, the quality of smear microscopy and culture and other diagnostic 
results will be monitored, and therefore participants will be more thoroughly investigated and 
results are likely to be received earlier.  
Prompt diagnosis and treatment of DM could improve treatment outcome and reduce the risk of 
developing TB among the participants.  
Within the context of a research study, patients are also likely to benefit from good medical 
services. No re-imbursement of patients’ costs will be offered as costs for patients will be equal or 
less than those incurred by attending the routine diagnostic services. 
Incentives: There are no financial incentives for participating in the study. 
D.3  PRIVACY AND CONFIDENTIALITY: Please describe how participant privacy and confidentiality will be 
maintained during data collection, analysis and storage.  Please include what will be collected (data, 
samples etc.) and where and for how long it will be stored. 
 
The information and other data that will be collected from this study’s participants, will be kept 
strictly confidential under lock and key and in a secured database.  
Only the authorised members of the research team, the research sponsors, the clinic officials and 
ethics committee members, may have access to the information/data.  
We will give and attach a number instead of participants’ names, to any information about each of 
them. The number given to each participant will only be known by the researchers and we will 
make sure that the information is kept where no one else can have access to it. 
Sputum, blood, exhaled air and urine are the participants’ biological specimens that will be collected 
during this study. Because the reference standard test for TB (sputum culture) and the new 
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diagnostics that we want to evaluate are not available at the study centres, the specimens will be 
stored under appropriate condition and transported to a research laboratory, where all the needed 
tests can be done. Some of the specimens (sputum, breathed air and urine) may be stored for some 
months for the evaluation performance of one of the new TB diagnostics, which will be available in 
the first quarter of next year (2016). As there is a need to transport breathed air outside Abuja, a 
separate consent will be taken from the participants for this purpose. All specimens will only be used 
for investigations/tests that are related to the study objectives and will be destroyed five years after 
this study 
D.4 DISSEMINATION: Please outline what plans you have for dissemination of results 
The results of this research will be disseminated through the following means; 
(1) Discussion of the study’s findings with the stakeholders (management, health care workers 
and patients) in the health facilities used for the study 
(2) The findings of the study will be discussed in Abuja, Nigeria, immediately after the study, in 
a larger forum comprising the national TB and HIV stakeholders, such as National TB and 
Leprosy Control Program(NTLCP), National Agency for the Control of AIDS (NACA), 
National AIDS and STI Control Program (NASCAP), FCT’s Agency for the Control of 
AIDS (FACA) and its TB control program (FTBLCP), United Nations’ agencies, HIV/AIDS 
and TB control plans implementing partners, Network of People Living with HV in Nigeria 
(NEPLWHAN), traditional and religious leaders, academia and researchers. 
(3) Academic data will be presented at selected scientific conferences (such as the conferences of 
the International Union Against Tuberculosis and Lund Diseases (The Union), International 
AIDS Society(IAS), and International Association of Providers of AIDS Care (IAPAC)) 
(4) We will publish this study’s findings in reputable peer-reviewed Journals 
(5) My PhD dissertation, which will be based on the study’s findings, will be submitted to the 
University of Liverpool and LSTM. 
 
 
SECTION E 
MAJOR ETHICAL ISSUES 
E.1  MAJOR ETHICAL ISSUES 
Outline what you consider to be the major ethical issues involved in this research. 
Please indicate how you plan to deal with these ethical issues. 
 
The main ethical issues to be considered in this study are as follows: 
• Autonomy 
To ensure autonomy of every participant in this study, the investigators must make sure that every 
patient is fully/well informed about the research and its procedures, given enough time to consider 
his/her participation, make an informed decision whether to participate or not, without any 
coercion or undue inducement, and if he/she decides to participate, he/she should be able to 
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determine how the biological specimens and information collected from him/her should be stored 
and used. 
In this proposed study, we consider autonomy in the following ways: 
1. Informed Consent 
To obtain informed consent from this study’s participants, we will fully describe the processes and 
procedures that will be used in the study and also discuss the possible constraints that may be 
encountered in the process and modalities put in place to overcome these constrains.  Please see 
sections D.1.1 and D.1.2 for more details. 
2. Confidentiality 
The information and other data that will be collected from this study’s participants, will be kept 
strictly confidential under lock and key and in highly secured databases. Only the authorised 
members of the research teams will have access to the information/data. Full details on how this 
will be achieved is discussed in section D.3 
3. Storage and further use of biological specimens 
Sputum, blood, air and urine are the participants’ biological specimens that will be collected during 
this study. Because the reference standard test for TB (sputum culture) and the new diagnostics that 
we want to evaluate are not available at the study centres, the specimens will be stored under 
appropriate condition and transported to a research laboratory where all the needed tests can be 
done. Some of the specimens (sputum, breathed air and urine) may be stored for some months for 
the evaluation of performance of one of the new TB diagnostics (Xpert MTB/RIF Ultra), which 
will be available in the first quarter of next year (2016). As there is a need to transport breathed air 
outside Abuja, a separate consent will be taken from the participants for this purpose. All 
specimens will only be used for investigations/tests that are related to the study objectives and will 
be destroyed five years after this study. The specimens’ storage and further use plans are discussed 
in the patients’ information sheet and section D.1.1 
• Non-maleficence 
Because this study is not an interventional study/a clinical trial, the possibility of any harm to the 
participants, investigators or public is minimal. The potential adverse effects, discomfort and risks 
that may result from this research and plans to prevent them, are outlined for each category of 
people, in sections C.1.1 to C.1.3. 
• Beneficence 
 
The proposed study will be highly beneficial to the participants and the public at large. Presently, it 
is difficult to diagnosed TB among HIV patients because of high proportion of smear-negative TB 
cases (which cannot be diagnosed by the commonly available diagnostic (smear microscopy)) and 
reduced sensitivity of Xpert MTB/RIF among them. Through this research, the reference standard 
TB diagnostic (sputum culture), which is not available at any of the selected ART sites, will be 
used in addition with routine diagnostics, for the participants. Thereby making their TB screening 
of very highly standard with resultant appropriate and prompt treatment. Validation of the current 
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WHO algorithms for TB among HIV patients, will also inform decisions by policy makers in 
TB/HIV control programs. 
Evaluation of the TB diagnostics may also lead to discoveries that will solve the problem 
associated with TB diagnosis among HIV patients and thereby prevent/reduce the deaths and 
public health hazards that may be due to missed cases of TB among the study population. 
Prompt diagnosis and treatment of DM will also improve treatment outcome and reduce the risk of 
developing TB among the participants. As a result of this, the policy makers in TB/HIV control 
program may include routine DM screening among TB and HIV patients in the national policy. 
• Justice considerations 
 
 Improved TB diagnosis among HIV patients is highly needed in Nigeria and other high-burden TB 
and HIV setting, because a lot of TB cases among this population are diagnosed late or missed, and 
thereby making TB the commonest cause of death among them.  In addition, public health hazards 
that may result from TB transmission from undetected cases, will also be prevented if they are 
diagnosed early and promptly treated. 
This study will follow the routine HIV/TB care procedures, collect the same specimens’ samples 
(except urine and breathed airs) for routine care, but take the samples to a well-equipped research 
Laboratory for both routine and specialised TB tests. As a result of this, patients participating in 
this research will have better/higher quality diagnosis than what they would have if they had not 
participated in the study. 
This study will also reduce the clinical and laboratory workloads of the selected ART sites, 
because all the study participants will be seen by the research doctors who are well trained in 
TB/HIV care, and all the specimens will be tested in the research laboratory with the research fund.  
Lastly, findings from this study will be of great benefit to the participants, other persons living with 
HIV, general public, and the nation (Nigeria) at large. Please, see sections C2.1 and C2,2, for more 
details on the impact of this research on local services 
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From time to time the committee uses ethics applications for training purposes or to give examples 
to new applicants.  In all cases the applications are anonymised.  If you DO NOT consent to your 
application being used for these purposes please tick the box.      
DECLARATION:   TO BE SIGNED BY MAIN APPLICANT 
Applicants must initial each declaration or tick N/A in the right hand column if applicable 
Initial  
(by 
hand) 
N/A 
(1) I confirm that the details of this proposal are a true representation of the research to 
be undertaken. 
  
(2) I will ensure that the research does not deviate from the protocol described. 
  
(3) If significant protocol amendments are required as the research progresses, I will submit 
these to the Liverpool School of Tropical Medicine Research Ethics Committee for 
approval.  
  
(4) Where an appropriate mechanism exists, I undertake to seek additional in-country 
Ethical Approval in the country(ies) where the research is to be carried out.   
  
(5) I agree to abide by the ethical principles underlying the Declaration of Helsinki and all 
relevant LSTM Standard Operating Procedures (SOP) relating to research conduct 
(available on LSTM intranet at 
http://pcwww.liv.ac.uk/lstmintranet/research_management/governance_polices_cod
es.htm or by contacting the Research Office). 
  
(6) I understand that all conditions apply to any co-applicants, researchers and other staff 
involved in the study, and that it is my responsibility to ensure that they abide by them. 
  
For studies over two years in duration 
(7) I will provide the Research Ethics Committee with an annual report. 
  
For studies using ‘human tissue’* 
(8) I confirm I will abide by LSTM’s Policies and Standard Operating Procedures relating to 
activities involving human tissue 
*Human tissue (relevant material) is defined as any material that has come from a human body and consists of, or 
includes, human cells, but excludes such things as blood and plasma.  Further detail can be found at 
http://www.hta.gov.ac.uk/legislationpoliciesandcodesofpractice/definitionofrelevantmaterial.cfm. 
  
For studies that involve a clinical trial or participation of humans (the use of their data or 
tissue) 
(9) I confirm that I have completed a sponsorship and indemnity form 
http://pcwww.liv.ac.uk/lstmintranet/research_management/applyingforRG/intro.htm 
  
I expect the project to  
commence on (Date) 
Complete by (date) 
 
Signed:  Date:  
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8.4. Appendix 4. Patient Information Sheet 
 
Title: Optimising diagnosis and management of Tuberculosis among HIV patients 
 
Name of Principal Investigator:    Dr Rotimi OWOLABI 
 
Name of Organization:                   Liverpool School of Tropical Medicine 
 
 
This Informed Consent Form is for men and women attending this clinic (Special Treatment 
Clinic), who we are inviting to participate in a research on how to improve detection of 
Tuberculosis (TB) and Diabetes among people living with HIV (PLHIV). The title of our 
research project is “Optimising diagnosis and management of Tuberculosis among HIV 
patients in a high TB and HIV burden setting” 
This Informed Consent Form has two parts: 
1. Information Sheet (to share information about the research with you) 
2. Certificate of Consent (for signatures if you agree to take part) 
 
You will be given a copy of the full Informed Consent Form 
PART I: Information Sheet 
Introduction  
Good morning/afternoon. I am Dr Owolabi, doing a PhD program at the Liverpool School of 
Tropical Medicine (LSTM), United Kingdom. We are doing a research on Tuberculosis (TB), 
which are common in this country. I am going to give you information and invite you to be 
part of this research.  
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TB is a very common infection among people living with the Human Immunodeficiency Virus 
(HIV), and it is sometimes difficult to diagnosis the disease among them. Because people living 
with HIV (PLHIV) usually have low amount of TB germ in their sputum, which most of the 
current tests used for TB may not be able to detect. Also, because HIV reduces the ability of 
the body to fight other infections, PLHIV may not have the signs and symptoms which may 
make doctors or other health care workers to suspect this disease.  Many PLHIV with TB were 
discovered very late or missed. To improve the way we identify and properly treat this disease, 
we decided to look for better ways of detecting it in anyone that has it. There are better methods 
to identify this disease by using new tests called Xpert MTB/RIF Ultra, Genedrive and BlaC. 
Apart from sputum which is commonly used for TB diagnosis by the currently used TB tests, 
some of these new tests can also identify TB causing germ in urine, saliva/particles in the 
mouth, and other body fluids. 
People who have diabetes are more likely to have TB and people with HIV are more likely to 
develop diabetes. And if it occurs together with TB in a person, it makes tuberculosis treatment 
difficult, and poorly treated/control diabetes can lead to many long term health 
problems/disabilities like loss of vision, poor blood flow, kidney damage and damage to many 
organs/parts of the body. 
You do not have to decide now whether or not you will participate in the research. We will 
give you about two hours to consider your participation, but if you want to take more time, we 
are happy to wait until you come back to your next visit”. Before you decide, you can talk to 
anyone you feel comfortable with about the research. 
If you decided to participate, we would ask you some questions about you and your current and 
previous illnesses. If there are some words in these pages or later in the interview that you do 
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not understand, please ask me to stop as we go through the information, and I will take time to 
explain. If you have questions later, you can ask them of me, the study doctor or the staff. 
 
Purpose of the Research 
 We are investigating three diseases that are often found together and make the appropriate 
management of people with these diseases more complicated.  These three diseases are 
diabetes, tuberculosis and HIV infection. Tuberculosis is a severe disease caused by a germ 
(bacterium) that infects the lung; it can cause cough, weight loss, hotness of the body (fever), 
general body weakness and night sweats.  This disease is diagnosed by using a microscope to 
the look into sputum samples and check TB germ. Other tests that are sometimes performed 
for the diagnosis are culture and X-ray. With the current commonly used TB tests, a lot of 
cases of TB among PLHIV are not detected. Because of this, there is a need to look for better 
ways of identifying if someone among them has this disease or not. 
In this research, which aim to examine current ways of identifying people who have or do not 
have TB and diabetes among PLHIV are good enough, and determine whether the new tests 
to find if a person has these diseases are better than the tests currently being used, in order to 
come up with better ways of detecting the diseases among them.  To carry out this study, we 
will test the samples you provide with the new tests and compare its results with that of the 
current tests. 
Participant Selection 
All adults who have been diagnosed with HIV infection and are attending this clinic will be 
approached and asked to participate in this study, because TB is the most important 
opportunistic infection and commonest cause of death among PLHIV, but the death caused by 
TB can be prevented if this disease is properly identified and treated on time. Through this 
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research, we want to discover better methods of identifying persons with and without TB 
among PLHIV, so that persons with the disease among them can be properly treat on time and 
prevented from spreading the disease to others. While those found not have TB, can also be 
given drug to prevent them from developing the disease 
Voluntary Participation 
Your participation in this research is entirely voluntary. It is your choice to decide whether to 
participate or not. Whether you choose to participate or not, all the services you receive at 
this clinic will continue and nothing will change. If you choose not to participate in this 
research project, you will be offered the test that is routinely offered in this clinic to find out 
if someone has TB or not, and we will tell you more about it late. You may change your mind 
later and stop participating, even, if you had agreed earlier 
Procedures and Protocol  
Because we do not know if the current ways of identifying whether someone with HIV 
infection has TB or not, is good enough, we need to use some specialised tests (Culture and 
Xpert MTB/RIF), which are not usually done for patients in this clinic, to know how good the 
current methods are. Because we also do not know if the new Tuberculosis tests are better 
than the tests currently available for diagnosing the disease, we need to compare them in the 
same samples. To determine which of the tests is better, all the people participating in this 
research will be tested with the current and the new tests. Participants will be tested with the 
standard diagnostic tests and with the new tests called Xpert MTB/RIF ultra, Genedrive, 
BlaC and e-nose.  The usual test used at this centre is to check with a microscope whether 
your sputum has the Tuberculosis germ.  This is called smear-microscopy.  Apart from these, 
we will also conduct other tests that are more specialised, such as culture, current Xpert 
MTB/RIF and Xpert MTB/RIF ultra.  These tests are currently reserved for special 
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circumstances, but we need to conduct them here to be able to determine how good the new 
tests are.  This study’s results will be used to make your treatment decisions by the staff of 
the clinic.  Current treatment is decided on the basis of sputum specimens.  The main 
difference is that we will also have Xpert and culture results and we will provide this 
additional information to your doctor.  However, we will not provide the information on 
Xpert MTB/RIF ultra, Genedrive, BlaC and e-nose, because we need to be sure that the tests 
are working properly before using it for treatment decision.  All patients that participate in the 
study will also receive the same treatment given to patients not participating in the study. 
To check your blood sugar and determine whether you have diabetes or not, we will collect 
your blood. This will be collected at the same time your blood will be collected for other tests 
that are usually done for all patients in this clinic, before they can start treatment. The amount 
of blood to be collected for this test is small and can not affect you negatively. 
Risks: This study is not associated with any additional risks.  
Discomforts: The study will not cause you any additional discomforts. 
Samples to be collected and stored: We will ask you to submit three sputum samples for 
examination (which is the same with what other patients who are not participating in this study 
will be asked to submit). Two on the spot, one, the first time we are seeing you, the second, 
one hour after the first, and the third one, in the morning of the second day.  One of these 
samples will be cultured, to see if the germs grow in the following weeks.  If the germs grow, 
we will store them in small tubes for further description (called genotyping) and to check if the 
germ is susceptible to the drugs for treatment.  The isolates will be stored for 3 years to facilitate 
the completion of these tests and then will be destroyed.  We will also collect your urine and 
some of air you breathe out, and check them with the new TB tests, to see if they contain the 
germ that causes the disease.  
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All the samples (sputum, blood and urine) that will be collected from you (except the air you 
breathe out/out-breathe air) will be taken to a well-equipped research laboratory here in Abuja, 
where it can be done, because the specialised (culture) and the new tests are not available in 
this clinic/hospital. 
Because the test that we will use to check the air you breathe out and determine whether you 
have TB or not, is a new test and is not available in this hospital, our research laboratory or 
anywhere in Nigeria, we have to collect the air you breathe out, in a small bag and take it to a 
laboratory in the United Kingdom, where it can be done. Once we do it there, and we are sure 
that the test is working well, the machine/equipment needed for this test, will be brought to 
Nigeria and it can be available in this hospital for everyone that needs it. 
Benefits: If you participate, we will test your sputum with culture and Xpert, which are the 
best tests for this disease available. This is not routinely offered in the diagnosis of TB in this 
centre.  If culture is positive, we will call you back to start you on treatment. 
You will also have your blood sugar tested to check if you have diabetes.  If you do, you will 
be referred to the appropriate unit for its treatment. 
Incentives: There are no financial incentives for participating in the study. 
Confidentiality: We will not be sharing the identity of those participating in the research.  
The information that we collect from this research project will be kept confidential. Information 
that will be collecting about you during the research will be properly kept from unauthorised 
persons and only the research sponsors, the institutional officials and ethics committee 
members may have access to the data. We will give and attach a number instead of your name, 
to any information about you. The number given to you will only be known by the researchers 
and we will make sure that the information is kept where no one else can have access to it. 
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Right to Refuse or Withdraw: You do not have to take part in this research if you do not wish 
to do so and refusing to participate will not affect your treatment at this clinic in any way. You 
will still have all the benefits that you would otherwise have at this clinic. You may stop 
participating in the research at any time that you wish without losing any of your rights as a 
patient here. Your treatment at this clinic will not be affected in any way. 
Who to Contact: If you have any questions you may ask them now or later, even after the 
study has started. If you wish to ask questions later, you may contact any of the following: 
[name, address/telephone number/e-mail]. 
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Study Title: Optimising diagnosis and management of Tuberculosis among HIV patients 
in a high TB and HIV burden setting 
Principal Investigator: Dr Rotimi Owolabi Study Site: Abuja, Nigeria 
   
 
 
 
     
 
Signing this declaration does not affect your right to decline to take part in any future study. 
 
                                                                  
Name of participant        Date   Signature 
 
                                                         
Name of person taking          Date   Signature 
Consent  
 
 
 
8.5. Appendix 5. Informed Consent form         
                                                     Consent Form 
           CONFIDENTIAL 
 
 
 Please 
initial 
box 
(1) I confirm I have read and understood the information sheet dated......... 
(Version.......) for the above study.  I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily. 
 
(2) I understand that participation in this study is voluntary and I am free to 
withdraw   consent at any time, without giving a reason, without any 
penalties. 
 
(3) I understand that data collected during the study, may be looked at by 
individuals from LSTM and from regulatory authorities.  I give permission 
for these individuals to have access to my records. 
 
(4) I hereby declare that I have not been subjected to any form of coercion in 
giving this consent. 
 
(5) I agree / do NOT agree to the data about me, collected in this study being 
stored for further use in the future.  
 
(6) I agree to take part in this study.  
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*For patients LARs who can not read/write 
 
                                                               
Name of participant       Date          Thumbprint 
 
 
                                                         
Name of an impartial witness                        Date   Signature 
 
 
*For patients who are willing to participate but too sick to give consent  
 
                                                                  
Name of participant       Date                Signature 
 
                                                         
Name of a legally            Date   Signature 
authorized representative  
 
 
When complete: 1 copy for participant; 1 copy (original) for research 
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8.6. Appendix 6. Questionnaires 
 
8.6.1 Questionnaire on Optimising the Diagnosis and Management of Tuberculosis and Diabetes 
among HIV patients in a high TB and HIV burden setting 
 
 
Facility Name                                                                                           Date   
 
Patient’s Name                                                                             
                                                    Surname                                                            First name 
Patient’s Hospital Number          Enrolment Number                                     
 
ART Clinic Enrolment Number                                             Research Code 
 
ART Site’ code              (UATH, Gwagwalada = 1, Wuse General Hospital = 2) 
 
Address  
Mobile phone                                   
Demographic characteristics                                  
Age (Years)  Sex (Male=1, Female=2) 
Marital status        (Single=1, with partner/married=2, separated=3, divorced=4, widowed=5)  
Education             (None=0, primary=1, secondary=2, higher education=3, 
                              prefer not to answer=4) 
Occupation           (Student=1, Unemployed=2, Civil Servant=3, Artisan=4, Business/trading=5,  
                              Farming=6, House wife=7, other=8)   
If occupation is others, please, specify 
Ethicity                  (Hausa=1, Igbo=2, Yoruba=3, other=4)   
If other ethinicity, please specify           
Religion                 (Christianity=1, Islam=2, Traditional=3, other=4)      
 
d d m m
m 
y y 
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Family Type           (Monogamy=1, Polygamy=2)       
       Current Medical History 
 
    
 
 
 
 
 
 
 
 
 
How long ago did you notice the first symptom of this illness?   Months                          Weeks 
 
 
Symptoms in the last months                                                                                     Duration 
 
Fever                                        (Yes=1, No=2)                                        If yes, duration (weeks) 
  
                     
Night sweats                             (Yes=1, No=2)                                       If yes, duration (weeks) 
 
 
Muscle pain                             (Yes=1, No=2)                                         If yes, duration (weeks)                                      
 
 
Fatigue/weakness                    (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Weight loss                              (Yes=1, No=2)                                        If yes, duration (weeks)    
 
Presenting Complaints 
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Weight gain                              (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Cough                                      (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Difficulty with breathing            (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Chest pain                               (Yes=1, No=2)                                         If yes, duration (weeks) 
 
 
Oral thrush                              (Yes=1, No=2)                                         If yes, duration (weeks) 
 
 
Poor appetite                           (Yes=1, No=2)                                        If yes, duration (weeks)   
 
 
Painful swallowing                   (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Nausea and/or vomiting          (Yes=1, No=2)                                        If yes, duration (weeks)  
 
 
Diarrhoea                                 (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Abdominal pain                        (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Abnormal genital discharge     (Yes=1, No=2)                                        If yes, duration (weeks) 
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Genital/rectal pain/sores          (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Painful urination                       (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Headache                                (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Poor vision/visual loss             (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Depression                              (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Memory loss                            (Yes=1, No=2)                                        If yes, duration (weeks) 
 
 
Other (please, specify)  
 
 
 
Past Medical History 
 
Hypertension                           (Yes=1, No=2)                                       If yes, duration (months) 
 
 
Diabetes                                  (Yes=1, No=2)                                       If yes, duration (months)                                                                               
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Asthma                                    (Yes=1, No=2)                                       If yes, duration (months)                                                     
 
 
Other (specify)  
 
 
Are you currently on any medication?    (Yes=1, No=2) 
 
If yes, what are you using the medication(s) for?  
 
 
When did you first know you have HIV? 
 
How long (in months) did you first know you have HIV?  
 
 
Where were you first tested for HIV? (In this health facility=1,   other health facility within FCT=2, 
outside FCT=3, don’t know=4, do not want to say=5) 
 
Have you taken HIV medications before?      (Yes=1, No=2)                                                                            
 
 
If yes, purpose of the HIV medications:        PMTCT        Treatment       PEP       others      Not known 
(please thick as many as appropriate from the options)                        
 
Do you have allergy to any medicine?              (Yes=1, No=2, don’t know=3)                                                                                             
 
 
If yes, what medicine(s) are you allergic to?           Sulfonamides             Chloroquine           
Penicillins 
                                                                    
                                                                                 Don’t know                Other (specify)        
 
d d m m
m 
y y 
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Family and Social History 
 
Do you drink alcohol?           (Yes=1, No=2, do not want to say=3)   
 
If yes, how frequently?    (Occasionally=1, once a week=2, regularly=3) 
 
 
Do you use illicit drug(s)?      (Yes=1, No=2, do not want to say=3)   
 
 
Do you take herbal supplements             (Yes=1, No=2)         
 
 
Do you take traditional medicine(s)         (Yes=1, No=2)       
 
 
Do you smoke?        (Yes=1, No=2, ex-smoker=3, do not want to say =4)                
 
 
Do you have a sexual partner?    (Yes=1, No=2) 
 
 
If yes, has he/she been tested for HIV?   (Yes=1, No=2, don’t know=3)                                                                                                                                     
 
If yes, does he/she have HIV?                 (Yes=1, No=2, don’t know=3)                                              
 
*Please, tick all the possible answers in the next question 
 
Which of your relatives/partners have been tested for HIV?      Spouse               Sexual partners                 
                                                                                                    Child/children     None       Don’t know    
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Do you have any relatives who have HIV?  (Yes=1, No=2, don’t know=3)                                              
 
 
*Please, tick all the possible answers in the next two questions 
 
If yes, who?                                                                                Spouse               Son/Daughter                           
                                                                                                     Father                 Mother      Sibling(s)                                                                                                                                 
                                                                                                                                                                                                                
Which of your relatives are receiving treatment for HIV?          Spouse               Sexual partners                 
                                                                                                    Child/children      None       Don’t know                                                                              
                                                                                                    Father                  Mother       Siblings 
 
Do you have any relatives who have diabetes?       (Yes=1, No=2, don’t know =3)   
                                                                                  
*Please, tick all the possible answers in the next question 
 
If yes, who?                                                                                   Father                Mother       Siblings              
                                                                                                      Uncle                 Aunt           Child                          
                                                                                                     Child/Children     Other  
 
FOR FEMALE PATIENTS ONLY 
 
Last menstrual period               
 
 
Are you currently pregnant?       (Yes=1, No=2, uncertain=3)                  
 
If yes, gestational age (weeks)  
 
 
 
 
d d m m
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TB Treatment  
 
Have you ever been treated for TB?    (Yes=1, No=2, don’t know=3)                                                           
 
If yes,  currently or previously?               (Currently on treatment=1, previously treated=2) 
 
If previously treated, how many months ago? 
 
 
TB symptom currently present?                (Yes=1, No=2)                                                                                     
 
TB status:       (No signs or symptoms suggesting TB=1, signs or symptoms of TB present=2) 
                              
       
Anthropometric Measurements 
Height (m)                                                                            Hip (cm)            
Weight (kg)                                                                                             Waist (cm)   
BMI (kg/m2)                                                                                               Waist/Hip Ratio (WHR)      
                                                         
                                         
Physical Examinations 
General appearance  (Normal=1, abnormal=2, not checked=3)                                                                       
Respiratory distress  (Present=1, Absent=2)                                                                                                                                                                                                                                                                   
 
Pallor        (Present=1, Absent=2)                                                                                                                                                                                                                                               
 
Jaundice       (Present=1, Absent=2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 
Oral thrush     (Present=1, Absent=2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
Skin rashes     (Present=1, Absent=2)                                                                                                                                                                                                                                            
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Paedal oedema    (Present=1, Absent=2) 
                                                                     
Temperature (0C)                                                                                 Pulse Rate (beats/min)                     
 Systolic blood pressure (mmHg)                                           Diastolic blood pressure (mmHg) 
 Respiratory Rate (breaths/min)    
 
Functional status:     (Working=1, Ambulatory=2, Bedridden=3) 
 
 
WHO clinical staging:     (Stage 1=1, stage 2=2, stage 3=3, stage 4=4)    
 
 
                                                             
 
Other clinical findings   
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                                                  Laboratory Investigations   
 
Facility Name                                                                             Age (in years) 
 
Date of specimens’ collection                                                    Date received 
Patient’s Name  
                                               Surname                                                                     Other names 
Patient’s Hospital Number              Enrolment Number  
ART Clinic Enrolment Number                                                 Research Code 
ART Site’ code   (UATH = 1, Wuse GH = 2)                             Lab Number   
Specimen code  (Blood = 1, Sputum = 2, Urine=3)         Gender (Male=1, Female=2)       
  
 
                                                                                  
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d d m m
m 
y y 
Tests                            Results 
 
           CD4                                                     cells/uL 
           CD4%                                         % 
 
           WBC                                                     X 109 /L 
 
            PCV                                                   % 
 
            Hb                                                       g/dl 
 
          Platelets                                               X 109 /L 
 
           HBsAg   (Positive=1, Negative=2)  
 
         Creatinine                                            umol/L 
 
 
      ALT/SPGT                                                    U/L 
 
 
 
  
                                
   
   
 
 
Tests                           Results 
 
 Viral Load                                                              copies  
 
 FBS                                                             g/dl   
 
 FBS                                                           umol/L 
   
HbA1C                                                       % 
 
 HbA1C                                                        umol/L   
 
Total Cholesterol                                         umol/L  
  
  LDL                                                                umol/L                                                                                                                                                                                                                                                                                           
  
 HDL                                                                 umol/L                                                                                                                                                                                                                                                                   
                       
 
   AST/SGOT                                                U/L                                                                                
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                                             TB Screening Tests’ Results Sheet 
 
Facility Name                                                                             Age (in years)                                   
 
Date of specimens’ collection                                                    Date received 
 
 
Patient’s Name  
                                               Surname                                                                     First name 
 
Patient’s Hospital Number              Enrolment Number  
 
ART Clinic Enrolment Number                                                 Research Code 
  
ART Site’ code    (UATH = 1, Wuse GH = 2)                            Lab Number      
    
Specimen code  (Blood = 1, Sputum = 2, Urine=3)                  Gender (Male=1, Female=2)       
 
                                                                                                Sputum 1                                Sputum 2 
 
Available             (Yes = 1, No = 2)  
 
Quality                 (Saliva = 1, mucoid = 2,                                                                                               
                             mucopurulent = 3, purulent = 4) 
 
Blood stained      (Yes=1, No=2)                                                          
 
Amount > 2ml?    (Yes=1, No=2) 
 
 
d d m m
m 
y y d d m m
m 
y y 
 272 
 
*If sputum is salivary or insufficient, request new samples 
 
LED-FM               (Neg = 1, Scanty = 2, + = 3, 
                                     ++ = 4, +++ = 5) 
 
                            If scanty, number of FAB 
 
Xpert                   MTB (Not detected = 1, Detected = 2, Invalid = 3, Error = 4, No result = 5) 
 
                            If MTB detected (Very low = 1, Low = 2, Medium = 3, High = 4)                                                        
 
                            Rif Resistance (Detected = 1, Not detected = 2, Indeterminate = 3) 
 
If Xpert is invalid, error or no result: repeat Xpert using sputum 1 or request a new sputum if 
specimen is insufficient 
 
 
Xpert Ultra         MTB (Not detected = 1, Detected = 2, Invalid = 3, Error = 4, No result = 5) 
 
                            If MTB detected (Very low = 1, Low = 2, Medium = 3, High = 4)                                                        
 
                            Rif Resistance (Detected = 1, Not detected = 2, Indeterminate = 3) 
 
If Xpert Ultra is invalid, error or no result: repeat Xpert ultra using sputum 1 or request a new 
sputum if specimen is insufficient 
 
 
 
Genedrive          Done?  (Yes = 1, No = 2)                                                                                                                                                     
                           
                            Genedrive machine used (1, 2, 3, 4 or 5)                       
 
                            Genedrive consecutive number                                                                           
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                            MTB       (Undetected OK = 1, 
                                           Detected sensitive = 2, 
                                           Detected resistant = 3, Retest = 4, Retest control failed = 5) 
     
                            Observations_____________________________________________________  
 
 
 
BlaC                    Done? (Yes = 1, No = 2)                                                                                                                   
 
                            If, yes, MTB (Detected = 1, Not detected = 2, Indeterminate = 3)                                                                                             
 
 
 
Culture               Done? (Yes = 1, No = 2)                                                (Pos = 1, Neg = 2,                        
                                                                                                               Cont = 3 Missing = 4)                                                          
                         
                           Time to positive (days)                                               Date                                            
 
                            Number of colonies                                                             Sample saved  
                                                                                                                   (Yes = 1, No = 2) 
 
DST (Sens = 1, Res = 2, Not done = 3)           Rif                  INH              ETH                 STR                        
 
 
 
                                                                                                                                            
 
 
 
 
d d m m
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Urine Sample 
 
Xpert Ultra  
 
                           Specimen available? (Yes = 1, No = 2)  
     
                           Specimen in good conditions? (Yes = 1, No = 2) 
 
                           Ultra done?   (Yes = 1, No = 2)                                                                                                                                                          
 
                           MTB (Not detected = 1, Detected = 2, Invalid = 3, Error = 4, No result = 5) 
 
                           If MTB detected (Very low = 1, Low = 2, Medium = 3, High = 4)                                                        
 
                           Rif Resistance (Detected = 1, Not detected = 2, Indeterminate = 3) 
 
 
E-nose  
                                                                                                                                 Date 
 
                           Sample     taken? (Yes = 1, No = 2)                                                                                                              
 
                           Sample sent to UK? (Yes = 1, No = 2)                                                                                                                                                                                                                                                                                                                                   
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8.6.2 Questionnaire of evaluation of CRP and IP-10 as screening tool for active TB  
 
 
Hospital Registration Number    Date   
 
Name of hospital      
Name               Address 
Mobile phone                                  Other phone  
Age Years [not known = 99]   Sex (Male=1, Female=2) 
Marital status                     [Single=1, with partner/married=2, divorced/separated=3, widowed=4]  
Patients is  (New=1, Not new= 2) 
Treatment for TB                    (Never treated=1, previous treatment=2, currently on treatment=3) 
If treated before, classification:       (Retreatment=1, Relapse=2, new treatment=3) 
If previously treated, months ago? 
How long ago did you notice the first symptom of this illness?   Months       Weeks 
For how many weeks have you had cough?       Weeks 
            [Y =1, N=2]          Weeks 
Do you have     Hemoptysis (nose bleeds)  
      Fever 
      Weight loss 
      Chest pain 
      Night sweats 
      Weakness 
      Loss appetite 
      Other illness        Specify  
HIV                                       [Positive = 1, negative = 2, Does not want to say = 3, unknown = 4]
d d m m y y 
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Laboratory 
 
Hospital           Patient Name 
 
Date sputum collected      time        
 
 Date received       time  
 
Date blood collected      time        
 
 Date received       time  
 
Laboratory Number 
              Sputum 1  Sputum 2 Sputum 3    
 
Available   [Yes =1, No=2]   
Quality*   [saliva=1, mucoid=2, 
mucopurulent=3, purulent = 4] 
Blood stained  [Yes =1, No=2] 
Amount > 2 ml?* [Yes =1, No=2] 
*if sputum is salivary or insufficient request further sputum samples 
Were further samples requested? [Yes =1, No=2] 
          Sputum 1  Sputum 2 
ZN smear microscopy  [Neg =1, Scanty =2, + =3,                 
++ =4, +++ = 5]  
If scanty, N. of FAB 
      
Culture  Done? [Yes =1, No=2]                 Pos =1, Neg =2, Cont =3, Missing =4] 
Time to positive [days]     Date  
Number of colonies     Sample saved [Y =1, N=2] 
DST [Sens =1, Res =2, Not done =3]            Rif    INH     ETH           STR 
 
h
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Xpert  Test used (Xpert= 1, Ultra =2) 
  MTB [Not detected = 1, Detected =2, Invalid =3, Error =4, No result = 5]* 
If MTB detected [Very Low=1, Low =2, Medium=3, High =4] 
Rif Resistance [DETECTED=1, NOT DETECTED=2, INDETERMINATE=3] 
*If Xpert is invalid, error or no result: repeat Xpert using sputum 1, or request a new sputum if specimen is insufficient. 
CRP-ELISA   Done? [Yes =1, No=2]  Result: (ng/mL)                                     . 
CRP-rapid test   Done? [Yes =1, No=2]    result: (mg/l ) <10            (check one) 
 10-40              
40-80 
>80 
 
IP-10-ELISA   Done? [Yes =1, No=2]      Result: (pg/mL)                                     .            
  
      Sputum 1    Sputum 2 
xRapid    Done? [Yes =1, No=2] 
  Result  [Neg =1, Scanty =2, + =3,                 
++ =4, +++ = 5]  
 
If scanty, N of FAB 
 
Date/time examined  
 
Observations  
 
                  Sputum 1    Sputum 2 
Fluorobot   Done? [Yes =1, No=2]  Done? [Yes =1, No=2] 
  Result  [Neg=1, Scanty=2, +=3,             [Neg=1, Scanty=2, +=3,    
++=4, +++= 5]   ++=4, +++= 5]  
 
If scanty, N of FAB 
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Date/time examined  
 
Observations  
 
                  Sputum 1    Sputum 2 
QuantumDx             Done? [Yes =1, No=2]    Done? [Yes =1, No=2] 
  Result            [Neg=1, Scanty=2, +=3,                [Neg=1, Scanty=2, +=3,  
  
           ++=4, +++= 5]      ++=4, +++= 5]  
 
If scanty, N of FAB 
 
Date/time examined  
 
Observations  
 
HIV viral load   Done? [Yes =1, No=2]                    Result (cp/ml) 
 
Observations  
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8.6.3 Data abstraction/collection form for the study on TB treatment outcome 
 
 
Enrolment Date                                                                  Data abstraction Date   
 
Patient’s Name                                                                             
                                                    Surname                                                            First name 
Patient’s Hospital Number          Enrolment Number                                     
 
Demographic characteristics                                  
Age (Years)                             Sex (Male=1, Female=2, Not known = 9) 
Marital status        (Single=1, with partner/married =2, separated=3, divorced=4, widowed=5)  
Education             (No formal education=0, primary=1, secondary=2, higher education=3, 
                              prefer not to answer=4) 
Occupation           (Student=1, Unemployed=2, Civil Servant=3, Artisan=4, Business/trading=5,  
                              Farming=6, Full House wife=7, other=8)   
If occupation is others, please, specify 
Ethicity                  (Hausa=1, Igbo=2, Yoruba=3, other=4)   
If other ethinicity, please specify           
Religion                 (Christianity=1, Islam=2, Traditional=3, other=4)      
Family Type           (Monogamy=1, Polygamy=2)       
Baseline clinical history 
 
Mode of entry to DOTs clinic (ART clinic =1, wards = 2, MOPD = 3, SOPD = 4, GOPD= 5, others 
=6)  
 
Smear microscopy                  (Positive = 1, Negative = 2, not done = 3) 
 
If smear-positive: smear grade          (Scanty = 1, + = 2, ++ = 3, +++ = 4) 
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Xpert MTB/RIF   (MTB detected = 1, MTB not detected = 2, error = 3, not done = 4) 
 
If MTB detected, (Low = 1, medium = 2, high = 3)                       Rif resistance (Yes = 1, No = 2) 
 
X-rays:        (Not suggestive = 1, Suggestive = 2, Not done = 3) 
 
Culture:       (Positive = 1, Negative = 2, Contaminated = 3, Not done = 4) 
 
TB diagnosis: (PTB = 1, EPTB = 2)  
 
If EPTB: which types? (TB of lymph nodes = 1,   Abdominal TB = 2, TB meningitis = 3, TB  
                                      pleuritis = 4, Others = 5)  
If other forms of EPTB (please, specify) _________________________________ 
TB classification based on treatment history       (New = 1, re-treatment = 2, Not known = 9)  
 
TB drug susceptibility     (Drug susceptible =1, MDR= 2, other forms of DR-TB = 3, Not tested = 4)  
 
 
Anthropometric Measurements 
Height (m)                                                                                             Weight at 2 months (kg)            
Weight at start of treatment (kg)                                                             Weight at 5 months  (kg) 
 Systolic blood pressure                                                                           Diastolic blood pressure   
HIV testing done                      (Yes=1, No =2, Not known = 9)    
HIV status                               (Positive = 1, Negative = 2, Undetermined =3, Not known = 9) 
If HIV positive, is the patient receiving HIV care in this facility? (Yes=1, No =2. Not known = 9) 
If HIV positive, is the patient on ART? (Yes=1, No =2, Not known = 9) 
If on ART, what regimen?  ( TDF/FTC/EFV = 1, TDF/FTC/NVP  = 2,  ZVD/3TC/NVP = 3, 
ZVD/3TC/EFV = 4, TDF/FTC/ATV = 5, TDF/FTC/LPV/r = 6, ZVD/3TC/ATV = 7,  
ZVD/3TC/LPV/r = 8, Others (please specify) ___________________ 
If HIV positive, is the patient on Co-trimoxazole preventive therapy (CPT)          (Yes = 1, No =2)  
 281 
 
Past Medical History 
Hypertension                                    (Yes =1, No = 2)  
Diabetes                                           (Yes =1, No = 2)  
Asthma                                             (Yes =1, No = 2)      
Others   (please, specify)--------------------------------------- 
Date TB treatment started 
Anti-TB regimen                      (Category 1=1, Category 2 = 2, second line =3) 
Duration of TB treatment (months)                                  
Follow up smear microscopy: 
Month 2: done (yes = 1, no = 2, NK = 9) If done, (Sc = 1, + = 2, ++ = 3, +++ = 4, Neg = 5, result 
missing = 6) 
Month 6: done (yes = 1, no = 2, NK = 9) If done, (Sc = 1, + = 2, ++ = 3, +++ = 4, Neg = 5, result 
missing = 6) 
Treatment outcome                 (Cured = 1, treatment completed = 2,  default/LTFU = 3,   failure = 4,      
Transferred out = 5, died = 6, not evaluated = 7) 
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8.6.4 Data abstraction/collection form for the study on prevalence and incidence of 
hypertension among HIV patients 
 
Enrolment Date                                                         Data abstraction Date   
 
Patient’s Name                                                                                               
                                               Surname                                                            First name 
Patient’s Hospital Number          Enrolment Number                                     
Demographic characteristics on first attendance to UATH ART site                               
Age (Years)  Sex (Male=1, Female=2) 
Marital status      (Single=1, with partner/married=2, separated=3, divorced=4, widowed=5)
  
Education             (None=0, primary=1, secondary=2, higher education=3, 
                              prefer not to answer=4) 
Occupation           (Student=1, Unemployed=2, Civil Servant=3, Artisan=4, 
Business/trading=5,  
                              Farming=6, House wife=7, other=8)   
If occupation is others, please, specify 
Ethicity                  (Hausa=1, Igbo=2, Yoruba=3, other=4)   
If other ethinicity, please specify           
Religion                 (Christianity=1, Islam=2, Traditional=3, other=4)      
Family Type           (Monogamy=1, Polygamy=2)       
        
Baseline vital signs measurement 
Anthropometric and Blood Pressure Measurements 
Height (m)                                                                   Hip (cm)            
Weight (kg)                                                                 Waist (cm)                                                                                                      
Systolic blood pressure (mmHg)                                 Diastolic blood pressure (mmHg) 
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Please note that, if systolic blood pressure is >120mmHg or  diastolic blood pressure 
>90mmHg, then, patient is hypertensive.   
 
Is the patient hypertensive                  (Yes = 1, No = 2) 
Functional status:                (Working=1, Ambulatory=2, Bedridden=3) 
WHO clinical staging:                        (Stage 1=1, stage 2=2, stage 3=3, stage 4=4)    
Eligible for ART                                (Yes=1, No=2)                               
                                                  
                                                             Routine Investigations 
 
     Baseline/at enrolment                                                         1 year after enrolment 
 
 
                                      
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Tests                            Results 
  CD4                                                cells/uL 
   
 FBS                                              mg/dl 
    
WBC                                               X 109 /L 
 
    PCV                                                % 
 
    Hb                                                 g/dl 
 
    Platelets                                          X 109 /L 
 
   HBsAg    (Positive=1, Negative=2)  
   Creatinine                                       umol/L 
   ALT/SPGT                                       U/L 
 
 Viral Load  
 
 
 
 
       
Tests                            Results 
CD4                                                 cells/uL 
  
FBS                                                 mg/dl 
  
WBC                                          X 109 /L 
 
  PCV                                                   % 
 
    Hb                                                       g/dl 
 
    Platelets                                        X 109 /L 
 
   HBsAg (Positive=1, Negative=2)  
   Creatinine                                       umol/L 
   ALT/SPGT                                         U/L 
 
Viral Load  
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Date of attendance (1 year later):            Check here if patient did not return 
 
Functional status after 1 year:         (Working=1, Ambulatory=2, Bedridden=3)  
 
WHO clinical staging after 1 year:    (Stage 1=1, stage 2=2, stage 3=3, stage 4=4)    
 
ART status after 1 year?                    (On ART = 1, Not on ART = 2)                               
If on ART, for how long (in month)?  
If on ART, what regimen?  ( TDF/FTC/EFV = 1, TDF/FTC/NVP  = 2,  ZVD/3TC/NVP = 3, 
ZVD/3TC/EFV = 4, TDF/FTC/ATV = 5, TDF/FTC/LPV/r = 6, ZVD/3TC/ATV = 7, 
ZVD/3TC/LPV/r = 8, ZVD/TDF/3TC/LPV/r = 9, ZVD/TDF/3TC/ATV = 10 
Others (please specify) --------------------------------- 
 
ART Class               (Protease Inhibitor (PI) included = 1, PI  not included = 2)                                                
 
ART regimen after 1 year, compared to the regimen at ART initiation (same = 1, substituted     
                                                                                                                   = 2,  switched = 3) 
  
 
Patient’s status 1 year after enrolment  (On care/active = 1, Transferred out = 2, LTFU=3,      
                                                                  Dead = 4) 
Anthropometric and Blood Pressure Measurements 1 year after enrolment 
Height (m)                                                                        Hip (cm)            
Weight (kg)                                                                      Waist (cm)   
Systolic blood pressure (mmHg)                                     Diastolic blood pressure (mmHg) 
 
Please note that, if systolic blood pressure is >120mmHg or  diastolic blood pressure 
>90mmHg, then, patient is hypertensive.   
 
Is the patient hypertensive                                    (Yes = 1, No = 2) 
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8.7. Appendix 7. Research Ethics approval letters 
8.7.1 Ethics approval letter from the Research Ethics Committee of the University of 
Abuja Teaching Hospital, Abuja, Nigeria 
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8.7.2 Initial ethics approval letter from the LSTM Research Ethics Committee (15.045) 
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8.7.3 LSTM Research Ethics Committee’s approval letter for the consent form 
amendment 
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8.7.4 Ethics approval letter from the Research Ethics Committee of the Nigeria’s 
Federal Capital Territory (FCT), Abuja 
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8.7.5 Ethics approval letter for research protocol amendment, from LSTM Research 
Ethics Committee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
